category,datetime,headline,id,image,related,source,summary,url
company,2022-09-23 13:37:33,10 Best ETFs to Diversify Your Portfolio and Avoid Risks,116219473,https://s.yimg.com/uu/api/res/1.2/QDj5nOtqGBZzyMfKHFL_eA--~B/aD02MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/fa0b8bb863ca7cb691d99a09ad4c4ed6,REGN,Yahoo,"In this article, we discuss 10 best ETFs to diversify your portfolio and avoid risks. If you want to see more exchange traded funds in this list, click 5 Best ETFs to Diversify Your Portfolio and Avoid Risks. The importance of ETFs has redoubled in 2022 as the stock market takes a beating amid volatility, […]",https://finnhub.io/api/news?id=d25a8f660037bbd3fd6c8f714b7eff7a8e0cd102983175cf3ca810fa0e9a1c88
company,2022-09-23 13:19:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market",116240394,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.32% to $697.33 Friday, on what proved to be an all-around rough trading session for the stock market,...",https://finnhub.io/api/news?id=0fb05f4e80926605a014b14e7b9f017f42713c9b0993cec05439dcbd6eae6d52
company,2022-09-23 08:01:00,"Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$16m worth of stock",116217139,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the company...",https://finnhub.io/api/news?id=e8f5b609d90ca543cf8876239cfe2b9f0e0d56b291ce28406885b393bc2d6b7a
company,2022-09-22 23:44:00,The Top 5 Stocks Cathie Wood Is Buying This Week,116223442,https://investorplace.com/wp-content/uploads/2022/03/cathie-wood-stocks-1600.png,REGN,InvestorPlace,Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys.,https://finnhub.io/api/news?id=87eedfb10ba6e9d19f7ed661425a8c2df4100df88f60d5a1fc7d0137c63ee839
company,2022-09-22 21:32:00,"Friday Sector Leaders: Healthcare, Utilities",116223610,,REGN,Market News Video,"The best performing sector as of midday Friday is the Healthcare sector, losing just 1.4% - Within that group, Regeneron Pharmaceuticals, Inc. - REGN,IDXX,XLV,EXC,WEC.",https://finnhub.io/api/news?id=5a5c75533f2e40d46ff2a8230ccebb5875cf4b4dfd0a73078fb538fd3717029b
company,2022-09-28 17:44:00,Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis,116312819,https://s.yimg.com/uu/api/res/1.2/DSP9dtJln7_yznmNwJAl.w--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/6afc92702ae63dff1677767295cc8228,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent becomes the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest among",https://finnhub.io/api/news?id=9e72238fbedcb6a7eb9f0bbb038cb4e0d565978574115b5e3fc48b80e56093a5
company,2022-09-28 14:39:00,Regeneron Stock Is Attempting an Upside Breakout,116310560,https://s.yimg.com/ny/api/res/1.2/EA00bG1LEEE8uCVyjwL5zQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/thestreet.com/051bf1e72c5b2fbc37dba13f312ad017,REGN,Yahoo,"Regeneron Pharmaceuticals  soared sharply higher earlier this month and made a ""normal"" correction as prices pulled back to unwind overbought conditions.  The On-Balance-Volume (OBV) line shows gains in September and that is a positive development.  The weekly OBV line is pointed lower and suggests that sellers of REGN are more aggressive.",https://finnhub.io/api/news?id=f038905ac8b86d3d465edb61c84a320f62a91528a535ba525c7fe56f80b643e6
company,2022-09-28 00:46:00,"Regeneron, Sanofi announce FDA approval of Dupixent",116315463,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,"Regeneron (REGN) and Sano... REGN, SNY",https://finnhub.io/api/news?id=189a59bad98e807914313fa19006aa8e49837bf831d29b83874961c77c86bf82
company,2022-09-27 09:00:52,"Insiders who sold Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) earlier year may find some solace in the 4.1% drop",116289562,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) stock price has dropped 4.1% in the previous week, but insiders who...",https://finnhub.io/api/news?id=c1f5398cf4d11b572fda9daae0b750afa9a8b378a7b9748fe63e952d658b4a31
company,2022-09-27 02:20:00,The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market,116283880,https://investorplace.com/wp-content/uploads/2022/08/hidden-bull-market.png,REGN,InvestorPlace,"Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market.",https://finnhub.io/api/news?id=ccc1b727bde4a72205d89981df541b60c99d71a5b442550ed973da6cf3feb072
company,2022-09-26 08:21:00,Can Healthcare Stocks Continue To Outperform? ,116261307,https://i2.wp.com/raygent.com/wp-content/uploads/2022/09/image-6.png,REGN,TalkMarkets,Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis.,https://finnhub.io/api/news?id=db12f381290d9ccfc92cc5725bf1c5dd297fad1fe2826a86fd122e123e15cb37
company,2022-09-25 20:13:40,Connect Biopharma Is A Sleeper Heading Into October Data Readout,116246380,https://media.gettyimages.com/photos/woman-with-a-skin-disorder-of-atopic-dermatitis-picture-id165665917?b=1&k=20&m=165665917&s=170667a&w=0&h=UKQsg6bYCY4TUhYS33ujqIhHNXM9GZsfXkqEcSGIiH4=,REGN,SeekingAlpha,Connect Biopharma expects top-line results next month for the pivotal CBP-201 atopic dermatitis (or AD) trial in Chinese adults. See why CNTB stock is a buy.,https://finnhub.io/api/news?id=35dbac5752eeb51bf80dbdde94a27c4cb484ef674a63e7282147e14a0cddc7c0
company,2022-10-01 21:40:00,"The One-Minute Market Report - Sunday, Oct. 2",116428549,https://cdn.pixabay.com/photo/2016/11/27/21/42/stock-1863880__340.jpg,REGN,TalkMarkets,"In today's issue of the One-Minute Market Report, I examine the damage done in September and highlight the parts of the market that were hit the hardest.",https://finnhub.io/api/news?id=a722035174b925d6a4015ec8f5b452590f2a73de677e68e822f64c4704b51301
company,2022-10-01 11:00:00,3 Biotech Stocks For Your October 2022 Watchlist,116375843,https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2022/10/biotech-stocks.jpg,REGN,StockMarket,Could now be a good time to add these top biotech stocks to your October 2022 watchlist?,https://finnhub.io/api/news?id=46771863520795c171784c803a5c263f1669ecb2cc275496db8f20aef2232a67
company,2022-10-01 10:00:34,"Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$16m worth of stock",116376861,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the...",https://finnhub.io/api/news?id=a8e8d9856d56a471e23ccc5b2fba6055eb2cc3a022214d7a215d11e4ba72c95e
company,2022-09-30 17:04:00,Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO,116365629,https://s.yimg.com/uu/api/res/1.2/PdtTzVzLaGQRS.MFWurnXg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/4cf64e26f6297cbe2bba3e1ef19e79b4,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® (aflibercept) Injection, in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The data were presented in a late-breaking session at the American Academy of Ophthalmology (AAO) annual meeting in Chicago and will support the s",https://finnhub.io/api/news?id=1beac0d1c47c9a335f4f93b36f9a45938afbd39ff4df8fba45445b053ab45652
company,2022-09-30 05:24:00,Cowen biotech/pharma analysts hold an analyst/industry conference call,116364387,https://thefly.com/images/meta/converenceevents.jpg,REGN,Thefly.com,"Biotech Analysts Van Bure... REGN, BAYRY",https://finnhub.io/api/news?id=e87336e7db8072204dc785052836f3bdd132c933bc436b69331a2ec95f50a2a3
company,2022-09-30 00:07:00,Regeneron reports 'positive' results from trials of novel aflibercept 8mg,116384014,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,Regeneron announced the f... REGN,https://finnhub.io/api/news?id=d755b1416edc1b8a269e161acf4ff2bf27664f9025a3a59d8357b3427f0281fc
company,2022-09-29 14:11:42,Illumina Aims to Push Genetics Beyond the Lab With $200 Genome,116365630,https://s.yimg.com/ny/api/res/1.2/kLyqF0HFLUy1rYLOR_UmTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/5e5cddca30df471cedb9c8f606709e4e,REGN,Yahoo,"(Bloomberg) -- Illumina Inc. says it can read a person’s entire genetic code for as little as $200 with its new sequencing machine, bringing the company within reach of its long-promised goal of the $100 genome.Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite Hurri",https://finnhub.io/api/news?id=a045ae9b7a8bae0b164266c770d072af1c7fd1a7de814fce43d0c3568d8fbf88
company,2022-09-29 12:12:04,"Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates",116334709,https://s.yimg.com/uu/api/res/1.2/gw9hjYsV9oVXUgeEGEfgLQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3,REGN,Yahoo,Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=95114d70e3e00726c744376c0cadc782e56463127381bed1c0acf8c162c9be25
company,2022-09-29 11:09:03,Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis,116333847,https://s.yimg.com/uu/api/res/1.2/MPLv._QOfr9ekgf5qyZbUA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966,REGN,Yahoo,The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.,https://finnhub.io/api/news?id=c0b68db4971f72d634737af279ce14bade138f4b13284349fb01a50c771aaf6e
company,2022-09-29 09:54:10,Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis,116333848,https://s.yimg.com/uu/api/res/1.2/56BPyjb5S_VOUoJ10sCeqA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/1a5eebd96817b0be87b5979b54942e17,REGN,Yahoo,"The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent became the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation. The FDA evaluated the Dupixent application for prurigo nodularis under Priority Review. Related: Regeneron",https://finnhub.io/api/news?id=e0b3cb5b251a08f2262d5b944c8b0749d371d7701571b8e4446daabd4312a328
company,2022-09-29 09:02:39,Compounders And Dividends: Building A Watchlist,116333865,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/477583982/image_477583982.jpg?io=getty-c-w750,REGN,SeekingAlpha,I explain how I generate ideas and my methodology of adding companies to my watchlist. Read here to know the stocks in areas/sectors that I find interesting.,https://finnhub.io/api/news?id=8cab9cb15f70677d7d2889730140311e882a97b2f565dd47307b6781b383c6aa
company,2022-09-29 06:20:24,Dow Jones Futures Fall As Treasury Yields Rebound; Eli Lilly Leads 7 Bullish Stocks,116324656,https://s.yimg.com/uu/api/res/1.2/PpHQWLIKatr9D7NT7X6nnw--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/89039c0e4d3b6c6a5f27c761dcb0809f,REGN,Yahoo,"Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks.",https://finnhub.io/api/news?id=5596d102dae6d549536ed411eb8b5d7e71235e1e8ae25344a07eb7046363fb72
company,2022-09-29 05:40:48,REGENERON - DUPIXENT APPROVED BY FDA AS THE FIRST AND ONLY TREATMENT INDICATED FOR PRURIGO NODULARIS,116331106,,REGN,Finnhub,"TARRYTOWN - Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adult patients with prurigo... | September 29, 2022",https://finnhub.io/api/news?id=22264f382200e71cb07e488d30d3e6182497c6126dea6e8154d24752aa32636d
company,2022-09-28 17:28:24,"Dow Jones Jumps 549 Points As Treasury Yields Tumble, But Now What? Eli Lilly Leads 7 Bullish Stocks",116312650,https://s.yimg.com/uu/api/res/1.2/PpHQWLIKatr9D7NT7X6nnw--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/89039c0e4d3b6c6a5f27c761dcb0809f,REGN,Yahoo,The major indexes rebounded as Treasury yields tumbled from 4% as the Bank of England resumed bond buying. Eli Lilly led stocks showing bullish action. Here's what to do now.,https://finnhub.io/api/news?id=dd7b5102c636ca527fdd64221477eb93a54efae85b46cff250765ae2843d0404
company,2022-10-06 13:19:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,116593289,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 1.85% to $731.86 Thursday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=a8a576a6fd5608074d0150e21b8815dea5bdc4db92fb2a400c6bb2902b564d18
company,2022-10-06 10:02:04,Best Stocks To Buy For October 2022? 2 Healthcare Stocks In Focus,116503618,https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2022/10/best-stocks-to-buy-for-2022-.jpg,REGN,StockMarket,2 top healthcare stocks to watch in October 2022.,https://finnhub.io/api/news?id=9b1f715367cf72792095e019fec0d9b4fd174473a63a344bbb13139097787043
company,2022-10-05 20:49:29,Tracking William Nygren's Harris Associates Portfolio - Q2 2022 Update,116488228,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250038049/image_1250038049.jpg?io=getty-c-w750,REGN,SeekingAlpha,Harris Associates' 13F portfolio value decreased from $75.90B to $62.85B this quarter. Read more to see about Harris Associates' holdings and trades for Q2 2022.,https://finnhub.io/api/news?id=8057f7b492a1af046d6bf048ee1a1fe467d916f2f15366a328a3f5190434cb8c
company,2022-10-05 13:19:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,116593290,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.83% higher to $745.68 Wednesday, on what proved to be an all-around rough trading session for the stock...",https://finnhub.io/api/news?id=e50cfd51849a96a29cff0aa5088d9bacf5b92dcaa7c6cf1a638289845d531a05
company,2022-10-05 09:51:00,"Final Trades: Lamar, Wynn, Eaton & more",116479061,https://image.cnbcfm.com/api/v1/image/107129853-16649921424ED3-FMHR-FINAL-100522.jpg?v=1664992260&w=1920&h=1080,REGN,CNBC,"The ""Halftime Report"" traders give their top picks to watch for the second half.",https://finnhub.io/api/news?id=14747835736b3e8be76b37d47607c86de4610ccf00aeb352c429bdd470de1e56
company,2022-10-05 09:01:32,Regeneron Pharmaceuticals' (NASDAQ:REGN) three-year earnings growth trails the 37% YoY shareholder returns,116470878,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...,https://finnhub.io/api/news?id=692ac9ee1c1802119bea681c36bc49ab1d6e5e388af88ed31f3e944fb92e8370
company,2022-10-05 03:30:40,JOET: Mixing Quality And Momentum,116459248,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1360733079/image_1360733079.jpg?io=getty-c-w750,REGN,SeekingAlpha,"Virtus Terranova U.S. Quality Momentum picks large-cap companies with a ranking system based on trend, profitability, and growth. Click here to read why JOET is a hold.",https://finnhub.io/api/news?id=bba9b2ed66abc88bec49f0d25322c3f4a4dedff44f37a9f451fe2666eed0e2d6
company,2022-10-04 16:00:00,"Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022",116442600,https://s.yimg.com/uu/api/res/1.2/B21xrX5.7vRDap8MzUmV3Q--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/f1d40ced9f121fa9351b571773b5fcfc,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.",https://finnhub.io/api/news?id=540b6a7938eb74517884a1ef6043d9ff9e39b2c9e58eb24dfc5bf1e0e9c68d88
company,2022-10-04 13:19:00,"Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",116593291,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.60% higher to $739.54 Tuesday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=7ae2adcbe99b67857cc29b91594cd1544a8b0dd1b387a7f5e6276cba2b772ec5
company,2022-10-04 11:40:03,REGN vs. RGEN: Which Stock Is the Better Value Option?,116442601,https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209,REGN,Yahoo,REGN vs. RGEN: Which Stock Is the Better Value Option?,https://finnhub.io/api/news?id=f27f812dabde758ff5d05b37bff3e587361ebd92ca20aef801047743e482acdb
company,2022-10-04 10:23:00,3 Revolutionary Stocks I'd Buy Right Now Without Hesitation,116436642,https://s.yimg.com/ny/api/res/1.2/hnZFB7fl9o8lqdw2dmj0Eg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/50dc77772b8361f2764b3b6e9b2d5476,REGN,Yahoo,"Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ: BIIB) are developing remarkable therapies that, instead of merely treating disorders, have the potential to cure them or at least make an impact that no other drug has to date.  The reason that's not a big cause for alarm is that the company's second-quarter revenue of $2.86 billion would be up 20% over the same period in 2021 if its COVID-19 therapy, REGEN-COV, was excluded from total revenue.  The company's sales of the treatment ended late last year when government contracts for the therapy ended.",https://finnhub.io/api/news?id=0da62927d857d82005a1a42b9d3cccac3a20b124d22d516c5b00bbbb66f8f59a
company,2022-10-04 09:35:01,Regeneron (REGN) Recently Broke Out Above the 20-Day Moving Average,116442603,https://s.yimg.com/uu/api/res/1.2/wXNaNKXxuWlbebD.cUCv9g--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653,REGN,Yahoo,Should investors be excited or worried when a stock crosses above the 20-day simple moving average?,https://finnhub.io/api/news?id=5ed34120f10b86fe93037c7bdc9c6514f6f1957b5796b6ea1d1c9942ddcbc234
company,2022-10-04 09:15:01,Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?,116440720,https://s.yimg.com/uu/api/res/1.2/cfvqiX3O.R_SNhQ3sdOrIg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d4b401a428473a34a4480748dd329007,REGN,Yahoo,Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.,https://finnhub.io/api/news?id=6f338c270022655ab2c5332bc6f738a0f55c2a95cf5843c97d63270cd330794e
company,2022-10-04 09:10:01,Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth,116436900,https://s.yimg.com/uu/api/res/1.2/HNGK8KXbnuM7D3xIxBkleg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c,REGN,Yahoo,"Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.",https://finnhub.io/api/news?id=597f8a371e229a23b59eb89095c464fdebc642ac3e829425bb896e8d023de55a
company,2022-10-04 08:30:12,"If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now",116436901,https://s.yimg.com/uu/api/res/1.2/5w_iAw5naBqMPrzpIECi9Q--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/670d1917693293f70179651625deb88f,REGN,Yahoo,Holding on to popular or trending stocks for the long-term can make your portfolio a winner.,https://finnhub.io/api/news?id=e79a37942ad99b3e51cfd4e6f0ffb207f8e50b37494d5a3b776fe04ff778a522
company,2022-10-04 06:18:00,"Video: Nasdaq 100 Movers: REGN, ILMN",116429489,,REGN,Market News Video,"In early trading on Tuesday, shares of Illumina topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.7% - Year to date, Illumina has lost about 47.0% of its value - REGN,ILMN,NFLX,ASML.",https://finnhub.io/api/news?id=6bcdb2886805d59daf0c9535bd01c6f5a5772197476107068c9b371ede10ec4a
company,2022-10-04 05:08:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Aeglea Biotherapeutics (AGLE) and Autolus Therapeutics (AUTL)",116429490,,REGN,TipRanks,Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (<a h...,https://finnhub.io/api/news?id=6c110aa24f2fe9bb778ff3cbb5651cf1fa405922d6dd68e7985f875120532346
company,2022-10-04 01:42:00,Regenxbio price target lowered to $29 from $47 at RBC Capital,116429491,https://thefly.com/images/meta/streetresearch_recommendations.jpg,REGN,Thefly.com,"RBC Capital analyst Luca ... RGNX, REGN",https://finnhub.io/api/news?id=68a9af2113039b91043fc50f6748bca6a43c96f844791a0b1c81ef5fd0766b48
company,2022-10-03 17:12:16,"ARKG: Too Hard To Pin Down, Too Volatile For Comfort",116406377,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/181898348/image_181898348.jpg?io=getty-c-w750,REGN,SeekingAlpha,"ARKG's objective is compelling and inoffensive, but their current approach to realizing it feels too vague and scattershot. Click here to read more.",https://finnhub.io/api/news?id=e08b9d23664aeefb061aad387c2e81fd836a1aa1b454b45973502a869837816e
company,2022-10-03 13:33:32,Regeneron Pharmaceuticals : Management Change/Compensation - Form 8-K,116403905,,REGN,Finnhub,"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT ... | October 3, 2022",https://finnhub.io/api/news?id=d53f24431695f8809a118931375f1c6c16cd16e788f684022a6271af78785a2e
company,2022-10-03 11:40:00,"The 1-Minute Market Report October 2, 2022",116401656,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1334907481/image_1334907481.jpg?io=getty-c-w750,REGN,SeekingAlpha,"Asian markets continue to struggle this year, thanks in large part to the weak China market. The only asset class showing positive performance is volatility.",https://finnhub.io/api/news?id=8085a2416292eaabac197502eca434cfbd0652d9a3354d4bfe35f22f49be8612
company,2022-10-03 07:40:00,Goldman Sachs Sticks to Their Buy Rating for Regeneron (REGN),116429492,,REGN,TipRanks,Goldman Sachs analyst Salveen Richter maintained a Buy rating on Regeneron (REGN &#8211; Research Report) today and set a price target of $970.00. The company&#8217...,https://finnhub.io/api/news?id=8c3c25721bbd1f95d2680eafc6fbf285ef5dd7cea13f5323919b45150f8c9440
company,2022-10-03 07:00:00,Regeneron Elects Dr. Craig B. Thompson to Board of Directors,116405016,https://s.yimg.com/uu/api/res/1.2/RZEm_ygiTT.n_nNjYLjcLQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/3084031f2be90e6b44c8127f50f71ad3,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Craig B. Thompson, M.D., has been elected to the Board of Directors, effective immediately. Dr. Thompson has also been appointed to serve on the Technology Committee of the Regeneron Board. Dr. Thompson is a renowned healthcare business leader with exceptional senior executive experience and scientific expertise in multiple therapeutic areas, including oncology. Regeneron's Board of Directors has been expanded from 12 to 13 memb",https://finnhub.io/api/news?id=58f84d3c346148565772b4583d9e4665beb5b86804fa934a31fe423419fd7df4
company,2022-10-03 05:18:17,REGENERON - AFLIBERCEPT 8 MG POSITIVE PIVOTAL RESULTS IN DIABETIC MACULAR EDEMA AND WET AGE-RELATED MACULAR DEGENERATION PRESENTED AT AAO,116397462,,REGN,Finnhub,"TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept 8 mg with 12-and 16-week... | October 3, 2022",https://finnhub.io/api/news?id=8444791ee98d7ae37f159a3d877d9628708797f3da6534377684a274eb45befd
company,2022-10-03 03:26:06,"REGENERON PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)",116393285,,REGN,Finnhub,"Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.On October... | October 3, 2022",https://finnhub.io/api/news?id=81af77331b87cdaabb84b92c82ffd1768608d7be705a9ea5aa5a19686dc64c21
company,2022-10-03 03:09:00,GLOBAL BROKER RATINGS: Goldman Sachs cuts Citi but lifts Wells Fargo,116400192,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=61148e3d12853bdf0454aec8491ac4fb5a386f5e800b289f46a54ef919896689
company,2022-10-03 00:36:00,Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio ,116429088,https://cdn.pixabay.com/photo/2018/07/15/10/44/dna-3539309_960_720.jpg,REGN,TalkMarkets,Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.,https://finnhub.io/api/news?id=e586d7b067baa4caedf4f0bf0873b3145abd9657570bee9335d39e0401f9311e
company,2022-10-10 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,116593286,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.18% to $730.92 Monday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=4e2d2602c6091be62a603187afe1a6831905141e5d11f38b51ea97103c380566
company,2022-10-10 01:20:00,7 Biotech Stocks Set to Boom in 2023,116574701,https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063.png,REGN,InvestorPlace,This article looks at seven biotech stocks that look like good options to move significantly higher in 2023,https://finnhub.io/api/news?id=4058fe2d03c000dcbefa38211357ac3e738f205fae0e796f38aaf2d8855c3126
company,2022-10-09 09:01:08,"Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Recent Stock Performance Tethered To Its Strong Fundamentals?",116601500,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,Most readers would already be aware that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased significantly by 16...,https://finnhub.io/api/news?id=3e88f0ef844c214c1e5d63e96f7e3e2ee8f392a61a6f9b19180ac15dd73c7aa2
company,2022-10-07 13:57:55,10 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital,116533537,https://s.yimg.com/uu/api/res/1.2/5iMGcPKO4skbZ8ye0.xPlQ--~B/aD0yNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/92d702cb1939a07ee3904ea9dae314aa,REGN,Yahoo,"In this article, we will take a look at some of the notable pharma stocks to buy according to Steven Boyd’s Armistice Capital. To skip our analysis of Steven Boyd’s profile, investment strategy, and 13F holdings, you can go directly to see the 5 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital. […]",https://finnhub.io/api/news?id=2ff637e8c840ba5fee4d1c499e590031dff1d7c96a61200ba217db7477c1a9d5
company,2022-10-07 13:19:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,116593288,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.30% to $722.37 Friday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=1179c376595f6d85445fabc44e9576f71f4db6d4835803f59f3042db3310ebcf
company,2022-10-06 22:45:00,Buy Illumina Stock. The Biotech Is Lowering the Cost of Gene Sequencing.,116572794,https://images.barrons.com/im-636971/social,REGN,MarketWatch,Illumina CEO Francis deSouza told analysts that the company can cut sequencing’s cost without crimping its 60%-plus gross margins.,https://finnhub.io/api/news?id=e0934c02afc3a395f4c174cf513e53e6c5f10b146164bad133254ae9bf93a37f
company,2022-10-14 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Friday, still outperforms market",116727416,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 2.19% to $736.06 Friday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=78dbe8039f09e71619461a16be2717f1d190084f3416465736d17c85d163aad3
company,2022-10-14 07:04:00,Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer,116636041,https://s.yimg.com/uu/api/res/1.2/hMg5xEA0u7TIaeu.oqSuCA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/7edd283edfde1b98273eaf1cad4332c2,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo® (cemiplimab) as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The European Commission is expected to make a final decision on the application in the coming months.",https://finnhub.io/api/news?id=116a556cc661a108180b9e6523dd708c7b9ae42dcb373e3bb99aed769b2ab391
company,2022-10-14 06:41:00,Why Cash-Rich Companies And #ETFs Are Beating The Market?,116665536,https://talkmarkets.com/contributor/mirjana-mishevska/user_content/ckimages/orig_etfs.jpg,REGN,TalkMarkets,"Investors believe that “cash is king” in the current environment of surging inflation, rising rates, and a potential economic downturn. ETFs that hold cash-rich companies have seen a lot of interest from investors lately.",https://finnhub.io/api/news?id=4880d597dff16d9861b8c95b928523c9800ed87159d8ea7f2e4c1c98422aa982
company,2022-10-14 03:28:00,Regeneron Gets CHMP Backing for Libtayo for Advanced Cervical Cancer >REGN,116717512,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Regeneron Pharmaceuticals Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended...,https://finnhub.io/api/news?id=c130a8475f66d3440166f9df2d31a35b8c5e6b854def39311660ce466de803d3
company,2022-10-14 02:12:00,Regeneron announces positive CHMP opinion for for Libtayo,116640460,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,Regeneron announced the E... REGN,https://finnhub.io/api/news?id=b8058571ecc2f1b1dc854c9d0407ed79a66a581817c292b4393ee0282b6e229d
company,2022-10-13 13:20:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market",116727418,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 3.37% to $752.56 Thursday, on what proved to be an all-around great trading session for the stock market,...",https://finnhub.io/api/news?id=89b95bb6cf2142b88a0a3d066326fd4eefaf8543780bb5d69a15c356dcd41e0a
company,2022-10-13 12:56:04,Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review,116627114,https://s.yimg.com/uu/api/res/1.2/c23rHSrGLTeyi6ecjtGakg--~B/aD0zNDY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/88c5b382e5e9e4ea852e01bfc1435a7b,REGN,Yahoo,"The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.",https://finnhub.io/api/news?id=3f599a947fdf9d9ee3680415f2ad0bfc95fec3ba8abaddbd58e4008fe30487b9
company,2022-10-13 10:00:22,"Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?",116622891,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 22% over the past three months. Given that the...,https://finnhub.io/api/news?id=ffd0f29910deb8dce9caab04888d225dfca8fff7d172795ad65caf79c89ea324
company,2022-10-13 06:30:00,3 Red-Hot Stocks That Could Continue to Beat the Market,116622892,https://s.yimg.com/ny/api/res/1.2/AA7oL3R4sqV6h3DlX1dnLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/f0a5cd166bee5505afaa514b7d8c6018,REGN,Yahoo,"Investors often favor that industry during tough times because its earnings are less at risk -- patients can't do without the products these companies sell.  Shares of Axsome Therapeutics (NASDAQ: AXSM), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX) have actually been climbing this year, and it doesn't look as if those trends will end any time soon.  Axsome Therapeutics attracted investors' attention as it moved closer to product commercialization.",https://finnhub.io/api/news?id=6b4b4e3f12830d211c8c49bb6be0de5656c608bbe39aa2a4b67a6054d9663531
company,2022-10-12 13:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors,116727419,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.27% to $728.06 Wednesday, on what proved to be an all-around grim trading session for the stock market,...",https://finnhub.io/api/news?id=86a76c639a28d7cdc5ca63bb6c4474a2d073e3ae95f28a5382ccb194abd774b8
company,2022-10-12 07:00:00,EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review,116604164,https://s.yimg.com/uu/api/res/1.2/mml6zZiTWEYIJkPsXTPpcg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/8580229d101de30c204a5ed8ae21ee56,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. The target action date for the FDA decision is February 11, 2023.",https://finnhub.io/api/news?id=732597eb599ae29ea792245148ba38ae0572d36ab0bea14a14ce7abdd1dcf76f
company,2022-10-12 03:15:00,Regeneron Gets FDA Priority Review of Eylea in Retinopathy of Prematurity >REGN,116727420,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration granted priority review to its application seeking...,https://finnhub.io/api/news?id=8c23d4b545f8658c320a35f9d85113518d8281746b04cf7f871bb6d54762b21d
company,2022-10-12 02:58:00,Regeneron announces U.S. FDA accepted for priority review the sBLA for EYLEA,116608583,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,"Regeneron Pharmaceuticals... REGN, BAYRY",https://finnhub.io/api/news?id=0e5c358d9b885bf091294f9ba7de72016ca9e2970ef1bcaf3b0e32a15d6da4ba
company,2022-10-11 13:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains,116593285,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.89% higher to $737.41 Tuesday, on what proved to be an all-around mixed trading session for the stock...",https://finnhub.io/api/news?id=f6b411c936d0d53927143e9db5fb50e8ae82d4ded4846b95e0725578ddd1bfbf
company,2022-10-11 07:43:48,Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product,116596341,https://s.yimg.com/uu/api/res/1.2/swWfmUeENUUKi.uV31yEEA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/beb02c905889a9068e7c4004a32590d3,REGN,Yahoo,"Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) presented more positive data for their Dupixent product. The companies said new Dupixent data showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly. In May 2022, FDA approved Dupixent 300 mg weekly for EoE in people aged 12 years and older, weighing at l",https://finnhub.io/api/news?id=5da8ed63fabf091f11730d5440b2b89fd4a502646ae6f3bbf92356577f29abd1
company,2022-10-11 00:59:00,Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old,116583918,https://s.yimg.com/uu/api/res/1.2/rIuvKTbmgkDGbkMnksTRIQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/5369c54a82dc0ba5ce47ad53425a8607,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented late-breaking positive results from a Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) in children aged 1 to 11 years with active eosinophilic esophagitis (EoE). The data will be shared at United European Gastroenterology (UEG) Week 2022 and submitted to regulatory authorities around the world, starting with the U.S. Food and Drug Administration (FDA) next year. In May 2022, Dupixent 300 mg weekly",https://finnhub.io/api/news?id=205cf0890a363cf5fbead254c0539c2be489802dca1169a0e0688f952f8f7627
company,2022-10-11 00:30:00,"Regeneron, Sanofi present late-breaking results from Dupixent trial",116586546,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,"Regeneron (REGN) and Sano... REGN, SNY",https://finnhub.io/api/news?id=70461e95344a470732284dcc17cb3175d3c147f0865f4c324c3fe2309fcf8f9a
company,2022-10-18 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market",116727413,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.80% to $722.71 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=b069d1f9ed37fb9104e2200fb45c49fa7788008f520100a0d2fd018ceb74d477
company,2022-10-18 09:53:00,2 Biotech Stocks You Can Buy and Hold for the Next Decade,116699139,,REGN,Yahoo,"Regulators in the U.S. restricted the use of REGEN-COV because they deemed it unlikely to work against what has now become the most widespread variant in the country, omicron.  The company's two key assets, Eylea and Dupixent, continue to perform well; Regeneron shares the rights to these products with Bayer and Sanofi, respectively.  It's worth noting that Eylea's patents start expiring next year, meaning Regeneron could face generic competition soon.",https://finnhub.io/api/news?id=b0cd574b3b417293c84613028adb617357e9bb33723f5ebd3cb0db03fd6feca1
company,2022-10-18 06:08:00,H.C. Wainwright says 'Decibel could certainly be acquired as well' after Akouos,116720297,https://thefly.com/images/meta/streetresearch_recommendations.jpg,REGN,Thefly.com,"After Akouos (AKUS) annou... DBTX, AKUS, LLY, REGN",https://finnhub.io/api/news?id=1b4f91dce205e8e5947a33f497b0eeb1e90f21d84f0cd732e7ba77f26548900d
company,2022-10-17 21:20:00,"Noteworthy Tuesday Option Activity: REGN, DOW, TSCO",116720298,,REGN,Stock Options Channel,"Staff article entitled Noteworthy Tuesday Option Activity: REGN, DOW, TSCO, about stock options, from Stock Options Channel.",https://finnhub.io/api/news?id=dc07851e7ea26dd63c0c96a91649af7a0775cdc213cb6050f282eba48775835d
company,2022-10-17 18:15:10,Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know,116689588,https://s.yimg.com/uu/api/res/1.2/I67vygGrP1BjgOjVx.apeA--~B/aD03Mjg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a,REGN,Yahoo,"Regeneron (REGN) closed the most recent trading day at $735.96, moving -0.01% from the previous trading session.",https://finnhub.io/api/news?id=5613974b6ca8cc020bf35a3574d003f3b7ba0dbcbb3859915b5368099b83e26f
company,2022-10-17 14:22:00,Biotech Investors Need Patience (And a Strong Stomach),116689589,https://s.yimg.com/ny/api/res/1.2/AZw5oBdg0siWRM6st_aKAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/35aef647a138b8995eadcadc6ce0ddb1,REGN,Yahoo,"The sector has been tricky for investors. Regeneron Pharmaceuticals is an example, getting a downgrade to In Line from Outperform from Evercore ISI.",https://finnhub.io/api/news?id=1c7ad3c0c12a2ca39d56c8e0d77c524323f56e2c7cccd7ebe52c72cace90c97c
company,2022-10-17 13:36:05,Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer,116689590,https://s.yimg.com/uu/api/res/1.2/obPyvmV.XkzkKLrDxW_bcA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5bd570f285e4b6d4e9b1a8c6dc8600e6,REGN,Yahoo,Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.,https://finnhub.io/api/news?id=b2e5859bee60c03deed24e036a0a54f8d1d88edf7773482eb48315691eb97dc6
company,2022-10-17 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market",116727414,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. dropped 0.01% to $735.96 Monday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=4f9890dfe919b837311a3163d692f38002aa42f0041169f42fdd453e23ac412e
company,2022-10-17 10:00:18,"An Intrinsic Calculation For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Suggests It's 37% Undervalued",116689591,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Today we will run through one way of estimating the intrinsic value of Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN...",https://finnhub.io/api/news?id=0f7c8b3df087750553d113cd67aca1267fbfbf41991bd88ba13336a0203039a3
company,2022-10-17 07:04:00,What You Missed On Wall Street This Morning,116701000,https://image.thefly.com/catalog/201904/img_457.jpg,REGN,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. NWSA, FOXA, BAC, BP, LFG, CLR, SPLK, OPEN, NET, CLX, CHD, REGN, FRPT, PG, TSLA, TWTR, AAPL, CANO, CVS, GOEV, RBLX, APPS, NGM, KR, SCHW, TPB, BK, GNTY, ECOR, NWS, FOX",https://finnhub.io/api/news?id=6f297950eda346075a146f5405de4f6b22aadd87a2f931b65d72645ad7c7e491
company,2022-10-17 05:32:00,"Video: Nasdaq 100 Movers: REGN, MELI",116720300,,REGN,Market News Video,"In early trading on Monday, shares of MercadoLibre topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.2% - Year to date, MercadoLibre has lost about 38.7% of its value - REGN,MELI,AMGN,PDD.",https://finnhub.io/api/news?id=b99c726b10b579e4f2ce42fbd9819bfed509cfb4af904708c0d2151b7d17f1ed
company,2022-10-17 05:03:00,"Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations",116700286,https://image.thefly.com/catalog/201811/img_112.jpg,REGN,Thefly.com,"Cloudflare upgrade, Regeneron downgrade and Salesforce initiation among today's top calls on Wall Street NET, CLX, CHD, PLD, FRC, FCFS, REGN, FOXA, ACI, XPO, OPEN, CRM, LTHM, NOVA, SPWR, PPG",https://finnhub.io/api/news?id=1068343073a0e2347d9083809bb6346bceb55fdf0c505d803dbadb4a8e067b73
company,2022-10-17 04:00:00,Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron,116683829,,REGN,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3c7c0814747f266ade998700f75d70fd70fbb31d8fe03bf254e6a4cd3cac1444
company,2022-10-17 03:20:00,Regeneron downgraded to In Line at Evercore ISI with stock near $760 target,116683830,https://thefly.com/images/meta/streetresearch_downgrade.jpg,REGN,Thefly.com,"As previously reported, E... REGN",https://finnhub.io/api/news?id=0b91c4f1f20fb60dba542b914c9434064bf46b8b34407f1a3741dc15ce477634
company,2022-10-17 02:25:00,Regeneron downgraded to In Line from Outperform at Evercore ISI,116683831,https://thefly.com/images/meta/streetresearch_downgrade.jpg,REGN,Thefly.com,Evercore ISI analyst Josh... REGN,https://finnhub.io/api/news?id=5325ef092e8a92be63e9742aa2417e824747253fdf6ed22b0670705329853643
company,2022-10-17 02:16:00,Decibel Therapeutics receives FDA clearance of IND for DB-OTO,116683832,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,"Decibel Therapeutics (DBT... DBTX, REGN",https://finnhub.io/api/news?id=da2be7ecf4e57c2508a5414c609c16a0b44ac87caa7caf5a984ac02bb5bbb7ff
company,2022-10-16 23:35:00,What You Missed On Wall Street On Monday,116716126,https://image.thefly.com/catalog/201810/img_66.png,REGN,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. NWS, NWSA, FOX, FOXA, BAC, BP, LFG, CLR, SPLK, OPEN, NET, CLX, CHD, REGN, TSLA, TWTR, AAPL, CVS, CS, CANO, V, MA, GOEV, RBLX, APPS, NGM, KR, ACI, SCHW, TPB, BK, GNTY, ECOR",https://finnhub.io/api/news?id=afbb9f082e67bd3c1d4ab236f492554573ddc7f2ad284a1264c9897d58d8ae2a
company,2022-10-16 21:01:00,Top 5 3rd Quarter Trades of RO - GuruFocus.com,116718439,https://static.gurufocus.com/images/logo_global.png,REGN,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=0bb4210dfab3983424637e5d5895aae4b443a7be09b11cd046c6257af4834418
company,2022-10-21 09:00:32,"Are Strong Financial Prospects The Force That Is Driving The Momentum In Regeneron Pharmaceuticals, Inc.'s NASDAQ:REGN) Stock?",116776914,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 20...,https://finnhub.io/api/news?id=c038884025d5a42dfcb6349b69af6fbe10f233d30e22d09731117e44359ea71a
company,2022-10-21 07:00:00,Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection,116776915,https://s.yimg.com/uu/api/res/1.2/SNgyqn0a6RbX5hxrBZpB8A--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/ec1c35c728f5325179ac7c095acd19a6,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA® (aflibercept) Injection. This grant extends the period of U.S. market exclusivity for EYLEA by an additional six months through May 17, 2024.",https://finnhub.io/api/news?id=eeb7afdd8a0947bc826ee89d8982b60d2b89f54b369710a74ac264d333a11dde
company,2022-10-21 02:03:00,Regeneron granted pediatric exclusivity for EYLEA from FDA,116788411,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,Regeneron Pharmaceuticals... REGN,https://finnhub.io/api/news?id=e8d2d004f32211ac5040fb32e67b3854ded950b8ff55936fe0e7a0daf215c615
company,2022-10-20 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,116780008,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 0.49% to $705.89 Thursday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=b7efb58cca0d68388642c619cf11190c88426f64f8727fb2f5991e50f2df2895
company,2022-10-20 02:44:00,Regeneron price target raised to $750 from $655 at Cowen,116749775,https://thefly.com/images/meta/streetresearch_recommendations.jpg,REGN,Thefly.com,Cowen analyst Tyler Van B... REGN,https://finnhub.io/api/news?id=7e32d4c73d0f2a3dbfd3acd5ed7f2ff7c7c906b88aebdc06fb20fa63642ea880
company,2022-10-20 01:01:00,Top 5 3rd Quarter Trades of St - GuruFocus.com,116755416,https://static.gurufocus.com/images/logo_global.png,REGN,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=81917b52b7e05d7dd53ef3502d14173960bd228eeb5bae3f89ebb1338bad937a
company,2022-10-20 00:31:33,HQH: A Dividend Paymaster That Fails To Register Price Growth,116736568,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363842522/image_1363842522.jpg?io=getty-c-w750,REGN,SeekingAlpha,Tekla Healthcare Investors is able to generate steady yield and currently trades at a good discount to its NAV. Read more to see why HQH is a Buy.,https://finnhub.io/api/news?id=44e3ceaa6735a44d2ae48e01c7a49530361cf5019b93c83838fca7214c20dbc4
company,2022-10-19 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",116727412,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.85% to $709.37 Wednesday, on what proved to be an all-around poor trading session for the stock market,...",https://finnhub.io/api/news?id=e403f09787e7c156ebb453c1106813145bdcfb15fbad66ce42697577d1b6af24
company,2022-10-26 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",116884902,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.79% to $733.98 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=07ab881ac2a64c899de107826e4bdc473820057eceae2c339955c9b1dea79604
company,2022-10-25 19:59:00,Bronte Capital Amalthea Fund September 2022 Fund Letter,116832400,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347345879/image_1347345879.jpg?io=getty-c-w750,REGN,SeekingAlpha,Bronte Capital Amalthea Fund gained 6.68% for September and lost 0.32% across the quarter. Click here to read the full fund letter.,https://finnhub.io/api/news?id=492d71f1d07b0da4c01c1fdf0363b712d27d2f8dee0157a7ff386ab848f6bd01
company,2022-10-25 18:15:10,Regeneron (REGN) Gains But Lags Market: What You Should Know,116829960,https://s.yimg.com/uu/api/res/1.2/w.ILboV799eZj6zbyZJ3SQ--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0,REGN,Yahoo,"In the latest trading session, Regeneron (REGN) closed at $747.33, marking a +1.38% move from the previous day.",https://finnhub.io/api/news?id=753f1be910a08aecde974ef6ab7a253a4a95a9609c7bcdd9fa2f441f56fee176
company,2022-10-25 13:20:00,"Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",116828510,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 1.38% to $747.33 Tuesday, on what proved to be an all-around great trading session for the stock market, with...",https://finnhub.io/api/news?id=7e591c64c867320992fdee2883682feb65a0d527e650c8d7884e7b7b4c38b589
company,2022-10-25 09:00:43,"Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$16m worth of stock",116827255,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the...",https://finnhub.io/api/news?id=ccded5efa6953a1e174e117bf919aa981040c78587649691ce21acb12e6e4e85
company,2022-10-25 05:01:00,Top 5 3rd Quarter Trades of DO - GuruFocus.com,116818769,https://static.gurufocus.com/images/logo_global.png,REGN,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=a3b7e2216b920fb8d663b7e67e9a129df9ab3c7daec26f69b4a9ccac30a14f0d
company,2022-10-24 13:21:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,116828511,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 3.26% to $737.15 Monday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=74feacb35a5a33ff2975856f7cf1466873c84492f0019c74aadd755923a673fe
company,2022-10-23 19:28:43,Is it a Good Decision to Add Regeneron Pharmaceuticals (REGN) to Your Portfolio?,116804496,https://s.yimg.com/uu/api/res/1.2/Jl4fWeoF8ihTJrwNHo8_Yg--~B/aD02MDA7dz02NzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c7f1e5e050318cd4f160ccc3086917fd,REGN,Yahoo,"Investment management company RGA Investment Advisors recently released its third-quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the market continued the declining trend from the first half of 2022, and September was the worst month for the fund. But the firm believes this is a good time […]",https://finnhub.io/api/news?id=0fe71f7285ec35f74f3f3944a255d7f04001ff6a99746a3bd9e94ad94d2178b0
company,2022-10-23 07:45:00,RGA Investment Advisors Q3 2022 Investment Commentary,116794839,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397687090/image_1397687090.jpg?io=getty-c-w750,REGN,SeekingAlpha,"For RGA Investment Advisors, the third quarter saw a continuation of the ugly trend from the first half of the year. Click here to read the full fund letter.",https://finnhub.io/api/news?id=a0f37b8d8eb7e1270c4dab59bd801ec8082ff70aa03bc5e752a6bce9573e437b
company,2022-10-23 04:39:54,Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV,116794447,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397335462/image_1397335462.jpg?io=getty-c-w750,REGN,SeekingAlpha,Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV. Read why investors are getting HQL at an attractive valuation.,https://finnhub.io/api/news?id=39f2b2da6ea132f39340c41a4d82c407e545c5a52652e5ce189b8614ec2d043a
company,2022-10-29 09:00:47,"Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?",116863816,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 29% over the past three months. Given the...,https://finnhub.io/api/news?id=6117ec75977e62c54619b35657d54c146525e04b97bb545718bc165a646a148d
company,2022-10-28 13:19:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,116884900,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 3.57% to $750.76 Friday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=16535ab771a40e2d4eaf50c16d84497f491a7fad42414e569cb580083157b8e5
company,2022-10-28 12:51:04,"Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push Sales",116863817,https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966,REGN,Yahoo,Sanofi (SNY) beats third-quarter estimates for earnings and sales. Dupixent and flu vaccines drive sales growth. The company raises its earnings growth guidance for 2022.,https://finnhub.io/api/news?id=02d386ccc277083258042fe18e6978bd4b3728f4117992147c50f8eaf2dba52e
company,2022-10-28 09:58:41,"Final Trades: Boeing, Amazon, Regeneron & more",116862263,https://image.cnbcfm.com/api/v1/image/107142670-16669783296ED5-FMHR-102822-FINAL.jpg?v=1666979921&w=1920&h=1080,REGN,CNBC,"The ""Halftime Report"" traders give their top picks to watch for the second half.",https://finnhub.io/api/news?id=9a80ef69e38e9c434a777fcc9fdc18546b42412db97fece9188469c7557abeb4
company,2022-10-28 08:00:00,"Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award",116863818,https://media.zenfs.com/en/prnewswire.com/fdb13bd70e25ddbd04bad0d8389da2f3,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) has been recognized as the ""Best Biotechnology Product"" of 2022 by the Galien Foundation, which acknowledges extraordinary scientific innovations that improve the human condition. The Prix Galien USA Award was presented in a ceremony in New York City last night.",https://finnhub.io/api/news?id=73616bdaf4e97d6a6ee8fb24bc4fcacd1b9d3b142f77b634bf969e925174cffa
company,2022-10-28 02:12:58,"UPDATE 2-Sanofi sees faster profit growth on Dupixent, flu vaccine demand",116863819,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"French drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price.  Sanofi said it now expects 2022 adjusted earnings per share to grow by about 16%, not taking into account an expected positive currency impact of between 9.5% and 10.5%.  It also reported a 26.5% rise in third-quarter business operating income, or adjusted earnings before interest and tax, to 4.5 billion euros ($4.5 billion), well ahead of an average analyst estimate of 4.17 billion.",https://finnhub.io/api/news?id=42bea00bc376c1eebff57abfc1a716b7b2acd0f9881c6ec0413368f197a7bf2f
company,2022-10-27 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market",116884901,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.24% to $724.88 Thursday, on what proved to be an all-around mixed trading session for the stock market,...",https://finnhub.io/api/news?id=fa63a8e2813e09a8403161548e2be46445ea2ad1c7ff4c78682af8467c121750
company,2022-10-27 13:01:18,Is Regeneron Pharmaceuticals (REGN) an Attractive Long-Term Stock?,116863820,https://media.zenfs.com/en/insidermonkey.com/ed00a52ede51cc58de1413ff82641b81,REGN,Yahoo,"Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2022 investor letter. A copy of the same can be downloaded here. The fund lost 0.32% in the third quarter compared to a 0.17% gain for the MSCI ACWI (in $A). For September, the fund gained 6.68% compared to a 3.58% loss for the MSCI […]",https://finnhub.io/api/news?id=f9601f597fb72234fbbddb8d557020e42d80aabb36ea6865c08c78741c48ce68
company,2022-10-27 12:10:04,Why Regeneron (REGN) Could Beat Earnings Estimates Again,116863821,https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0,REGN,Yahoo,Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://finnhub.io/api/news?id=44eef9cb24bb59bd5cbba2967dace2a5276ffaed5ffa1c3f50401101f1d6ddde
company,2022-10-27 10:02:02,Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?,116863822,https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4,REGN,Yahoo,Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=457cdd08ba73a67bb4b016abd257aea0bd7a99f36113e2835fc81f8eea8d2891
company,2022-10-27 06:56:00,Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a 'Blue Wave',116847015,https://investorplace.com/wp-content/uploads/2022/10/bluewave1600.png,REGN,InvestorPlace,"If you see a blue wave coming get out of the oilpatch, crypto, and pharmaceuticals that are subject to price regulation.",https://finnhub.io/api/news?id=c97a02e4ff1a13cdca4d679ee1c64812f07917fe6de0c41d67c10f005364e1f4
company,2022-11-03 17:02:06,Regeneron Sinks Despite Massive Earnings Beat On A Notable Blockbuster Miss,116953463,https://media.zenfs.com/en/ibd.com/b727993c80cd23c03b1f42c9321ae4f1,REGN,Yahoo,"Regeneron Pharma topped third-quarter expectations Thursday, reporting less of a decline than expected. But REGN stock was down early.",https://finnhub.io/api/news?id=169ccb11962e3dacf720e9b9c745dae7d2686f2ce1ee893560f10c3dccc0c28e
company,2022-11-03 16:05:00,Regeneron Announces Investor Conference Presentations,116953464,https://media.zenfs.com/en/prnewswire.com/c03bb06f487fbc7ab39c67e8f925377b,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:",https://finnhub.io/api/news?id=1a57478a76ae0cce2740aad0f52b44b25b3fa858e95c688fd700c9d7768be6ff
company,2022-11-03 13:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,116971925,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. dropped 0.24% to $738.68 Thursday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=d83a42e90661ca68a294011885c7b7f00684c91c27650611de582eea5179a3a6
company,2022-11-03 12:03:14,"Stock Market Extends Losses Despite Easing Labor Costs; Qualcomm, Roku At New Lows",116936211,https://media.zenfs.com/en/ibd.com/34c941d3bdc8940e40b5b4d42f1a2bf3,REGN,Yahoo,The stock market fell Thursday despite weaker-than-expected labor costs. Qualcomm and Roku dragged stocks lower.,https://finnhub.io/api/news?id=99563ebf4fdebf5564bcfca2c55d5825f982296cba81364a6e716f84be7d0a4a
company,2022-11-03 11:43:03,"Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent",116947281,https://media.zenfs.com/en/zacks.com/6f2cab89bf2cbad1966358e04258e202,REGN,Yahoo,"Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.",https://finnhub.io/api/news?id=5f5300b4630e5ad682966ee01518d571e3f3cc0cd9d83c976acb717a7cbbd334
company,2022-11-03 09:00:00,Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders,116953467,https://media.zenfs.com/en/prnewswire.com/88d893572d7f8096bedf64b865d5e8ba,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new data across its hematology pipeline will be highlighted in 17 presentations at the 2022 American Society of Hematology (ASH) Annual Meeting from December 10-13 in New Orleans, LA.",https://finnhub.io/api/news?id=8923901d753fcebcf7e52c4f7011ae515571abbc606cf4cef58f19664391e1a1
company,2022-11-03 08:07:07,"Regeneron Pharmaceuticals, Inc. (REGN) Q3 2022 Earnings Call Transcript",116935047,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (AAPL) Q3 2022 Earnings Conference Call November 3, 2022 8:30 a.m.",https://finnhub.io/api/news?id=8f9c3c6367debd8f2e8c9829b3ed2bc13a58f3fd67c350e21490e4591b83ff59
company,2022-11-03 08:05:12,Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates,116953468,https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94,REGN,Yahoo,"Regeneron (REGN) delivered earnings and revenue surprises of 14.85% and 5.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=001b35b78d317f56b26ec7ce4f1e74dd51da6abab8135ec05de63d28cd487c3e
company,2022-11-03 07:15:00,Regeneron's revenue falls on decline of Covid-19 product sales,116956932,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=46c621410a565674c7242562ccbcf71b0ac0cfe4e61425bf68c8fe5fb68d4e5e
company,2022-11-03 06:51:10,Regeneron Pharmaceuticals Q3 tops earnings and revenue marks,116931111,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,REGN,Yahoo,"Regeneron Pharmaceuticals Inc. said Thursday its third-quarter net income fell 19% to $1.32 billion or $11.66 a share, from $1.63 billion or $14.33 a share, in the year-ago period. Adjusted net income fell to $11.14 a share from $15.37 a share. Revenue at the Tarrytown, N.Y., drug maker dropped 15% to $2.94 billion from $3.45 billion. Wall Street analysts expected Regeneron to earn $9.76 a share on revenue of $2.92 billion, according to a survey by FactSet. Regeneron CFO Robert Landry said the t",https://finnhub.io/api/news?id=fb4b5cf740309f14b007b7a526c8b070dffdd241d179bce54cbd20aab3ac3c1a
company,2022-11-03 06:30:00,Regeneron Reports Third Quarter 2022 Financial and Operating Results,116931112,https://media.zenfs.com/en/prnewswire.com/3e51823aaf4059fa66db62e50b2990a8,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2022 and provided a business update. The full press release can be accessed on Regeneron's media and investor relations website (http://newsroom.regeneron.com).",https://finnhub.io/api/news?id=e3e364543c660c14d071ec397fe8ef250590478eedaf81addf8c8a8d6151ec59
company,2022-11-03 02:56:00,Regeneron: Q3 Earnings Snapshot,116956936,,REGN,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9ec9254c6263ff525bd74f57432ed53416e68614064a35a33653de5109fa7363
company,2022-11-03 01:47:00,"Regeneron reports Q3 EPS $11.14, consensus $9.48",116956940,https://thefly.com/images/meta/earnings.jpg,REGN,Thefly.com,Reports Q3 revenue $2.94B... REGN,https://finnhub.io/api/news?id=e7f61c33bd13c9a5f40f41a34c240811c25d300992b2df84fbe7e14162b5d13b
company,2022-11-02 23:23:00,Regeneron price target lowered to $765 from $775 at Piper Sandler,116956941,https://thefly.com/images/meta/streetresearch_recommendations.jpg,REGN,Thefly.com,Piper Sandler analyst Chr... REGN,https://finnhub.io/api/news?id=8c739d25f7392e928ee1cf11f2f404b2dab541042bc238ed8d7dd060dd5f1342
company,2022-11-02 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",116919345,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 2.56% to $740.48 Wednesday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=31683bf92e80454209079147c5fa629f075796a695736e577e6fbe215e5f7e79
company,2022-11-02 09:25:01,"Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More",116911369,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,REGN,Yahoo,"Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.",https://finnhub.io/api/news?id=f948929d16fd04d050ab5a3be8f5cd404dd81883dbecc6afc1f1a9f184469b32
company,2022-11-02 09:00:27,"Are Investors Undervaluing Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) By 29%?",116931114,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Does the November share price for Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) reflect what it's really worth...",https://finnhub.io/api/news?id=c570875089ca8e58b7bcaa7c29da214773f96635d27baa756dcceb877ad59ac5
company,2022-11-02 04:06:00,AbCellera announces Regeneron exercises right to advance antibody candidate,116919715,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,"AbCellera (ABCL) announce... ABCL, REGN",https://finnhub.io/api/news?id=a70259d2edda924b84470949834bdb534a0af77a3638cfdfbd62cfa565aa0ffe
company,2022-11-02 03:25:00,Notable companies reporting before tomorrow's open,116921097,https://thefly.com/images/meta/earnings.jpg,REGN,Thefly.com,"Notable companies reporti... COP, CI, REGN, ZTS, MRNA, MAR, FIS, DDOG, K, RCL, PENN, TPX, W, UAA, UA, PTON, COMM, PZZA, SPR, NKLA",https://finnhub.io/api/news?id=ed3c6a447568a45075bf290b85c09767f484505668e60bf8384148033958a2c9
company,2022-11-02 01:01:00,Top 5 3rd Quarter Trades of SE - GuruFocus.com,116919521,https://static.gurufocus.com/images/logo_global.png,REGN,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=999a1b2ebe79d94d1f3a8829d5a0c1acd7fa1e198d4e19fd0c7af1bb06cbbe82
company,2022-11-02 00:01:00,"Tyra Biosciences CFO Esther van den Boom to step down, Alan Fuhrman to succeed",116919717,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,"Tyra Biosciences (TYRA) a... TYRA, REGN",https://finnhub.io/api/news?id=3fdcbc6f175ec04911b8df422475abd4c7e406c8b19e44a74c1b86e015cd1858
company,2022-11-01 13:20:00,"Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market",116919346,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.49% to $759.91 Tuesday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=ed0b125769a1bbef01321a04ff6e1c8192ffb826fa21a62c9eaf0edd6496ffdf
company,2022-11-01 05:02:55,JPMorgan Chase hires OrbiMed Advisors executive for new life sciences venture capital unit,116884898,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,REGN,MarketWatch,JPMorgan Chase & Co. undefined said Tuesday its J.P. Morgan Asset Management unit is launching a new private capital team aimed at investments in life...,https://finnhub.io/api/news?id=cff7544004f7a11e9679d0bcf88859442ab3cea4d7ca998d122863d7651c5052
company,2022-10-31 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,116884899,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.27% to $748.75 Monday, on what proved to be an all-around poor trading session for the stock market, with the...",https://finnhub.io/api/news?id=a7a20f1d756a07e6bd4e9623346a928f54105571929759e060f2e11db90a6dcf
company,2022-10-31 11:49:03,Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?,116876566,https://media.zenfs.com/en/zacks.com/f54f709ae65e32f6086a21eeef8d44f3,REGN,Yahoo,Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.,https://finnhub.io/api/news?id=2b7a3321a0a29b700984c007c32d871c79b81ef214389cd584615566141df579
company,2022-10-31 10:51:27,Biogen: Super-Strong Momentum In A Defensive Sector,116872770,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/164478117/image_164478117.jpg?io=getty-c-w750,REGN,SeekingAlpha,"Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. See why I would reenter a position in BIIB stock.",https://finnhub.io/api/news?id=02cc49fce4d5cfc67af2c78349a703259b473657c3c0dfc24fa85d4c927866f4
company,2022-11-07 12:20:00,"Regeneron Pharmaceuticals Inc. stock rises Monday, outperforms market",117023845,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 1.45% to $750.93 Monday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=7db132224abe316ec71976b072e982686ecbfeb5961b8ca74a54fcc0f035298e
company,2022-11-06 08:00:29,"Subdued Growth No Barrier To Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price",116969006,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of...",https://finnhub.io/api/news?id=aea7c6227db4d488608235f05deedfc61df8a435ca547080d50e13c64877c9bd
company,2022-11-04 19:30:00,Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration,116969008,https://media.zenfs.com/en/prnewswire.com/78a70b6c88609bcfc520080c48eb78a8,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced late-breaking presentations of updated results from two positive pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® (aflibercept) Injection, in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The positive data from PHOTON and PULSAR were presented at the 55th Annual Scientific Session of The Retina Society in Pasadena, California.",https://finnhub.io/api/news?id=b2b7c04b7ac8fecf1e969c8812fc6a3dacb4e2ae5419ebd22387b1ff509c9257
company,2022-11-04 18:03:50,10 Latest Earnings That Surprised Wall Street,116960548,https://media.zenfs.com/en/insidermonkey.com/682558d4d8619d4982268143dfb75bf7,REGN,Yahoo,"In this article, we will take a look at the 10 latest earnings that surprised Wall Street. If you want to see more such earnings reports on the list, go directly to 5 Latest Earnings That Surprised Wall Street. All three major U.S. indices struggled to find direction on Friday following the latest jobs data […]",https://finnhub.io/api/news?id=07c49a45f29082121cd37fe91fde3f0d98b67c704b82a146b67c3e215824ab9a
company,2022-11-04 15:05:33,Regeneron accelerates research spending as drug pipeline grows,116969011,https://s.yimg.com/ny/api/res/1.2/oP5raOBtI951.sTFe7ncNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTk-/https://media.zenfs.com/en/bizjournals.com/71edb8406f9a63fcdcb5345bdb9d9379,REGN,Yahoo,"""Our strategy continues to focus on investing in our internal [research and development] capabilities while exploring potential collaborations that will enable us to fully realize the power of our science,"" chief executive Len Schleifer told analysts.",https://finnhub.io/api/news?id=203fb8698ca5a468ba6094f18e3ab8cfc8b3a56bdebd3c65d3fd3bd88b589ce0
company,2022-11-04 14:22:18,7 Cash-Rich Stocks to Buy for Peace of Mind,116968625,https://media.zenfs.com/en/investorplace_417/49d59d6b2c0a054aae935125e02570ff,REGN,Yahoo,"Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes their way. However, when investing, it’s not enough to look for businesses with cash. They should also have limited debt and strong cash flow generation in good times and bad. So, who are these companies? For this article, I selected four large-cap and three mid-cap cash-rich stocks to buy. Cash-rich",https://finnhub.io/api/news?id=eb5d725b63169cd3ffa901ceddb2bbc6ba77109631bd01ceda156852bfa0bba8
company,2022-11-04 14:09:34,U.S. Supreme Court to hear Amgen bid to revive cholesterol drug patents,116957968,https://media.zenfs.com/en/reuters-finance.com/e8e92ef6d14b427778c4da66fcc7cc0c,REGN,Yahoo,WASHINGTON (Reuters) -The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents.,https://finnhub.io/api/news?id=4435589fa6b7a4243161dcc562341688afc9326a043e794a58432c07908a1db0
company,2022-11-04 14:08:56,UPDATE 3-U.S. Supreme Court to hear Amgen bid to revive cholesterol drug patents,116957969,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents.,https://finnhub.io/api/news?id=de12a8fbcef6876d57ce715841cdf404ce6d6b1696eca7ec4b34f70e9a7b8a09
company,2022-11-04 13:40:44,RPT-U.S. Supreme Court to hear Amgen bid to revive Repatha patents,116957970,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents.  Amgen and other drugmakers have called the case a test of their ability to earn and defend patents for important drugs.,https://finnhub.io/api/news?id=b28c80e7b8b0d980e742529145c7a4709f44b3840fad2d1a11a6838d82bd8672
company,2022-11-04 13:32:47,U.S. Supreme Court to hear Amgen bid to revive Repatha patents,116957971,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents.  Amgen and other drugmakers have called the case a test of their ability to earn and defend patents for important drugs.,https://finnhub.io/api/news?id=c69e88866eab6a9d267a74d378126cbe275ee6db851e7c0d667eccbf0436cc0b
company,2022-11-04 13:20:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market",116971924,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.21% higher to $740.21 Friday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=26462ae384997e11093e8c2ba127aeabf4d9646b5aaa54799dc711b202c9ddce
company,2022-11-04 12:18:04,"Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y",116956786,https://media.zenfs.com/en/zacks.com/181d5ab1675d8aae9c53428215552644,REGN,Yahoo,Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.,https://finnhub.io/api/news?id=d5da46c462d4c674c547bad5d997d7cb7bd9e6bc2906ea0678338c4062644fd5
company,2022-11-04 04:57:00,BMO Capital Sticks to Their Buy Rating for Regeneron (REGN),116956925,,REGN,TipRanks,"BMO Capital analyst Evan Seigerman maintained a Buy rating on Regeneron (REGN &#8211; Research Report) today and set a price target of $1,025.00. The company&#8217;...",https://finnhub.io/api/news?id=d8a67f135d1d43e45c30e2261d667d26a45427a71253a53800e27a8e04fb770b
company,2022-11-04 03:54:00,"Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Illumina (ILMN) and Regeneron (REGN)",116956927,,REGN,TipRanks,Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avadel Pharmaceuticals (<span class='tr-stock-ticker' style='color:blue; font-weig...,https://finnhub.io/api/news?id=8a8a4a529a778f8f36e5a8e83ba0c5ed78a27aaafe33cff389e07fdab1b29db5
company,2022-11-04 03:22:00,"Analysts Conflicted on These Healthcare Names: Humana (HUM), Myriad Genetics (MYGN) and Regeneron (REGN)",116956929,,REGN,TipRanks,Analysts have been eager to weigh in on the Healthcare sector with new ratings on Humana (<a href...,https://finnhub.io/api/news?id=bdc8d2dd4e03a5857be6ebf7e95db93224073bf387dc3bb1a578d25c655fd8e6
company,2022-11-11 12:19:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,117127657,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. dropped 0.89% to $734.45 Friday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=4752507538db540315bd9afbf7829fde8fa88ba69d187403460c8c570855947e
company,2022-11-11 10:26:00,"Regeneron, Sanofi, Bayer report positive opinions from EU regulators",117118629,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ff6d6f47e256b94f4d36afd38c67cd47e91643213c3492cc740d86f47f8545c3
company,2022-11-11 06:59:00,Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis,117108281,https://media.zenfs.com/en/prnewswire.com/0eceec4e319d8111680aa088c02921a5,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. In Septembe",https://finnhub.io/api/news?id=aee816b05b6b092e7a7bce63cb8e7f90d3893c8a480fbeb3f3e6276333738922
company,2022-11-11 02:26:00,"Regeneron, Sanofi Get CHMP Backing for Dupixent in Prurigo Nodularis >REGN SNY",117127658,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use...,https://finnhub.io/api/news?id=f5f1a6c1c98ea78ca6259cb1fc57ea2fc456ba1ea0a5841503d70722ce0990c3
company,2022-11-11 01:01:00,"Regeneron, Sanofi announce CHMP recommendation for Dupixent approval",117114392,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,"Regeneron (REGN) and Sano... REGN, SNY",https://finnhub.io/api/news?id=4da9124cc2e871a42a0def7567bf375be940e950f631c2861d5ceb60a85997a6
company,2022-11-10 22:55:00,Society for Immunotherapy of Cancer to hold a meeting,117112365,https://thefly.com/images/meta/converenceevents.jpg,REGN,Thefly.com,"37th Annual Meeting SITC ... ABMD, ADPT, ALKS, AMGN, ASND, BMY, CGEN, CLRB, CRL, INKT, INCY, PHIO, INBX, XNCR, VCYT, TXG, TPST, TMO, TIL, SGEN, REGN, REPL, RHHBY, DNA, CUE, IOVA, IPSC, LH, MRK, MXCT, EXEL, FATE, GMAB",https://finnhub.io/api/news?id=493c235846ace483ca40b45ea7a40effa78d1110ce947113b8ee980e9e5acf46
company,2022-11-10 12:19:00,"Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market",117127659,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.25% to $741.08 Thursday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=4bf2db9aa6e46898848d364a5bc67c504c0c2ed52c54d3f053e416250c221a2a
company,2022-11-09 12:35:05,"Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update",117031360,https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96,REGN,Yahoo,Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=1404a85bb43f55b571118ed66958ee73589eb2dba083397795c16a7a4570babd
company,2022-11-09 12:19:00,Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors,117127660,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 1.20% to $742.95 Wednesday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=5a3b04235ea4eb6c3265ea61d4817801a3000e1a1cce7ae4bbcedbeba4479f47
company,2022-11-09 10:43:03,Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion,117031362,https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2,REGN,Yahoo,"Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels.",https://finnhub.io/api/news?id=b598bedc310c67b3867b72d27fd3931e329da3c6339b466a68742de7e13eb139
company,2022-11-09 03:43:00,Regeneron price target raised to $856 from $790 at Truist,117030087,https://thefly.com/images/meta/streetresearch_recommendations.jpg,REGN,Thefly.com,Truist analyst Robyn Karn... REGN,https://finnhub.io/api/news?id=f8d7d6a56c190a0fc4b0abe479f10c768da42978496555107d73dd4d4bc7c1c5
company,2022-11-08 20:45:16,AbCellera Biologics: Q3 Commentary - Moving Up The Value Stack,117012791,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1309776504/image_1309776504.jpg?io=getty-c-w750,REGN,SeekingAlpha,AbCellera Biologics has multiple high-value opportunities that should become clear in the next few years. Find out why I'm confident in the long-term return potential of ABCL.,https://finnhub.io/api/news?id=e27a07228d7886222f06f714e9d514acb0f559fa5b5b17b46c6b7be7ece78bff
company,2022-11-08 16:41:00,Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC),117005684,https://media.zenfs.com/en/prnewswire.com/9f4e6befb7f274c4cd5b54bedcd2e5f7,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation. Patie",https://finnhub.io/api/news?id=6cb0f8d30fab7668cc89ac7fe5b55131711a82948a43e6d980d88666e14987c6
company,2022-11-08 12:20:00,"Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",117023844,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.14% higher to $751.95 Tuesday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=409caef7cb2939506726e2d16f6e06b6b4e55ce2e7d8be85737d8e48b29ec7cb
company,2022-11-08 07:42:22,Regeneron Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations,117005686,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,Regeneron Pharmaceuticals ( NASDAQ:REGN ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.94b (down 15...,https://finnhub.io/api/news?id=957cb2cec522fbf8bb2dfaa2184d5047f5d163a599ae73eeac78e9069e479507
company,2022-11-07 22:43:00,Regeneron: FDA approves Libtayo in combination with platinum-based chemotherapy,117030091,https://thefly.com/images/meta/hotstocks.jpg,REGN,Thefly.com,Regeneron Pharmaceuticals... REGN,https://finnhub.io/api/news?id=adec323788564fc6855ae22a939334b52af5dbdc5afaab50e4bebdefbc318a65
company,2022-11-14 10:10:03,Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion,117145806,https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372,REGN,Yahoo,Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.,https://finnhub.io/api/news?id=e5d3311040f7ffecb40c8ca39f7b1e758d4481155458d57120a03ce5094dc183
company,2022-11-14 08:17:47,Kodiak: Turnaround Strategy Has Shown Life Thus Far,117145767,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1435393731/image_1435393731.jpg?io=getty-c-w750,REGN,SeekingAlpha,"Primary endpoint of phase 3 BEACON study, using tarcocimab tedromer for the treatment of patients with macular edema due to retinal vein occlusion, was met. Read the outlook here.",https://finnhub.io/api/news?id=b35c6a16647b51518f326c33aaa8944dd4282b0873bca6ae1d4d38ddd1c0c3dc
company,2022-11-14 07:43:12,"Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease",117143376,https://media.zenfs.com/en/zacks.com/17664ed95646b97db9beb170298a16b3,REGN,Yahoo,"The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.",https://finnhub.io/api/news?id=a591fd3f51b151c596aea5ebc1c85afa16cf31929645558e2394ac726261be43
company,2022-11-13 22:40:00,"Regeneron Pharmaceuticals Moves Up In Market Cap Rank, Passing Altria Group",117166214,,REGN,The Online Investor,"the online investor,REGN,MO,",https://finnhub.io/api/news?id=80cbd4406c0030334d5cf99bdf67c6648673706d1a23bfbfefa31a53ceb71e73
company,2022-11-13 13:28:25,Vertex: High Growth For Years Ahead,117138953,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326625612/image_1326625612.jpg?io=getty-c-w750,REGN,SeekingAlpha,Vertex is the market leader company for Cystic Fibrosis disease. The company reports unexpected sales and earnings growth in recent quarters Q3.,https://finnhub.io/api/news?id=dd7b258b859f483ba7892042f817363216b6d69ae6da141055e9c4c0b7fa6eac
company,2022-11-12 10:15:00,2 Top Biotech Stocks to Buy in November,117130485,,REGN,Yahoo,Biotech giants Regeneron Pharmaceuticals (NASDAQ: REGN) and Gilead Sciences (NASDAQ: GILD) are among them.  Eylea could lose patent protection as early as next year.  Why is Regeneron beating the market this year despite these issues?,https://finnhub.io/api/news?id=91a5a2027ae547ca7199eda1e67fd989781bca4f561ae1b8d06678539d1c3e5c
company,2022-11-12 09:00:10,"Subdued Growth No Barrier To Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price",117130486,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of...",https://finnhub.io/api/news?id=e683cdfc19428dc93324f6875e1e3cd775690e77c3f1706e5cc1e4a3c992dd13
company,2022-11-18 13:18:06,CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron,117199464,https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2,REGN,Yahoo,CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.,https://finnhub.io/api/news?id=c83d059f6c242112268597b02822b50e9b2585fb2d12b02a1d4e55d06fb26f1f
company,2022-11-18 08:33:21,Compounders And Dividends: November 2022 Watch List Update,117197960,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/477583982/image_477583982.jpg?io=getty-c-w750,REGN,SeekingAlpha,"Since my original watch list article in September 2022, I have purchased three companies, two of which were on my September 2022 watch list. Click to read.",https://finnhub.io/api/news?id=de6d78ec347f64291ab555cebd3cfe0db2120f95e1b69536e8cb1bf4e3d1aa45
company,2022-11-18 06:00:38,Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders have earned a 28% CAGR over the last three years,117196601,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...",https://finnhub.io/api/news?id=7a7684eebd7429636ea40f5da526a18d00ab3b38a804e47f18787e45364b9a5c
company,2022-11-17 14:18:09,Cramer's lightning round: BioXcel Therapeutics may be home run or nothing,117195139,https://image.cnbcfm.com/api/v1/image/102086320-mad-money-lightning-2.jpg?v=1668730689&w=1920&h=1080,REGN,CNBC,"""Mad Money"" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.",https://finnhub.io/api/news?id=d26b5ebfe68c8ba290e4960b5f49a18617dbb2e78a022bb3e1933f9546864c08
company,2022-11-17 11:14:02,CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron,117187251,https://media.zenfs.com/en/Benzinga/a0e59feb33ae31e7e00826ac2515deb6,REGN,Yahoo,"CytomX Therapeutics Inc (NASDAQ: CTMX) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a collaboration and licensing agreement to create conditionally-activated bispecific cancer therapies. The collaboration will utilize CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform. Under the agreement, Regeneron and CytomX will collaborate on the discovery activities to identify and validate conditionally active bispecific antibodies. Regene",https://finnhub.io/api/news?id=20236a43661689e29e5c683f01672b1addde1a9e0799624372d5a3bbc2993af9
company,2022-11-17 11:09:36,Peninsula biotech moves from layoffs to cancer-fighting deal with potential $2B payoff,117187252,https://media.zenfs.com/en/bizjournals.com/52f29288ee08105eced1f05bdd26e82d,REGN,Yahoo,The deal is the company's third to help larger pharmaceutical companies power up their bispecific antibodies while getting those drugs closer to cancer cells instead of healthy tissue.,https://finnhub.io/api/news?id=ebfd786fdc65be71ec657081259a7f1fc69364cef83a6ae9717acaa982321880
company,2022-11-17 07:00:00,CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer,117187254,https://media.zenfs.com/en/globenewswire.com/75dce85ff5e3b40eeb16fbf6328b5bf6,REGN,Yahoo,"- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - - CytomX to receive $30 million upfront payment with the potential for up to $2 billion in research, development, regulatory and sales-based milestones - SOUTH SAN FRANCISCO, Calif. and TARRYTOWN, N.Y., Nov. 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to",https://finnhub.io/api/news?id=aaa65057d47c91789f95a8ad66a66f9e56752ef1f507859d31cd5e95871058ad
company,2022-11-17 07:00:00,Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer,117187253,https://media.zenfs.com/en/prnewswire.com/9fa6401b4131daa7528bbf6e52dce007,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX) today announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody® therapeutic platform and Regeneron's Veloci-Bi® bispecific antibody development platform.",https://finnhub.io/api/news?id=6c1c7cbbc59a62e3b2fc81e2d83c36c9c4591f9e21285fdbb181656f1380c757
company,2022-11-17 05:48:00,CytomX Therapeutics Shares Rally on Regeneron Pact,117202676,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Shares of CytomX Therapeutics Inc. jumped more than 25% Thursday after the clinical-stage biopharmaceutical company unveiled a...,https://finnhub.io/api/news?id=2af778c58999f02a4ffa5635bc69f05c1ea99da33a6183365ae6d90dacd02818
company,2022-11-17 02:27:00,"Regeneron, CytomX Set Cancer-Therapy Collaboration >REGN CTMX",117202677,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Regeneron Pharmaceuticals Inc. and CytomX Therapeutics Inc. on Thursday said they plan to create bispecific cancer therapies under a...,https://finnhub.io/api/news?id=d3195004d52de895d232cae196f6e55ffbfb702d84f81fad792bae8bb6865352
company,2022-11-16 07:26:02,IDNA: Healthcare Dashboard For November,117172493,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1224202684/image_1224202684.jpg?io=getty-c-w750,REGN,SeekingAlpha,The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Read how this ties into the IDNA healthcare ETF.,https://finnhub.io/api/news?id=22c548708b2e201e0de533d4b94edc94de36d3b03561215c71ce42d37870ff59
company,2022-11-16 07:24:19,"Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference - (Transcript)",117172509,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Jefferies London Healthcare Conference November 16, 2022 10:15 AM ET Company Participants Ryan Crowe - VP, IR Robert Landry - EVP,...",https://finnhub.io/api/news?id=f9c80e7d4f79ec5455a6216a2fbc4b1cbf7ffe7121a7eb9eba2a400e9a7cf401
company,2022-11-23 12:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors,117332424,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.85% to $735.36 Wednesday, on what proved to be an all-around great trading session for the stock market,...",https://finnhub.io/api/news?id=a4f33cb1b5df646daaa41a7fb0f798b898b8d0ec30154281cd81e9d7f02822cb
company,2022-11-23 12:18:05,"Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update",117269230,https://media.zenfs.com/en/zacks.com/5bd570f285e4b6d4e9b1a8c6dc8600e6,REGN,Yahoo,Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=1b6de4e831b3ff53ab0b7c5d5b1947913963c11487df7bf9e109d7c24fb3d2d2
company,2022-11-23 10:41:03,Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer,117269231,https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2,REGN,Yahoo,Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.,https://finnhub.io/api/news?id=66ee3b792d378ba9356c602dd100181c95784b6f7c318b1b4159380a109a0726
company,2022-11-23 00:12:50,Regeneron: Q3 Results Show Eylea's Strength Despite Vabysmo Launch,117262169,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/629802096/image_629802096.jpg?io=getty-c-w750,REGN,SeekingAlpha,Regeneron has multiple and potentially significant growth drivers in the following years. Find out why REGN stock is a Buy.,https://finnhub.io/api/news?id=eaf83d8ade0e1ab4247f6a7f4f88b90afd31ee442499e7bcde2ad0d5eb64403f
company,2022-11-22 12:19:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,117332426,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.39% to $749.23 Tuesday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=ced0d336a1b92be6db1428d0060b75523761cfd2d0e039b69ec28f99cf8bce71
company,2022-11-22 09:08:38,"Regeneron: Stock Priced Too High To Buy, But Keep One Eye On This Pharma",117254475,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1409383663/image_1409383663.jpg?io=getty-c-w750,REGN,SeekingAlpha,Regeneron Pharmaceuticals is hoping to establish itself as a major oncology player. See why I no longer see REGN stock price upside in the near term.,https://finnhub.io/api/news?id=b8c46582b0d89b08aace9733554a204afafd5345f8cbb557d8a9442edca1de7a
company,2022-11-22 07:00:00,Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology,117249635,https://media.zenfs.com/en/prnewswire.com/1d714a65e1262e53a570b246d4afd874,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.",https://finnhub.io/api/news?id=5af6bbd5768b9a704c95b5dc7b2f65cc2e9df93184acb7d41e3a0bda357e2018
company,2022-11-22 06:02:00,"There's Reason For Concern Over Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price",117249637,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of...",https://finnhub.io/api/news?id=d01cbd2b960716bad5c7ff046da9431f716339943261e27e8c886fca55d7ac77
company,2022-11-21 12:59:36,Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week,117241482,https://pennystocks.com/wp-content/uploads/2022/11/best-biotech-penny-stocks-to-buy-this-week.jpg,REGN,PennyStocks,Biotech penny stocks to watch this week. Are they a buy now?,https://finnhub.io/api/news?id=0de3425ae4b1d9324a34cb6d34301aadd1a84fa5c1617449854907c8c970ed5e
company,2022-11-26 23:56:37,SPGP: 'GARP' ETF Has Opposite Strategy Of ARK Funds,117302005,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314086348/image_1314086348.jpg?io=getty-c-w750,REGN,SeekingAlpha,Invesco S&P 500 GARP ETF has certainly proven itself over the long term to deliver upside growth as compared to the S&P 500. Click here to find out why SPGP is a Buy.,https://finnhub.io/api/news?id=1bc304bd8c24ab14bff0aa9f5b34955400e1883257e39e545091d8aa2597f792
company,2022-11-26 06:00:53,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold US$7.0m worth of stock suggesting impending weakness.",117294483,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the company...",https://finnhub.io/api/news?id=45a484bb125f21c0983a13622f1324a8c897668593af220266be742ef04ea03f
company,2022-11-25 09:13:02,Regeneron (REGN) Outperforms YTD: What's in Store for 2023?,117287558,https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7,REGN,Yahoo,Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.,https://finnhub.io/api/news?id=3fd729178edc1373b906aa5b1c4d00907a017c01ac7afea08ac5de27d2293f45
company,2022-11-25 07:45:48,Dexcom Leads 5 Stocks Near Buy Points,117286438,,REGN,Yahoo,Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.,https://finnhub.io/api/news?id=95f99e524eaf569c984719d6f724a36fd9b3f897e641b2c44b141acbb8a08694
company,2022-12-01 12:32:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,117410191,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 1.27% to $761.24 Thursday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=9e2f79beb0ad956c029f2b9bf93fdd980979c5888ea669ed3668fcf8ce432ecb
company,2022-12-01 08:46:01,Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review,117365677,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,REGN,Yahoo,"The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.",https://finnhub.io/api/news?id=281589f9f34f3c6482d53eb511ca51a59639aa8cb21497858a232e1e045f2c2c
company,2022-12-01 07:00:00,Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types,117365678,https://media.zenfs.com/en/prnewswire.com/445db9bc5bbd64dc040221fbbda70340,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data across its oncology pipeline will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) Congress 2022 from December 7 to 9 in Geneva, Switzerland. Presentation highlights include first clinical results and new exploratory analyses from trials investigating LAG-3 inhibitor fianlimab and/or PD-1 inhibitor Libtayo® (cemiplimab) in non-small cell lung cancer (NSCLC), melanoma and cervica",https://finnhub.io/api/news?id=df74f0fcfb5f7c317eb694c4cf5de830671e37bf53c272e237251a29e6befb77
company,2022-11-30 10:51:38,Regeneron's Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol,117351258,https://media.zenfs.com/en/Benzinga/0fbe76ab34bca6445f309dca57abad16,REGN,Yahoo,"The FDA has accepted Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) supplemental marketing application seeking approval for Evkeeza (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies for children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). The FDA target action date is March 30, 2023. HoFH is an ultra-rare inherited condition that occurs when two copies of the FH-causing genes are inherited, resulting in dangerously high levels of low-density lipoprote",https://finnhub.io/api/news?id=0ffd94f3c8e8164cac94dc3207213fed086b78e2e76358a5aec75c606c97cce7
company,2022-11-30 09:06:06,UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent,117345930,https://media.zenfs.com/en/Benzinga/fdeecb8ff2851834718f597ae11e2d28,REGN,Yahoo,"The UK's Medicines and Healthcare Regulatory Agency (MHRA) warned of some new and severe eye-related side effects following the use of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) atopic dermatitis and asthma treatment Dupixent (dupilumab). Dupixent is already associated with cases of conjunctivitis and allergic conjunctivitis, dry eye, and infrequent cases of keratitis and ulcerative keratitis. The MHRA added that health professionals should look for any of these e",https://finnhub.io/api/news?id=9a3bc2fd1ca35df501571f950836c8811f918939ccf70acf8d4c3df482d2afc5
company,2022-11-30 08:53:06,"Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 34th Annual Healthcare Conference (Transcript)",117347416,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Piper Sandler 34th Annual Healthcare Conference Call November 30, 2022 08:00 ET Company Participants Ryan Crowe - Vice President of...",https://finnhub.io/api/news?id=c1cba2ff0c290a10a73d4b81b540b21bd1536fbc6929dd6fcd2a627e32b70a6d
company,2022-11-30 08:05:00,Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review,117344581,https://media.zenfs.com/en/prnewswire.com/ab0d5b03076fc9788e2442be71b58d9c,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). The FDA target action date is March 30, 2023.",https://finnhub.io/api/news?id=521d155ab07eb880efb0860f8cd8d24209b2527771c8ddc3e5ea97ff70704e58
company,2022-11-30 07:00:46,"Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings",117344582,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of...",https://finnhub.io/api/news?id=5f62d5e84141269f836e5246c3c7fc7976a5301f9ecf631e6bf51e634ee18d2e
company,2022-11-30 05:35:00,2 Market-Beating Stocks That Can Continue Rising in 2023,117341705,https://s.yimg.com/ny/api/res/1.2/MIFeg6wzo6F2ocUZ5cOdxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/fc4d88e8a1d91d6bd816b665e884f1d9,REGN,Yahoo,"A couple of stocks that have been hot buys this year are Regeneron Pharmaceuticals (NASDAQ: REGN) and T-Mobile US (NASDAQ: TMUS).  Unlike the S&P 500, which is down about 17% this year, these two stocks have generated positive returns of 15% or more.  Here's a closer look at why both of these stocks can still soar higher in 2023.",https://finnhub.io/api/news?id=6940dc1dd2fea15d6e98e635102212ad691cd2f9a52f2aec86c7eb6598486257
company,2022-11-29 15:53:44,Pfizer: COVID-19 May Never End,117335889,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1391123438/image_1391123438.jpg?io=getty-c-w750,REGN,SeekingAlpha,"Pfizer's net income was $8,609M in Q3 2022, up 5.7% YoY. See why PFE stock could be a great healthcare sector candidate for long-term investment strategy.",https://finnhub.io/api/news?id=fc442add6982d5d630ba3b377aaea03cd053d2d4827a8d38460d6f59d5c3324c
company,2022-11-29 12:32:00,Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors,117410193,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slumped 0.73% to $736.08 Tuesday, on what proved to be an all-around mixed trading session for the stock market,...",https://finnhub.io/api/news?id=30eb35a99d7d53003604f890fa120b51acb9f661d8a60bc020cf201218f17a71
company,2022-11-29 09:50:04,"Regeneron Pharmaceuticals, Inc. (REGN) 5th Annual Evercore ISI HealthCONx Conference (Transcript)",117329711,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) 5th Annual Evercore ISI HealthCONx Conference November 29, 2022 11:45 AM ET Company Participants Ryan Crowe - Vice President, Investor...",https://finnhub.io/api/news?id=a3a6e252a3432ced57d17ddab46d746829386e24c1a90bad86b0a2f12c1f2b6f
company,2022-12-05 12:32:00,"Regeneron Pharmaceuticals Inc. stock falls Monday, still outperforms market",117410188,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.43% to $755.45 Monday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=2888059741e9a49939de9a3adececa132bea02c7eeff6b3d722c90f3fc1424e5
company,2022-12-05 06:24:26,2 Generational REIT Buying Opportunities,117403027,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155142981/image_155142981.jpg?io=getty-c-w750,REGN,SeekingAlpha,REITs are volatile and this results in a lot of opportunities to profit. Read why REITs are again priced at historically low valuations.,https://finnhub.io/api/news?id=0fc84bcfd9d2cbd2918ce3206d76948ce09b50263fc46543d8a7c55580f3de8f
company,2022-12-04 09:37:00,Can These 2 Stocks Crush the Market Again in 2023?,117396298,,REGN,Yahoo,"The list includes Regeneron Pharmaceuticals (NASDAQ: REGN) and Biogen (NASDAQ: BIIB).  Regeneron was having an unimpressive year on the stock market until its shares soared by double-digit percentages in one day in September.  As is often the case with biotechs, Regeneron owes this move to positive clinical developments.",https://finnhub.io/api/news?id=be1e0f1972d63b9b747ce485bd241e107eb608e7b5cf7e722db08c88e4456954
company,2022-12-04 07:01:42,Regeneron Pharmaceuticals' (NASDAQ:REGN) three-year earnings growth trails the stellar shareholder returns,117394917,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...",https://finnhub.io/api/news?id=c788dc6e2614f80d2a993deba626fd62184952c401824bcd554eb3d659cb880f
company,2022-12-02 12:33:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market",117410190,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.68% higher to $766.39 Friday, on what proved to be an all-around mixed trading session for the stock...",https://finnhub.io/api/news?id=c7a6b0ea3a05c22b8336754ec2c805f07d1acb10f3f786ff1a594b3d9047d5de
company,2022-12-02 12:19:06,Stocks To Invest In Right Now? 3 Biotech Stocks To Watch,117376989,https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2022/12/stocks-to-invest-in-right-now-.jpg,REGN,StockMarket,Is now a good time to add these biotech stocks to your watchlsit?,https://finnhub.io/api/news?id=5899dbe25e5de551c0300ddea8d902ad52a5e9a1de70c6742e9221172bae3d63
company,2022-12-02 09:45:08,BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns,117378542,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358625679/image_1358625679.jpg?io=getty-c-w750,REGN,SeekingAlpha,"BBH has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic price range. Click here to learn more.",https://finnhub.io/api/news?id=5e5f3f8e58df8e06fb2eb5be86c731e7de3eec7229b466a5c6ffc5c13a637f5a
company,2022-12-09 17:42:48,Our 7 Top Biotech Stock Picks for 2023,117487530,https://media.zenfs.com/en/investorplace_417/180ce84be58b62c67d477717f09599bb,REGN,Yahoo,"If there’s a silver lining regarding the coronavirus pandemic, it’s that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 crisis proved that when humanity comes together, it can foster incredible advancements at breakneck speed. Moving forward, this segment will carry this momentum toward other breakthroughs. Nevertheless, even the top biotech stock picks for 2023 can’t avoid economic realities. With macro",https://finnhub.io/api/news?id=fb20577934e7b2ab9b2fc1a8af3fe648462fc51c2bbc170166bfef1363357450
company,2022-12-09 10:23:00,Will This Potential Approval Be a Winner for Sanofi's Shareholders?,117454770,,REGN,Yahoo,Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.,https://finnhub.io/api/news?id=65f1559ef419cd12a26fd088a053dc811a147b1091458d1510186e8fcdf789db
company,2022-12-08 12:33:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market",117489696,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.15% higher to $765.42 Thursday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=ce9d80885333ae0c27bdc24a63d85d499f3b2bf73b48c5ab82aa645cb0423df6
company,2022-12-08 07:01:55,"There's Reason For Concern Over Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price",117440933,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of...",https://finnhub.io/api/news?id=b8274faecd426724586e153ce6325b148cb950f76608cf4f97593afcae348e28
company,2022-12-08 06:41:00,This fund beats the S&P 500 by using just 75 of its components. Here`s how it works.,117662179,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7d6f7dc0e7c64b494fd0a8f97aec5471ff7301635a7f70339aee067e544aca7e
company,2022-12-08 05:25:00,Cantor Fitzgerald pharma/biotech analyst hold a luncheon,117637080,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0cbc205259410536e8b2730320877db13890040c15d309062224fcc34a0dde33
company,2022-12-08 05:04:00,This fund beats the S&P 500 by using just 75 of its components. Here's how it works.,117477551,https://images.mktw.net/im-537282/social,REGN,MarketWatch,A combination of quality and lower prices has worked well through bull and bear markets — it may be just the ticket for investors worried about a recession.,https://finnhub.io/api/news?id=1e7cd8ca1f5bf20127bd55afc0b8acf19f76173dc23f2c8ab9d7163f131cb596
company,2022-12-07 23:25:00,Cantor Fitzgerald pharma/biotech analysts hold a dinner,117637082,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=341529d4885916f78f75dca3ed15d9befd1b4f308213eee0cbd40ce6a1a7872e
company,2022-12-07 12:32:00,"Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market",117489698,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 2.25% to $764.27 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=7790bb3cca940a612ff65793be2a0d3f4003bda97ae819633217ae91e6be7ec8
company,2022-12-07 02:14:00,"Replimune, Roche to Develop RP3 in Colorectal Cancer, Hepatocellular Carcinoma >REPL",117489700,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Replimune Group Inc. on Tuesday said it inked a deal to work with Swiss pharmaceutical company Roche Holding AG to advance Replimune RP2/3...,https://finnhub.io/api/news?id=e2b17120dda04cf7d73700ac6dc231baebf76cc6eb9b3be99bc5e7bd5c821067
company,2022-12-06 12:33:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,117489701,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.06% to $747.47 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=159c919074294a66d91f9232786381938fa4b913497844f4dfab720fef5ff7e9
company,2022-12-13 12:21:00,"Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",117559289,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.68% higher to $747.56 Tuesday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=56c78581f288a3f9bb2bd545216d1107d7d18c4705a89ed6c0062c5376eddfe9
company,2022-12-13 11:07:04,Regeneron (REGN) Presents Positive Data on MM and FL Drugs,117504054,https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2,REGN,Yahoo,Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.,https://finnhub.io/api/news?id=d5ed3f780911150aaaa1fd718428e498bd1ab7d58146795d708bc2cc65dbed8f
company,2022-12-13 10:39:27,15 Best S&P 500 Stocks That Don’t Pay Dividends,117498373,https://s.yimg.com/ny/api/res/1.2/ewJkRdFaq.2XGQWUyjLf7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xODAw/https://media.zenfs.com/en/insidermonkey.com/d56904bb36b5a45d4abc684b7368cf3c,REGN,Yahoo,"In this article, we will be taking a look at the 15 best S&P 500 stocks that don’t pay dividends. To skip our detailed analysis of these stocks and the performance of the S&P 500 so far this year, you can go directly to see the 5 Best S&P 500 Stocks That Don’t Pay Dividends. […]",https://finnhub.io/api/news?id=90ff9030b8df1b846d707851e0980e6e723719f807660c1e281da202ffc7b6bb
company,2022-12-13 08:31:54,Regeneron Reveals An Early Cut Data From Follicular Lymphoma Study At ASH Meeting,117504057,https://media.zenfs.com/en/Benzinga/33bd83602aba901799bd53ae97633647,REGN,Yahoo,"Regeneron Pharmaceuticals Inc (NASDAQ: REGN) gave the first look at interim results from its Phase 2 study of odronextamab, a CD20xCD3 bispecific antibody in patients with relapsed/refractory follicular lymphoma. Trial investigators said 82% of 121 patients with the disease responded to Regeneron’s drug odronextamab, and 75% had a complete response. Related: Regeneron Highlights Its First Phase 2 Data To Build Case In CD20xC3 Bispecific Space. The median duration of complete response was 20.5 mo",https://finnhub.io/api/news?id=7e6fb49c089b065ffea5f262c4dd74f1070399dfd90ae210ed1091043546af8b
company,2022-12-12 17:30:00,Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial,117490651,https://media.zenfs.com/en/prnewswire.com/f55841bca5fc48fb55b2d18a8fbd6514,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive first data from a cohort of a pivotal Phase 2 trial evaluating investigational odronextamab in patients with heavily pre-treated, relapsed/refractory (R/R) follicular lymphoma (FL) grades 1 to 3a. The data were presented in an oral session at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA, and follow the first Phase 2 results for odronextamab in R/R diffuse large B-cell lymphom",https://finnhub.io/api/news?id=1fa1611be22c905177cb16e6f32bfbbeae09d0a94763cda01bf3917c441521c7
company,2022-12-12 12:21:00,Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors,117489694,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.01% to $742.48 Monday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=693a18035119f8790397cd814eecc37600324063b5f10edb1e7eb3b7ebefaa1a
company,2022-12-12 10:00:00,Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma,117490652,https://media.zenfs.com/en/prnewswire.com/77584f4dfa0888b974da18e06dc98d90,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive initial data from a pivotal Phase 2 expansion cohort evaluating investigational linvoseltamab (formerly REGN5458) at the 200 mg dose recommended for further development in patients with heavily pre-treated, relapsed/refractory (R/R) multiple myeloma. The results were part of a broader presentation of new and updated data from a Phase 1/2 trial and were shared at the 64th American Society of Hematology (ASH) Annual Meeting an",https://finnhub.io/api/news?id=3b669615b195b89d61c574ed3a2bc63ddb013bf44146fe5a9752d898718671c7
company,2022-12-12 09:01:12,"A Look At The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)",117490653,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Regeneron...,https://finnhub.io/api/news?id=f793d1f541fbf98cb21b0a31280a4718456bbcbb00a6d8a13619de7be45c4f0e
company,2022-12-12 07:30:00,Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year,117481649,https://media.zenfs.com/en/prnewswire.com/2557a9966f0f942f872ed4bd4cfc30dc,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company has been included on the Dow Jones Sustainability World Index (DJSI World) for the fourth consecutive year and on the Dow Jones Sustainability North America Index (DJSI North America) for the third year. These indices recognize Regeneron's enduring leadership in supporting its patients, colleagues, communities and planet.",https://finnhub.io/api/news?id=737279a490c83ec6cfd65dfbf64e84d59f1f02f5b48f3dd8a935970428e7ba1d
company,2022-12-12 06:42:32,Regeneron Highlights Its First Phase 2 Data To Build Case In CD20xC3 Bispecific Space,117490654,https://media.zenfs.com/en/Benzinga/fdfb3637791bc64427208028412837ad,REGN,Yahoo,"Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced updated data from a Phase 1 and Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). These included first data from a Phase 2 cohort of CAR-T naïve patients and updated data from a dose expansion cohort of a Phase 1 trial in patients who had progressed on CAR-T therapy. In the first look at the Phase 2 portion, Regeneron said the objective re",https://finnhub.io/api/news?id=52b5ac4a863be2d698ead3b705130e598a4a2bb116b47967bb0492025b904f0f
company,2022-12-12 04:55:00,Regeneron announces data from Phase 2 trial of linvoseltamab,117662171,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1a2bc0e5b96655185975b60ba7e65693b4d1786c5b827c0e3c7db021084694fc
company,2022-12-12 04:54:00,Interesting REGN Put And Call Options For December 30th,117662172,,REGN,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ecb0ee7405c4a98383401184954916cebd647c957d432dd120d9ff154d21e222
company,2022-12-11 23:37:00,Regeneron announces data on trial of odronextamab to treat R/R  FL,117662174,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f4672a73dc3badf0bd110f9b3ba32b9c74bf12a42ba90605b478b707ef0ca6bb
company,2022-12-11 10:30:00,Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH,117475655,https://media.zenfs.com/en/prnewswire.com/afb8c171b5fe5b9cceac5225e7da74a6,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new and updated data from a Phase 1 and pivotal Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). These included first data from a Phase 2 cohort of patients naïve to prior CAR-T therapy (CAR-T naïve), as well as updated data from a dose expansion cohort of a Phase 1 trial in patients who had progressed on CAR-T therapy (p",https://finnhub.io/api/news?id=9eee188bdcfac6a09255decc96ca9eabffef7f1f995fc6ca5819db63eb3f5abb
company,2022-12-10 22:43:00,Regeneron announces data from trials evaluating investigational odronextamab,117662177,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b2158ce1fbe90300ea035c0fe5ba70158cd7d218bd4c28834dc15907d65d76a2
company,2022-12-16 12:21:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,117559283,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.11% to $723.17 Friday, on what proved to be an all-around poor trading session for the stock market, with the...",https://finnhub.io/api/news?id=a0c925085b0ab541f3bca9571b647f5c5a710167d1f461e8d7a390717859ed73
company,2022-12-16 08:31:35,Regeneron Pharmaceuticals (REGN) Presents at 64th ASH Annual Meeting & Exposition,117541678,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"The following slide deck was published by Regeneron Pharmaceuticals, Inc.",https://finnhub.io/api/news?id=792ccb0cd63237656057464613edf04bee6b4bdc1f2b100fce1359889d90b7f3
company,2022-12-16 08:01:55,"Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$7.0m worth of stock",117537925,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the...",https://finnhub.io/api/news?id=be53b4ffdf6e6cf2e049c405ab2e06237a344db42a557394ecec7356d9829ccd
company,2022-12-16 07:29:00,Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis,117536250,https://media.zenfs.com/en/prnewswire.com/f02658a8d25807d2be474aec33fad142,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults and adolescents with eosinophilic esophagitis (EoE). This positive opinion covers those who are 12 years and older, weighing at least 40 kg, and inadequately controlled by, are intolerant to or who are not can",https://finnhub.io/api/news?id=e36221cfb533c10337c46481200363800dc5fc844b00b98a2f49c98cd09fa19c
company,2022-12-16 02:54:00,"Regeneron, Sanofi Get CHMP Backing for Dupixent in Eosinophilic Esophagitis",117558819,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use...,https://finnhub.io/api/news?id=1b8ce6552f8c90142d0571ad7f3a27efa702e024bce8dec927868d23a8f4e424
company,2022-12-16 01:31:00,"Regeneron, Sanofi: EMA`s CHMP recommends approval of Dupixent in EU",117658944,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c7f8e3e2a1680c119ca7b5eeceee48d2fa0b0e2f1c102bfa511f0c95064a4642
company,2022-12-15 12:21:00,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,117559285,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 2.50% to $731.27 Thursday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=3acafce4dc341ab05c66480c9a238133beadb2152afd14c38ee108722ba62639
company,2022-12-15 10:10:03,Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis,117527565,https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966,REGN,Yahoo,The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.,https://finnhub.io/api/news?id=74ebbda0f6352f426affb958c84acd834d530cd742f7f9ddcc85e74400135704
company,2022-12-15 07:05:58,Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis,117527567,https://media.zenfs.com/en/Benzinga/2929c5870c461f1526d684818f7893df,REGN,Yahoo,"The European Commission (EC) has expanded the marketing authorization of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for moderate-to-severe prurigo nodularis. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation. With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat prurigo nodularis in Europe and the U.S. Related: UK Drug Regulator Warns Of Severe Eye React",https://finnhub.io/api/news?id=de975100aa97502f90822bea56110fb3b325ef8646eae8159e3d8436925cb42c
company,2022-12-15 06:26:00,SVB Securities Keeps Their Hold Rating on Regeneron (REGN),117662161,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f5bae80866d46a246292a239e6e00ba24dc0206875d7e05ef099e05005367fae
company,2022-12-15 00:59:00,Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis,117523356,https://media.zenfs.com/en/prnewswire.com/89c6dad00c46bfbe77137b8b48c5caa5,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest among inflammatory skin diseases. With this approval,",https://finnhub.io/api/news?id=fd268c7a42c86aaebaf59efe286e0fa74afe245d0ab3e1782d12f81668066f0f
company,2022-12-14 23:31:00,"Regeneron, Sanofi announce EC expansion for Dupixent marketing authorization",117658947,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=34acffc7b604579a146a415e77de59e5b21daddd9df768c7a772d28e861b171f
company,2022-12-14 23:05:00,"Sanofi, Regeneron Dupixent gets approval in EU for expanded use in skin disorder",117662164,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=688abae3aae9538e4e1a38cbb482b3c2ddb107838d9ca179fa4f7165fd9b057a
company,2022-12-14 21:35:00,Regeneron and Sanofi note fourth EU approval for Dupixent,117658948,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=11a7a9b140a3096d9dcb10bf378bef869acc460f20409abd4cce23d3b64a6f3b
company,2022-12-14 12:21:00,"Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market",117559287,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.33% higher to $750.00 Wednesday, on what proved to be an all-around grim trading session for the stock...",https://finnhub.io/api/news?id=934365af74aa047e53b9ce2403ba2fe522c331456274cec0c84d89c21ca5b7e1
company,2022-12-21 17:29:00,Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine,117608253,https://media.zenfs.com/en/prnewswire.com/9eacb044b2a178456d01835d81b9172a,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents treated with Dupixent® (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (EoE), which were sustained for up to one year.",https://finnhub.io/api/news?id=73daa9553731404f801a29df56e6ee36cf44992e6b1b35331bbadb483f9cb46f
company,2022-12-21 12:21:00,"Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market",117690693,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.36% higher to $736.19 Wednesday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=cd3354361269c86e0fc3d752c9620164fea3c72a1c41a9c0f156b2dab2413da1
company,2022-12-21 06:16:46,XBI: Attractive Value In Diversified Biotech Growth,117601011,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1395657542/image_1395657542.jpg?io=getty-c-w750,REGN,SeekingAlpha,Valuations on biotechnology stocks have moderated substantially since the pandemic peak in 2021. Click to read my analysis of the SPDR S&P Biotech ETF (XBI).,https://finnhub.io/api/news?id=58c417a94bece7fd134bf3fa546f31167f009d6ce8721ed13a50843061b8a486
company,2022-12-20 23:36:00,Regeneron`s Dupixent shows disease remission in Phase 3 esophagitis trial,117658920,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f8ea39f3543692b41912c51e03eae8a8e74cd301386013bec1823795fc2abaf1
company,2022-12-20 12:21:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,117690696,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.72% to $733.53 Tuesday, on what proved to be an all-around great trading session for the stock market,...",https://finnhub.io/api/news?id=1aed5a44e3cf275f11fd7957831acb134832b7140c44c163a51210ebc74085b3
company,2022-12-20 12:00:00,IN BRIEF: Regeneron signs for USD750 million five-year credit facility,117662147,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b1a154c3a419d5691fc2be84afd44f7836a06f337c8295e4ddf87c2b3867408d
company,2022-12-20 09:01:04,"Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) insiders who sold earlier this year may be offered solace in this recent price drop",117584805,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Even though Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) has fallen by 3.5% over the past week , insiders who sold...",https://finnhub.io/api/news?id=62a079189821dc761b5ce10bcd44160244d6a7ffd49807b74bef4093be085274
company,2022-12-20 05:30:14,Top Net Payout Yields - December 2022,117585695,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1285391934/image_1285391934.jpg?io=getty-c-w750,REGN,SeekingAlpha,The top net payout yield stock failed to match the total return of the S&P 500 during 2H' 22 as tech stocks soared. Check out our list of stocks.,https://finnhub.io/api/news?id=a6b724624bc5857c4b0adcfacc6d91445b0254feda670e02a10f760a59fde47a
company,2022-12-20 03:25:58,Intellia: In-Vivo Gene Editing Platform Continues To Deliver,117584355,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1432011732/image_1432011732.jpg?io=getty-c-w750,REGN,SeekingAlpha,Intellia has already been able to establish proof of concept in using NTLA-2002 for HAE and then NTLA-2001 for ATTR. Read our buy thesis on NTLA stock here.,https://finnhub.io/api/news?id=b8e22ba0d6d32685463373b1d8568bfa99414fa46c4b6f3105a96b906268a926
company,2022-12-20 02:57:02,Intellia: Most Advanced In A Tough Field,117584155,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345098965/image_1345098965.jpg?io=getty-c-w750,REGN,SeekingAlpha,Intellia announced positive biomarker data from two of its one-off gene therapies. Read why NTLA is one to watch but not one to base your retirement against.,https://finnhub.io/api/news?id=e21621693b9dd9a5f299d2a37ba5b6895820cb9ce04c51e4f5f1ec87bbf4d368
company,2022-12-19 23:22:00,Tuesday Talk: Where is Santa?,117662151,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9b7e4d67a3e28c03d35b7b106245c73c1edb99f517a48112219c9c13cd89c1c7
company,2022-12-19 16:01:00,Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference,117579589,https://media.zenfs.com/en/prnewswire.com/675cab157b2a50f2b39086046042d9fc,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023. The presentation is scheduled for 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) and may be accessed from the ""Investors & Media"" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. An archived version of the presentation will be available for at least 30 days.",https://finnhub.io/api/news?id=9d0cd2e09e2698cce17153e6d098ef83c1e8294a825eadc273c3c62b88710014
company,2022-12-19 13:53:06,Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis,117577506,https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966,REGN,Yahoo,The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.,https://finnhub.io/api/news?id=97cce36cab4e859cb160d94b14f9f1cb1716d54135e03566adbe8cddccb7959f
company,2022-12-19 12:21:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,117690698,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slumped 0.29% to $721.10 Monday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=3c54e5ca2e27c42a852a1c2ed95a5c5a5c50daba099849a1deab01b85c601b6b
company,2022-12-19 00:26:00,Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro,117662154,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=62c8b2068425af5206972caa3ebf25b16dfdf4626961cfbfa3337a370300eeef
company,2022-12-18 00:00:17,IBBQ: Healthcare Dashboard For December,117565452,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310024666/image_1310024666.jpg?io=getty-c-w750,REGN,SeekingAlpha,The pharmaceuticals/biotechnology subsector has good value and quality scores. Click here to read more about IBBQ ETF.,https://finnhub.io/api/news?id=e5bf97def27912b4a2d83c6964251e037ef37a2457f0e776d37832fcc5e3cfcb
company,2022-12-24 09:00:44,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold US$7.0m worth of stock, possibly signalling a downtrend",117678348,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...",https://finnhub.io/api/news?id=72072e84d241cca033f3482562fc9c05f62b071f5eb94b5dd412c1e423460e0e
company,2022-12-23 12:20:00,"Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market",117690690,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. dropped 0.94% to $726.74 Friday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=820ccf1e71dcd2dcf0aba47c0323811793dcdc57d95fafab925d5653a6efdfe1
company,2022-12-23 10:05:03,Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma,117631289,https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0,REGN,Yahoo,"Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma.",https://finnhub.io/api/news?id=b66a09959d2cb8d1acc81d0bdbbceeb2bb95c9bb6823864038f7f6f1882dae7d
company,2022-12-23 08:30:00,Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer,117625648,https://media.zenfs.com/en/prnewswire.com/3230874815d85e12d74bad2fb0c69180,REGN,Yahoo,"Regeneron Pharmaceuticals (NASDAQ: REGN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Libtayo® (cemiplimab) as monotherapy to treat patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy.",https://finnhub.io/api/news?id=461360aa6ca6e372e198a7230fea22da7447558aff66d70315752e06c49daeb0
company,2022-12-23 07:42:00,IN BRIEF: Regeneron says cervical cancer treatment approved in Japan,117662136,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ce1eaacf70c13977415c15d896de7b18e377ccb5df7a0f3c003f64ed0b6aaebe
company,2022-12-23 03:03:00,Regeneron`s Libtayo approved in Japan for cervical cancer,117662138,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bd29ddbd3084fbe737432f0e074af1ce0cd9abf42cd7274f8ddad9f43ca9e0ac
company,2022-12-23 02:33:00,"Regeneron: MHLW in Japan grants marketing, manufacturing approval for Libtayo",117662139,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c8a4664dece6edc6fabc480630e31374e8a943149158ebb327bd139380928b4f
company,2022-12-22 12:21:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,117690692,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slumped 0.35% to $733.62 Thursday, on what proved to be an all-around grim trading session for the stock market,...",https://finnhub.io/api/news?id=3b56c27023c685d041a4ee554445001226abe24702b85c104caf0640a648da04
company,2022-12-21 23:18:00,"Sanofi, Regeneron's Dupixent phase 3 results show disease remission",117658911,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=212479cf6c767a419450ce4b1b5dcafd891de3e8339fafeee33ee70bd41c8727
company,2022-12-29 12:20:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market",117954745,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 1.16% to $721.29 Thursday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=94ce2e6f9333d41f8b35c4abfa5b418fb52e581812c3232713f0eeaf5b2aae7e
company,2022-12-28 16:54:20,Tracking William Nygren's Harris Associates Portfolio - Q3 2022 Update,117838843,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250038049/image_1250038049.jpg?io=getty-c-w750,REGN,SeekingAlpha,Harris Associatesâ 13F portfolio value decreased from $62.85B to $59.68B this quarter. Click to read an update on the portfolio's trades for Q3 2022.,https://finnhub.io/api/news?id=11fa2d9e68bf79fc6564f7252ee50f4b2eee62dd81c42b2837d4e2b9ee99e307
company,2022-12-28 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,117954749,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.24% higher to $713.03 Wednesday, on what proved to be an all-around rough trading session for the stock...",https://finnhub.io/api/news?id=d48dfd59ea108ff8252a00cbffe71e6741ea5051f7e62314ad640c92af11984c
company,2022-12-28 09:00:39,"Insiders who sold Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) earlier this year didn't have to weather this week's 3.4% slide",117821978,,REGN,Yahoo,"Even though Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) has fallen by 3.4% over the past week , insiders who sold...",https://finnhub.io/api/news?id=c978a43b6346dc1338193cec9dad2b32e6e078ae33261d831b7001381aaa6a5e
company,2022-12-28 03:57:00,Tracking William Nygren`s Harris Associates Portfolio - Q3 2022 Update,117840439,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a212d1e25cb9cafe8ca8d2c758aff0b6a08b064e78458f03b3cd6e80743b4a1b
company,2022-12-28 00:00:49,Race is on to develop new generation of weight-loss drugs,117812470,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Surging demand and tight supply for a new class of obesity drugs has sparked a race among several of the world’s largest pharmaceutical companies to develop rival medications for a market projected to be worth $50bn in annual revenues by the end of the decade.  Eli Lilly, Amgen, Pfizer and Regeneron are among the companies aiming to compete with market leader Novo Nordisk in a category which analysts say is rapidly becoming a healthcare priority and could produce several blockbuster obesity treatments this decade.  Mounjaro, a similar medication already marketed by Lilly for treating diabetes but which is expected to get a green light from regulators next year for obesity, is also scarce at least in part because of off-label use by patients with obesity.",https://finnhub.io/api/news?id=2d850e6c2e37aa6b7b1c865a76d6d5f5a7a1dd7dcf45db48a6e87bba78cdb7be
company,2022-12-27 12:20:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market",117954751,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 2.12% to $711.35 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=d1e1db74eb33201f4dcca9e9573c75e1424fc6c7dc7226232a51e7521b1ee9fa
company,2023-01-01 09:00:44,"Calculating The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)",118084328,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Does the January share price for Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) reflect what it's really worth? Today...",https://finnhub.io/api/news?id=6a1b7f4746e54e8087e4edcbb422d1f9bd5bf17c119242b8ababf807abe82fb9
company,2022-12-30 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,117954741,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.03% higher to $721.49 Friday, on what proved to be an all-around grim trading session for the stock market,...",https://finnhub.io/api/news?id=ceac791db22d71ce0df4ed5916d2a9b966d8967aa764985efdcfe73365c2c5f4
company,2022-12-30 06:12:00,What You Missed On Wall Street This Morning,117923825,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=567ebe15151cb6f530f1e68bb3860edef0865909adc587d5398a91e23d2891b9
company,2022-12-30 02:02:00,Opco reveals three biotech stocks that will outperform in 2023,117923828,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f4c27c66a2e6ca0ce8b0745fd25e94d0f73977a46b1fb157d66ee343d29006eb
company,2023-01-06 18:26:24,5 Top Pharma Stocks of 2022 to Buy for the Long Haul,118198216,https://media.zenfs.com/en/investorplace_417/1a613ad1908304f1ed68cbe5ec644590,REGN,Yahoo,"Not every stock went down in 2022. Shares in some the biggest pharmaceutical companies rose in price. If you can make it in a market like 2022, imagine what can happen in 2023 for many top pharma stocks. What the best pharma stocks have in common is pricing power, patented medicines, big moats and wide margins. They’re also members of Pharmaceutical Research and Manufacturers of America, the trade group that has fought for decades to keep prices high. Pricing is the key risk for these companies.",https://finnhub.io/api/news?id=351a1f185737f906081ed405f80b026db85c7f682be77d9e0b130752be6044c1
company,2023-01-06 13:46:06,CytomX (CTMX) Up 55% on Strategic Partnership With Moderna,118175667,https://media.zenfs.com/en/zacks.com/c0c563b233f28a1874a33c46aadaa70e,REGN,Yahoo,CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.,https://finnhub.io/api/news?id=59452602cf6c8946b6809b6e6cb5ac1a2a8536ea00c88d64275cf80f9b991c08
company,2023-01-06 12:22:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market",118224773,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 1.85% to $737.15 Friday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=aff155fb6d0a6b0e65644ca50fbe34387548c5756a307c1d66907adc0b11f9ed
company,2023-01-06 05:39:00,3 Growth Stocks That Could Rocket Higher in 2023,118166153,https://s.yimg.com/ny/api/res/1.2/peRuesMt_MEvEAPLxyE2kw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/307746af7cd75985905df8fa2554aafb,REGN,Yahoo,"If you're looking for stocks that can make dramatic gains quickly, it's hard to do any better than the biotechnology industry.  Hardly a week goes by without at least one biotech stock shooting higher or tumbling lower in response to exciting news about experimental treatments.  In 2023, all three of these drugmakers will report study results that are awfully important to their futures.",https://finnhub.io/api/news?id=b3c8eeeb878c072b538e49997fdc504106938cc9f9f0037982d5664513a020db
company,2023-01-06 04:43:00,"2seventy Bio, Regeneron in Amended Collaboration >TSVT REGN",118220819,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,"By Colin Kellaher 2seventy bio Inc. on Friday said it inked an expanded collaboration with fellow biotechnology company Regeneron Pharmaceuticals Inc.,...",https://finnhub.io/api/news?id=e17e329292f592f8a27c38f850924f9b086a59ba174ecca4051110497482ac57
company,2023-01-06 03:25:00,2seventy Bio announces amendment to collaboration with Regeneron,118168288,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f1a0ed3599a5a29ffd02dd24628ae7ddd4ac236c21bb76653ea3c0ab3df38084
company,2023-01-05 23:19:00,FDA Dermatologic & Ophthalmic Drugs Advisory Committee Virtual Meeting,118180406,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=247679f8266f692c2e720f980f5bfa81ad8445d2f320350ed8369c04ded399a7
company,2023-01-05 14:08:21,Jim Cramer says he likes these 5 Nasdaq stocks for 2023,118154139,https://image.cnbcfm.com/api/v1/image/106952694-1633458798763-gettyimages-1344991010-cg4a6495_20211005125127938.jpeg?v=1672963701&w=1920&h=1080,REGN,CNBC,Cramer offered investors a list of stocks listed in the Nasdaq Composite that he believes could be winners this year.,https://finnhub.io/api/news?id=104a24df31c31c0e9601ae4ff6bd4e3ed0430241eef5b9e209656f5f756d5909
company,2023-01-05 01:37:00,Sensei announces clinical supply agreement with Regeneron for Libtayo,118163111,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3e18bb16f6a4a9cc8c42add2161b74e87bb8c03501b150f43671033cf72e938d
company,2023-01-04 23:22:00,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,118180408,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b4e06e0eaeb4d96a3504dc1eb7c583f69351ddb32b7b00e921814c386b3d399c
company,2023-01-04 22:20:00,"CytomX Therapeutics updates business, announces 2023 relationship with Moderna",118170691,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=58bbe841b3a0a24de86a06cbcb0a8f438bb84e1a069bee918e31fe7b6f3a603e
company,2023-01-04 12:20:00,"Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market",118127600,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.84% higher to $726.49 Wednesday, on what proved to be an all-around great trading session for the stock...",https://finnhub.io/api/news?id=71efec9e3f0e6409440e3e4bc697191708173b61d6add8cd157e3d40f8c1aa59
company,2023-01-03 16:01:00,"Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023",118108689,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"TARRYTOWN, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2022 financial and operating results on Friday, February 3, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call InformationParticipants may access the conference call live via webcast on the ’Investors and Media’ page of Reg",https://finnhub.io/api/news?id=edbd7d5970b067a8004810fe0c3c8bb1f400501ca79536fd7676f5bffe349b04
company,2023-01-03 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,118127602,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. dropped 0.14% to $720.47 Tuesday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=d78af561313aa99a09795f38f2c2d7d6fc6bbab41cbfc0539401b0f837e41a62
company,2023-01-03 12:13:05,What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?,118100055,https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7,REGN,Yahoo,Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.,https://finnhub.io/api/news?id=a66c0a87e2dd400a08c6bda14d354caa494c23b94df64bf4a79e3f5cdaefd248
company,2023-01-10 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,118224768,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 2.71% to $698.95 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=ea3ee613c1fb2259b5fee117033a466f6d0008f4ae99566427ee09156fd65bc5
company,2023-01-10 09:46:02,Regeneron (REGN) Down on Ophthalmology Drug Eylea Sales Update,118198210,https://media.zenfs.com/en/zacks.com/e6ffe54834ffe5e6a081956bbf05ac91,REGN,Yahoo,Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.,https://finnhub.io/api/news?id=bf21e34087fb3d99578bca7007b56fa1bd3a8463b0b008d947587ab5ee270dab
company,2023-01-10 09:32:02,"Company News for Jan 10, 2023",118198211,https://media.zenfs.com/en/zacks.com/9573f9e887d84f4e61d55c39f7894550,REGN,Yahoo,"Companies In The News Are: REGN, LULU, DCT, BAX.",https://finnhub.io/api/news?id=eebbd8f59442843ecfd589e8dc5efe2ee437d8e2393c063358699ea3ecaa4c51
company,2023-01-10 07:43:40,"Stocks making the biggest moves midday: Bed Bath & Beyond, Coinbase, Virgin Orbit and more",118197406,https://image.cnbcfm.com/api/v1/image/106998378-1641575583614-Image_from_iOS_17.jpg?v=1673372620&w=1920&h=1080,REGN,CNBC,These are the stocks posting the largest moves midday.,https://finnhub.io/api/news?id=2e3e8f5ea34bc8434de1390b2bd78fca3e15a0b302900bb96fdbb8ff466faaa7
company,2023-01-09 16:15:45,Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin,118198212,https://media.zenfs.com/en/ibd.com/4795b98ccb889179b7e4c69d8fd230c8,REGN,Yahoo,Regeneron Pharmaceuticals said sales of its linchpin Eylea drug have been negatively impacted by a short-term shift to rival drug Avastin.,https://finnhub.io/api/news?id=279de429fafe50f31d6f95c485589088d4f6ec5e90d9ce01c88f43b9cadd4737
company,2023-01-09 15:37:00,Regeneron Stock Sinks on Disappointing Sales of Eylea Treatment,118198213,https://s.yimg.com/ny/api/res/1.2/6byZBGiRWyDK.ZHjwTS25g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/f504cc73449c1c196ffc2c155f96516d,REGN,Yahoo,"Eylea is meant to treat conditions such as macular degeneration, macular edema, and diabetic retinopathy.",https://finnhub.io/api/news?id=a54a63638d986d4888ed624601e8a3a7ce8dcf6fe15f371cf519446799c98081
company,2023-01-09 12:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors,118224769,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 7.69% to $680.49 Monday, on what proved to be an all-around grim trading session for the stock market, with the...",https://finnhub.io/api/news?id=f207ff808f882f0da4774c19c76dce82bb11d3ce2266e3b5645a3ece79bc8359
company,2023-01-09 12:16:00,Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup,118224770,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,Health-care companies fell sharply as traders rotated into sectors with more to gain from falling Treasury yields. Moderna said it's considering pricing its...,https://finnhub.io/api/news?id=a26bb195c1b58d09ec70abb270e7444e28d0d3025ef3d5b348791c51d5fcfdcf
company,2023-01-09 10:45:01,Healthcare Stocks See Winners and Losers on Monday,118198214,https://media.zenfs.com/en/wsj.com/5a1902233c88bbfaa2f551e2508cb061,REGN,Yahoo,"Healthcare companies are pre-announcing fourth-quarter results ahead of the industry's [most important investor](https://www.wsj.com/livecoverage/stock-market-news-today-01-09-2023/card/inflation-banks-biotech-what-s-on-tap-for-this-week-SwgbGitBuQOyISoLL9Mx) conference—stocks are reacting. + Diagnostics company Exact Sciences is a Monday morning winner. The stock is up 20% after Exact, which makes the Cologuard test to detect colon cancer, said it expects to report fourth-quarter sales of $550.",https://finnhub.io/api/news?id=d2163c69d601032e2d9407832aa3291dc5723d8d6235e92fb7559529e479d6fe
company,2023-01-09 07:36:10,"Stocks making the biggest moves midday: Tesla, Nvidia, Lululemon and more",118199790,https://image.cnbcfm.com/api/v1/image/107174939-1672989843877-gettyimages-1243173359-fernandes-hongkong220912_npeC0.jpeg?v=1673285770&w=1920&h=1080,REGN,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=065015d8575e46bb370eeee8e9e9be6f8bb43bbeb4c0e6469a8313c91a170253
company,2023-01-09 00:13:00,"These Stocks Are Moving the Most Monday: Tesla, Zillow, Regeneron, Macy’s, and More",118224026,https://images.barrons.com/im-533441/social,REGN,MarketWatch,"CinCor Pharma, Albireo and Duck Creek Technologies also made big moves Monday.",https://finnhub.io/api/news?id=aeccb185eefe60fd445d0ec5d0627c50fa7259be5774bc1dff6c3b88dffa65c1
company,2023-01-08 15:32:41,15 Most Advanced Countries in Medicine,118198215,https://media.zenfs.com/en/insidermonkey.com/d7b54ab6c172424f8eb29273c1277201,REGN,Yahoo,"In this article, we take a look at the 15 most advanced countries in medicine. You can skip our detailed analysis of the healthcare industry and go directly to 5 Most Advanced Countries in Medicine. The recent pandemic was the best reflection of the advancements in the field of medicine. Vaccines were developed at a […]",https://finnhub.io/api/news?id=ee4a88d8d355e64ac5e48c764eee76d1c59c3a65f3ee25d49eae8acfb2da06f8
company,2023-01-12 18:15:11,Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know,118231828,https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619,REGN,Yahoo,"Regeneron (REGN) closed the most recent trading day at $714.57, moving +0.65% from the previous trading session.",https://finnhub.io/api/news?id=53f24ca32fa5976046a72209dcc8d84c44fd600c45a6ea60ac565a8d052fa615
company,2023-01-12 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,118224766,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.65% higher to $714.57 Thursday, on what proved to be an all-around great trading session for the stock...",https://finnhub.io/api/news?id=e4064ae6321dfb42a67267d78345d82a27a188a978d04de761bbbee3386f2abe
company,2023-01-11 19:15:36,Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics,118198086,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295493003/image_1295493003.jpg?io=getty-c-w750,REGN,SeekingAlpha,"Despite being founded 10 years ago, CRISPR Therapeutics could very well lose out to 3-year-old Prime Medicine. Read more to see the comparison.",https://finnhub.io/api/news?id=68bcc5234ef762b08fe83cce27e20d9a485ab42200f1fe44481a048e96cb650e
company,2023-01-11 12:21:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,118224767,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.57% to $709.94 Wednesday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=303e136670c6e89656a6f52e6248f253eb743cb002f76c579d1a2c1d729d9896
company,2023-01-11 11:40:04,REGN or TECH: Which Is the Better Value Stock Right Now?,118198207,https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781,REGN,Yahoo,REGN vs. TECH: Which Stock Is the Better Value Option?,https://finnhub.io/api/news?id=c85753360c5537add455a062ba0f5acfafad4777b9018c4ebb5795a38b3696ad
company,2023-01-11 11:10:04,"Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More",118198208,https://media.zenfs.com/en/zacks.com/b8005943688573a12f9c191d15a5c1be,REGN,Yahoo,Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=948aa8b12f158a112e452552c5466f83e5deec4b8840ab708ee271fe68e93de7
company,2023-01-11 06:00:35,"Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?",118198209,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"With its stock down 7.1% over the past three months, it is easy to disregard Regeneron Pharmaceuticals (NASDAQ:REGN...",https://finnhub.io/api/news?id=35fb596ff552d4938cfba944a97f4a46ea440838929de7982d7f558cdbdee7ea
company,2023-01-18 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,118323785,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 0.49% to $724.55 Wednesday, on what proved to be an all-around poor trading session for the stock market,...",https://finnhub.io/api/news?id=a9ef089d53173223e1dd65e84247e3ebf94dde942b8604ea4a8235653c6e016c
company,2023-01-17 21:00:00,Covid Isn’t Going Away. New Drugs Are Coming.,118306341,https://images.barrons.com/im-704479/social,REGN,MarketWatch,Drug makers are preparing everything from a vaccine that comes as a pill to a better version of Paxlovid.,https://finnhub.io/api/news?id=afdcb6edbb4380b8fa559e315ff94b0c470d6571d57742653087be166fddcfdb
company,2023-01-17 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,118323787,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.83% higher to $728.11 Tuesday, on what proved to be an all-around rough trading session for the stock...",https://finnhub.io/api/news?id=573ed4c213a53f55b3debbb11039e483c25657305cbac603550d4e0d6c89fb36
company,2023-01-16 17:00:00,Why Regeneron's CEO remains bullish on Eylea drug after 11 years on the market,118285791,,REGN,Yahoo,"""What's driving the category are demographics, aging of the population, as well as [an] increase in diabetes and diabetic eye disease,"" Regeneron CEO Len Schleifer said during the 41st annual J.P. Morgan Healthcare Conference in San Francisco.",https://finnhub.io/api/news?id=bc39b288d90aceba90437269fa13b672fb2dd4dc4ce58113eb6d1b412a3db864
company,2023-01-15 06:00:44,Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 94% return over the last five years,118272869,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying...",https://finnhub.io/api/news?id=4d189e3ed86279e6ef380cc12870eaea8ed77a173f5ad39b6d92262b0af275bd
company,2023-01-20 02:43:22,"Stocks making the biggest moves premarket: Netflix, Alphabet, Nordstrom, PagerDuty and more",118330938,https://image.cnbcfm.com/api/v1/image/107145898-1667510273534-gettyimages-1393876536-0j7a4557_34171d4c-3964-4bfa-ac93-3394a0db95ff.jpeg?v=1674218602&w=1920&h=1080,REGN,CNBC,These are the stocks posting the largest moves in early trading. ,https://finnhub.io/api/news?id=c0d7c6e66de484e7161828538e6b3fd7bb2d854a6abfe1d6f8e584e1a2465381
company,2023-01-19 12:20:00,"Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market",118323784,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 1.24% to $715.57 Thursday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=6b5c1e016f425e2d184ef80e020f910ac0cf99b02708e17c9d42a014bb70246f
company,2023-01-19 06:00:59,Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?,118322192,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...",https://finnhub.io/api/news?id=2f62938e779b1b9e1e55e0918437435d5219c6127641f977eb44d3a150ce1e6a
company,2023-01-26 09:16:33,15 Most Undervalued Quality Stocks To Buy According To Hedge Funds,118379475,https://media.zenfs.com/en/insidermonkey.com/fa0b8bb863ca7cb691d99a09ad4c4ed6,REGN,Yahoo,"In this article, we discuss 15 most undervalued quality stocks to buy according to hedge funds. If you want to see more stocks in this selection, 5 Most Undervalued Quality Stocks To Buy According To Hedge Funds. Quality stocks usually have little debt, steady earnings, regular growth in assets, and effective leadership. Investors can identify […]",https://finnhub.io/api/news?id=5750e5347ad96c45e6a9c3cf6aabea9c9dad648af25e40e38f507926a1d1f622
company,2023-01-25 10:37:27,12 Cheap Biotech Stocks To Buy,118361756,https://s.yimg.com/ny/api/res/1.2/7b0r1_vGfNZHKiXf31EiMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/784ede8f3979aaba79334aeecd7f7d27,REGN,Yahoo,"In this article, we will be taking a look at 12 cheap biotech stocks to buy. To skip our detailed analysis of the biotech sector, you can go directly to see 5 Cheap Biotech Stocks To Buy. The biotechnology sector has been on the rise over the past three decades. Several forecasts expect the sector […]",https://finnhub.io/api/news?id=6b7c0c22b775d7d66f08c9206eba774a660986fd967c344694c8ce743f4dd147
company,2023-01-24 12:02:00,"Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition",118364359,https://media.zenfs.com/en/prnewswire.com/d9d5df1e59b6dffd1b6b6101e323a806,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors. The competition, now in its 82nd year, celebrates and rewards young scientists focused on a wide range of scientific topics from the space race to the AIDS epidemic to climate change. Many past winners continue to pursue innovation for",https://finnhub.io/api/news?id=c4de8cc1ff73e7eff054fd2d7bf28305811bfda638f7a5f9feeddf67337f4d48
company,2023-01-23 18:15:11,Regeneron (REGN) Gains But Lags Market: What You Should Know,118364360,https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2,REGN,Yahoo,"Regeneron (REGN) closed the most recent trading day at $729.91, moving +1.1% from the previous trading session.",https://finnhub.io/api/news?id=83faf2faa351d91947e584bf555d17da00a768055cef7599479f74acfcc07466
company,2023-01-30 01:15:27,Sanofi and Regeneron's Dupixent wins new European Commission approval,118399607,https://static.reuters.com/resources/r/?m=02&d=20230130&t=2&i=1621775476&r=LYNXMPEJ0T06G,REGN,Reuters,"Healthcare companies Sanofi and Regeneron said on Monday that their Dupixent product had won approval from the European Commission to treat eosinophilic esophagitis (EoE), which is a condition that damages the esophagus.",https://finnhub.io/api/news?id=6cafc7c55bcf540a83a83c093657a2edc82b692bcc4973a93f35ed5a15f46367
company,2023-01-27 12:10:05,Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again,118387181,https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a,REGN,Yahoo,Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://finnhub.io/api/news?id=51e3dad6fd76033ffa70448aa594d7baed81745a6bbd2e7bb433f8fc0bb7c4d9
company,2023-01-27 10:00:03,Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?,118387182,https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a,REGN,Yahoo,Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=58dc005c1b9dff0399b897a2fe03b9b43057ba2e6b151bb966f975f459966b9d
company,2023-01-27 09:00:18,"Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$7.0m worth of stock",118387183,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the company...",https://finnhub.io/api/news?id=ca27da6f5ca0af38e3ddd20d8677a10893884dbc43d5df3d46122fc9ed89b687
company,2023-01-27 08:27:00,"Regeneron, Sanofi’s Dupixent is one step closer to approval for young children in Europe",118387164,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,REGN,Yahoo,"MARKET PULSE Shares of Regeneron Pharmaceuticals Inc. (REGN) gained about 2.5% in premarket trading on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Dupixent, the atopic dermatitis therapy developed with Sanofi (FR:SAN) (SNY) for children as young as six months old.",https://finnhub.io/api/news?id=1599198185cfd5b4074f7f16d03928d7490627fe7623660d3358d8ae941f2c6b
company,2023-01-27 01:37:50,Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval,118383114,https://static.reuters.com/resources/r/?m=02&d=20230127&t=2&i=1621514174&r=LYNXMPEJ0Q054,REGN,Reuters,Healthcare companies Sanofi and Regeneron said on Friday the European Union's medicines regulator had given a new stage of approval for their Dupixent product to treat children as young as 6 months old with severe atopic dermatitis.,https://finnhub.io/api/news?id=555904fee93ee001528e2ab0de28fc1a3c884090a30a60c1b9a6eb80ea90cb32
company,2023-01-27 01:24:36,UPDATE 1-Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval,118387166,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,Healthcare companies Sanofi and Regeneron said on Friday the European Union's medicines regulator had given a new stage of approval for their Dupixent product to treat children as young as 6 months old with severe atopic dermatitis.  The European Commission is expected to announce a final decision on the Dupixent application in coming months.  Dupixent was approved in June 2022 by the U.S. Food and Drug Administration (FDA) regulator for children in this age group.,https://finnhub.io/api/news?id=bc92438fb627764690c8071472c609bd93f596b6240f58367a1974ae82dfd026
company,2023-01-27 01:08:11,Sanofi/Regeneron: Dupixent wins new stage of EU regulatory approval,118383115,,REGN,Reuters,Healthcare companies Sanofi and Regeneron announced on Friday that the European Union's medicines regulator had given a new stage of approval for their Dupixent product to treat children as young as six months old with severe atopic dermatitis.,https://finnhub.io/api/news?id=52af64884db2bd978f9531d0471b3c6e8b984e7462d504db07e3e9106f38ee21
company,2023-01-27 00:59:00,Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis,118387186,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"If approved, Dupixent would be the first and only targeted medicine in the EU for these young children Recommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent improved skin clearance, reduced overall disease severity and improved health-related quality of life In Europe, about 80,000 children aged 6 months to 5 years with uncontrolled severe atopic dermatitis are candidates for systemic therapy TARRYTOWN, N.Y. and PARIS, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Rege",https://finnhub.io/api/news?id=71b6e95e02603f776cd3a735b4944f0cd420ed3e81f8ee64740b70399d20f70c
company,2023-02-03 16:20:03,"Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart Pattern",118472434,https://media.zenfs.com/en/ibd.com/3db3da6c65c6fe9bf4e314e6d2e118a2,REGN,Yahoo,Regeneron and Analog Devices hit new highs and break out. REGN had strong fourth quarter earnings. ADI is leader in the chip industry,https://finnhub.io/api/news?id=bcfd33c776a29a553cd4fef3685f2c1ffc03bc5bd9c9e6368460d2f3cb77d71a
company,2023-02-03 10:29:47,"Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples",118452999,https://media.zenfs.com/en/ibd.com/d18db5553406b2c6bc95b990fd80640e,REGN,Yahoo,"Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.",https://finnhub.io/api/news?id=cd58c6564e30a241b2ee682657008690f1fbad290793728b4dbfb235dee71774
company,2023-02-03 12:45:05,"Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics",118472436,https://media.zenfs.com/en/zacks.com/2db9674ed3dae8b5017b58b4e4b808c0,REGN,Yahoo,"While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",https://finnhub.io/api/news?id=552b0f53061f650f86f780d209610ebf7adb6f6ec622e1e56f913d768b2fadaa
company,2023-02-03 12:04:00,Health Care Edge Lower After Solid Earnings -- Health Care Roundup,118729039,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,"Health-care companies fell, but not by as much as the broad market, after a solid week of earnings. Regeneron Pharmaceuticals rallied after the biotech...",https://finnhub.io/api/news?id=e9855d973c90e890a1186dc5f5a47993c1f61109941cc7f82ea5031cfa5e335e
company,2023-02-03 11:35:04,"Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline",118471778,https://media.zenfs.com/en/zacks.com/294fae4854e7183caa1fdfbfcdc9418c,REGN,Yahoo,"Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.",https://finnhub.io/api/news?id=af72710b0b5622d60968d5417d0d684d1fdea987726370f49a472ec4a04fc33a
company,2023-02-03 08:15:00,"Regeneron’s Earnings Beat Forecasts, With No Sales of Covid-19 Treatment",118452940,https://s.yimg.com/ny/api/res/1.2/.plfMHKFZsM0Yyu7VAiWQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/f5f46673fe73e5f10195c3223af41aaa,REGN,Yahoo,The pharmaceuticals company's total revenue dropped by 31% to $3.41 billion but beat the FactSet consensus of $3.13 billion.,https://finnhub.io/api/news?id=d807c288c0afccd8d7df652447e1186145acc300b6a1f7d18bf79f02fa6dbe29
company,2023-02-03 08:01:37,Regeneron profit beats estimates on Dupixent strength,118454165,https://static.reuters.com/resources/r/?m=02&d=20230203&t=2&i=1622352982&r=LYNXMPEJ120G8,REGN,Reuters,"Regeneron Pharmaceuticals Inc reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea.",https://finnhub.io/api/news?id=0a69aa0ce9d6b69a9704353e05f16caae0caadec85602cb7e2b9b5e2510e7267
company,2023-02-03 07:45:12,Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates,118472439,https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2,REGN,Yahoo,"Regeneron (REGN) delivered earnings and revenue surprises of 29.75% and 7.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=19127a48226451b6fb7bd66d9378942cfd8ffc98e9f62be419b544bf861b49c0
company,2023-02-03 07:43:06,"Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Call Transcript",118452969,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor RelationsLeonard...",https://finnhub.io/api/news?id=259bfe54107d2244ba453d6aefa65ee32efc02855a923a66661430091c377033
company,2023-02-03 07:42:09,"Regeneron Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation",118452970,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"The following slide deck was published by Regeneron Pharmaceuticals, Inc.",https://finnhub.io/api/news?id=db42ee9b01242680c41ac7c5039fdce647190298fada83f351668b5758497105
company,2023-02-03 06:50:27,UPDATE 2-Regeneron profit beats estimates on Dupixent strength,118472440,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Regeneron Pharmaceuticals Inc reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea.  Eylea, which recorded total sales of $9.65 billion in 2022, has been a key growth driver for the company ever since its launch more than a decade ago.  Sales of Eylea, used to treat vision loss causing age-related macular degeneration, were impacted by temporary closing of a fund during the quarter that provides co-pay assistance to patients.",https://finnhub.io/api/news?id=daca4d94caf1f929920193de16cae788817fb1275be2ff644527ac1094d60e45
company,2023-02-03 06:45:00,Regeneron stock rallies after profit and revenue beat expectations by wide margins,118472441,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,REGN,Yahoo,"MARKET PULSE Shares of Regeneron Pharmaceuticals Inc. (REGN) rallied 1.9% toward a two-month high in premarket trading Friday, after the biotechnology company reported fourth-quarter profit and revenue that fell, as sales of its COVID-19 treatment dropped, but beat expectations by wide margins.",https://finnhub.io/api/news?id=fbdf4d9a716b7e564baeb8f987a77223789a28dcc73f556834c5d15817db60c8
company,2023-02-03 06:43:04,CORRECTED-Regeneron quarterly profit drops 46%,118454167,,REGN,Reuters,"Regeneron Pharmaceuticals Inc reported an about 46% plunge in its fourth-quarter profit on Friday, hurt by a drop in U.S. sales of its blockbuster eye drug, Eylea, and drying up of its COVID-19 antibody cocktail sales.",https://finnhub.io/api/news?id=19b512b17b113f491bf3960976bcd6910b2decb623f918e842572fd60adcf55f
company,2023-02-03 06:30:00,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results,118472444,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV® and RonapreveTM(a)(b), revenues increased 14%Full year 2022 revenues decreased 24% to $12.17 billion versus full year 2021; excluding REGEN-COV and Ronapreve(a)(b), revenues increased 17%Fourth quarter 2022 EYLEA® U.S. net sales decreased 3% to $1.50 billion versus fourth quarter 2021; full year 2022 EYLEA U.S. net sales increased 8% to $6.26 billion versus 2021Fourth quarter 2022 Dupixen",https://finnhub.io/api/news?id=ad61812bb8d299d462ac0abc738c56b93da37e165b92f1b51e51ccb077d2251a
company,2023-02-03 05:23:43,Regeneron shares rise as eczema drug sales help drugmaker post Q4 earnings beat,118472445,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,By Scott Kanowsky,https://finnhub.io/api/news?id=19fc8d772a4aca04712326349b23e0c835d95c348fb678051886e4e1962be574
company,2023-02-03 05:00:00,Here's why 2seventy bio's chief executive thinks 2023 will be a 'special year',118472447,https://s.yimg.com/ny/api/res/1.2/vXb0fElpys.hfL_Q2w0pFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xODAw/https://media.zenfs.com/en/bizjournals.com/28d5388dd40faed62ca1c2d121ab679f,REGN,Yahoo,"The chief executive of bluebird bio's oncology-focused spinout believes that this year, it will take off as a company in its own right.",https://finnhub.io/api/news?id=ec06960534e30bce63819016fb82e61b0eead9c17e1d89a1697a2c4c9ea150d1
company,2023-02-03 02:29:24,UPDATE 4-Sanofi forecasts moderate profit growth on Dupixent demand,118453007,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Sanofi forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent would be partly offset by competition for its multiple sclerosis pill Aubagio and product launch costs.  Aubagio, with 2 billion euros ($2.2 billion) in sales last year, will face competition from cheaper products over the next few months after losing patent protection, Sanofi said.  Sanofi shares were down 3% at 1107 GMT, having earlier fallen as much as 5.2% to their lowest since mid-November with JP Morgan analysts saying investors had expected a better 2023 outlook and a more benign view on foreign exchange headwinds.",https://finnhub.io/api/news?id=4b205ee7353eb98de85ceb0139fb830f0fe4b0966e5414af20699a8254263b5c
company,2023-02-02 15:19:36,The 7 Most Undervalued Stocks to Buy in February 2023,118476125,https://media.zenfs.com/en/investorplace_417/61c74602354cfbb3fef7c1986361cacf,REGN,Yahoo,"As Feb. gets underway, I’m finding under-appreciated, undervalued stocks to buy. When seeking value in the stock market the hope is that other investors will see what you see: The underappreciated value inherent in strong businesses that don’t necessarily garner a lot of attention. In turn, they follow your lead, purchase en masse, and the price of your shares rises with demand. Short-term volatility will remain for those who take this approach now. But market cyclicality will do its magic and m",https://finnhub.io/api/news?id=607fe7343782686b75130b5ca1109521a897fb1bf89159eea25d6768feb697ab
company,2023-02-02 14:19:39,The 7 Most Undervalued Biotech Stocks to Buy in February 2023,118475271,https://media.zenfs.com/en/investorplace_417/15560f4ac90506a3a1b885bba9b2e625,REGN,Yahoo,"You don’t have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science. At the same time, the established players tend to be pricey. By picking up underappreciated names, it’s possible to secure significant upside down the line. However, anytime a discussion about the most undervalued biotech stocks to buy materializes, a question comes up: how doe",https://finnhub.io/api/news?id=f7931a3bdba6865dee7409636f8dcd2108cc856e6932e9dc059492fd32fe879b
company,2023-02-02 08:32:01,Why Regeneron (REGN) Might Surprise This Earnings Season,118472450,https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5,REGN,Yahoo,Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,https://finnhub.io/api/news?id=3a81ca3c5120af9518fb10ea48a2717e027f875407c814439b43c158550e19c5
company,2023-02-01 19:00:12,Time to Buy Cigna or Regeneron Stock Before Earnings?,118472451,https://media.zenfs.com/en/zacks.com/527c0969278fdbbc2f2ca619ecd26f14,REGN,Yahoo,"Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.",https://finnhub.io/api/news?id=4e157a1285a7ff5ce32d2a5842a6c29f9c0337915b0a2d63e626d5abf387f9c5
company,2023-02-01 16:10:43,The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023,118472452,https://media.zenfs.com/en/investorplace_417/49d59d6b2c0a054aae935125e02570ff,REGN,Yahoo,"Thanks to the wild events of 2022, discerning investors enjoy plenty of bargains, particularly in the arena of the most undervalued Nasdaq stocks. Given the exchange’s bias toward technology players (including biotech), wagering in this space carries the advantage of relevance. Even if circumstances look shoddy right now, at some point, these enterprises have a shot at upside eventually. Now, a word of caution is in order following the utterances of the last few words above. With the most underv",https://finnhub.io/api/news?id=586f08732fbf253cf48fd50d3a77da22784887d51a254e52c37162eef04c2408
company,2023-02-01 10:16:19,Top 25 Smartest Companies To Buy According To Hedge Funds,118418136,https://media.zenfs.com/en/insidermonkey.com/f2be6cdaebf0756384c85c09099e48f8,REGN,Yahoo,"In this piece, we will take a look at the top 25 smartest companies to buy according to hedge funds. For more companies, head on over to Top 5 Smartest Companies To Buy According To Hedge Funds. Surviving in the modern day corporate world is not for the faint of heart. Business is a ruthless […]",https://finnhub.io/api/news?id=46eeda16f64ea23e7da6ee1cab9c199cd87637a58ca42ea239a84953f98bc78a
company,2023-02-01 09:00:02,How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings,118472454,https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2,REGN,Yahoo,Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.,https://finnhub.io/api/news?id=5bffec9dfba78f4047921eecea32868aec97e03e1ae93e8f30d66b709b73a030
company,2023-02-01 06:00:27,"Are Investors Undervaluing Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) By 31%?",118472455,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Today we will run through one way of estimating the intrinsic value of Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN...",https://finnhub.io/api/news?id=6050524e42aa727977347239565fbc4d9664bc57dbc7134553e80aba28fbcf56
company,2023-01-31 18:18:17,Cowen & Co. Upgrades Regeneron Pharmaceuticals (REGN),118403831,,REGN,Fintel,,https://finnhub.io/api/news?id=a3e9152700e55205b3eacb7ba01d71c3c1710b6111f1d6f2e91d688eeaf48051
company,2023-01-31 16:01:00,Regeneron Announces Investor Conference Presentations,118472457,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"TARRYTON, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: SVB Securities Global Biopharma Conference at 9:20 a.m. ET on Tuesday, February 14, 2023Cowen 43rd Annual Health Care Conference at 12:50 p.m. ET on Monday, March 6, 2023Oppenheimer 33rd Annual Healthcare Conference at 9:20 a.m. ET on Monday, March 13, 2023Barclays Global Healthcare Conference at 9:00 a.m. ET on Wednesday, March 15, 2023 The sessions",https://finnhub.io/api/news?id=4bdba52a185b0dd57bb5989a87454a0673350f5f26da8bb084659056247c546e
company,2023-02-07 17:15:07,Regeneron will accelerate capital spending by at least 40%,118509570,,REGN,Yahoo,Regeneron anticipates spending will increase to somewhere between $825 million and $950 million this year.,https://finnhub.io/api/news?id=7039ae5be826bbb9470d864adc0bfac33a153c4b82f6a5802ba6fd8e442956d2
company,2023-02-07 13:51:59,The 7 Best Biotech Stocks to Buy for February 2023,118528661,https://media.zenfs.com/en/investorplace_417/180ce84be58b62c67d477717f09599bb,REGN,Yahoo,"While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy. By that, I mean biotechnology firms may enjoy some economic insulation as their relevance supersedes variables like interest rate dynamics. Still, it doesn’t mean that the best biotech stocks to buy are immune from",https://finnhub.io/api/news?id=df33961c885a560d0273d1958cf8e5414b5058dcf4897d765ffc02b45654badc
company,2023-02-07 01:01:00,Top 5 4th Quarter Trades of MCDONALD CAPITAL INVESTORS INC/CA,118585856,,REGN,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=312d51053d862dd898bae1630cab1fbb4f427ccf8c33484013d2eb976b8428d5
company,2023-02-06 23:21:00,Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors,118816566,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3b7eddfd72f21e8b6738b0cab4396ec8e327f843c19a640a4a0c659e5a401fac
company,2023-02-06 10:14:17,Top 3 Healthcare Stocks for February 2023,118481834,https://media.zenfs.com/en/fx_empire_176/811cb8e37d7cba2ffa82d0d84653cc14,REGN,Yahoo,Many healthcare stocks are surging higher in 2023. Plenty of companies in the sector have seen large inflows recently. Chances are this theme can continue.,https://finnhub.io/api/news?id=554c58e471dcd4ee1bbff37f898c5314847c720b0f5b55136ddc111e02e23eea
company,2023-02-06 08:58:00,Bayer seeks EU approval for retinal eye disease treatment aflibercept,118671299,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a2bdd05a17b190b56cdceb29252e8af3093b26a422bbfd1a258a5b063a915068
company,2023-02-06 05:31:00,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Regeneron (REGN) and Seagen (SGEN)",118634613,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b8fd26efe573a71f4ecb1603e73e45cb45ca11f50fb417325c5bc8a793eb99af
company,2023-02-06 02:53:00,Regeneron price target lowered to $787 from $789 at RBC Capital,118816571,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cf792529b02e67c15dcc89149773905bfc879a128ce60efb890fcc85a68c2e5b
company,2023-02-06 02:06:45,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript",118481839,https://media.zenfs.com/en/insidermonkey.com/6e9f593b63e4bd2cafce0ac9eeb85b86,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript February 3, 2023 Operator: Welcome to the Regeneron Pharmaceuticals’ Fourth Quarter 2022 Earnings Conference Call. My name is Shannon and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please […]",https://finnhub.io/api/news?id=515f50d979a81c75454c134290f55fdd1afc2cf65d7a41bd1c9d2229ada51818
company,2023-02-06 01:31:00,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Genmab (GMAB) and Immunovant (IMVT)",118594753,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=df4db4d462b098cfa855ac028b5ec4070f3c342d4a40eb33f0f73b192128bcc9
company,2023-02-06 01:15:00,Regeneron price target raised to $853 from $750 at Canaccord,118816575,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=af69a9c29955023d297324166b38dbc2255154e66b8ff6925a9573e19b8d6c0e
company,2023-02-06 01:11:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,118792587,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ca5217428689e1957369ff61e2cd5055e9be597eb66d5dce0e7da2d0de677f4d
company,2023-02-06 01:06:00,BMO Capital Releases a Buy Rating on Regeneron (REGN),118816579,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7bbcb386538a79297d1bd55ca84f36ca93b94699d9135a561ffc6c92204f053e
company,2023-02-06 01:01:00,"Top 5 4th Quarter Trades of Pacer Advisors, Inc.",118715575,,REGN,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0231b47f70e73765261e631b0e23b7250529d94bb7374afb3eb5c26cc251103f
company,2023-02-06 00:53:00,Regeneron price target raised to $756 from $670 at Baird,118816582,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f71100e399daf3eba60c84cc077b365531f15e04db0d94ae93e333f721ee9d96
company,2023-02-05 23:22:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,118816584,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4dac21de917823e1d5524bf47613dea5ea2184b9e50a8773adae7d0beac7334b
company,2023-02-05 21:11:00,"Tom Gayner`s Firm Buys Brookfield Asset Management, Dumps Texas Pacific Land",118594143,,REGN,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9440cf88185ee142e29de70521f2999f40a0d06ef3329ffb4da0b1042243a479
company,2023-02-04 05:00:00,"Stocks To Watch: Spotlight On Google, Disney, Regeneron Pharmaceuticals And Hesai Group IPO",118470252,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week",https://finnhub.io/api/news?id=18fd2ffcd9b2f9f4b5a506c7bedf6f0612ac1a2028be5acaf1522553a7e71ca9
company,2023-02-11 13:13:00,2 Biotech Stocks That Could Help Set You Up for Life,118555236,,REGN,Yahoo,Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) are each up about 20% over the past year.  The biotech companies have shown increased revenue and earnings per share (EPS) over the past three years and have burgeoning pipelines that should continue to drive growth.,https://finnhub.io/api/news?id=d527aa1563591411f79ed4eb8a297fd81dedfa288f7ff5d35b37d16b7b3d70c4
company,2023-02-10 08:00:23,"Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Recent Performance Tethered To Its Attractive Financial Prospects?",118537970,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Given that the market rewards strong...,https://finnhub.io/api/news?id=0c4fc7c9560074db96a20bd70b7fdd237fb60200324e0874a092b9f5fa8d6962
company,2023-02-10 07:26:00,Pfizer Gets FDA Nod for Cibinqo in Adolescents With Atopic Dermatitis >PFE,118640496,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Pfizer Inc. on Friday said the U.S. Food and Drug Administration expanded its approval of Cibinqo to include adolescents with atopic...,https://finnhub.io/api/news?id=971aaa86f19d2e1c37e7575221a0eb57969c51473d123f4d3355aaac8fc39252
company,2023-02-09 23:32:00,Roche Vabysmo matches Eylea in 2 phase 3 trials for eye disorder,118661143,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=be7811838393ec0da1315ade0f84d18b212f1aa3126df77f604b3526f066b910
company,2023-02-09 23:22:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market",118816536,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dc2206f5f9d046460df10b1aef517fab989f9afa86293ae10ffe166d2980dc71
company,2023-02-09 13:35:06,Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants,118522972,https://media.zenfs.com/en/zacks.com/88c5b382e5e9e4ea852e01bfc1435a7b,REGN,Yahoo,Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).,https://finnhub.io/api/news?id=8fe63420b497c5375d76b24bc2c5f94bd575810690fdc874d66e784aff9e6754
company,2023-02-09 12:00:05,"Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update",118524985,https://media.zenfs.com/en/zacks.com/8b33b42379a93cd496db139197a8738b,REGN,Yahoo,"Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.",https://finnhub.io/api/news?id=6f32190c405c2d087d26beb33f95ab22380bb04413faf756db2fa5a0eac1cdae
company,2023-02-09 01:51:00,Regeneron wins FDA nod for Eylea to prevent infant blindness,118816537,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7fb924af816c97ff5b5f84accf3f77b61e697d54e1a352e4bf9fdc6bc5397023
company,2023-02-09 01:38:00,GLOBAL BROKER RATINGS: DZ Bank cuts Adyen; Kepler cuts Segro,118589109,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c4a3e4d3eaddffcb5b76a93b15fa3a504236dbc4afcf7eb894cbfff15c730415
company,2023-02-08 23:21:00,"Regeneron Pharmaceuticals Inc. stock falls Thursday, still outperforms market",118816542,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=381f383e96a8361a287cc43365eadc0718e4dee71218ed6c87d8e6de224ab558
company,2023-02-08 18:45:00,EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA,118537973,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"ROP is a leading cause of childhood blindness worldwide EYLEA now approved to treat five retinal conditions caused by ocular angiogenesis TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection to treat preterm infants with retinopathy of prematurity (ROP). Following this first pediatric approval, EYLEA is now indicated to treat five retinal condi",https://finnhub.io/api/news?id=0c8d17b98c3cfe107b788c44461de42c0f027c634a576b16eabcf73f4cd4da59
company,2023-02-08 07:31:00,Should Investors Worry About Regeneron Pharmaceuticals Inc`s Insider Sells?,118816546,,REGN,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=832e2a64ed02df6173eba1d740dc3b7b7592f55d8373afb5d4990bbf19f43e35
company,2023-02-08 05:01:00,"Freedom Day Solutions, LLC Buys 3, Sells 2 in 4th Quarter",118587075,,REGN,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c6a3ed212f78b80f32022ba7e7e9b93aa2621282713bf3a6da92aa4a3b765bf0
company,2023-02-08 01:34:00,GLOBAL BROKER RATINGS: Bernstein cuts Deutsche Post; MS raises Amex,118589113,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f9233fef160a6e0ebcf4251c573713a886b41d76576ab5f0d4fceb40df98f182
company,2023-02-08 00:49:00,Regeneron`s Eylea injection approved by FDA for treatment of preterm infants,118816554,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e84c207bc4b1910369e83b6c8b540677e7a9458a5b1fa8066f48e58049c2f743
company,2023-02-08 00:10:58,Government Contracts Trading Strategy,118500475,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1211494875/image_1211494875.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"As discussions about trillion-dollar debt ceiling question intensify on Capitol Hill, we bring you one of our budget-spending-oriented trading strategies. Click here to read more.",https://finnhub.io/api/news?id=64303e8a354ef00cd8aa6038bd3541bb94db1296945537d7beff31a2d5b5ac7c
company,2023-02-07 23:22:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",118816556,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8b4bc142cb5c4da1f14bf871c3c6285d804c10cf4ebd5d3a5fd8a43a943a9e41
company,2023-02-07 22:31:00,Regeneron named `Catalyst Driven Idea` at Morgan Stanley ahead of COPD data,118762189,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b8e0546cde5003d54e32469d8cf0970028615e5ee2ea92966c36bfd2beebe901
company,2023-02-15 13:00:06,5 Least-Hurt Biotech ETFs of the Last Week,118741851,https://media.zenfs.com/en/zacks.com/db2169c6d655802146ef1d23651e1726,REGN,Yahoo,"Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.",https://finnhub.io/api/news?id=74a6fc5839a6ae00d3d6a13e65a944a95619d23744c2f49a9a3484699a4809db
company,2023-02-15 12:20:33,Regeneron poised to benefit from bounce-back of eye drug,118741853,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Regeneron Pharmaceuticals Inc (NASDAQ:REGN) could benefit from a bounce-back in share for its drug to treat macular degeneration, according to analysts at Piper Sandler.  The analysts rate the stock overweight with an $800 price target.  Regeneron shares were down 0.2% on Wednesday but up 4.3% so far this year.",https://finnhub.io/api/news?id=fcc1c263ab5b8ff3bf9bf878b92be50264e00d98e97b3bd386fe3ac0016610f8
company,2023-02-15 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,118729032,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. sank 0.24% to $752.40 Wednesday, on what proved to be an all-around great trading session for the stock market, with...",https://finnhub.io/api/news?id=d039fa2f1a4163fc17b8e6cfbbda0379d477d70a68d502bf41c155582c655a0e
company,2023-02-14 20:45:00,9 Healthcare Stocks Where the Doubters Are on the Run,118650535,https://images.barrons.com/im-725002/social,REGN,MarketWatch,"Cigna, Regeneron, Centene, and six other healthcare stocks have seen short interest drop by at least 40% recently. Fewer investors are betting against them.",https://finnhub.io/api/news?id=68ec5fdc94b4e933eb1dc472ec86bb1cf6186500e1cac802c0a6566415af6d3b
company,2023-02-14 12:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors,118729034,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.28% to $754.21 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=442efccc42949b3825ad4de65e38736ca82b4520630ff09e3746e696e1154ca9
company,2023-02-14 10:00:00,2 Top Healthcare Stocks Defying the Bear Market,118622716,https://s.yimg.com/ny/api/res/1.2/iUviEVAyB4tGmVkQb5kSUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/9af439e3161c5ccd761288f813a0d329,REGN,Yahoo,"Among them are HCA Healthcare (NYSE: HCA) and Regeneron (NASDAQ: REGN).  With recession fears alive and well, HCA Healthcare might be an excellent stock to turn to  now.  The company is a leading hospital chain operator in the U.S., a business that is sure to remain somewhat in high demand even if a recession hits.",https://finnhub.io/api/news?id=2530aa4eb81327067297d5ad0f651e9f937c235ecae193b07b7c5ca54a43d6c0
company,2023-02-14 09:00:33,Investing in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago would have delivered you a 136% gain,118741857,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...,https://finnhub.io/api/news?id=17d959155e08e9704d14e33cb5fadeec4d3c2fb0eb78b0b48a98604b394ba064
company,2023-02-14 07:32:00,Regeneron: Waiting For A More Lucrative Price To Buy,118816510,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=064a10469ace69bb6c85745c035d3dc9551cb91178d4895d27139f74cffe871f
company,2023-02-13 21:49:00,"Regeneron Pharmaceuticals, Inc. (REGN) SVB Securities Global Biopharma Conference (Transcript)",118816516,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d776bddbcc65066d38429db87aa4e4e1fe09226f13e8b7105fb6e0502a999b1c
company,2023-02-13 12:20:00,"Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market",118729035,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.84% higher to $763.97 Monday, on what proved to be an all-around great trading session for the stock...",https://finnhub.io/api/news?id=7db4198195962662b0a168c7675cbd1b3ae6abd2be60015677365de1f0aae0f8
company,2023-02-13 07:17:00,New 52-Week Highs In 2023,118591282,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d659000c9b8fb2b065b2e63e81b49c4c0efa250506172396b7199bd9c4907fb5
company,2023-02-12 23:39:00,Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers,118592318,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=10f08388234bf361f3f17cd986888c2f377c7bf59f6e899a840fb4850b3dd7c3
company,2023-02-12 23:34:00,Large Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers,118592319,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e6051668d3b39c62d477e1c3305e73c31b5437fed8ea9d8961632f332b36e4da
company,2023-02-12 23:10:00,Ocular stock rises ~15% as eye drug implant shows promise in ongoing phase 1 trial,118591926,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9c21c5d3d91a2c64f9398c4470cbeef480e3eed6894f700dec362302c5e0dcb4
company,2023-02-12 20:53:00,ARK Invest: The 7 Words That Explain Why Wall Street Can`t Stand Cathie Wood,118605873,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e88856163950f64ea175b7ac9baf270496aecf35a5e97f930f6994f22f0f20ed
company,2023-02-12 03:01:00,"LOOMIS SAYLES & CO L P Buys 2, Sells 3 in 4th Quarter",118585445,,REGN,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=231a190b216af6ac0cd860867eadb3498d25a3becd561a304c7815515f399032
company,2023-02-19 06:04:00,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise ��� report,118703185,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7d7b8afdaa60b85249d7939f032e971e697e467730fb880335f22d0bc25feb2c
company,2023-02-18 08:00:13,Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?,118741849,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",https://finnhub.io/api/news?id=f3c90f576a0df1253f294bfc96c4d483958a02f0e63117c43c2556a1658de3bb
company,2023-02-17 12:20:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market",118729030,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.69% to $748.74 Friday, on what proved to be an all-around mixed trading session for the stock market,...",https://finnhub.io/api/news?id=610d09c1f119d72d8028e55317ac90bfd29988a97d10642e7b7fe4cb7772f258
company,2023-02-17 05:32:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Shockwave Medical (SWAV) and Regeneron (REGN)",118790447,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a1b30b41adeee5955e5c812110fb53c348734d15a06d6c1e1ab0277b179d65e5
company,2023-02-16 12:20:00,"Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market",118729031,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 2.14% to $736.33 Thursday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=dcf6f51900c58f440c5b83c2055f7621f82a004a22c11b498f9ea86a690a2ef8
company,2023-02-16 10:45:22,IDNA: Healthcare Dashboard For February,118621828,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1366661187/image_1366661187.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Pharmaceuticals and biotechs still look attractive. We focus on iShares Genomics Immunology and Healthcare ETF. IDNA is an ETF in genomics and immunology. Click here for more.,https://finnhub.io/api/news?id=02ff59f3491ef9d924c5fa16033715651ae598476ddde305fdbc4dbaf766eb8c
company,2023-02-16 07:09:00,Competition Coming For AbbVie`s Blockbuster Humira,118618034,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f6c865b4e01d989b1445b7bd3d19ca84447145bd48ad2abdfe11bcd848004ac6
company,2023-02-16 02:52:00,"3 Super Profitable S&P 500 Stocks to Buy, Other Than ExxonMobil",118715553,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=94687660d4e242a515045483bb850cea19b90712e80aaef5fe60c83521402e56
company,2023-02-15 20:08:45,Competition Coming For AbbVie's Blockbuster Humira,118604987,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/869181602/image_869181602.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Itâs among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper âbiosimilarâ copycats. Read how price relief is on the way for Humira.,https://finnhub.io/api/news?id=94309f2d4791524c683859826652a56ac008d0cabe97ce2cbb486d227857f192
company,2023-02-23 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,118916775,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 1.55% to $759.66 Thursday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=fd79e36f5aec1a2575f16267c7137cf03dd11b954a17514a9412d2ba6473e053
company,2023-02-23 07:00:00,Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review,118867854,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks If approved, aflibercept 8 mg will be second ophthalmology medicine developed by Regeneron TARRYTOWN, N.Y., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics Lic",https://finnhub.io/api/news?id=e9ad5bfb5e4830125e135e4111d45244ebaec1aadf23d38e88862ee0e576d5c2
company,2023-02-23 02:43:00,"Intellia, Novartis end gene editing partnership for sickle cell disease",118863462,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0ada335e240f0ce3f5020fc3e829836b93e816de468427eb6c98b06456886bb6
company,2023-02-23 02:26:00,Regeneron`s high-dose Eylea application accepted for FDA priority review,118878268,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8c5d47a9acf591c80cd94b14bb11dda05c90d1cecba68bb2341be24d9532528c
company,2023-02-23 01:16:00,Regeneron announces U.S. FDA accepted priority review for BLA for aflibercept,118878270,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b2512ab7a7f8b1de002cf1dda2ed50ddf38b0a287fc2800463bc082b9c2e5780
company,2023-02-22 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,118916777,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.21% higher to $748.08 Wednesday, on what proved to be an all-around dismal trading session for the stock...",https://finnhub.io/api/news?id=12d0c33c2c6bdee2929f7f6f19ccb4a224e634d3cce9331718eaeafa73823c5f
company,2023-02-21 12:20:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market",118836132,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. sank 0.30% to $746.52 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=04a9ddca5230d9f826a97033aeab83efea3bfc30ac65a41d5bef27ab8beb12a6
company,2023-02-21 11:36:04,Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review,118819040,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,REGN,Yahoo,Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.,https://finnhub.io/api/news?id=37495afdec0a38b26050632db5904e50bd69522b2fb7dce6eaefc61ea8879a7b
company,2023-02-21 10:22:57,"Three-Stock Lunch: Regeneron, General Mills and DocuSign",118810097,https://image.cnbcfm.com/api/v1/image/107197732-16770102361677010233-28290318024-1080pnbcnews.jpg?v=1677010977&w=1920&h=1080,REGN,CNBC,"Eva Ados, chief investment strategist at ERShares, joins ‘Power Lunch’ to discuss Regeneron, General Mills and DocuSign.",https://finnhub.io/api/news?id=73d845feb768f45645d51c588e840cb5cf84464163bb73030d95a2346cd30911
company,2023-02-21 09:22:00,Regeneron’s pozelimab approved by US FDA for priority review,118816476,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=abe0f8f5fbdb2fa1e64d86cdc4d68351930e30c3e2bde28ed224320395a5a250
company,2023-02-21 07:00:00,Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review,118774241,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"If approved, pozelimab would be the first and only treatment for those living with CHAPLE CHAPLE is an ultra-rare hereditary immune disease that causes overactivation of the complement system, leading to potentially life-threatening abdominal and cardiovascular symptoms TARRYTOWN, N.Y., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA",https://finnhub.io/api/news?id=db16c76b6d56140dc606ab7b6efccf4197ffc0792c67b2fe9afd512529a66036
company,2023-02-21 02:35:00,Regeneron Gets FDA Priority Review of Pozelimab in Chaple >REGN,118836134,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Regeneron Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review to its application seeking...,https://finnhub.io/api/news?id=ee06e77a74e8d57912643e629784151a749feadff56632f6c2306fd71d177306
company,2023-02-21 01:25:00,Regeneron announces U.S. FDA accepted priority review for BLA for pozelimab,118816480,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5b1c88a7c6379828540dd32da5478a82c2bc1e16024c0d0f724e580ce63b7d36
company,2023-02-21 00:56:00,Regeneron price target raised to $860 from $800 at Wells Fargo,118816483,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1f017ff1435c700be951c87511f742ec61b9b08fb5c1446d1a007a474cff3784
company,2023-02-20 10:34:56,25 Most Profitable NASDAQ Stocks Today,118735034,https://media.zenfs.com/en/insidermonkey.com/539c1476c92038449b5d6db89592cd32,REGN,Yahoo,"In this article, we will look at the 25 most profitable NASDAQ stocks today. If you want to explore similar stocks, you can also take a look at 10 Most Profitable NASDAQ Stocks Today. 2022 was one of the worst years for the NASDAQ, primarily because it is dominated by tech, and tech stocks crashed as […]",https://finnhub.io/api/news?id=46c243eb27931c44e28ce6ab9a4ea19be96b4014088a839ceb0bbb603c881906
company,2023-02-27 16:11:57,Top 10 Drug Companies in USA and Their China Reliance,118956096,https://s.yimg.com/ny/api/res/1.2/vHK7nPQRMeCWZZgibmLvSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/insidermonkey.com/e064e59836b880f2abe5ba1c0fce3a66,REGN,Yahoo,"In this article, we will be taking a look at the top 10 drug companies in USA and their China reliance. To skip our detailed analysis of the pharmaceutical sector, you can go directly to see the Top 5 Drug Companies in USA and Their China Reliance. The US has long been reliant on China […]",https://finnhub.io/api/news?id=86958b0c5a58ac9101f66221457a58bbb2e1acac6ce275e356e019d479d123aa
company,2023-02-27 12:20:00,"Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market",119000450,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.11% higher to $757.79 Monday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=0e2a0a26db05d794589a57bc8a986188e83dbb085382b97930bcfd0bbf67682e
company,2023-02-26 20:48:00,Replimune ends selloff after FDA response to mid-stage cancer trial,118953513,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5dfb969892d751ee22dd5a1046b4642e87c3899b0aff0ea6427a9a23759e1e86
company,2023-02-25 23:55:00,"FDA PDUFA Date for Regeneron Pharma Eylea-Aflibercept is February 28, 2023",118957535,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d692b1d62e11a0f3a5dda49ecff6d9e4d7525d67b078b49d3bdba522b8e942d8
company,2023-02-25 04:07:10,Regeneron: Innovation And Disruption Done Right,118926893,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1370480661/image_1370480661.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Regeneron Pharmaceuticals' collaborative energy is strong and the medium-term looks good. Check out why we rate REGN stock a Hold for now.,https://finnhub.io/api/news?id=a0537f0792321a4426cd98a5b6e3902631dc380c93824d6f0fe41d50d6e21c46
company,2023-02-24 22:02:00,"Pharmas, medtechs dominate list of innovation leaders thanks to patents",118932763,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=03542cca690d4d875627f22e4c8336b43c6a1bda8f1a81555cdbefd262c2c045
company,2023-02-24 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,118916771,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.35% to $756.99 Friday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=5804af49343098625f3fdc01bb2b1f7dceeb4f0b3e200b11d3e73ee8a838a4d3
company,2023-02-24 11:36:04,"Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y",118907197,https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7,REGN,Yahoo,"Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.",https://finnhub.io/api/news?id=5d137cd0ce630e7f951073f9452344b47dd96994ee0b43c842b7cfe9edabebab
company,2023-02-24 11:22:00,NEW YORK MARKET CLOSE: US stocks tumble after strong inflation data,118909414,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ec507e5940c3b926ea567be7ac148ce1ddc3479f7d0ddaa4ffc9cbf7e1a7788d
company,2023-02-24 07:45:00,Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC),118907199,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy aloneTARRYTOWN, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo® (cemiplimab) in combination with platinum-based chemotherapy. Specifically, the CHMP recommended the Libtayo",https://finnhub.io/api/news?id=6c5f8ffad3500479c8c86fb6f4245ed4ba9128a5b1abc8a374b6730d44f7724d
company,2023-02-24 05:11:00,IN BRIEF: Regeneron's Libtayo combination wins EU positive opinion,118912387,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c96e8a6d4106b0e560bfe059ca5f3e63bff5ed66f401fa8e63627be779af21a0
company,2023-02-24 03:08:00,Regeneron: CHMP Backs Libtayo/Chemotherapy Combo in Advanced Non-Small Cell Lung Cancer,118916773,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Regeneron Pharmaceuticals Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended...,https://finnhub.io/api/news?id=ed23404d4e853849545e29b43f0c8224b1c3c6710847526a4923ba5b16c92672
company,2023-02-24 03:02:00,Regeneron wins EU nod for Libtayo in PD-L1 positive lung cancer,118902286,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=31eb974e1d24803407bab2607cf4602a24eb00693ba41022bf861f703e06e72c
company,2023-02-24 01:49:00,Regeneron says CHMP adopts positive opinion on Libtayo with chemotherapy,118912390,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7bcbde95223be3e1afaa4e17cb858b2a2b544102b65455a9a082fbd427c97b4d
company,2023-02-24 01:30:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,118902254,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a82280d2016213a1aab0525eb6fbfe77832062be841f24e506a2383db9661e42
company,2023-02-23 21:32:00,"Notable Friday Option Activity: REGN, ORA, FSR",118912393,,REGN,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3f7dc05ac258420e164ea44087f238d7f3d9dd61a14bea5d30b9223a1ee5e61f
company,2023-03-03 12:21:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market",119067385,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 1.35% to $779.30 Friday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=25b439c644efedaabf2ee04691f16b4a5577289ad974c731ed2b923e89e5e2e0
company,2023-03-02 12:21:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,119028161,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 0.20% to $768.90 Thursday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=4f1cf1b6e35146af27d7660b7d72ba18d95f7d7d4304ac78796e31e6d420bf1c
company,2023-03-02 05:34:00,REGN April 14th Options Begin Trading,119035666,,REGN,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b00214c8460da32b379b27d60acaa72f881b92f1ded74ed052de7be019696905
company,2023-03-01 12:28:34,"FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles",119001847,https://media.zenfs.com/en/Benzinga/e3493860cecb536483e47517a8c626d6,REGN,Yahoo,"The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The approval covers adult patients who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid taper. Kevzara is now approved to treat two chronic inflammatory disorders. PMR often initially presents with pain and stiffness around the neck, shoulder, and hip area, and symptoms include fa",https://finnhub.io/api/news?id=29d04461f5f27fccddba8c8c6477556d519a9d96931478cae03286dbe081829d
company,2023-03-01 12:24:05,"Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback",119007667,https://media.zenfs.com/en/zacks.com/955c0f2ed0992898cedf76a9efa5b1f2,REGN,Yahoo,Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=14fbfe1bf60c7eb324addab2c5f81487b70a3f058bd6c899738b606dd96db041
company,2023-03-01 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,119013349,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 1.32% to $770.44 Wednesday, on what proved to be an all-around mixed trading session for the stock market,...",https://finnhub.io/api/news?id=48ad3e56e785c1ff69e8bed46222ba92b71ee7f9838398c45b89b6e5b49a3a35
company,2023-03-01 06:45:00,Cantor Fitzgerald biotech analyst to hold analyst/industry conference call,118998995,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b18b20fd45665e638c105a80197aa97027d5a296d5f6ad2cc5e1d92de8d6e2a0
company,2023-02-28 23:23:00,"Regeneron Pharmaceuticals Now #94 Largest Company, Surpassing Altria Group",119006605,,REGN,The Online Investor,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e61be88922ef265437f62b89a2d3217b86c544f84d8872b9141efc755d1e0ad2
company,2023-02-28 20:00:00,Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica,118986182,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial Kevzara now approved to treat two chronic inflammatory disorders TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, in adul",https://finnhub.io/api/news?id=aa5816550a9f724fb20d0c6ad6e152d7de6fb0657fde6d2e71c5521eb70f2d39
company,2023-02-28 12:22:00,"Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market",119000448,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.35% higher to $760.42 Tuesday, on what proved to be an all-around dismal trading session for the stock...",https://finnhub.io/api/news?id=0b9fc62ff0cd9359bf25442e76def2dd4c7a73e7e4aab0fe3d7b6f8bdec7f533
company,2023-02-28 08:00:13,"A Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insider lowered their holding by 26% earlier this year",118967104,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Insiders were net sellers of Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock during the past year. That is...",https://finnhub.io/api/news?id=087fb491849b667a206ddcfe37e58d832488519f13d3378e3508cf50d8b8cd11
company,2023-02-28 02:04:00,Regeneron and Sanofi`s Kevzara approved by FDA for polymyalgia rheumatica,118999000,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5285623c3ba6f0d0131dd6867f488cb7d01520bc21100bd99f40652000273a8e
company,2023-02-27 23:45:00,"Bayer`s Q4 sales grow on back of crop products, pharma declines; FY23 EPS to see impact",118974275,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b1884870c7aaf57232d7cb7cab9931e679601a5c412f1faad1cad48f804ece32
company,2023-02-27 22:57:00,"FDA PDUFA Date for Regeneron Pharma Eylea-Aflibercept is February 28, 2023",118974276,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9be234dca7167b58ea3af0cebf6a6597c7f32c8f2ed8deb51a1abf8f441a01da
company,2023-03-07 12:21:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market",119194750,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.84% to $773.85 Tuesday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=f61c5e57ff112a4671a3862a234f4fcf77f3a7229b8495ebe5403249c4c07457
company,2023-03-07 01:00:00,Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review,119094676,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistaminesTARRYTOWN, N.Y. and PARIS, March 07, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) that is not",https://finnhub.io/api/news?id=795521c309fc7de1d3866cd01f471a46133e4e596235be10ffe36ea7cb9a45f8
company,2023-03-07 00:44:00,FDA accepts for review Regeneron/Sanofi`s Dupixent application for inflammatory skin condition,119100150,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=783028f14ec29cf13f78202e5c804ad21cefcfce504c09b8ad65db9709a3f302
company,2023-03-06 23:22:00,"Regeneron, Sanofi announces FDA acceptance for review of Dupixent sBLA",119100151,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=149797e5d30340fc1197fbd52239106962c99864b929339f057600145ac6beaf
company,2023-03-06 12:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,119097028,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.14% higher to $780.38 Monday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=83743c01b830bf9b7fb3259fc0ba4103c8d06e947b2943edacfae625b16f317f
company,2023-03-06 12:00:01,Merck's drug boosts exercise capacity in pulmonary hypertension patients,119091027,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Merck & Co Inc said on Monday its experimental therapy, sotatercept, helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood vessels of the heart and lungs in a late-stage study.  A second experimental heart drug, MK-0616, helped reduce levels of low-density lipoprotein (LDL) cholesterol by between 41.2% at a low 6 mg dose to 60.9% at a higher 30 mg dose in a mid-stage study, the drugmaker said.  Sotatercept, which Merck gained through its $11.5 billion buyout of Acceleron Pharma, combined with background therapy helped extend the distance that patients with pulmonary arterial hypertension could walk in six minutes by 40.8 meters.",https://finnhub.io/api/news?id=fa301fc6c43273a0347e9a29013d480f4aecf65dc5a140668a0124e976e7c4b0
company,2023-03-06 11:23:07,"Regeneron Pharmaceuticals, Inc. (REGN) Cowen 43rd Annual Health Care Conference (Transcript)",119088886,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Cowen 43rd Annual Health Care Conference March 6, 2023 12:50 PM ETCompany ParticipantsMarion McCourt - EVP of CommercialRyan Crowe -...",https://finnhub.io/api/news?id=02050ce08d30b8d5eddc1eb927075b96d788af9425b8a7cffbc96461db9c8547
company,2023-03-06 07:49:00,Merck to start phase 3 of oral PCSK9 inhibitor for cholesterol following mid-stage results,119086630,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7de17756bbe4ca5d5a600fdcd785418aa7d4f849a6d17856beed985e16548d00
company,2023-03-06 07:35:00,Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading,119086631,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8b8302d6b1a7654c3b2ff6725677b6687c4c7322180b7eda4b335ed1ef243f2c
company,2023-03-05 22:11:42,What To Expect From Pfizer In The Post-COVID-19 Era,119080395,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1226994328/image_1226994328.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19.",https://finnhub.io/api/news?id=f0266308bf3d1ecfb85e06d98bccea73e8532b3ad94dcf2391f7bcda60a0a54e
company,2023-03-05 05:20:00,Cantor biopharma/biotech analysts to hold analyst/industry conference call,119084201,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d6a70c9f26e1722ce1817a278a265c18025403a18618e13e0ac62a45bd09347a
company,2023-03-05 02:14:56,Unity Biotechnology: One Last Chance With UBX1325,119075088,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/612729064/image_612729064.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Unity Biotechnology has spent its existence identifying the root causes of age-related diseases. Read more to see my full investment analysis on UBX stock.,https://finnhub.io/api/news?id=10d90f487027670b99ac4588db2a96eaaec1170cba6a2eb53a68b07ece617026
company,2023-03-04 06:00:47,"A Look At The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)",119072635,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Key Insights Using the 2 Stage Free Cash Flow to Equity, Regeneron Pharmaceuticals fair value estimate is US$923...",https://finnhub.io/api/news?id=2ef868c270483927ca93b86eefabb3a437bf77c3d83487c6b41782908e8a5904
company,2023-03-11 10:00:00,"Regeneron Borrows From Big Pharma Playbook to Keep Roche, Shorts at Bay",119181330,https://s.yimg.com/ny/api/res/1.2/h6yURs5ZyNF3gayXrLXlEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/123d330ba829a0d9c33f9f3451abdc0e,REGN,Yahoo,"Leonard Schleifer,  the longtime  Regeneron  boss, likes to point out that, unlike many giant drug companies gaming the healthcare system with all kinds of gimmicks, his biotech focuses on true innovation.  Roche is indeed grabbing market share, reporting Vabysmo revenue of 591 million Swiss francs, equivalent to about $640 million, last year—an impressive figure for its first year on the market.",https://finnhub.io/api/news?id=b8bbab03b82a42fc2329c4a62a1c8631cccf948a27d06fb19ca0aa882ee9b55a
company,2023-03-10 12:20:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market",119194747,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.44% higher to $747.00 Friday, on what proved to be an all-around rough trading session for the stock...",https://finnhub.io/api/news?id=95e11b33f780c1f64d04823916a6151d30835eaba495a69c9f010707a431a38d
company,2023-03-09 18:15:11,Regeneron (REGN) Stock Moves -0.19%: What You Should Know,119150842,https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177,REGN,Yahoo,"Regeneron (REGN) closed the most recent trading day at $743.75, moving -0.19% from the previous trading session.",https://finnhub.io/api/news?id=2a51f211e094393a2118c53ab6020a277392fcd13d909626228511cc28617118
company,2023-03-09 12:20:00,"Regeneron Pharmaceuticals Inc. stock falls Thursday, still outperforms market",119194748,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 0.19% to $743.75 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=b65ee242339fb309fb7019aa43db63e0d32dae035e294b1cf7790ae82a094f09
company,2023-03-09 08:30:00,2 Biotech Stocks You Can Buy and Hold for the Next Decade,119136986,,REGN,Yahoo,"The U.S. market is highly likely to deliver attractive returns over periods of five years or more.  With that said, let's consider two biotech stocks that could deliver outsized returns in the next decade: Regeneron Pharmaceuticals (NASDAQ: REGN) and Sarepta Therapeutics (NASDAQ: SRPT).  One of the keys to success for biotech companies is the ability to develop newer medicines.",https://finnhub.io/api/news?id=260e396da70bc8d29a0c25ee2714a5eb9fc42cd12de47eb33507afa89e6961ff
company,2023-03-09 04:55:00,Cantor biopharma/biotech analysts to hold analyst/industry conference call,119136760,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fb7640a1032a904ad4b59dfeea365efe5b8afbaf256e2845145833758cfce62e
company,2023-03-09 03:45:09,2seventy Bio: KarMMa-3 Finally Releases Positive Results,119133935,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396855772/image_1396855772.jpg?io=getty-c-w1536,REGN,SeekingAlpha,2seventy Bio's strong focus on cell therapy-based combinations for solid tumors positions them as a potential leader in the immuno-oncology market. Read more here.,https://finnhub.io/api/news?id=79a3ea29ff79d41445c0343beb8a58941513df834562e2250e564fd73de7ad4c
company,2023-03-09 01:55:00,Regeneron price target raised to $806 from $787 at RBC Capital,119142312,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=29782f0a3ab23714cdb6249329946015c272d7e4ca7d6e1d2a6c3aa7a626f0bf
company,2023-03-08 20:01:00,Biden budget to save $160B by allowing Medicare to negotiate prices for more drugs,119140074,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7dd71163453457185336f106a3ea39a983016fe2c8731be2de5f3712cf1c454f
company,2023-03-08 12:20:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",119194749,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 3.70% to $745.20 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=ca34e7af4d7c71572fab64d38d6fd87c0fa5b065b486880898ad2dc35bdae40f
company,2023-03-08 09:10:02,"Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review",119123405,https://media.zenfs.com/en/zacks.com/c0c563b233f28a1874a33c46aadaa70e,REGN,Yahoo,Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA,https://finnhub.io/api/news?id=f36b459bf0995dfa8098699f56ff12702924a95f7576a74dc24cef06e42a9ecc
company,2023-03-08 05:51:52,Roche: Ongoing Pipeline Issues Sap Growth And Increase M&A Likelihood,119108228,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1300036753/image_1300036753.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Roche hasn't scored the sort of big wins that change investment theses or drive lasting changes in sentiment. Find out our recommendation on RHHBY stock.,https://finnhub.io/api/news?id=8aecc435878230c8dda4a55d9e22fa1d6e276f9a05560e94df24885fe54c93c3
company,2023-03-15 18:15:10,Regeneron (REGN) Dips More Than Broader Markets: What You Should Know,119266093,https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462,REGN,Yahoo,"In the latest trading session, Regeneron (REGN) closed at $760.30, marking a -0.85% move from the previous day.",https://finnhub.io/api/news?id=64def585cea055d49bccd432e7bdcdc8eab605da4c76b83acfa77ba6b0649ad1
company,2023-03-15 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",119266410,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 0.85% to $760.30 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=b678c4bcf149bb5647c4370b78a6217817488de86fb985f6625e18d100007607
company,2023-03-15 07:39:06,"Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays Global Healthcare Conference (Transcript)",119251603,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Barclays Global Healthcare Conference March 15, 2023 9:00 AM ETCompany ParticipantsRyan Crowe - Vice President of Investor...",https://finnhub.io/api/news?id=e2b21ccf6f92d3175102fe2d38d0dda0980793fe3231521f53478627f0175fae
company,2023-03-15 06:37:00,The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector,119251784,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=859fe55302bf1e8c62a6c49ca81800a5404438c89f0b1f6d9cf12581d8f075e0
company,2023-03-14 22:56:00,"Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease",119246404,https://media.zenfs.com/en/prnewswire.com/48e293029033f372db9a02cf23cdb3b1,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Neel Moudgal, 17, of Saline, Mich., won the top $250,000 award in the 2023 Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.",https://finnhub.io/api/news?id=567e8cac1b185976a100ac7e37299d66d6a6c0086a0ffcd88f302ea42712848d
company,2023-03-14 13:21:00,"Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market",119266411,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 1.92% to $766.80 Tuesday, on what proved to be an all-around great trading session for the stock market, with...",https://finnhub.io/api/news?id=f7c4a7c80f275ddd47f279406683be144e8846cf1604ff831a6afbc29e366119
company,2023-03-14 07:00:28,"Declining Stock and Solid Fundamentals: Is The Market Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)?",119246405,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...",https://finnhub.io/api/news?id=1726873cef8c78bbf82103f996ca65e60567b83aafa523645774ed7880d4df2f
company,2023-03-14 02:11:00,"Regeneron price target raised to $1,025 from $1,001 at BMO Capital",119229544,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ef3a16c587f9887f5d97e8fa6e3078db355a1c6e4e091002f9629d0ae2252c3d
company,2023-03-13 13:21:00,Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains,119218211,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.71% higher to $752.33 Monday, on what proved to be an all-around poor trading session for the stock market,...",https://finnhub.io/api/news?id=490a4a30bbdbd99e89aac1e4944ab1335e0f792ea74d8f469ae91f8e621ba995
company,2023-03-13 10:49:10,"Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 33rd Annual Healthcare Conference",119202716,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Oppenheimer 33rd Annual Healthcare Conference March 13, 2023 9:20 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor...",https://finnhub.io/api/news?id=7a730d968ff4411bc2bc275ae405ba8d685ed46af49066443e0bf18bde8db4c0
company,2023-03-13 00:21:00,Analysts` Opinions Are Mixed on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD) and Regeneron (REGN),119201830,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6b596f0cba79a74c5e7910ffd7b81f190db4568854b9b963d5938a7335ae6aab
company,2023-03-18 22:52:00,Easing COVID pandemic sees many pharmas seeking alternate revenue streams,119303324,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=10557dd675779416b1658cbccf9884812b4ff61a39387638d37b9ab521a640fe
company,2023-03-18 22:37:00,"Regeneron, Sanofi present results from Dupixent clinical trial",119303326,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e5febc0e3849dced32ac0a46c5c132cdb049386ba28281e7bba5cc71cbd9c242
company,2023-03-18 10:00:00,Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis,119305534,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week TARRYTOWN, N.Y. and PARIS, March 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrol",https://finnhub.io/api/news?id=b089df5263622d08297e242e96f31be3977cced9edd1979be3fba2e0ca97cbc6
company,2023-03-18 08:00:54,Investing in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago would have delivered you a 133% gain,119311374,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...",https://finnhub.io/api/news?id=9107b0bf5ab717667215ccaab64330f0771502b168cedbcb290f67ce50f28d70
company,2023-03-17 21:40:00,Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement,119303328,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ebd7d8962d9b82337bcdf49814d459d9744c75f077b426fd1afa8e3f476f51a0
company,2023-03-17 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Friday, still outperforms market",119329083,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 0.28% to $747.65 Friday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=ee5b3cae9cfccf4eb7431b1408b9799346a2c10dc4f893359d9d53d541950d7b
company,2023-03-17 12:17:04,Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?,119311375,https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7,REGN,Yahoo,"Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.",https://finnhub.io/api/news?id=33f77a7f1b65fc0c022f0348b0f5af0ade1cfd2f935b86e2bf1119758990dc2e
company,2023-03-17 02:21:00,"Regeneron pressure from CMS draft a buying opportunity, says Morgan Stanley",119303329,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=18444ce931ea43fff26164155922e22c5669d5380412c6c2b4d0adb7c55baa5c
company,2023-03-16 17:52:41,2 Biotech Stocks To Watch In March 2023,119289767,https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/03/biotech-stocks.jpg,REGN,StockMarket,Check out these 2 biotech stocks in the stock market today.,https://finnhub.io/api/news?id=755987878e93edd9a3354295f6bb2b64e3250f2ff096e539521b1b25484b1d63
company,2023-03-16 17:52:41,2 Biotech Stocks To Watch In March 2022,119279691,https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/03/biotech-stocks.jpg,REGN,StockMarket,Check out these 2 biotech stocks in the stock market today.,https://finnhub.io/api/news?id=7b4bf064f8d88c77846dd2a2b46548537deb2644a45f66e27346c9da6e4bed46
company,2023-03-16 16:29:06,"Dow Jones Hits Session Highs; Tesla Faces New Lawsuit From Customers, Agrees To Open 7500 Charging Stations",119280267,https://media.zenfs.com/en/ibd.com/1856de03212e386cb58e628bf758fa91,REGN,Yahoo,"The Dow Jones Industrial Average rose throughout the session Thursday and closed near the day's highs. The blue chip index gained 1.2%, its best day since March 3. Intel was the Dow's clear leader, with a hefty 6% gain.",https://finnhub.io/api/news?id=6810f5cc9d20c57e1090a783dabe69629e1bb6af7747c4ca8f21456c958c6d3b
company,2023-03-16 16:06:45,"Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme",119283740,https://media.zenfs.com/en/ibd.com/b727993c80cd23c03b1f42c9321ae4f1,REGN,Yahoo,Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday.,https://finnhub.io/api/news?id=2f6f4ac4989026896d04aa9a78aac765d7bf79b541683781d1455a7abf81717e
company,2023-03-16 13:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,119290299,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.39% to $749.75 Thursday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=2edf484853582e9081c3b634c42d14f6ae452ab75492874334d0165fd46e9034
company,2023-03-16 05:22:00,"Video: Nasdaq 100 Movers: REGN, INTC",119271977,,REGN,Market News Video,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f89a205302a81687272654357ce9b4c79fbddd1b38aee342174a27db8c03e5ca
company,2023-03-16 02:31:14,PBE: Healthcare Dashboard For March,119269693,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1175270464/image_1175270464.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold.,https://finnhub.io/api/news?id=c7491c8078cc18110f8ca9e1d2dcf1d8feefea9645b61548bc31df0b181e1f03
company,2023-03-23 16:02:59,Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars,119380631,https://media.zenfs.com/en/ibd.com/6fe9488e6037c71a19f4fb4a4ed23b2d,REGN,Yahoo,"Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with ""smoker's lung,"" leading SNY and REGN stocks to rocket.",https://finnhub.io/api/news?id=4ba5cff0c87cef36b5148011b3902d208df756e4195c8a3c1f9fbe5081701352
company,2023-03-23 14:17:28,Regeneron's Dupixent shows promise as COPD treatment,119383368,https://image.cnbcfm.com/api/v1/image/107214330-16796014381679601436-28707651043-1080pnbcnews.jpg?v=1679609848&w=1920&h=1080,REGN,CNBC,CNBC's Meg Tirrell joins 'Closing Bell' to report that Regeneron's drug Dupixent has shown promise in treating COPD during phase 3 results.,https://finnhub.io/api/news?id=a22a1b465f8add3f9818685e33471371f430e7f3167de891f5511911e91f31ea
company,2023-03-23 14:13:41,Options Action: Regeneron in reverse?,119383369,https://image.cnbcfm.com/api/v1/image/107214421-16796096095ED3-FM-F-BLOCK-032323.jpg?v=1679609621&w=1920&h=1080,REGN,CNBC,"Optimize Advisors' Mike Khouw looks at bearish options bets on Regeneron. With CNBC's Melissa Lee and the Fast Money traders, Karen Finerman, Tim Seymour, Guy Adami and Dan Nathan.",https://finnhub.io/api/news?id=f7f296aeea76c5b9bbc6d000302fe21b7cdcb6537d68c53e1c8130be32c09e84
company,2023-03-23 13:53:00,"ADRs End Mostly Higher, Tencent and Sanofi Trade Actively",119448592,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Sabela Ojea International stocks trading in New York closed mostly higher on Thursday. The S&P/BNY Mellon index of American depositary receipts rose 0.5%...,https://finnhub.io/api/news?id=fe9561596f5c4073c2223ce7c98b38ed74b63b3d9de571aad164f5defd5f5b2d
company,2023-03-23 13:39:05,Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study,119380632,https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966,REGN,Yahoo,Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.,https://finnhub.io/api/news?id=06ba23d8b972b61a8365adf71cf0866313b8330b4705344b397d2a03d67b2e4f
company,2023-03-23 13:21:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,119498955,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 6.77% to $802.16 Thursday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=efeed20aca114c16b80a7aab54be36e0582b2b52b93b8b13ccb5910929e1b849
company,2023-03-23 13:18:00,"Health Care Down as Sanofi, Regeneron Rise -- Health Care Roundup",119498956,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,"Health-care companies fell, but not by as much as the broad market, amid optimism about drug developments. Regeneron shares rallied after the biotech concern...",https://finnhub.io/api/news?id=799f9cc4cd46ecd1ab9232b09f43208d5499d7f4fd950751294628b5ce1e2057
company,2023-03-23 12:27:47,"Pharma delivers, for others",119374234,https://static.reuters.com/resources/r/?m=02&d=20230323&t=2&i=1627785716&r=LYNXMPEJ2M0PJ,REGN,Reuters,(The author is a Reuters Breakingviews columnist. The opinions expressed are their own.),https://finnhub.io/api/news?id=a07a370bc623f15143e57bdeb98033625db1f243d022f04ae454e12971ee1478
company,2023-03-23 12:18:00,"KB Home, Worthington rise; MillerKnoll, Trupanion fall",119376665,,REGN,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=76148b28023b0cb091d511860f35678befadc38334615eda192de869fe1c6a2a
company,2023-03-23 12:08:33,Why Shares of Regeneron Are Rising Thursday,119380633,https://s.yimg.com/ny/api/res/1.2/9pae6rW.bkiqPMudNjglTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/3e3ac9bdfd13301401658e5ac0dd1830,REGN,Yahoo,"Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) were up as much as 8.2% on Thursday morning after the biotech company announced positive news on Thursday for a phase 3 trial for Dupixent (dupilumab) to treat patients with chronic obstructive pulmonary disease (COPD).  Regeneron's shares are up more than 18% this year, and the stock has a 52-week low of $538.01 and a 52-week high of $812.69.  Regeneron partnered with Sanofi (NASDAQ: SNY) on the phase 3 trial and said it met all primary and secondary endpoints compared to a placebo on patients with uncontrolled COPD and evidence of type 2 inflammation.",https://finnhub.io/api/news?id=6e78177cadfa658996a4a421f5f2eed98b8fa2b1784a31465ea9a46fa0b72d8b
company,2023-03-23 10:31:20,"Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD",119383370,https://image.cnbcfm.com/api/v1/image/104844697-IMG_5073-Schleifer-regeneron.jpg?v=1679596280&w=1920&h=1080,REGN,CNBC,"Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say ""exceeded expectations.""",https://finnhub.io/api/news?id=889b0f74d103d81f2e06c18e84c258e9494fc880c663cd942d2432fe21d6cedc
company,2023-03-23 10:00:44,Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?,119380634,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...",https://finnhub.io/api/news?id=68d8cd1956f6f63a9dba73e12799fab084640d1b15b14f9bc03e1a10dfd1a025
company,2023-03-23 09:24:35,"Stocks making the biggest moves midday: Netflix, Block, Snap, KB Home and more",119375000,https://image.cnbcfm.com/api/v1/image/107187269-1675265377947-gettyimages-1240099891-220419b6_netflix_campus_gv_b-gr_09.jpeg?v=1679592275&w=1920&h=1080,REGN,CNBC,Block fell after Hindenburg Research unveiled its latest short position on the stock. KB Home popped on earnings. ,https://finnhub.io/api/news?id=94a79ea8d6973f0fefa6fbc0d6e31afe4228721a633f2103e49a1a162e361426
company,2023-03-23 09:20:07,Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today,119380635,https://media.zenfs.com/en/Benzinga/e5f9e9eb44339778f7becdd402e4ab34,REGN,Yahoo,Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Phase 3 trial of Dupixent (dupilumab) for uncontrolled chronic obstructive pulmonary disease (COPD) met its primary and secondary endpoints. Dupixent exhibited a 30% reduction in moderate or severe acute exacerbations compared to the placebo. The Phase 3 trial involving 939 current or former smokers also showed impro,https://finnhub.io/api/news?id=e86eab1c55278a18b95b4b0dfdfd6f6466771801fe0a9181a1173f5e315cba1b
company,2023-03-23 08:14:56,"Sanofi, Regeneron’s Drug Succeeds in High-Stakes Lung Trial",119380636,https://s.yimg.com/ny/api/res/1.2/F_MS7kmr3TPTW8bftrrNUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/7139db89deba74092d703c19c08fd594,REGN,Yahoo,"(Bloomberg) -- Sanofi’s prescription drug Dupixent helped patients with a chronic lung disorder breathe better and regain lung function, opening a new avenue of growth for the blockbuster medicine. Most Read from BloombergJack Dorsey’s Block Vows to Fight Back After Hindenburg Says It’s Short the StockShort Seller Hindenburg Says ‘Another Big One’ Coming SoonUS Fears a War-Weary World May Embrace China’s Ukraine Peace BidJPMorgan Sold $10 Million in Jewels Left in Bank Safe Deposit Box, Suit Cla",https://finnhub.io/api/news?id=27e751a8e8e2f6909876460eb1a9253df4fb2b5a2c72b2162a0a013dbf5164b1
company,2023-03-23 07:13:00,What You Missed On Wall Street This Morning,119373517,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d4114627f4f683f7d31452261511e7459bbd498d678db034d9a5d7d9bfe2ae3e
company,2023-03-23 06:14:00,"Regeneron up 7% following Dupixent data, Raymond James upgrade",119376231,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=92a29f232ef19595088c9bfd1430a4711409ab8cb19c1a2d4dbedd101b06c598
company,2023-03-23 06:13:00,Why Are Stocks Up Today?,119375125,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=eade382cd4379423b872c83f5b1985fadcc6c39f9fd99556b04c811d6d37be07
company,2023-03-23 05:46:00,REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data,119374357,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=47acca58fa4cdbc3c4f8669f2868a575bd0ebb93a72695cf809a0f6448070545
company,2023-03-23 05:37:00,Raymond James ups Regeneron to Market Perform as few downside catalysts remain,119442426,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0d1a847ef9459e6e338edee5ff619a080153da85756fd705c8cbcd056bc12c25
company,2023-03-23 05:34:00,Regeneron upgraded to Market Perform from Underperform at Raymond James,119442427,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=40216efb5deaaba4ae116d3da88ae3ef971e7b495673d26a0de39ceb4f43ee06
company,2023-03-23 04:55:00,Early notable gainers among liquid option names on March 23rd,119374359,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ff3f8e099609ea22cf181551761b9cc6c6afdfd38b5a7a9a473ecb4379057abb
company,2023-03-23 04:42:18,"Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data",119368765,https://static.reuters.com/resources/r/?m=02&d=20230323&t=2&i=1627719824&r=LYNXMPEJ2M04N,REGN,Reuters,"Sanofi's asthma drug Dupixent met all targets in a trial to treat ""smoker's lung"", potentially adding billions to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller.",https://finnhub.io/api/news?id=77481780d5b49bec2f7083ee853cd5f2b26f4f2cb301ea34dc2da35b76b6bdc8
company,2023-03-23 04:12:54,Sanofi rises as analysts eye results from smoker's lung drug trial,119380637,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,By Scott Kanowsky,https://finnhub.io/api/news?id=1a96e9e86927ce002420ad510e972e072aa5f28db64b97eb667038fc73c13be4
company,2023-03-23 04:00:00,"Coinbase’s stock tumbles after SEC warning, Regeneron shares rally, and other stocks on the move",119384525,https://images.mktw.net/im-749459/social,REGN,MarketWatch,"Coinbase, Chewy, Regeneron, Accenture and First Republic were some of the most active shares on Thursday.",https://finnhub.io/api/news?id=d7cd2fa7f252ab644aba0b029687557a7c7c02939a6c74fb7c6f6f4de8d9d5ac
company,2023-03-23 03:56:00,"Regeneron, Sanofi say Dupixent works in COPD",119498960,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,REGN,MarketWatch,Shares of Regeneron Pharmaceuticals Inc. rallied about 7% in premarket trading on Thursday after the company said a pivotal Phase 3 clinical trial showed...,https://finnhub.io/api/news?id=e9857f70fbab52af564a5f902ff01c51a7f06a0f0972aa4ad76c7c4ae5f8b6b4
company,2023-03-23 03:31:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC)",119378286,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7f67381e1c19b0942a43582e982a58f182b934a52d263b3a8d447b351361828e
company,2023-03-23 03:30:00,"S&P 500 Futures Rise in Premarket Trading; Coinbase Global, Apellis Pharmaceuticals Lag",119371171,https://s.wsj.net/public/resources/MWimages/MW-HA919_barron_NS_20181226134502.png,REGN,MarketWatch,"With U.S. stock markets set to open in two hours, (REGN) was up 6.7% in pre-market trading, and (DOOO) was up 5.0%. (ACN), (SMAR), and (FDS) were all posting...",https://finnhub.io/api/news?id=4d78481560f0da1b6e3a65ab5342c9f9aa7d8b84e02c1c436709711149aff6db
company,2023-03-23 03:14:00,"The Fed pivot is near, and yield curve inversion has likely peaked. That`s usually bad news for stocks, this Fidelity strategist says.",119373865,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=07ac0b37578d08f5aafb5ffbcce6685c5eff3dedaa6a9a4fe4514b0be337ce27
company,2023-03-23 02:59:00,Regeneron Shares Rise Premarket on Dupixent COPD Study Success >REGN,119498964,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Shares of Regeneron Pharmaceuticals Inc. rose sharply in premarket trading Thursday after the biotechnology company and partner Sanofi SA...,https://finnhub.io/api/news?id=500850988b6e011a835733bc69bcd741ef1a7e600b2878b6e4f77ef33feffb7c
company,2023-03-23 02:45:09,"UPDATE 3-Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data",119367038,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Sanofi's asthma and eczema drug Dupixent met all targets in a trial to treat ""smoker's lung"", giving a major boost to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller.  In a late stage trial Dupixent, jointly developed with Regeneron, led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a potentially deadly disease marked by progressive lung function decline.  Sanofi and Regeneron said in a statement on Thursday a Phase III trial involving 939 current or former smokers also showed improvements in lung function, quality of life and COPD respiratory symptoms.",https://finnhub.io/api/news?id=05b6b53d556f17966ac1545652f68fa6873d4facca05e8eac13799f704aa862d
company,2023-03-23 02:38:00,"Sanofi Shares Rise After Dupixent Trial Hits Targets, Adding to Drug Potential",119498967,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Adria Calatayud Shares in Sanofi SA rose Thursday after the French pharmaceutical company and Regeneron Pharmaceuticals Inc. said their jointly developed...,https://finnhub.io/api/news?id=a27e451d692e0ef7e6e65f0aed3fe3a3841e6834af9415bcc91a6f0d687e45dd
company,2023-03-23 02:00:01,Sanofi and Regeneron's Dupixent meets endpoints in clinical trial,119367039,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Healthcare firms Sanofi and Regeneron said their Dupixent product, which treats the skin disease atopic dermatitis, has met primary and all secondary endpoints in a trial to treat chronic obstructive pulmonary disease (COPD).  Dupixent showed a 30% reduction in moderate or severe acute exacerbations of COPD, a respiratory disease that damages the lungs and causes progressive lung function decline, in the Phase 3 trial, while also showing improvements in lung function, quality of life and COPD respiratory symptoms, the companies said on Thursday.",https://finnhub.io/api/news?id=e6b0cca4d3f9d7aad3ccfc94972b42d6882c9dab6fbd99313866e951e3fa0f6f
company,2023-03-23 02:00:00,Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial,119380642,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo First and only biologic to show rapid and significant improvement in lung function (160 mL in FEV1) compared to placebo (77 mL in FEV1) First and only biologic to demonstrate significant improvements in quality of life and respiratory symptoms COPD is the third leading cause of death worldwide with no new treatment approaches approved in more than a deca,https://finnhub.io/api/news?id=e0860ab72b174c44fa430ee5826e98d03382c41c3d0cc8da3543cd8ce4627314
company,2023-03-23 00:16:00,"Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints",119376239,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=739630418da47eb001c7c05c67ade26ed99afbe93a5d893f8b46fa105aec5563
company,2023-03-22 23:56:00,What You Missed On Wall Street On Thursday,119377298,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6f9814120e7ff15898154287946963671604576f0455e390efacc93cbf599333
company,2023-03-22 22:53:00,"IN BRIEF: Sanofi, Regeneron's Dupixent shows promise for COPD in trial",119376020,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=88d99c2cd98b5c5f440bde53a0dd25db00d86871b9fb57c60579fb5042d86907
company,2023-03-22 14:15:06,Regeneron (REGN) Gets Label Extension for Cholesterol Drug,119363421,https://media.zenfs.com/en/zacks.com/4043e725c7008a4cc075c53e1421f50c,REGN,Yahoo,Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.,https://finnhub.io/api/news?id=1768a7b6e58a3d5ff8bb57c3cfbc6b4c01dcc53c8eeb4dfab19c8c03e510d9bb
company,2023-03-22 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,119498970,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.11% to $751.30 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=3fd95c5d5e4993d18388800cb73952f0de4f6fd230bfd1e7066e988fb28455cf
company,2023-03-22 09:44:57,US FDA expands use of Regeneron's cholesterol drug in young children,119353662,https://static.reuters.com/resources/r/?m=02&d=20230322&t=2&i=1627626347&r=LYNXMPEJ2L0EU,REGN,Reuters,Regeneron Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration had approved the expanded use of its drug in children aged 5 to 11 years to treat an ultra-rare disease that causes high cholesterol.,https://finnhub.io/api/news?id=5ecc074fcf67d4031344916d6819356e511ab3eed60caf6cd3ddcebaf3051963
company,2023-03-22 07:26:19,UPDATE 3-US FDA expands use of Regeneron's cholesterol drug in young children,119363422,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Regeneron Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration had approved the expanded use of its drug in children aged 5 to 11 years to treat an ultra-rare disease that causes high cholesterol.  The drug, Evkeeza, was approved in February 2021 as an additional treatment with other lipid-lowering therapies for patients aged 12 years and above with homozygous familial hypercholesterolemia (HoFH).  It causes elevated levels of low-density lipoprotein (LDL) cholesterol and types of premature cardiovascular diseases.",https://finnhub.io/api/news?id=43408d34febe31aef0306838031fa71d77a67c33dceae7e86fbf0fa12ab0ff41
company,2023-03-22 07:06:12,Regeneron gets US FDA nod for expanded use of cholesterol drug in children,119353663,,REGN,Reuters,Regeneron Pharmaceuticals Inc said on Wednesday the U.S. health regulator has approved expanded use of its drug to treat high cholesterol in children aged 5 to 11. (Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli),https://finnhub.io/api/news?id=1e692b43509997664a3c034f9cc3bb230bc764f7ba58161bf00af0a72aa98090
company,2023-03-22 07:00:00,FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol,119363423,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Approval extends Evkeeza to children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), an inherited condition characterized by extremely high low-density lipoprotein cholesterol (LDL-C) 48% reduction in LDL-C from baseline at week 24 when Evkeeza was added to other lipid-lowering therapies in the pivotal trial TARRYTOWN, N.Y., March 22, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has extended",https://finnhub.io/api/news?id=6993350b3d24e1ba607b14a1fab80ca4f7c43ef8548931dd70de612ad3a6c232
company,2023-03-22 03:15:00,Regeneron: FDA Extends Evkeeza Approval to Children Ages 5 to 11 >REGN,119498971,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration extended the approval of its Evkeeza cholesterol...,https://finnhub.io/api/news?id=cb6f5c1235ef548210bcc81f0a50e821394bbc513536e5fe7537fddb134539d0
company,2023-03-22 02:56:00,Regeneron gets FDA approval for expanded use of high cholesterol drug Evkeeza in kids,119361386,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c378c234b55ea4cc905701c2ddae005d1d7e5ff2f59a4eb938612e1d3581d7b9
company,2023-03-22 02:16:00,Regeneron announces FDA approval of Evkeeza for young children,119361388,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bb06f5c09f7deeb4d394e95749ed588eb3ab4adab5cfbb31cb3ae6f6d51590ac
company,2023-03-21 22:47:00,7 Value Stocks Worth Buying at These 52-Week Highs,119356913,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5eff460e93f2e9cee9f9a6d550ff6273a4aef998bf239cac307a97db633e95eb
company,2023-03-21 18:15:10,Regeneron (REGN) Gains But Lags Market: What You Should Know,119343124,https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926,REGN,Yahoo,"Regeneron (REGN) closed the most recent trading day at $759.76, moving +0.07% from the previous trading session.",https://finnhub.io/api/news?id=a2dc2617816abbd19b8c6a320538ad525b803bcf368659a7b96a9101dee419e2
company,2023-03-21 06:04:10,Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids,119343125,https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e,REGN,Yahoo,Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.,https://finnhub.io/api/news?id=fb464e1ff0203fca44f54afd224c2dd7f016da0fb49430d1bb7d76d32e1cd886
company,2023-03-21 02:11:44,Sanofi/Regeneron say Dupixent skin treatment wins new regulatory approval in Europe,119328038,,REGN,Reuters,"Healthcare companies Sanofi and Regeneron announced on Tuesday that their Dupixent product, which treats the skin disease atopic dermatitis, had won a new regulatory approval from the European Commission.",https://finnhub.io/api/news?id=3a24b4d2e048362cf2960d6b6e850c3d745e67e941752d536b0ee4c013a43e4c
company,2023-03-21 01:59:00,Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis,119343126,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo Patients treated with Dupixent achieved rapid itch reduction as early as three weeks after start of therapy, with significant improvements at 16 weeks sustained through one year Dupixent is now a treatment option for the approximately 80,000 infants and young children living with unc",https://finnhub.io/api/news?id=00a2113d3d5563a928e83be8baf9f7c4f7c2f581f087168603584e2864ee845d
company,2023-03-21 00:26:00,"Regeneron, Sanofi announce EC approval of Dupixent",119337374,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4217e1a7ced7860892321bebba2a66cfe2b40fe57543ea17c38bc8e00be1acea
company,2023-03-21 00:21:00,"Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",119340598,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=45b199aca600cf7e624d7a1bdb3cd8233580872768b457f3fef9230ad38d1447
company,2023-03-20 22:36:00,"IN BRIEF: Sanofi, Regeneron's Dupixent wins another EU approval",119336484,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=94cdf8578cb834ef8f3863720a4ac9dad75e94cd8d9f79aabc87da9759eec1b3
company,2023-03-20 03:27:00,Regeneron price target lowered to $802 from $806 at RBC Capital,119303322,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=26de2416896a192bc402bd8fd494d494d93f4d3248e9cffe65f02a0fd25c9bf3
company,2023-03-19 23:32:00,IN BRIEF: Regeneron and Sanofi share positive data for Dupixent,119303323,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e2d3e15828d93373a639e11976ffa124be0480263af354d76d45fe682f12e8cd
company,2023-03-27 18:51:01,Amgen-Sanofi patent case divides makers of antibody drugs,119451711,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.  In the dispute with Sanofi and partner Regeneron, whose cholesterol-lowering monoclonal antibody drug Praluent works in a similar way as Repatha, Amgen wants the court to rule on how much information it and others need to disclose when describing inventions in patents.",https://finnhub.io/api/news?id=fa4a1a83a4ddb9d63ad274d22b4dd25827311ce87aae87e878c34ddab147e3af
company,2023-03-27 16:20:29,SVB Leerink Upgrades Regeneron Pharmaceuticals (REGN),119443986,,REGN,Fintel,,https://finnhub.io/api/news?id=9280178a4a129f1780b8d5418893392cad470a4325d24fb340398c8f6544fb12
company,2023-03-27 13:28:23,UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug,119443475,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy. UBX1325 treatment generally maintained visual acuity for six months, with most patients not requiring anti-VEGF rescue. Patients in the every 8-week Rengeron Pharmaceuticals Inc (NASDAQ: REGN) Eylea (aflibercept) arm had an early and unexpected gain of 3",https://finnhub.io/api/news?id=a9db5daf23cf07cd56b9d57b82b31110a21adbc8387ecf4456b8c8531ea70cd3
company,2023-03-27 13:20:00,"Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market",119498947,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.05% higher to $820.41 Monday, on what proved to be an all-around great trading session for the stock...",https://finnhub.io/api/news?id=db42971a8b2ce63737dead519b2983f084a218b9e3cbabf6224350dc80725e79
company,2023-03-27 10:35:02,UPDATE 1-U.S. Supreme Court hears Amgen bid to revive cholesterol drug patents,119435915,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"The U.S. Supreme Court on Monday began hearing a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a ""blatant attempt"" to squeeze competitors out of the market.  Amgen is appealing a lower court's ruling that invalidated two of its patents on Repatha, a drug that can reduce risk of heart attack and stroke in people with heart disease, after a legal fight with French drugmaker Sanofi and its partner Regeneron Pharmaceuticals Inc.",https://finnhub.io/api/news?id=f1beaf8dadaee8fa0e5388a5a5a5b22f9a30d62ac955023c592f5d70e32339d3
company,2023-03-27 10:01:50,"Final Trades: Regeneron, Hess & Bank of America",119440954,https://image.cnbcfm.com/api/v1/image/107215732-16799380642ED3-FMHR-FINAL-032723.jpg?v=1679940110&w=1920&h=1080,REGN,CNBC,"The ""Halftime Report"" traders give their top picks to watch for the second half.",https://finnhub.io/api/news?id=cdc53a716113eedf6eaed2ad51c4ff000f61bc4e1821e4a2de1331248ffccae3
company,2023-03-27 08:48:00,"Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations",119438732,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=439b5e7f60abc953261525a05bb59386b7b77d31b7539046047de0574eeba8f4
company,2023-03-27 07:45:00,Video: S&P 500 Analyst Moves: REGN,119442386,,REGN,Market News Video,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=98e6e544556c48dec7313809fa27c8c2931c06defae2dc9a40feda5f7235d0fc
company,2023-03-27 07:41:11,"The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly",119432174,https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966,REGN,Yahoo,"Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.",https://finnhub.io/api/news?id=22c5e27e09888bf22199b0bd2b2c0a075b80fc11e0201ea8cb5b94346ecbd521
company,2023-03-27 07:38:00,Regeneron Pharmaceuticals Takes Over #146 Spot From Arthur J. Gallagher,119442387,,REGN,ETF Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=57dfbde6bfa9bae8e76b19acdf91b90d70923fbc4c3b98705846ce5da32f81f0
company,2023-03-27 06:00:00,Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court,119435920,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"The U.S. Supreme Court on Monday is set to hear a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a ""blatant attempt"" to squeeze competitors out of the market.  Amgen is appealing a lower court's ruling that invalidated two of its patents on Repatha, a drug that can reduce risk of heart attack and stroke in people with heart disease, after a legal fight with French drugmaker Sanofi and its partner Regeneron Pharmaceuticals Inc.",https://finnhub.io/api/news?id=342a9eff5d0886ca0d1884a3f7eb2eea7ebb8d536f39f1d27b773e065bbafae7
company,2023-03-27 03:37:00,Unity Biotech sheds 48% after mid-stage setback for wet AMD candidate,119436827,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4212593b657c0918b9cf21dcce6f177a545392c43f8d034ac9b6ab41bec8fd30
company,2023-03-27 02:32:00,REGN Crosses Above Average Analyst Target,119442393,,REGN,ETF Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=97878e137772b359f1e30d05d5de5b8d3b14635586c7c0cd59cd9ef264afa968
company,2023-03-27 01:25:00,"SVB Securities upgrades Regeneron to Outperform, sees positive drivers ahead",119442394,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4a255e84edb14aca9b68f6405de40e5118584ec4581db25a7a8c68f329962938
company,2023-03-27 01:19:00,Regeneron upgraded to Outperform from Market Perform at SVB Securities,119442396,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f3ef76d01b3753a83bfb74e85785d5d0d947b6a7da5467cd8fa045f43965fb4a
company,2023-03-26 05:22:00,"FDA PDUFA Date for Regeneron Evkeeza (evinacumab) March 30, 2023",119442398,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0a00b9bd9d623574498240e02f07d15424f38f67f7eb1927f29409705c587bd5
company,2023-03-25 12:54:00,Regeneron and Sanofi Look for Billions From COPD Drug,119423847,https://s.yimg.com/ny/api/res/1.2/eWQEHI4FPyVE1q34CAeNYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/4af1944de92d737d1fc3f822a56d0783,REGN,Yahoo,The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.,https://finnhub.io/api/news?id=b58225019301b65cbd2d08de0e3881135d5d5511ab14c706ea240dd66b89728b
company,2023-03-25 09:32:04,Wall Street Breakfast: What Moved Markets,119385420,https://static.seekingalpha.com/uploads/2021/7/24/saupload_Wall_Street_-_Generic.jpg,REGN,SeekingAlpha,"Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.",https://finnhub.io/api/news?id=dbad2d54f61b65f7dd7fffcd5b26edffc17ab634661359fde806a9554cc25c52
company,2023-03-25 01:58:00,Regeneron Pharmaceuticals Boosted By COPD Data,119442401,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=41e1e856e86aa56bdf8058c01f38a8923d7793474975d695612665b69d6eb1fa
company,2023-03-24 16:31:25,Jefferies Upgrades Regeneron Pharmaceuticals (REGN),119385369,,REGN,Fintel,,https://finnhub.io/api/news?id=51f5ab548f5c7d7b21223d65d03bf6d8ca665cf8223ff17f03afa73706740b61
company,2023-03-24 16:29:36,Raymond James Upgrades Regeneron Pharmaceuticals (REGN),119385385,,REGN,Fintel,,https://finnhub.io/api/news?id=6ca6cd29f93ac001f69736475de171c3874b1e8bf62d75fec0d555108408f68e
company,2023-03-24 14:29:06,"Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%",119422226,https://media.zenfs.com/en/zacks.com/c0c563b233f28a1874a33c46aadaa70e,REGN,Yahoo,Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.,https://finnhub.io/api/news?id=261ef40b290eb6c48591a4989a3310aeaeacc77df1a35437422e056e32776db1
company,2023-03-24 14:17:54,Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough,119427270,https://media.zenfs.com/en/ibd.com/9740f3ecddfb49b1d626a4e35f12ec63,REGN,Yahoo,"Growth stock Regeneron Pharmaceuticals broke out in strong volume from a flat base and 800.58 entry this week.  News of the first breakthrough in a decade for a leading cause of death drove the biotech to new highs.  On Thursday, phase 3 clinical trials showed successful results for Regeneron's Dupixent in treating chronic obstructive pulmonary disease (COPD).",https://finnhub.io/api/news?id=5ad7de450fc3a2f9e4c0c33e7641fcfe40d061a07a2fafdbc0f3ccecf7c83291
company,2023-03-24 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,119498949,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 2.22% to $820.00 Friday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=73e68faf47c7d514523b368d8f65d1154796500a23f0b379bd196257e915d327
company,2023-03-24 12:02:33,Wall Street Has High Hopes for These 2 Nasdaq Stocks,119425174,https://s.yimg.com/ny/api/res/1.2/N9QJvpN0wHIRVsXxd6NeoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/8267d25d761d4f8083726de1620cb2c2,REGN,Yahoo,"The stock market started out on an uncertain note on Friday, initially falling but cutting its losses in the first hour of the trading day.  Two that they recently focused on were Regeneron Pharmaceuticals (NASDAQ: REGN) and Cracker Barrel Old Country Store (NASDAQ: CBRL).  Although the duo are in very different industries and don't necessarily have much in common other than being listed on the Nasdaq, positive assessments from stock analysts indicate optimism about the prospects for their respective businesses.",https://finnhub.io/api/news?id=39a147412c3681f8704a9a167bd007de0b78efe37092d18d70b3b72c4de5d5b5
company,2023-03-24 09:17:00,Regeneron’s Asthma Drug Results Were ‘Stellar.’ Analyst Sees a Sales Bonanza.,119423852,https://s.yimg.com/ny/api/res/1.2/WyeJ.RwR6aL3jod7aPTBiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/962b554f4e0204f5480cb71f50f82eed,REGN,Yahoo,The company and its partner Sanofi presented data from a trial of the drug as a treatment for chronic obstructive pulmonary disease.,https://finnhub.io/api/news?id=f5d0320de4265cbc5fd4d5363512ab0bdccdb5eb12591017987c67a51064f5ce
company,2023-03-24 09:05:09,"Stocks making the biggest moves midday: Block, Deutsche Bank, GameStop, Activision and more",119420667,https://image.cnbcfm.com/api/v1/image/105469655-1537877938166gettyimages-497875206.jpeg?v=1679677509&w=1920&h=1080,REGN,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=73ace0c25838bf01e8ac0e7e35c88cff43471e4133132ef8668b0e9d3b03dd05
company,2023-03-24 09:04:01,"Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL",119422013,https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3,REGN,Yahoo,"Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951",https://finnhub.io/api/news?id=f17c610ad44719d5503cfde3da61487613c626e9e35927d43c72f9bc8f7b05a7
company,2023-03-24 08:00:12,ETFs in Focus on Sanofi and Regeneron's COPD Drug Data,119423854,https://media.zenfs.com/en/zacks.com/0127186cf6d7cf117799d304c710dd00,REGN,Yahoo,Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.,https://finnhub.io/api/news?id=fd38ab720bcb0db3f26567231d0a4c33eac0849be114cba14e05c1b0c2a371cf
company,2023-03-24 07:47:38,5 analyst picks of the day: Nike upped on Q3 beat | Pro Recap,119422329,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Barclays upgraded  Nike  (NYSE:NKE) to Overweight from Equalweight and raised its price target to $154.00 from $110.00 on its belief in a high probability of margin upside.  The company reported its Q3 earnings results on Tuesday, which, according to Barclays, demonstrated the company’s “broad-based brand strength in spite of a weakening consumer macro backdrop.”  Q3 EPS came in at $0.79, better than the consensus estimate of $0.55.",https://finnhub.io/api/news?id=b3d02612e1e863e30ed326e69df8c2cb17f3b77af922efb1e522ed31258eaa3d
company,2023-03-24 07:01:00,What You Missed On Wall Street This Morning,119435257,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c3762debe796c891e9ab5a8360cace41a719b837b4d1be360cb918c9731c62fc
company,2023-03-24 04:07:10,"First Republic, Deutsche Bank, Chevon, Block fall premarket; Regeneron rises",119421846,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,By Peter Nurse,https://finnhub.io/api/news?id=786e782ba48cda39354d0282c818357b9ae1e1f03209f78c3e25a9e2fb5540b0
company,2023-03-24 04:05:00,"Regeneron price target raised to $1,040 from $1,025 at BMO Capital",119442407,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f0e4a20c22e4766f363b69f8c5b46fef5594973346d42b7fe5f0901d6d0fb658
company,2023-03-24 03:58:00,GLOBAL BROKER RATINGS: Jefferies says 'buy' Regeneron and 'hold' UBS,119436717,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a0d235c5789c92d467acf7b5d925a7972ca41d3867f10fd1d772a84722b4dd35
company,2023-03-24 03:46:00,Regeneron draws more bullish views from analysts after Dupixent COPD data,119437451,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f60f3e8967e7f982ce138bd4a927c7351c124b45cc971717e39b313b13970e26
company,2023-03-24 03:04:07,Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?,119427277,https://media.zenfs.com/en/zacks.com/5e8265f9ff919fb797d3533dab9e8501,REGN,Yahoo,Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.,https://finnhub.io/api/news?id=e4a1addb2d9dfe57dbb86539a5afa31fbe4f03e1e2b2d0f5ac2a7e98c54453f5
company,2023-03-24 01:36:00,Regeneron price target raised to $915 from $860 at Wells Fargo,119442410,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1bd49c259281774368087a712ee517a451790d221266d1f880d62906d3dfd220
company,2023-03-24 01:32:00,Regeneron price target raised to $800 from $756 at Baird,119442411,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b5d7a771e935360acd3ff147c418637da9ded52b02c2bd459d5e6cd3c9a67e37
company,2023-03-24 01:26:00,Morgan Stanley Reaffirms Their Buy Rating on Regeneron (REGN),119442412,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=be300a910332d8e376d5a7b78f1c3db934f6efbec7b473530c7857b79f102d9f
company,2023-03-24 01:06:00,Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN),119442413,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7379a87c2f9266e770b18e4b01fbbdd39e47f0f49bd6a01f803dbaee0b161348
company,2023-03-24 01:01:00,Regeneron price target raised to $915 from $815 at Barclays,119442414,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d20cd82f49545ca26317390dc5af1cb504c52f938d114cc5c1d96f62da78e34b
company,2023-03-24 00:45:00,Regeneron upgraded to Buy on COPD opportunity at Jefferies,119442415,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=977c840849054d37985e6b9aa326dd22d4b4c98d86092fbf5aa3bd302575491a
company,2023-03-24 00:06:00,Regeneron upgraded to Buy from Hold at Jefferies,119442417,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=91bedb2d8e4bb7fd95781b585ffe406782169d5a1e1eeb84dfc590a0481087f8
company,2023-03-23 23:27:00,What You Missed On Wall Street On Friday,119435278,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=20b572e2d52ae4a6905b5221a76527d3b32ae054e289381fd17329618466d896
company,2023-03-23 23:18:00,Regeneron May Win Big with New Drug,119442419,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4c2ba3f86cfb27ad7a1b8d393186820def8bdd4f9b8f0a292768c4b6db193bd4
company,2023-03-31 18:15:10,Regeneron (REGN) Gains But Lags Market: What You Should Know,119546428,https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39,REGN,Yahoo,"Regeneron (REGN) closed at $821.67 in the latest trading session, marking a +1.25% move from the prior day.",https://finnhub.io/api/news?id=b28dc8203f41796e40c2f75a8b9a165c589cb89519e8e1cc19282d9921e9cd65
company,2023-03-31 13:24:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market",119555205,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.25% to $821.67 Friday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=f559665b91fdf3c21d4b4bf860a1b21cf6aabae44ffbe4e07b8bc7c893021194
company,2023-03-31 02:14:00,Regeneron price target raised to $950 from $900 at JPMorgan,119537396,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=508f96ba7f69952a6e0ffe6b3b9ccfbdebd26b7d76ddea1f0631393a9475026a
company,2023-03-30 13:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,119555206,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.96% to $811.50 Thursday, on what proved to be an all-around great trading session for the stock market, with...",https://finnhub.io/api/news?id=cc974d85f624c633aae302a19ce8d31c471f2d0fcb72bd4d150a89ceb78e0142
company,2023-03-30 03:31:00,Regeneron price target raised to $940 from $925 at Jefferies,119517391,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bc7d1fdc1da40a001527e548c808ae1a9f104ae3a032abece5caf881e5466165
company,2023-03-30 02:22:00,Regeneron in research agreement with Xeris Biopharma,119517718,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bcce11e8376a97e3661fcd09fa94069e6b10713fd4bcb6fa63d1c51610513deb
company,2023-03-29 23:55:00,"FDA PDUFA Date for Regeneron Evkeeza (evinacumab) March 30, 2023",119517719,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fdabe2d9a3d160878ba58ea7dfcac968f96ec13fefcfe16925a478404f59f9f9
company,2023-03-29 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",119512427,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slumped 0.92% to $819.35 Wednesday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=b9a940398fab695f863e0042cca64cc42b390b2de969ec7815b4f6066bad4a61
company,2023-03-29 11:24:03,"Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback",119497356,https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96,REGN,Yahoo,Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.,https://finnhub.io/api/news?id=c7f3bff0d34cfed88a9b2db35dc2a7281c8ce799a1d6532f9b9c391dd745c215
company,2023-03-29 07:43:55,Regeneron Shares Rally on Heavy Demand and Strong Fundamentals,119507585,https://media.zenfs.com/en/fx_empire_176/4d5357b1a21079252c341cdc92e3deb8,REGN,Yahoo,Regeneron Pharmaceuticals (REGN) has been a bright spot in the market lately.,https://finnhub.io/api/news?id=9fe9ecb17ce881d7a349af6219fa1e7d5ef40d7d76b247e668cb683270361bf8
company,2023-03-29 07:00:00,Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC),119490162,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday clinical practice Approval marks second first-line indication in NSCLC and fifth indication for Libtayo in the European Union (EU) TARRYTOWN, N.Y., March 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemipli",https://finnhub.io/api/news?id=1ca00be66d77cfa8c4300813badc61b7489cbff155e0bdeec56bc5f1270d9f4b
company,2023-03-29 05:00:00,"Kodiak Q4 update had `a few nice surprises,` says Capital One",119491599,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a95a5c528741b399a24486ee8261ee0547f7611519a14691952f437d13a7afa3
company,2023-03-29 02:36:00,Regeneron Libtayo gets expanded approval in EU for lung cancer subtype,119491603,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b25b5f73646c3129f622d2cb05c5833003454e5fac579489dabf3c62b818674c
company,2023-03-29 02:09:00,Regeneron announces EC approved Libtayo in combination with chemotherapy,119491604,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bd824c31b46879a5d8aaeab447d173d1ae6042349cd67f4ce84a03ed85d40664
company,2023-03-29 01:57:00,Regeneron price target raised to $650 from $605 at BofA,119491606,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4f04025c262c6d7660cc9940cba3da83d196d44beb7ac3ff29b4f1c1b6dd7823
company,2023-03-29 00:51:00,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Intra-Cellular Therapies (ITCI) and uniQure (QURE)",119491608,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3410278f149ecb0179d349353b6804bbd90467772a80b8d811f181cd2e4c3ffb
company,2023-03-29 00:32:00,"Amgen, AstraZeneca`s asthma therapy Tezspire gets UK`s NICE backing",119491609,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bf5449546502dcd2cdb09ab03cde69c0906d9c66b10f40ab2fb7fe0de43dff25
company,2023-03-28 15:25:07,Unity (UNX) Down on Disappointing Results From Wet AMD Study,119483653,https://media.zenfs.com/en/zacks.com/79da42a5951da395af5b31089b7ceda2,REGN,Yahoo,Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.,https://finnhub.io/api/news?id=94b95203ce2a0337c0311e208592123c4f45131b52973e06b9875853f8c1b843
company,2023-03-28 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,119498945,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.80% higher to $826.97 Tuesday, on what proved to be an all-around poor trading session for the stock...",https://finnhub.io/api/news?id=c875d4599ff7eca06eb3b2acc8985502eae0330e5d39bfa890f1aedc1c201c2e
company,2023-03-28 07:30:00,"Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases",119473656,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone paymentTARRYTOWN, N.Y., and SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development",https://finnhub.io/api/news?id=b7be98d7c8946c564f57d76252fa94037e7433eab09e3721f4d7acc72cc422c4
company,2023-03-28 07:30:00,"Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases",119473654,https://media.zenfs.com/en/business-wire.com/5d6d1b0b9b0f60c503c1b7b32a08255a,REGN,Yahoo,"SOUTH SAN FRANCISCO, Calif. & TARRYTOWN, N.Y., March 28, 2023--Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases",https://finnhub.io/api/news?id=a3daad1e05ea060fb6b396605b732ffcc42d54cd1c88517e67b23b0052f0f698
company,2023-03-28 04:56:00,"Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations",119471783,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5e8a95e437953d06e8dce9b8a4ea6d140ff93f4c6542dbbd6953dbbd0bc60f4b
company,2023-03-28 04:03:00,Regeneron resumed with a Buy at Erste Group,119478027,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=59a979608e2a27daa33a2a7614821ba80c9db94f03e7f43afab2b13bff1764a3
company,2023-03-28 03:55:00,Regeneron to pay Sonoma $75M upfront in pact to develop autoimmune disease drugs,119478028,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3351ce8f0035bac1aae12d203aa93846917594b2550915b1043c43b6683b504f
company,2023-03-28 03:09:00,Immuneering appoints Harold Brakewood as CBO,119476389,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d73931b964f1e8c32ec51535e00fb400e6e78e027dc5403b082646b3e602d5ff
company,2023-03-28 02:38:00,"Regeneron Pharmaceuticals, Sonoma Biotherapeutics announce collaboration",119478033,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1319031662240bcab8e87b01a1f12ffc0d38b44f042caeefc55a37674b3c2839
company,2023-03-28 01:26:00,RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN),119478034,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0d9b7aa1757eb86cc629e7a7dadae327847f0bdcad6060b696673aef4a11f88b
company,2023-04-04 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market",119688400,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. sank 0.50% to $822.09 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=3e9da068cfe5ac8640a33bf351caecd6f551e4820b8390a11de50f9a5a1288bb
company,2023-04-04 09:00:01,Why Investors Need to Take Advantage of These 2 Medical Stocks Now,119613799,https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4,REGN,Yahoo,Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.,https://finnhub.io/api/news?id=3af491db1832a9265a447c9fad9814145d6750976caa6a6daa8e330f9fb8f530
company,2023-04-04 07:00:21,"One Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insider reduced their stake by 26% in the previous year",119621766,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Looking at Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) insider transactions over the last year, we can see that...",https://finnhub.io/api/news?id=5f336880fe36cd022c036ab2df3ac37f3a09ff3fbbed3cdfbe1302557137e491
company,2023-04-04 04:30:01,$6 billion in college scholarships are awarded each year. Here's what you need to know about applying,119605210,https://image.cnbcfm.com/api/v1/image/107219441-1680539609365-gettyimages-1428218783-dscf7946.jpeg?v=1680611401&w=1920&h=1080,REGN,CNBC,Winning a scholarship can help students graduate with less student debt. Here's what you need to know about the awards. ,https://finnhub.io/api/news?id=742c83bf8e68717b16f13a473bce9ae52df736c0bd3fdc24ba207a304179053c
company,2023-04-03 16:00:00,"Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023",119600652,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"TARRYTOWN, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 4, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s website",https://finnhub.io/api/news?id=57639d3bfd1046817fc3f41405a832270b4584fddb6dc625958efb64948e7b41
company,2023-04-03 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,119688401,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.55% higher to $826.19 Monday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=49f24f254683cd70d628aae6a91269bd0eb297a8760b046cda8d6300c4d18209
company,2023-04-03 08:20:00,Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags,119590517,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=78d71d6fb7416983a527b8205e3b9fd6a0f8f68532f13bb7711c4a906774ce7c
company,2023-04-03 06:19:00,Capital One remains bullish on RPT193 as Rapt initiates Phase 2a Asthma study,119592315,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1a6c926252ae13bef2eb9861fcf2215c8e9bca07cb9f8f61cd914ca975d58fc5
company,2023-04-08 07:00:42,"A Look At The Intrinsic Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)",119688498,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,032 based on 2 Stage Free Cash Flow to...",https://finnhub.io/api/news?id=38f29361fa9a5018c8383fc743468d45bb77c8f4481d7f367abcbe3ef30a8eb1
company,2023-04-07 12:10:04,Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?,119672640,https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9,REGN,Yahoo,Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://finnhub.io/api/news?id=035e57200ad4e6b9006ef46a2aa9f06532d0d2cd7ba18e79bd3f3441648858d7
company,2023-04-07 04:52:00,"Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Amgen (AMGN) and Regeneron (REGN)",119683860,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=254bd22ad0d69c2f2f0ad4efe84063fc2df70e34cd25932c89361d37de95e7a7
company,2023-04-06 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,119688398,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.43% higher to $828.73 Thursday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=fb9fc5b37655b05ff26d082e9590bf3bf35af16a88ac96b69bd587ab0e0aa49e
company,2023-04-06 05:39:00,2 Top Growth Stocks That Could Soar This Spring,119661391,https://s.yimg.com/ny/api/res/1.2/c899zpEN77LHTxGVWwqFwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/52c8385ed8ec7e1ab36b55e31dbd17f5,REGN,Yahoo,Exciting news on the way for both of these companies could send their stock prices screaming higher.,https://finnhub.io/api/news?id=d73d41a19a9350578fdbba8c29cc24d4e8d208fbaf91b3bd920556d6532e6153
company,2023-04-05 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,119688399,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.38% higher to $825.22 Wednesday, on what proved to be an all-around mixed trading session for the stock...",https://finnhub.io/api/news?id=549ffc1367ff1200c4c3abd01dbfc35cc3e9288dfe4c615bbae61edd0e475d84
company,2023-04-12 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,119755521,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.10% higher to $820.43 Wednesday, on what proved to be an all-around poor trading session for the stock...",https://finnhub.io/api/news?id=ba0f7d489aad068b32a2b5ca6a159e71c4250e4fa9cdaff54bb1479db639c665
company,2023-04-12 02:42:00,Regeneron price target lowered to $880 from $883 at Morgan Stanley,119731554,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=116dfcca28db5f95f22f2c96f4db4ca1e1b49211a6826e2759ffbc50a4009134
company,2023-04-12 00:14:00,S&P 500 will see 11% upside from the current levels - Piper Sandler`s Craig Johnson,119743043,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0750362cb3f75db0a1329a9d18f645998c079338b440b23f290e71c79406ff9b
company,2023-04-11 22:26:28,Why Healthcare Stocks Are A Prescription For Investors In Q2 2023,119725087,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413600685/image_1413600685.jpg?io=getty-c-w1536,REGN,SeekingAlpha,The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.,https://finnhub.io/api/news?id=69173de72e70bacb9558918aee06ad651655d4ae31b435a26de7f0e4e7d3ba03
company,2023-04-11 16:00:00,Regeneron Announces Investor Conference Presentations,119737647,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"TARRYTOWN, N.Y., April 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities 2023 Health Care Conference at 1:40 p.m. PT (4:40 p.m. ET) on Tuesday, May 9, 20232023 RBC Capital Markets Global Healthcare Conference at 9:30 a.m. ET on Tuesday, May 16, 2023 The sessions may be accessed from the ""Investors & Media"" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays of t",https://finnhub.io/api/news?id=d1734d68904838d74f74050f40f818bf5f34f77493aa80ef8e2c4c7a5d8e99fe
company,2023-04-11 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market",119755522,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. dropped 0.50% to $819.64 Tuesday, on what proved to be an all-around mixed trading session for the stock market,...",https://finnhub.io/api/news?id=dd07f41fae407ff43f1b98ca3c36dcf95be2050bc6d59acd6cedb3000b3ca96b
company,2023-04-11 10:51:25,12 Best Covid Treatment Stocks to Buy Today,119724373,https://media.zenfs.com/en/insidermonkey.com/b59f475277cb8c4b57fab9a05923d82d,REGN,Yahoo,"In this piece, we will take a look at the 12 best covid treatment stocks to buy today. For more stocks, head on over to 5 Best Covid Treatment Stocks to Buy Today. If there’s one thing that can be said for sure, it’s that the coronavirus pandemic has changed the world. The deadly disease, […]",https://finnhub.io/api/news?id=fd0f172fc848f1ff1c605cdb4fcfd12850983672dad9f0febd405312d292ac29
company,2023-04-11 06:47:00,IN BRIEF: Regeneron expects USD56 million hit in first quarter,119723431,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f2ef046a74d6128047647b53895beb442af272ed0c8632cbf123347677a1935c
company,2023-04-10 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market",119722374,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 0.60% to $823.76 Monday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=b254d7d2105b7539355a8116d6383c60103568b677072603a90be46ccff0b0db
company,2023-04-10 05:31:00,U.S. launches $5B program to speed up development of next-gen COVID vaccines,119717908,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1b40a0028225f1427081f74fb49088f5ab3682f51314603e7295c9ec39f65220
company,2023-04-10 04:26:10,GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market,119701387,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365749374/image_1365749374.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. BMY's EBITDA margin was 43.7% for 2022, 11.4% more than GSK. Read more here.",https://finnhub.io/api/news?id=e40a30d8690c0777466a7237fc2ec01321a46e522555e287a37fdb3d28ebec26
company,2023-04-10 03:28:00,GSK Vs. Bristol-Myers Squibb: Who`s More Underrated By Mr. Market,119703326,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dfdd9a0ae6c915f7604373695064ece219a6010fb74e1318c733583f7d341ce4
company,2023-04-10 02:35:00,Regeneron Pharmaceuticals Q1 one-off charges to be ~$56M,119703327,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c427850ce0f168deefd08576ff31f8f6e24f698d5150f536ae3db23ea35481ce
company,2023-04-09 09:30:00,"Investing $1,000 In These 2 Top Stocks Would Be a Great Move",119699866,https://s.yimg.com/ny/api/res/1.2/xxISnd7C86lylWCUpU2ePg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/828b309e2eafab4053c3b6b035ddc01d,REGN,Yahoo,"For those with $1,000 that isn't being saved for emergencies, here are two excellent stocks to buy today: HCA Healthcare (NYSE: HCA) and Regeneron (NASDAQ: REGN).  HCA Healthcare is a leading hospital chain in the U.S. It makes money based on occupancy rates in its 182 hospitals (among other facilities) and based on the services physicians order for their patients.  For instance, occupancy levels in HCA Healthcare's hospitals would soar along with the number of cases of COVID-19 and then drop back down, sometimes rendering year-over-year comparisons difficult.",https://finnhub.io/api/news?id=15270e04b708cff50877cb5b433ae091395461462ed52a61d99a02124d4faf8e
company,2023-04-16 08:28:00,"Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air",119788473,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e2be623fb40a9ac81e08a95bac7fdc03a5159fae4fbede9114b1013961980321
company,2023-04-14 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,119766323,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. dropped 0.12% to $829.33 Friday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=1ddaa26baba5ab32c5886d33f32438d4f2df5693ee9aff12b7311a505c273563
company,2023-04-14 10:00:40,"Are Strong Financial Prospects The Force That Is Driving The Momentum In Regeneron Pharmaceuticals, Inc.'s NASDAQ:REGN) Stock?",119768697,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 15...,https://finnhub.io/api/news?id=dd8a8a069eb0e67d21e5ed503766bde72cc7f26b23cf31bbdf72b99ef5f8f5c2
company,2023-04-14 00:37:00,Ghana 1st in world to approve new malaria vaccine by Oxford,119759936,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0098cc36acdfb00757eadf4f6bae45f003b53a7e1489c49f79df4e2cd87e2bf8
company,2023-04-13 13:20:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market",119755520,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 1.21% to $830.35 Thursday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=6f17297c663a10b4ce8fe06b30bd93c6caacc52b363e6a207b46ac19b1a256cb
company,2023-04-13 06:59:00,Intellia up 12% as Canaccord starts with Buy citing gene editing approach,119746085,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fd8948c87af2ddcec88b43e55279c024031366a9c92c5a3bb1f566960c5cb4af
company,2023-04-13 02:12:29,Regeneron: New Highs Following Dupixent's COPD Data,119741183,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1360866086/image_1360866086.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Regeneron shares jumped to new all-time highs following the successful phase 3 results of Dupixent in COPD. See why I think REGN stock is well-positioned to grow.,https://finnhub.io/api/news?id=e6284513799735c53f76fc85e297f4a3dcdd5d78f84c983147324d5490a9c0bc
company,2023-04-13 01:16:00,Regeneron: New Highs Following Dupixent`s COPD Data,119745947,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7611a5ed577ed908030814824181d279520c94d6b3c61edc1bdd8a8099bb14c9
company,2023-04-20 16:30:44,TD Cowen Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation,119842795,,REGN,Fintel,,https://finnhub.io/api/news?id=f4e382ebc5fef47aa2f2c16ae0647d5b6659cb6e1b583b7b97b4d64565bde110
company,2023-04-20 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market",119868662,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.33% to $798.10 Thursday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=3250cf794a013feefbad34d167021ead16071dc575bdced1510cc66e9a21e06e
company,2023-04-20 13:07:09,The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio,119898326,https://media.zenfs.com/en/investorplace_417/8a7bfeab2308b052084c2160ea63daf7,REGN,Yahoo,"While the debate will certainly rage over which ideas legitimately rank as the greatest blue-chip stocks to buy of all time, for right now, certain enterprises stand out for a combination of their relevance and resilience. As well, a select few large-capitalization companies may be too undervalued and beaten down for their own good. Therefore, speculators may enjoy significant upside. To generate this list, I turned to the investment resource Gurufocus, specifically its screener function. Here,",https://finnhub.io/api/news?id=61b4efa864efaddf5ad49b19b534b4d552ff1d8260545cf0d3d06fb1a25a1392
company,2023-04-20 03:36:00,Jefferies Reaffirms Their Buy Rating on Regeneron (REGN),119848323,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cdee9a8b45894ccbb18aa0005046d08cbfffe363eed3116f6e79c3233e50486f
company,2023-04-20 03:21:00,Sensei gains FDA IND clearance for solid tumors candidate,119848325,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=01780a88f2e900412f02eacb1d981bd5672e76dfe26af92b205c2b88c46ae194
company,2023-04-20 02:34:00,Regeneron price target raised to $885 from $875 at TD Cowen,119848327,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ebc8b3b5deab0a9bdcff9a656fba8d03a01e49f61a17740028ac4aa5db5fc24f
company,2023-04-19 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,119868663,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.11% higher to $808.86 Wednesday, on what proved to be an all-around rough trading session for the stock...",https://finnhub.io/api/news?id=a5a89a61b9508a0fac2b557eda66dc377a26b2ad32476a3e2d11e152c38ee684
company,2023-04-18 21:12:00,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), UnitedHealth (UNH) and Sarepta Therapeutics (SRPT)",119830804,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b33e8c9c242a01f331c7a79d30935d45652dc9434a2e1a723db1a66d14415fd9
company,2023-04-18 13:32:00,Healthcare Shares Fall; J&J Boosts Earnings Outlook -- Healthcare Roundup,119868664,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,Healthcare companies sank as investors rotated into stocks with more to gain from a strong economy. Johnson &amp; Johnson raised its full-year sales and...,https://finnhub.io/api/news?id=245e4190f8597e453066cbc9beccc9fd30c059910b45322b92ee50147d86db20
company,2023-04-18 13:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors,119868665,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.43% to $808.01 Tuesday, on what proved to be an all-around mixed trading session for the stock market,...",https://finnhub.io/api/news?id=7216605a431ca0d67a73934a797213d52ea863f6cdbc1e769ea921d2a2cce800
company,2023-04-18 10:00:18,Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their splendid 159% return over the last five years,119890854,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...",https://finnhub.io/api/news?id=c04c283596b3c861754c3b562a5ec3ef946ef3ccdea6fc165129df60f6de5aaf
company,2023-04-18 03:41:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,119825771,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a99c3f6ffbd6f42a6d8e8e533bf7698e338cdec5b4aa353fc6d07357b1834355
company,2023-04-17 13:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors,119805982,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.16% to $819.74 Monday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=21a435b8f11d7f2084b088a0d8893d17c51ccbdc6ab69633b1f2fdba958701cc
company,2023-04-17 09:50:00,"Regeneron Set to Reach New Heights: $1,000 in Sight?",119890855,https://s.yimg.com/ny/api/res/1.2/oyZmSYazEMo8TUSVvukD7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/thestreet.com/72e962eb044693c2eac2019109d906cf,REGN,Yahoo,"Biotechnology company Regeneron Pharmaceuticals has posted strong stock gains since June but further gains look likely in the weeks and months ahead. Let's check out the charts. In the daily bar chart of REGN, below, I see a positive-looking picture.",https://finnhub.io/api/news?id=5b0f9fb3104c659c5ce3901e80a3f98fce5a50884de65ee5e97ca86fcdaa0a27
company,2023-04-17 07:30:00,"Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary",119890856,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent DirectorTARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company’s Board of Directors and will not stand for reelection at the Company’s 2023 Annual Meeting of Shareholders. Dr. Vagelos has served as Chair since January 1995 a",https://finnhub.io/api/news?id=1d147ff4835f3149e6115208a77146ffa7f3398f13c94e687ed9686f3e73e0fd
company,2023-04-17 07:00:00,Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases,119890857,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"New subgroup data and further analyses of the aflibercept 8 mg clinical trial program to highlight durability results of extended dosing intervals, patient characteristics, and efficacy and safety in wet age-related macular degeneration and diabetic macular edema 18 presentations reinforce Regeneron’s commitment to patients with serious retinal diseases TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced th",https://finnhub.io/api/news?id=539ff5564e7361cf0c84fa40fd984a112d58f28d96efdda74be13d74a5fb45be
company,2023-04-17 05:39:00,IN BRIEF: Regeneron Chair to retire; CEO and CSO to become co-chairs,119802383,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5711aa4b81af68df3443e672b6b07cb0530cc172b0963e56b2b428c0848d675d
company,2023-04-17 03:59:00,Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire,119805983,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,"By Colin Kellaher Regeneron Pharmaceuticals Inc. on Monday said its longtime chairman, P. Roy Vagelos, plans to retire in June. The Tarrytown, N.Y.,...",https://finnhub.io/api/news?id=5a6b57c58776f4396e1bc783bef834a06d451082fa0dbe2c87928b9232d6657f
company,2023-04-17 02:34:00,Regeneron announces retirement of board chair,119801991,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9c042445f16d2ce08bd3ab3a0f9faae7b1b18f1dc30fee850abebe9c3f7ba353
company,2023-04-17 02:11:00,"Regeneron aflibercept, EYLEA Injection to be featured at ARVO 2023 meeting",119802387,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0bd421a0fee59586f87742846e44b261a1c6edf4226af896859a91444683bc68
company,2023-04-24 13:34:52,"Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea",119905259,https://media.zenfs.com/en/Benzinga/35c60fa4733488539da1c19680dea3ad,REGN,Yahoo,"UNITY Biotechnology Inc (NASDAQ: UBX) announced results from the long-term follow-up of the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). Patients taking UBX1325 saw a mean change in best-corrected visual acuity of +6.2 ETDRS letters from baseline, a statistically significant result (p=0.0037). At 48 weeks, Unity also noted a difference of +5.6 ETDRS letters compared to sham-treated patients, but that part of the result was not statistically significant (p=0.1198",https://finnhub.io/api/news?id=b3883886ed3649fb1a9b34e2de1248b8d4cf29a6697c4444c0d3bac138294a1c
company,2023-04-24 13:21:00,Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors,119943709,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 0.46% to $797.04 Monday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=663a3ce6bdd4ccca7aad95f63db998e3a72f5586983bd8497ab0946bb03374f9
company,2023-04-24 08:38:12,"4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates",119904666,https://media.zenfs.com/en/zacks.com/313c748298bb3b2c7cf0ffa498259954,REGN,Yahoo,"We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.",https://finnhub.io/api/news?id=e8066ee13887180c9e079e02fef4f4398a8e3c566825c7d228f3d5a371f130a5
company,2023-04-24 08:00:33,Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet?,119909404,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...",https://finnhub.io/api/news?id=b0e3d1f3adee2e42e9acaff72d840e81ad5b27175a3143dfefeed363101603a6
company,2023-04-21 18:15:10,Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know,119890852,https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209,REGN,Yahoo,"In the latest trading session, Regeneron (REGN) closed at $800.73, marking a +0.33% move from the previous day.",https://finnhub.io/api/news?id=add9ae5d5b154681df777a7c445a4f825c2051dcaf82b8b748fc670fbed8bebe
company,2023-04-21 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,119943710,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.33% higher to $800.73 Friday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=b588c95daa19d0902b14ef0c558322e1a12e29f5559d93f86030fd7904b0e7fe
company,2023-04-21 09:45:05,Intellia Therapeutics: Signs Of Possible Life,119868394,,REGN,SeekingAlpha,,https://finnhub.io/api/news?id=e09f585998c6a970d77f934a1b30c8e50917022996bc74962249e7cbe254953f
company,2023-04-21 09:00:01,Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings,119878131,https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619,REGN,Yahoo,Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.,https://finnhub.io/api/news?id=3dd1ccf967d4a699be801bb76ae68b473b06b7124bf64f2e169b45ffbf4fdf74
company,2023-04-28 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,120134801,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 1.20% to $801.79 Friday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=18d6c49bb1061f197c04ade332ea0c387a92040286304793672c17c2aeec3f4b
company,2023-04-28 13:12:49,"Stock Charts Strategy, May 1-5: Fed Policy, April Payrolls, Apple Earnings",120031879,,REGN,Yahoo,"Fed policy and April payrolls may influence the stock market, but earnings will have Apple, Vertex and Albemarle stock charts in focus.",https://finnhub.io/api/news?id=bdbaff4399497e301b4549ca7b03945f9d7f1f4ff211a730ac6ebc22eb0fd804
company,2023-04-27 18:15:10,Regeneron (REGN) Gains But Lags Market: What You Should Know,119986158,https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1,REGN,Yahoo,"In the latest trading session, Regeneron (REGN) closed at $792.29, marking a +1.84% move from the previous day.",https://finnhub.io/api/news?id=6e16e9dba7587faa33a3e6c37a31d0d2eb5cee9b5a49d51689edbba73fe57a58
company,2023-04-27 13:52:05,"Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says",119966086,https://media.zenfs.com/en/Benzinga/bf7847569072934a0699c3841331e67b,REGN,Yahoo,"Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced preliminary data from their Phase I study of their experimental drug dubbed ALN-APP. ALN-APP is an investigational RNAi therapeutic targeting amyloid precursor protein (APP, a brain protein) in development for Alzheimer's disease and cerebral amyloid angiopathy (CAA). Patients treated with single-dose ALN-APP experienced dose-dependent, rapid and sustained reduction in cerebrospinal",https://finnhub.io/api/news?id=e0ff1c60b0bdd8938dcd7b5ad22e8e4a1ff41d820a4517b85dd30a3b035675ee
company,2023-04-27 13:21:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market",120134803,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.84% to $792.29 Thursday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=4ccf026e9f91f2f99f3a81ff158a6f6aa0308b7feb56fa4a5af1aa9fb55b5f34
company,2023-04-27 10:02:02,Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?,119966087,https://media.zenfs.com/en/zacks.com/670d1917693293f70179651625deb88f,REGN,Yahoo,Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=3c8712cf67011f8f102f8defc1ac51f284ceeedb3aa70070cfd0d3807e4a52b9
company,2023-04-27 02:21:00,"Analysts Are Bullish on Top Healthcare Stocks: Edwards Lifesciences (EW), Humana (HUM)",119962476,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8582235e71cf9e36d5542a815b4bd2039446de1647aa8bd14f5171b7f1376331
company,2023-04-27 01:13:00,Sanofi Q1 profit climbs on Dupixent as drug on track for ���10B this year,119976553,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b6e5485a9c12347adc1a525eae3e6171129d3790bf76dbe9f8afe4453c32f67d
company,2023-04-26 16:05:00,"Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy",119953209,https://media.zenfs.com/en/business-wire.com/1cbe60483c898c3adb73fb731acccede,REGN,Yahoo,"CAMBRIDGE, Mass. & TARRYTOWN, N.Y., April 26, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).",https://finnhub.io/api/news?id=90f37e97f3c41d2cf9d41c429d49bbf29dfd3a1e3ae69201a0f5b0180973e49a
company,2023-04-26 16:05:00,"Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy",119953208,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"- Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date - - Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the Human Brain Using Alnylam's Proprietary C16 Platform - TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,",https://finnhub.io/api/news?id=b447648e4dc4fa2eaaa33a743a98a75f767b359eb90b5ed84277c4ad22c6c2a3
company,2023-04-26 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,119943707,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.47% to $778.00 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=f7a5f024a519155cdbeff3dfc1ba40db619bc22c634fe12ae78c9295ae69f63d
company,2023-04-26 08:26:00,Democratic senators introduce bill to enhance CMS drug price negotiations,119976559,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=057a91fadb0828e84ddbaa3596aa9be24ca2bfbca6152df3c17864dee7717c66
company,2023-04-26 01:31:00,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akebia Therapeutics (AKBA) and Panbela Therapeutics (PBLA)",119975357,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0a66d92213c5ef79e30c69b151854bf45b80b278c0b9709d93932fd25dfb229b
company,2023-04-26 00:22:00,"Partial clinical hold placed on Alnylam, Regeneron RNAi Alzheimer`s candidate",119968007,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d0b64b8789993a30f74132a6d73b2d17a5800cff41b9f14ed768b7142991c2b4
company,2023-04-25 13:20:00,Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors,119943708,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.94% to $789.58 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=ec2931520b21fc718f4988aa1425b02698b55ce8366a8e8761399c4566bd3d98
company,2023-04-25 13:00:00,3 Biotech Stocks To Watch Today,119917018,https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/04/biotech-stocks-to-watch.jpg,REGN,StockMarket,Biotech stocks for your late-April 2023 watchlist.,https://finnhub.io/api/news?id=f454f77dee373668f5207d0fb9c803ff8972ad13ea05656eede8fd08306e2def
company,2023-05-02 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,120134798,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.03% to $798.45 Tuesday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=6281604eed27b1150f1e190893aa033297bf5a8504a409ee0f18c0324610f9eb
company,2023-05-02 11:40:03,LGND vs. REGN: Which Stock Is the Better Value Option?,120104123,https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9,REGN,Yahoo,LGND vs. REGN: Which Stock Is the Better Value Option?,https://finnhub.io/api/news?id=24eea9091f93f00a16600192032df87f32c9d59a0a9e376888d9bd8621e27218
company,2023-05-02 09:00:01,These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar,120112029,https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209,REGN,Yahoo,Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.,https://finnhub.io/api/news?id=a307cb81aebbb2686e6624aef205a939ff2e2ea2822c1bf00d74409bb2caaccd
company,2023-05-02 07:00:00,Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research,120112030,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Oral presentations include interim results from pivotal trial of linvoseltamab (BCMAxCD3) in relapsed/refractory multiple myeloma and three cohorts of fianlimab (LAG-3 inhibitor) combined with Libtayo® (cemiplimab-rwlc) in advanced melanoma Ten total presentations to cover clinical research across six solid tumors and blood cancers TARRYTOWN, N.Y., May 02, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of new and updated data from its div",https://finnhub.io/api/news?id=13c4a301cdee5fb890e7db7074201ca946f77bc07bcf94b7cdcd4389141b613a
company,2023-05-02 02:28:00,"Regeneron to highlight new, updates data at ASCO",120104211,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ad53fb385fb33732ab505290f97c18a3dc13869b36c49e17df5fb90d296b8bee
company,2023-05-01 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,120134799,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.61% higher to $806.72 Monday, on what proved to be an all-around grim trading session for the stock market,...",https://finnhub.io/api/news?id=37461ab17a090994eec361be07d118f7615dd8487fc3ab0694b4dbedb58bb4e5
company,2023-05-01 08:33:04,EF Hutton Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation,120077922,,REGN,Fintel,,https://finnhub.io/api/news?id=03614ce513b6c3cd7bf914962eb911e36d79506c9aade29643163b6cf7e69b6d
company,2023-05-01 08:02:12,Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?,120079641,https://media.zenfs.com/en/zacks.com/253e1f4ba631403e19576a0346277e39,REGN,Yahoo,Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.,https://finnhub.io/api/news?id=62177cc96af99a6df48ece6f5fbac8ed361c93398863dc83f7ad4d4dda06c190
company,2023-05-01 07:15:00,Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector,120080678,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0825110339ed2946101c117c8a6df3532441ee736c1d419bf58fd04b429fffc9
company,2023-05-01 03:41:00,"Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), PTC Therapeutics (PTCT) and Regeneron (REGN)",120080132,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d842e3c0bd095d8f13877823d6890b66f6072b8a05b4ab46a1d1db4e55ba3724
company,2023-05-05 16:32:03,Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation,120185187,,REGN,Fintel,,https://finnhub.io/api/news?id=c2174e3863278c825227dc1654a53c0bc3450ced43abc5e1c33f54b950b90009
company,2023-05-05 16:32:03,RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation,120185186,,REGN,Fintel,,https://finnhub.io/api/news?id=26acf403e331fa2deccf6250ef74dedc39296edb1ec548dc1d8235bea3fd2014
company,2023-05-05 13:21:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market",120255148,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 1.09% to $762.10 Friday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=be187114a4b4c364394cdc80e79190753c0fdd83d7b0a3426f36edcdc1d52cf5
company,2023-05-05 09:00:31,Regeneron Pharmaceuticals Insider Lowered Holding By 26% During Last Year \,120175498,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"From what we can see, insiders were net sellers in Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) during the past 12...",https://finnhub.io/api/news?id=5c5762b5ac6fce3679740288745ed916f4de9109bc12105fb9e36209fee0416b
company,2023-05-05 04:24:00,Regeneron price target raised to $927 from $880 at Morgan Stanley,120184045,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e7d60217b2eae0bc0ae890729f801c074d3fce4500d45e92f7f485292dd865c7
company,2023-05-05 04:08:00,Regeneron price target lowered to $895 from $976 at SVB Securities,120184046,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8c70faaa358b7970b50e02984c16cc79a29184d4995956cac16dd7dbbb0b0e43
company,2023-05-05 03:21:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,120184047,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bd85445a0c994e7709c1f1fa1f63db65b9c639329c413c82db1108927b64c49c
company,2023-05-05 02:40:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Ultragenyx Pharmaceutical (RARE) and Surface Oncology (SURF)",120179462,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fdd9b525370ed601ca9d3b547d62f174cb8326ffbb02f9d2fe5c255dc7b945b6
company,2023-05-05 01:30:00,"Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Regeneron (REGN) and Puma Biotechnology (PBYI)",120184049,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=de5482d27db947d09cd052fc6f1e0b5954cd1016949f1b56b90bf3a3bb74ee18
company,2023-05-04 23:18:16,Q1 2023 Regeneron Pharmaceuticals Inc Earnings Call,120166734,,REGN,Yahoo,Q1 2023 Regeneron Pharmaceuticals Inc Earnings Call,https://finnhub.io/api/news?id=c784cdeec50b162cdfb197be33bf1b95437700af4a03aecd963f5cdfe01824f4
company,2023-05-04 16:07:19,Regeneron Sacrifices A Breakout As Competition Hammers At Its Biggest Moneymaker,120161311,https://media.zenfs.com/en/ibd.com/6fe9488e6037c71a19f4fb4a4ed23b2d,REGN,Yahoo,"The struggles continued for Regeneron's blockbuster eye disease treatment, Eylea, in the first quarter — leading REGN stock to dive Thursday.",https://finnhub.io/api/news?id=1a1117ee6fc306cb9aee7c4e04b0b9d5e1f7325ae10a33c13aae2fe25e3f0d38
company,2023-05-04 15:50:24,Why Regeneron Pharmaceuticals Shares Are Trading Lower Today,120154997,https://media.zenfs.com/en/Benzinga/4e4537418ced596f7be097723d921c20,REGN,Yahoo,"Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating the $9.60 Street estimate. Revenues decreased 6% Y/Y to $3.16 billion, down from $3.41 billion in Q4 FY22, beating the consensus of $3.00 billion. Revenues from REGEN-COV, covid-19 antibody cocktail, reached $613.2 million, down 4% Y/Y. In the first quarter of 2023, Dupixent global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus the first quarter of 2022. Eylea U.S. net sales de",https://finnhub.io/api/news?id=828eeb040dc809709abc4c00e81e549f9d5771fd057fe1210e6f5cdeb80de29a
company,2023-05-04 13:23:55,Why Regeneron Pharmaceuticals Stock Is Tanking Today,120161313,https://s.yimg.com/ny/api/res/1.2/WSylTCIJg1eyxL8s07v_mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02ODY-/https://media.zenfs.com/en/motleyfool.com/eab65a9d57bfb76d1888bdb4cad1f680,REGN,Yahoo,"Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biotechnology company, is under heavy pressure today.  Specifically, the biotech's stock was down by an unsightly 6.5% on heavy volume as of 12:19 p.m. ET Thursday afternoon.  Regeneron's shares are moving southward in response to lower-than-expected sales of its flagship eye-care treatment, Eylea, during the first quarter of 2023.",https://finnhub.io/api/news?id=a0e3cc27e4ee877df472aabde7d30d7afda923a2cd64ce8e5d7d93266cd8f403
company,2023-05-04 13:21:00,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,120255149,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 6.14% to $753.88 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=72433ab156b94934179dc179e9ef8d7ceff94c70c752b73ce8a44933fd19fc1f
company,2023-05-04 12:03:04,"Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline",120150353,https://media.zenfs.com/en/zacks.com/24355c6e7e1e1646b8fe574e17a00185,REGN,Yahoo,"Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.",https://finnhub.io/api/news?id=c3e0c9624da9099ac5bbc401bae3b6762ef1ee00f0606f3306bb23727ae4c71e
company,2023-05-04 10:24:09,Regeneron Pharmaceuticals Inc. (REGN) Q1 2023 Earnings Call Transcript,120151391,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Investor RelationsLeonard Schleifer - Chief...",https://finnhub.io/api/news?id=59eefa70ddd9875bd691dbac786cde2f9e45d89f89297ec69eafe4eefd1720a7
company,2023-05-04 10:04:46,Regeneron's Eylea drug sales hit by competition from 'new kid in town',120149448,https://static.reuters.com/resources/r/?m=02&d=20230504&t=2&i=1632114564&r=LYNXMPEJ430DU,REGN,Reuters,"Regeneron Pharmaceuticals Inc's first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heated up, dragging the company's shares more than 5% lower in early trade.",https://finnhub.io/api/news?id=5ac99daf2d53c012203d786d87fe91b9afc7247113a45f6c1fbb4395eb8862b0
company,2023-05-04 09:30:01,Here's What Key Metrics Tell Us About Regeneron (REGN) Q1 Earnings,120161315,https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39,REGN,Yahoo,"While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",https://finnhub.io/api/news?id=5063c5d03b5e19ef264be067caf0197416a37f0f126d3ec7814f738b2a701c83
company,2023-05-04 08:50:00,Intellia jumps 13% after Q1 updates,120161521,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c46168355292ecb30f59c59cacddcb7f076291a9fd8d382c63ac5fd5cd4a27f9
company,2023-05-04 07:55:11,Regeneron (REGN) Q1 Earnings and Revenues Top Estimates,120161316,https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2,REGN,Yahoo,"Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=86257ca7dca372943fa38867c14731e5e3ed3f0fb2b98df42fb4628548985e64
company,2023-05-04 06:45:59,CORRECTED-Regeneron beats quarterly profit estimates ,120149449,,REGN,Reuters,"Regeneron Pharmaceuticals Inc beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent.",https://finnhub.io/api/news?id=1a3c1703a975a13b18c926da5cfde9cc102c71fe4d276b4d079ef3b1fa62510c
company,2023-05-04 06:35:00,Goldman Sachs Keeps Their Buy Rating on Regeneron (REGN),120184053,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=12e8bcc8bcdd3233256ca99b9122ebe9d2c8a76fce6a0a8d5387c3d7d01c2ed1
company,2023-05-04 06:30:00,Regeneron Reports First Quarter 2023 Financial and Operating Results,120146141,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,First quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022First quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus first quarter 2022First quarter 2023 EYLEA® U.S. net sales were $1.43 billionFirst quarter 2023 GAAP diluted EPS of $7.17 and non-GAAP diluted EPS(a) of $10.09; includes unfavorable $0.42 impact from acquired IPR&D chargeEuropean Commission approved Dupixent for atopic dermatitis in children aged 6 months to 5,https://finnhub.io/api/news?id=b68a0491dca30e7b165770350b2cc682764fac0524ce4d90035f5dcec02d2557
company,2023-05-04 06:05:35,Truist Securities Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation,120145208,,REGN,Fintel,,https://finnhub.io/api/news?id=87a49a050c7c2097ae956db9d3e945382415184e1621a719dcad0b3cf9ea80e0
company,2023-05-04 03:36:00,"Regeneron tops Q1 estimates but lowers margin guidance, sending stock lower",120255150,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,REGN,MarketWatch,"Regeneron Pharmaceuticals Inc. ‘s stock slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance...",https://finnhub.io/api/news?id=330fefae645f734cce5d91d69e7ffdd9cd3341cf2ef1e477aeb3b7299fd7c744
company,2023-05-04 02:44:00,"Regeneron Posts Higher 1Q Sales, Boosted by Sanofi Work",120171957,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,"By Will Feuer Regeneron Pharmaceuticals posted higher first-quarter sales, lifted by its collaboration with Sanofi. The Tarrytown, N.Y.-based company...",https://finnhub.io/api/news?id=b15cba3d9b3937ab0605d2340d0cd8dd7161063161daf3848ab979fc48d1a59e
company,2023-05-04 02:43:00,Regeneron: Q1 Earnings Snapshot,120148736,,REGN,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=706797d1307c324254a2d964d0e2a3af131638f9d687fd2b0bea4930bc8ba226
company,2023-05-04 02:33:00,Regeneron stock dips amid decline in Eylea sales despite Q1 beat,120148738,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7fba9f8454fa1f713bd5e9e60c671de6d10674dab275706ee7ea90cd7070e252
company,2023-05-04 01:35:00,"Regeneron Pharmaceuticals Non-GAAP EPS of $10.09 beats by $0.53, revenue of $3.16B beats by $160M",120148740,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3dca943b57e6de4c6424fbf28c60a258bd3a8b0aca234f66e65c64c784dd1245
company,2023-05-04 01:31:00,"Regeneron reports Q1 adjusted EPS $10.09, consensus $9.56",120148741,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9ee09972496dc3552d5aac9ccc11fa5fecd23b9f90b5e28bbd96730a90b159f0
company,2023-05-03 20:36:00,GLOBAL BRIEFING: China's manufacturing weakens; Fed enacts 25bp hike,120148742,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=160deea84eeef222b3902da5d82d8054ff584e0938f885efe1aa88337f2e9d4e
company,2023-05-03 13:21:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,120134796,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.59% higher to $803.17 Wednesday, on what proved to be an all-around dismal trading session for the stock...",https://finnhub.io/api/news?id=82da18b08dcb1baac581c6432555ad6785b10a8f8cabb86dd5c5f29688bfaeb2
company,2023-05-03 11:46:03,"Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More",120126771,https://media.zenfs.com/en/zacks.com/f84faa3d65021260b4cd14c75493ef6c,REGN,Yahoo,"Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.",https://finnhub.io/api/news?id=0fc9e26f5d372c9bee84edd2ec359e3cc9eaca2ccbde96443410be15ea5e892a
company,2023-05-03 08:44:00,Regeneron Pharmaceuticals Q1 2023 Earnings Preview,120133344,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a428f93fcd225f48ebbe2be407872eb92c63b5d34c6b02ddaecf32b55d22221f
company,2023-05-03 08:36:12,Why Earnings Season Could Be Great for Regeneron (REGN),120128500,https://media.zenfs.com/en/zacks.com/fe82c756c2e2ce84787ef1acee31f5c2,REGN,Yahoo,Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,https://finnhub.io/api/news?id=7b35b444689ce97ae60a6e2b2ba513bb7c19bf6cbf092d10e8f56484aee5991b
company,2023-05-03 04:40:00,"Regeneron price target raised to $1,050 from $856 at Truist",120133345,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a8161c406e587551befe1a6d1f48b4d8ea0737d6ca511b20cd0b9e0b38e1f321
company,2023-05-02 21:01:00,"Regeneron looks to strong Dupixent, Eylea sales in Q1 report",120133347,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=01577c9332e47b6c7e091ecf7cdab00e9b5144888c6e3d504656992c6b80df45
company,2023-05-10 13:21:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",120284863,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 0.70% to $749.59 Wednesday, on what proved to be an all-around mixed trading session for the stock market,...",https://finnhub.io/api/news?id=ab6d299e923219abb83c7d45b0b438a11e7687f988c48a71af42eee59b492a3c
company,2023-05-10 09:53:00,2 Cathie Wood Stocks That Can Get You Through Any Recession,120277439,,REGN,Yahoo,"Economists at the U.S. Federal Reserve recently uttered the dreaded ""R"" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a while now, so it shouldn't come as too much of a surprise.",https://finnhub.io/api/news?id=dffd26d8dce798e27eef292e242a08626ca215033860d65f267c652e9f1db74b
company,2023-05-10 01:23:00,"Alvotech, Polifarma ink pact to sell potential Eylea biosimilar in Turkey",120276084,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2b85092f94fa4d02482210cd8b8a1ffe46550738184352aae45045606f49c589
company,2023-05-09 23:33:17,Q1 2023 Xeris Biopharma Holdings Inc Earnings Call,120262279,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,Q1 2023 Xeris Biopharma Holdings Inc Earnings Call,https://finnhub.io/api/news?id=f9815d12c82bf8de0fca967a2900f17469f10e981a76b007ad40219fc800e709
company,2023-05-09 22:23:00,"Notable Wednesday Option Activity: REGN, YETI, RNG",120283117,,REGN,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=18dea88880f7d602d9dcdd08f6fa58003907c4cd729890cec6c5692be0c83b33
company,2023-05-09 16:09:59,15 Biggest Immunotherapy Companies in the World,120248234,https://media.zenfs.com/en/insidermonkey.com/152faade4bb55ed2f80bad06096a951e,REGN,Yahoo,"In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […]",https://finnhub.io/api/news?id=8f2ad8892373ea11de72ee1fef425193dffda9002847b675f7de14867872dc5b
company,2023-05-09 14:59:15,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2023 Earnings Call Transcript",120246068,https://media.zenfs.com/en/insidermonkey.com/22a2748753f24bdeffb0a97d2f3ca2e6,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2023 Earnings Call Transcript May 4, 2023 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $10.09, expectations were $9.56. Operator: Welcome to the Regeneron Pharmaceuticals First Quarter 2023 Earnings Conference Call. My name is Josh, and I will be your operator for today’s call. At this time, all participants […]",https://finnhub.io/api/news?id=14c6c8f094d468bbbb1833f24db625e7be8c18e207944b0ea9760514bb74dd27
company,2023-05-09 13:21:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,120255146,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.37% higher to $754.88 Tuesday, on what proved to be an all-around dismal trading session for the stock...",https://finnhub.io/api/news?id=bcf5270bc5500c6f9a184922240824e4415b3482bd4df56d5e6b56a5183178f4
company,2023-05-09 10:00:36,"Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 29% Discount?",120246069,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,053 based on 2 Stage Free Cash Flow to...",https://finnhub.io/api/news?id=e4082ca966872dfbfdc6790fc4360c4c6070da2ea966126963719524ae52f2b0
company,2023-05-09 02:56:23,Guggenheim Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation,120235264,,REGN,Fintel,,https://finnhub.io/api/news?id=63060a8c52252bd2a01dde185c12abc525a2b953dcc70cb4f63accbd6dbdd7d2
company,2023-05-08 13:22:00,"Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market",120255147,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 1.31% to $752.12 Monday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=b6bc0f47bf6bd3a2a3ddd301ffa37e8dcd3295f3c566d34440d5d58ef8b07d0e
company,2023-05-08 07:31:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Karuna Therapeutics (KRTX) and Pennant Group (PNTG)",120222366,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e8b79c7b45a634b10ff3f2d2f0102f74573997415b2ef1a47a79fbf6999be782
company,2023-05-08 05:22:00,Regeneron price target lowered to $935 from $960 at Guggenheim,120223631,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4fea805182be7169a7da3f38a8f01c315756529ebb5f7b0751ccaff30335eaf1
company,2023-05-13 18:19:05,"Regeneron Pharmaceuticals, Inc. (REGN) Bank of America Global Healthcare Conference Call Transcript",120340033,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Bank of America Global Healthcare Conference Call May 9, 2023 4:40 PM ETCompany ParticipantsRyan Crowe - VP, IRRobert Landry - EVP,...",https://finnhub.io/api/news?id=ba7914bc0739aee304c532e8aff9741d97b4a6689151124c2a989f86cfa02658
company,2023-05-12 13:21:00,Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors,120402414,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.16% to $744.35 Friday, on what proved to be an all-around poor trading session for the stock market, with the...",https://finnhub.io/api/news?id=28ef63dbf98113335e4ba9996483b9152c08f65fd13870aba7a862d2edabaa87
company,2023-05-11 13:21:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,120402415,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. sank 0.54% to $745.57 Thursday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=b001823bfebb0e5b4c331133c7c3616199feb9860def5bd16d2f9c2e8be4ed1b
company,2023-05-18 16:01:00,Regeneron Announces Investor Conference Presentations,120433859,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 4th Annual Oncology Innovation Summit at 12:30 p.m. ET on Tuesday, May 30, 2023Jefferies Healthcare Conference at 8:30 a.m. ET on Wednesday, June 7, 2023 Goldman Sachs 44th Annual Global Healthcare Conference at 8:40 a.m. PT (11:40 a.m. ET) on Wednesday, June 14, 2023 The sessions may be accessed from the ""Investors & Media"" page of Regeneron",https://finnhub.io/api/news?id=d69a588d3ba3cfb865942a685226815ae82391a5a88c60972fae1b45d4c3fc13
company,2023-05-18 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,120513824,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.29% to $747.48 Thursday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=e62eafcd03f9d94ba7900a80882d54d9e8df4df728311ec3a7f37894f9511603
company,2023-05-18 12:40:00,Sanofi Wins Supreme Court Patent Dispute With Amgen,120420249,,REGN,Yahoo,"The court said Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted by the patent office, handing a victory to rival pharmaceutical firm Sanofi.",https://finnhub.io/api/news?id=463e6398da4bbed42c8c5586a007b413cdf714470000ea9a49d4db7782e3f920
company,2023-05-18 11:45:00,Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation,120420251,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Decision ends nearly decade-long patent dispute related to Regeneron-invented Praluent® (alirocumab) TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) applauds the United States Supreme Court’s unanimous opinion1 ending a nearly decade-long patent dispute related to the Regeneron-invented PCSK9 inhibitor, Praluent® (alirocumab). The decision affirms the United States Court of Appeals for the Federal Circuit’s opinion, which held that Amgen’s asserte",https://finnhub.io/api/news?id=1725ce1bf14d3e949692e7da61a8fe0b9d7a98ae2f6c4957e6d9227f5851504b
company,2023-05-18 10:20:02,UPDATE 1-U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents,120416845,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha over a legal challenge by French rival Sanofi SA.  The nine justices unanimously upheld a lower court's ruling that had invalidated Amgen's patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating the full scope of its claimed innovation.  Amgen has waged a years-long court battle to restore two of its patents on Repatha, a drug that can reduce the risk of heart attack and stroke in people with heart disease, stemming from a legal fight with Sanofi and its partner Regeneron Pharmaceuticals Inc.",https://finnhub.io/api/news?id=56709820f3218dda3d9d5ddbe7647b9de073529aa291f23dea464071487ae6ea
company,2023-05-18 09:00:35,Ocular Therapeutix: I Still Don't See The Need,120420238,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399246824/image_1399246824.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Ocular Therapeutix is up since my last article. I am neutral to bearish because I don't see the molecule making a space for itself. Click here for more on OCUL.,https://finnhub.io/api/news?id=ded5fc6301f28fbf26d266bccaec1c6d5135b89e4e89138f44a0b1d955b7b67d
company,2023-05-18 08:30:00,Regeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen,120510683,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Denny Jacob Regeneron Pharmaceuticals on Thursday said a U.S. Supreme Court opinion affirms a lower court opinion that held Amgen's asserted U.S. PCSK9...,https://finnhub.io/api/news?id=834b465b554fddba63a6f98745edd110b293351d6ef06095d7d2479d0555c4ef
company,2023-05-18 08:03:00,Ocular Therapeutix: I Still Don`t See The Need,120425123,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4b69a7ff2b3735599d6730dfb8da716ffb261413f2a570613e3ab5517fae3779
company,2023-05-18 06:59:00,Sanofi `pleased` with Supreme Court`s ruling on Amgen`s asserted patent claims,120418629,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ec79966a4a4388436a4819db7d5c22bed4a2b76e185a9b25363b5d4a29265542
company,2023-05-18 06:49:00,Regeneron `applauds` Supreme Court`s striking down Amgen`s patent claims,120418630,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2fa893e218f015cec8319647417c541dda993e5fc2b386a57a338da37122cdfb
company,2023-05-18 06:00:00,"Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC",120415583,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1165010257/image_1165010257.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"Much of what the FTC attacks isnât anticompetitive, itâs competitive. Click here to find out more on HZNP and LQDA.",https://finnhub.io/api/news?id=679a1b1799fc5524e405d03096f51d8a61ead642f3646a3e4cf571b8ec0a5411
company,2023-05-17 15:15:57,The 7 Growth Stocks You Need to Own Now for Maximum Returns,120476414,https://media.zenfs.com/en/investorplace_417/6a2855fb706724e517509e0fb0a64d0f,REGN,Yahoo,"Although recent headwinds like stubbornly high inflation and the banking sector crisis knocked the wind out of several publicly traded enterprises, a select number of hardened survivors potentially represent growth stocks to buy now. Using Gurufocus, all the companies below feature (on a per-share basis) five-year and ten-year growth rates of 20% and 15%, respectively. However, companies that rank among the growth stocks to own may have already run their course; that is to say, there might not b",https://finnhub.io/api/news?id=2737e28490090bac413ed71b9f1f5a96c118b5e8c9ba9a62d81b4e8c32b5fc07
company,2023-05-17 13:20:00,"Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market",120402409,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.99% higher to $749.63 Wednesday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=185e4510ad936c36076ae8e91314bd1962518a9d378dc4dd04d86b5fd2b366e4
company,2023-05-17 05:44:00,Regeneron CEO supports FTC suit against Amgen acquisition of Horizon - FT,120401449,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=83cfc1e6c6fea3524a14b0a787fd33e100d53821ec37fdf502d95b9fd5542d62
company,2023-05-17 00:01:00,Regeneron boss backs attempt to block $28bn Amgen acquisition,120386562,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to prevent competition.  Leonard Schleifer said he supported the US Federal Trade Commission’s decision to tackle a “new area” after the agency made its first attempt to block a pharma deal in over a decade by filing a novel lawsuit against the Amgen transaction.  Drugmakers pay rebates to ensure their treatment is placed on the lists of drugs covered by insurance companies.,https://finnhub.io/api/news?id=f5ea34623244e10b0d63879bf8337c540814c02b9d48270cff8b3ae443794b00
company,2023-05-16 22:55:00,"Regeneron CEO backs regulators attempt to block Amgen deal, FT reports",120401451,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1b47c7135b45528a55c31e94a2e5a8bfd25fdc0aef309744e111dea708c3f087
company,2023-05-16 13:21:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market",120402410,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.16% to $742.28 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=ce0cd1473067180358be026296a1ebe4341c2a727a570c05905198a8d1e9f0cf
company,2023-05-16 11:14:42,RBC Capital Reiterates Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation,120369385,,REGN,Fintel,,https://finnhub.io/api/news?id=131ff11703b794c1855303487b7c8a070438a887a93bd24e8903a1fd4a7fafa2
company,2023-05-16 09:57:03,"Regeneron Pharmaceuticals, Inc. (REGN) 2023 RBC Capital Markets Global Healthcare Conference Transcript",120371859,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 9:30 AM ETCompany ParticipantsAris Baras â Senior Vice President,...",https://finnhub.io/api/news?id=4cad12e2b2915032da04ea6588a68487871fb1ae23ac4d4ef1f47457a83cad09
company,2023-05-16 09:00:55,"Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?",120386563,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Regeneron Pharmaceuticals (NASDAQ:REGN) has had a rough month with its share price down 9.4%. However, stock prices are...",https://finnhub.io/api/news?id=295d7709e4eaa63cb7628057b5ba81e04d5a42af2ebf02b7bbf53c384e7ce0a8
company,2023-05-16 08:32:00,What To Expect From GSK In 2023,120370173,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=462be399f26d8a6c2d424b91befe84f483c52f1d4a2219706d661c0be8aee284
company,2023-05-16 07:31:00,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Viking Therapeutics (VKTX) and UpHealth (UPH)",120372910,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9c08c66b6a47ac321e3e453c3e806fec61ef6959e499cf1bf7cb365ecf57bb5c
company,2023-05-15 05:30:00,CEO Pay Packages Fell Sharply in 2022 as the Stock Market Sank,120350658,https://s.yimg.com/ny/api/res/1.2/u0BOZaN026h2Sf27DjulUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/c7bb976266e5cbb66776d53535e1914c,REGN,Yahoo,"The annual WSJ analysis of compensation for CEOs in the S&P 500 reveals that the median pay held steady. But in a first, companies are also disclosing how much those pay packages rose or fell in the year.",https://finnhub.io/api/news?id=f5792f026d35827cb78e426a74a317b708ad206bc4ea532910ec66ad22aded6e
company,2023-05-15 13:21:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,120402412,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.89% higher to $750.96 Monday, on what proved to be an all-around great trading session for the stock...",https://finnhub.io/api/news?id=c19e439f2b7e08e3653d8175433933752fc79c8f492ba59512f0fdb795ff563c
company,2023-05-22 13:50:54,"Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained",120486868,https://media.zenfs.com/en/Benzinga/421c30a13ab09fdd8664e5cca03ec9aa,REGN,Yahoo,"Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) presented results from a Phase 3 study of Dupixent (dupilumab) in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation. Dupixent demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo, meeting the primary endpoint. Dupixent significantly improved lung",https://finnhub.io/api/news?id=a117c2941b293149d442519f8c42da0aee041c1cd3085290f80848caf6d01357
company,2023-05-22 13:20:00,"Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market",120513822,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slumped 0.99% to $751.50 Monday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=a9a2a2ae5ac88deaa42f8fffd971291ef02a6c4c5b44240f0152101859f6ab8c
company,2023-05-22 07:03:00,A Good Week For The Market But A Pause In The Biotech Rally,120481382,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=39557e457a0ef62f3c9d6da4756cc7e88ea099a0dded78960f7c1a45db72b7dc
company,2023-05-22 06:25:00,Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN),120503317,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f29393d85c31a0feedcc92cf24f8aa319ca091192997287e44faf672ebdad9b9
company,2023-05-22 02:30:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,120483890,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ada4699c13ddd5668005a055a460c154719975ea1a82e157b6dbb7e732ee2cd6
company,2023-05-22 02:21:29,Sanofi: smoker's lung drug benefit was swift and sustained in trial,120478505,https://static.reuters.com/resources/r/?m=02&d=20230522&t=2&i=1633410868&r=LYNXMPEJ4L060,REGN,Reuters,"The benefits of Sanofi and Regeneron's anti-inflammatory drug Dupixent set in quickly during a trial to treat ""smoker's lung"" and lasted for the duration of the 1-year study, French drugmaker Sanofi said late on Sunday.",https://finnhub.io/api/news?id=7269358dd685c70583742a477a14316ee042adb2b0e81101d30c4ce8dbe35b02
company,2023-05-22 00:34:00,Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today,120503320,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=395268bece9947363c20124ab313f019351299cbd46574da16a299332ae7081f
company,2023-05-21 14:18:00,Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine,120476413,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 weeks Dupixent significantly improved quality of life, with numerical improvements as early as 4 weeks after initiating treatment, and respira",https://finnhub.io/api/news?id=9283f648ea1f6442207dd4868542fa32760ff43517cd718ea2c7d03292efc900
company,2023-05-20 23:35:00,"Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results",120483891,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=abadbda4a7faa8ed5a3da40c46105d40e5628d5e0ddd63414adc803c87c9d3c6
company,2023-05-20 07:01:06,Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their solid 158% return over the last five years,120464376,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...",https://finnhub.io/api/news?id=aab00de6feab4b85aa0794fd0ff550689791e97618cd5f9a8a7d35a00422565f
company,2023-05-19 15:32:00,High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023,120459773,https://media.zenfs.com/en/prnewswire.com/444ecf4a8f27f672733ff73b48b01bcf,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San José, CA, won the $75,000 top award in the 2023 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest global pre-college science and engineering competition, for a project that explored planets that orbit very close around their suns. Other top prizes went to projects in the fields of computational biology, animal sciences and neurobiology.",https://finnhub.io/api/news?id=86590ef90dd6c7973f2a51ffd2d7eeb9a86e54efd67aacf0ccd9b0382704b411
company,2023-05-19 13:42:05,Regeneron (REGN) Faces Challenges as Eylea Sales Decline,120454375,https://media.zenfs.com/en/zacks.com/79091dbe958a0ceedc2cec88ba60b675,REGN,Yahoo,"Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.",https://finnhub.io/api/news?id=d62bfafd25065c5fb637990bba6f7a583ef88711149bd1a6047842882f0a91d7
company,2023-05-19 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,120513823,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 1.55% to $759.05 Friday, on what proved to be an all-around grim trading session for the stock market, with the...",https://finnhub.io/api/news?id=71ae4ef35e0ce6ec9bd685a267957e2935550733e0609eb1cf775e65dac3e216
company,2023-05-19 12:54:00,High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023,120449369,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"$75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teensTARRYTOWN, N.Y. and WASHINGTON, D.C., May 19, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San José, CA, won the $75,000 top award in the 2023 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world’s large",https://finnhub.io/api/news?id=03a7745c6d255864bcf81d0f4b375aeb3102d68643fa1cf15e27a97edab00431
company,2023-05-19 04:02:00,"Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Regeneron (REGN)",120447760,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9b6e68d4f42b9f085044e896d4c16fd2235661166711bb43f9ec04b13c3b668d
company,2023-05-19 03:42:00,"Regeneron Q1 Eylea miss `not about share, says Piper Sandler",120447761,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=57845e85095b56211a32cbac233f27cd9cab789d54be352c10209dc5f8c5d19d
company,2023-05-18 22:03:00,"Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference",120451038,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fa5a19489018c331692b679586f7a46c492b8c8b70ffa4ac8352f9264b0f101b
company,2023-05-18 21:43:00,"Amgen (NASDAQ:AMGN) Loses Patent Battle to Sanofi, Regeneron",120447763,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=96e8e61b1826f80205c3de710b97904c0e5f8a6a3c3c038ef8b6c53c243c7b42
company,2023-05-26 11:04:00,Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study,120568919,https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0,REGN,Yahoo,A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.,https://finnhub.io/api/news?id=18e374bf2b0078899cfcfed39039554995660225aef96d7af3a264644396c9c8
company,2023-05-26 04:25:00,TD Cowen pharma/biotech analysts hold an analyst/industry conference call,120570461,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=95a1f011294a9e01a64863124222cc67d32e52e6ebbb3223817f565854938a54
company,2023-05-26 00:22:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market",120594074,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=13afb0425fe8286bafea29cfd2de0f9482c668c071d718e25d3d320c3661a032
company,2023-05-25 23:38:00,"Brandywine Global Investment Management, LLC Buys 1, Sells 4 in 1st Quarter",120570462,,REGN,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e7e12ad797e637e39325609c6ec58d73b433c099fd460b610d0404a6dff9dd67
company,2023-05-25 22:25:00,"Notable Friday Option Activity: REGN, URI, KSS",120594075,,REGN,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4837de25e7ec5641c902c0b76871d5c72be48f9586b2487904ccdf7406ea2867
company,2023-05-25 17:05:00,"Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma",120557449,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also observed across prespecified subgroups, including patients with high disease burden and aggressive disease Data from this trial to form the basis of planned regulatory submissions, starting with the FDA in 2023 TARRYTOWN, N.Y., May 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: R",https://finnhub.io/api/news?id=03450cea755ba1fe6912769bf957d6b294039fc9c6e4bce82239c40f5a70a1a8
company,2023-05-25 17:00:00,Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations,120557450,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar settings – per trial results to be presented in an oral session at ASCO Clinically meaningful responses observed in post hoc analyses of populations of interest, including patients with poor prognosis factors, prior anti-PD-1 therapy in the adjuvant setting and varying tumor PD-L1 expression levels Pivot",https://finnhub.io/api/news?id=fb15e3cb31d8cb10a6a491a61178753225679d42743c87f289c7765a55c173bb
company,2023-05-25 13:21:00,"Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market",120573476,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.68% to $725.00 Thursday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=4c396caa242efa5f44bd6e4de0c923ac52753dae7be074ac9a76548db736a972
company,2023-05-25 07:22:56,"Biopharmaceutical Sector Revisited: Investor Interest Subdued, Valuations Attractive",120543453,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1370358685/image_1370358685.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"The dramatic correction seems to have bottomed in June 2022, and the Biopharma ETFs have rallied since then. See if it is a good time to enter into this sector.",https://finnhub.io/api/news?id=7b2f02469ab5300261a0f9ace487203e30e5c073ae41b9658127d2a4320ed705
company,2023-05-25 06:53:00,Regeneron Pharmaceuticals (REGN) Shares Cross Below 200 DMA,120544476,,REGN,Market News Video,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8a61789d8916c67fa383d046c1fab26a51279ee42326912b7f48d7620be6f9b4
company,2023-05-25 04:03:52,14 Best Biotech Stocks To Buy According To Hedge Funds,120540154,https://s.yimg.com/ny/api/res/1.2/RCKFyA_Orx5i7EcMSHyUbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/bbad2545b3b325a6c633bba783765287,REGN,Yahoo,"In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]",https://finnhub.io/api/news?id=ff97a82c779b607e8ec2abb9b141fe2da3a4c3bcde3559a105108d76f5c06c56
company,2023-05-25 00:07:00,Regeneron says updated Linvoseltamab data demonstrates durable responses,120570466,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cdaa7a9ce5995af7b5022ce2a283dafda89ee4f6f5bdbdfb6e4fcfc6642315f3
company,2023-05-25 00:02:00,Regeneron reports 'positive' data from Fianlimab-Libtayo combo trial,120570467,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cbcdbad7cfe109dcf63b8abfd8bb61a37cef6e5b668ed0d8dc73440b98c1da34
company,2023-05-24 13:21:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",120573478,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.49% to $737.40 Wednesday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=827cf280e557e50e030ffab1a82f5ead564a89dce298ff600100bdc10fa8452a
company,2023-05-23 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,120513821,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 0.39% to $748.56 Tuesday, on what proved to be an all-around rough trading session for the stock market,...",https://finnhub.io/api/news?id=d55f28818f4417b3b23c611d11b59ab54dde28b3007e3df80b789af8712dd607
company,2023-05-30 13:21:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,120721288,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.49% higher to $728.60 Tuesday, on what proved to be an all-around mixed trading session for the stock...",https://finnhub.io/api/news?id=fa66ad0b84d3537d6ce2cc92b7316e87f399430943a834b3398a3d6111704665
company,2023-05-30 11:18:10,"Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 4th Annual Oncology Innovation Summit (Transcript)",120615784,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) TD Cowen 4th Annual Oncology Innovation Summit May 30, 2023 12:30 PM ETCompany ParticipantsIzzy Lowy - SVP, Solid Organ Oncology...",https://finnhub.io/api/news?id=3a241b5e2b5ffa2af2d63ad4933c10264be7ef1847b601a8d147f9bc6868d7ba
company,2023-05-29 22:24:00,Oppenheimer biotech analyst to hold a reception,120616066,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=09626c437766390c804e459da5921cff37bf9bd1321d149b0fb3cb9eca301c4f
company,2023-05-29 21:33:00,Regeneron Pharmaceuticals Unusual Options Activity,120620941,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=eac33567b3dc00b6d081f97cb9343b3af7a0def698f7937ab250a378650565f9
company,2023-06-02 12:42:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market",120721285,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 1.20% to $739.95 Friday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=952ae0b11bb4371ec4ada3a31f59a0e6e73ccbfabab7ae3fa22b534b032d5ee0
company,2023-06-02 03:32:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,120673025,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c120083b67e2d48e37ecfdfb1f50974b4482aca2b047c81591f33aa6b1875d2c
company,2023-06-02 00:55:00,Oppenheimer biotech analyst to hold a reception,120679379,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=086230cd9ef7a222e6c074fd1496c6441cfb9f73161603984e43a88393bc3de1
company,2023-06-01 23:39:00,Cantor Fitzgerald biotech analyst to hold analyst/industry conference call,120677328,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2507bec23db23883270ab9913737f5dfd5ccb09cf05dae59e402940d59a0768b
company,2023-06-01 13:21:00,"Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market",120721286,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. dropped 0.60% to $731.17 Thursday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=4a9d3a5ccf1f0874d04e794ed410e1a8fd0e923afd58c8682d3489edf48f3abe
company,2023-06-01 04:01:00,"Thursday’s Top Analyst Upgrades and Downgrades: Chevron, Coty, Twilio, Viking Therapeutics, Xylem and More",120647014,,REGN,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=02f841e9093a6f5b001c5581fa1b7dca313a4cd893d47f294e7478953536b5b3
company,2023-06-01 03:33:00,Roche to divest biologics production plant in California – Reuters,120649826,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d2a523567cd072cdac830b771fc36370d491084e366178427db634423580ac0c
company,2023-05-31 13:20:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,120721287,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.96% higher to $735.56 Wednesday, on what proved to be an all-around dismal trading session for the stock...",https://finnhub.io/api/news?id=d1575f2ce56450b6aec82c7f7f7303583cbcd614e627923f642a1a12d0d5d122
company,2023-06-07 12:42:00,Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors,120761231,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 1.27% to $738.63 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=ac0d170979eb7b9d381a927cb2f84975164903c3b001c25e6ebdfbc0846d6173
company,2023-06-07 08:43:08,"Regeneron Pharmaceuticals, Inc. (REGN) Jefferies Global Healthcare Conference (Transcript)",120752143,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Jefferies Global Healthcare Conference Call June 7, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor...",https://finnhub.io/api/news?id=96cd2ac24a313f61149f5550c2365c6a48e06bc152c2b4ef77fb100f9fa29257
company,2023-06-06 12:42:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market",120761232,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.28% to $748.14 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=49b64698c2b4cb7a7ecccd6f44086b48d098ea5cd2f666944ec1201a4c166e5d
company,2023-06-06 09:11:23,3 Biotech Stocks to Sell in June Before They Crash and Burn,120826801,https://media.zenfs.com/en/investorplace_417/8c2b9d29333c9e0926d4ded6ea4622e9,REGN,Yahoo,"The biotechnology sector has seen better days. From the heady days of the pandemic when companies were racing to develop a vaccine against Covid-19, the industry is now enduring a hangover as both demand and sales decline. This means there’s more than a couple biotech stocks to sell. The iShares US Pharmaceuticals ETF (NYSEARCA:IHE) that tracks the industry is down 10% over the last 12 months and major players such as Pfizer (NYSE:PFE) have seen their share price decline 25% so far in 2023. The",https://finnhub.io/api/news?id=795f7987e9a02934302eca1e291f8b125fa6f12c0aca0c303dce5ad21dc4840b
company,2023-06-06 07:00:58,26% Of This Regeneron Pharmaceuticals Insider's Holdings Were Sold \,120728959,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Insiders were net sellers of Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock during the past year. That is...",https://finnhub.io/api/news?id=b07643ac4d0ffb097bebc9a26db674cc6b850d1667f4be854400355b8f7af0b2
company,2023-06-05 12:42:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,120721284,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 1.39% to $750.27 Monday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=0cbef1ba248f82bb91b387ec9c4349d0b63cf48d4650a410526f673627e5e3d7
company,2023-06-05 08:53:00,"Noteworthy Monday Option Activity: REGN, GNRC, ORCL",120736570,,REGN,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=98521fd07be47d71d7a367e208361529e02df99898a430524b0bfbe5a8120d9f
company,2023-06-05 06:45:00,Global company events calendar - next 7 days,120708995,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3247843c57b32eccd65324f117b9586777a87a5cd12c04afd0d9986bf171c01b
company,2023-06-04 22:25:00,Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.,120716191,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=07781a4488da2a2f2b16143ab9086452b067198e0b71b6f3453946b1aa0779a5
company,2023-06-04 22:07:00,Regeneron Pharmaceuticals Unusual Options Activity For June 05,120736573,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0a776794397bbbe320fada88c3b712100771c37e82497f0b8409a5b814b168ff
company,2023-06-04 03:30:00,Wall Street Breakfast: The Week Ahead,120698237,https://static.seekingalpha.com/uploads/2023/6/3/stock_market___generic_13__5_.jpg,REGN,SeekingAlpha,Investors head into next week with the debt ceiling crisis resolved for the near term.,https://finnhub.io/api/news?id=53b32f5589ce875fff458b1a890f740bc67e95765ab4201ed25b912884262d3f
company,2023-06-11 08:00:17,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 29% Below Their Intrinsic Value Estimate",120817494,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,045 based on 2 Stage Free Cash Flow to...",https://finnhub.io/api/news?id=1450487b142587ad287f117de3771809122f37ce3c843b76a380daaf2e50a8b4
company,2023-06-09 19:53:01,RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation,120807133,,REGN,Fintel,,https://finnhub.io/api/news?id=a58116974047deb686f70053017abd2527f0dd6e9fb66d13a5cd6d1ed9cd5e97
company,2023-06-09 12:42:00,"Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market",120899320,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. sank 0.48% to $746.52 Friday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=20c1ab1005f907411debaa9aeb2f965229c967abbb6148f48ef382ac3345b5a0
company,2023-06-09 08:32:12,Kiniksa Pharmaceuticals: A Somewhat Complicated Story,120794419,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1422967687/image_1422967687.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Kiniksa Pharmaceuticals is a commercial stage biopharma firm. KNSA sees growth in its primary drug asset and has an intriguing pipeline. Read more here.,https://finnhub.io/api/news?id=1a47c432955720c701879343d81892d45f7dd4b2ef8b8e33060fafb2d7aa1388
company,2023-06-09 05:55:00,Cantor Fitzgerald biotech analyst to hold analyst/industry conference call,120794083,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9dd8de765d2fa9be9178504efb97464cf582e1832c56205923f2bea231903627
company,2023-06-09 04:33:00,"AbbVie, Amgen among firms targeted for Medicare inflation penalties",120793579,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2af3b167890b7d2c7142f866825b367d0a3b4c14c49c213058579c779c998f14
company,2023-06-09 04:21:00,Regeneron price target raised to $816 from $811 at RBC Capital,120799142,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=89e78e97d11f418e34b1efdf75274d95b2969608212ce39eb006a277234effec
company,2023-06-09 02:18:00,AstraZeneca in pact with Quell Therapeutics for Treg cell therapies,120794085,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=eb96c625dc8652f9b020400f4b985e868d3232a2df693fb324a4c03d3faeb6ce
company,2023-06-08 23:06:00,18 Analysts Have This to Say About Regeneron Pharmaceuticals,120834542,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=729c37c429a278eddca35eeb040b7f4831baad2331ac751fd23223ebf711055e
company,2023-06-08 20:55:00,"GLOBAL BRIEFING: Chinese CPI stays near zero, producer prices plunge",120798989,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3a659ce2a9c5724cf6978dcf0d19a049dc97572a38b24220ab6d6234b6168892
company,2023-06-08 18:15:19,Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know,120786189,https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1,REGN,Yahoo,"In the latest trading session, Regeneron (REGN) closed at $750.12, marking a +1.56% move from the previous day.",https://finnhub.io/api/news?id=ab4555aeafea482cd6301f9fbb160542b64a01535b81ea74169d655baf775a22
company,2023-06-08 12:42:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market",120899321,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.56% to $750.12 Thursday, on what proved to be an all-around great trading session for the stock market,...",https://finnhub.io/api/news?id=50991ec36b031cc99840423d38367ea48bc196b138415f5e44f9712b09c501a6
company,2023-06-15 12:42:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market",120899316,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 1.55% to $783.07 Thursday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=844f51c3894d66e619e0cd44cf9119025c01529f59e7ed1cd07fd7ac2406c99a
company,2023-06-15 07:29:00,Video: S&P 500 Analyst Moves: REGN,120890727,,REGN,Market News Video,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=16324b5d10dcfeda2454c10b37778a3a8684bf8cad13fcdb09df365471c3a0f0
company,2023-06-15 07:07:00,"Regeneron Pharmaceuticals Achieves #131 Analyst Rank, Surpassing PulteGroup",120890728,,REGN,ETF Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c45b0b108ab016edfe02597ade65cef4d536deaf4f9ea452b228c2965bb7df73
company,2023-06-15 07:00:37,Regeneron Pharmaceuticals (NASDAQ:REGN) Seems To Use Debt Quite Sensibly,120883753,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",https://finnhub.io/api/news?id=ce9ac96f6759f1eaadab5492b54b987c0b0487d2b1d1cbd0a778858e582c1544
company,2023-06-15 02:10:00,Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and BioMarin Pharmaceutical (BMRN),120887619,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b4c5457fed5cd81eaa8a1463bd8cef750f2d25042bfed912f27dca18a2ded632
company,2023-06-15 01:11:00,"Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Healthequity (HQY) and Regeneron (REGN)",120890098,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=022b89a1a980edc4d39df2fe97a7105acc59bf69a271c3bd813f6401f9f57878
company,2023-06-14 18:15:26,Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know,120878608,,REGN,Yahoo,"Regeneron (REGN) closed at $771.11 in the latest trading session, marking a +0.49% move from the prior day.",https://finnhub.io/api/news?id=8aba29247ad0d5877d5f4ecd570408f2899d7430982907ad79e864863bf65be0
company,2023-06-14 12:42:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,120899317,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.49% higher to $771.11 Wednesday, on what proved to be an all-around mixed trading session for the stock...",https://finnhub.io/api/news?id=1a5340b4e5bde9402860de659df0b61e804d2f4cb32be54f08a727e9a1ba18c9
company,2023-06-14 10:39:07,Regeneron Pharmaceuticals Inc. (REGN) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript),120868888,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) Goldman Sachs 44th Annual Global Healthcare Conference June 14, 2023 11:40 AM ETCompany ParticipantsRyan Crowe - VP, IRBob Landry - EVP...",https://finnhub.io/api/news?id=87af5ff2da5ece7665c6c3b8272582d313b709f4bc5a5af7e9d92fb6d2887c87
company,2023-06-14 10:00:00,2 Stocks to Buy No Matter What Happens in June and Beyond,120868669,,REGN,Yahoo,"The first half of the year is almost over -- and so far, 2023 has been pretty kind to investors.  Buying shares of the right companies can help investors' portfolios do the same.  With that said, let's consider two stocks worth investing in regardless of what lies ahead: Regeneron Pharmaceuticals (NASDAQ: REGN) and Microsoft (NASDAQ: MSFT).",https://finnhub.io/api/news?id=99ca0cf72ae0370e295ed9e7a6bae3d11d2c9527244af026df9f162bad381146
company,2023-06-13 22:20:00,"EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035",120873750,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c4f880ad3c2e492334f4acf2f34d013c393facf45556130b3b13a079c8a980c6
company,2023-06-13 13:55:37,Regeneron: Solid Investment Based On Continued EYLEA Expansion,120853140,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1496903466/image_1496903466.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"Regeneron Pharmaceuticals has potential to receive FDA approval of higher dosing of 8 mg of EYLEA with FDA target action date of June 27, 2023. Click here for more on REGN.",https://finnhub.io/api/news?id=9c46b10ce2d1a5dc0ae5bb5c8aa8bb6b47eed751e270622f7d0cbead28f80854
company,2023-06-13 13:44:00,Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains,120899318,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rose 1.77% to $767.35 Tuesday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=ba38abfc7cdaab6ec9aa7deefdc17ca58a72b17f210741b39113f9e0787c85c5
company,2023-06-13 07:56:00,SVB Securities Remains a Buy on Regeneron (REGN),120874783,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3d0cd6316706964029020a76a9fd37b7f3aab43bad48b9fe08be7a9488fe6a48
company,2023-06-13 06:04:55,15 Most Profitable Drugs In The World,120841577,https://media.zenfs.com/en/insidermonkey.com/417a6a124aa2973d574f195a371d011f,REGN,Yahoo,"In this article, we will be taking a look at the 15 most profitable drugs in the world. If you wish to see the top ones, feel free to skip our detailed analysis of the pharma industry and head straight to the 5 Most Profitable Drugs In The World. The pharmaceutical industry has long been […]",https://finnhub.io/api/news?id=25bc6b18a938aed4ce4809e8199324b010068daa3560b6d8ba32dd3e2282c743
company,2023-06-13 03:15:00,Regeneron named 'Catalyst Driven Idea' at Morgan Stanley,120845829,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=472e16c686092f03284f5b30a16467eabd41bb1ffc85ca32afe2747bf84b1cea
company,2023-06-12 22:54:00,"Notable Tuesday Option Activity: REGN, TPC, TTD",120851634,,REGN,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=625a87b4679ab4ce7b0ce464b1f7e3968ba62a0c28e0b86d0c6dbf2170699aea
company,2023-06-12 03:06:00,Jefferies Reaffirms Their Buy Rating on Regeneron (REGN),120834538,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=97c7e2d79a37e98256d6a02df189837706f3e511069dfa9ef846a2d7a4bf0342
company,2023-06-11 22:08:00,Ocular falls after 12-month data for wet AMD candidate,120834540,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0eec9e4f4481d4805089f99000b3a43c3191d04605e7b0e359a60f6d0491d73a
company,2023-06-19 01:16:46,PBE: Healthcare Dashboard For June,120943664,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/655188172/image_655188172.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Click here for the June edition of the Healthcare Dashboard.,https://finnhub.io/api/news?id=b567e115a5c67f869d3513574b36147a748861f565307e34181e9fd2427d266f
company,2023-06-18 16:56:10,How to Retire Rich: Biotech Stocks Edition,121032614,https://media.zenfs.com/en/investorplace_417/155568656c3c7c82033d9d467e5e2a90,REGN,Yahoo,"Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector – which falls under the broad healthcare industry – is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement",https://finnhub.io/api/news?id=30a100653ec7406368a3a5492184101887e35c42255ecfcadc8086b9b655a955
company,2023-06-16 21:00:00,How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities,120929605,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=15265ab21d58d07aa200dc13c9257b8b82e6400561706dd01f51e6e7a2aa15b9
company,2023-06-16 12:42:00,"Regeneron Pharmaceuticals Inc. stock falls Friday, still outperforms market",120941879,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slumped 0.00% to $783.05 Friday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=78f96c92199e61b5dc2cd05575d81f3322637d6cdd3f960e690f1ab4d5051f0a
company,2023-06-23 12:42:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,121028071,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. dropped 0.01% to $779.73 Friday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=0fe063fb9f6dfa6fb7f5bac07232ab183ee8a36bfc53b64591b331a28be540ea
company,2023-06-23 04:00:00,"Friday’s Top Analyst Upgrades and Downgrades: Alcoa, Caterpillar, Dow, Kellogg, PagSeguro, Tesla, Tripadvisor, Walmart and More",121019181,,REGN,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=613d1676e334a868fb5c30087dab7a146827511acc49d92e039e2e52c5fd75dd
company,2023-06-23 03:32:00,"Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Kezar Life Sciences (KZR)",121024382,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=befaedb7445f1cdbd703e12a285942775204b89ff7f87263e72261e3ef2a87cc
company,2023-06-22 12:42:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market",121010541,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.13% higher to $779.81 Thursday, on what proved to be an all-around mixed trading session for the stock...",https://finnhub.io/api/news?id=feda5713bd29548c76ae7de0a497674e5b510063e05aff4d8083886ed3f803ca
company,2023-06-22 00:36:00,$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today,121027296,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=77a33a0aa909ac18ba98e6d180f17df7f169ef5b6531d03c024a26693cf17195
company,2023-06-21 12:42:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, still outperforms market",120991627,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. dropped 0.31% to $778.77 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=1992698bbceb7451482213457dfa8dfa64c634c07def5eeb47d1e2ac07ed05fc
company,2023-06-21 08:22:00,2 Biotech Stocks You Can Buy and Hold for the Next Decade,120973193,https://s.yimg.com/ny/api/res/1.2/VX9pu2GVHS1QuVPoV3K6iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MTY-/https://media.zenfs.com/en/motleyfool.com/ceac878ca1dd9c8a2000dd46a9942847,REGN,Yahoo,"Biotech companies use living organisms to develop their therapies, and much like some living things, biotech stocks can be notoriously volatile.  Part of that is due to the complexities of making biotech therapies.  The success rate for biotech start-ups is low, but Gilead Sciences (NASDAQ: GILD), founded 36 years ago and Regeneron Pharmaceuticals (NASDAQ: REGN), founded 35 years ago, have already stood the test of time.",https://finnhub.io/api/news?id=681e779585ed939c6a71bd3129ea66868301d3cb83176fb04ae7208516417dbc
company,2023-06-20 23:16:00,"Agree To Buy Regeneron Pharmaceuticals At $560, Earn 5.6% Using Options",121005502,,REGN,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fb920b4456dd3d8c1e92a3301e4a7e050e3db47e4e8dc1cbf046652eae5a301b
company,2023-06-20 22:21:00,Biotech And Healthcare Stocks Lagging,120982355,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b530c8edb5bfe9ec95b4e76429c0d428ac36bc618c861778b342691bf0093d3d
company,2023-06-20 12:42:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day,120991628,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 0.23% to $781.21 Tuesday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=c9a7efeb9c157e9bb234a819d93cf262af5d696845d95823654468aba536730e
company,2023-06-27 16:20:09,Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender,121102789,https://media.zenfs.com/en/ibd.com/b727993c80cd23c03b1f42c9321ae4f1,REGN,Yahoo,"The Food and Drug Administration rejected a high-dose version of Regeneron's eye drug Eylea on Tuesday, leading REGN stock to crumble.",https://finnhub.io/api/news?id=944aa28b865ec4be525093038d3caa97cfc07457e52929bbcedf7601422f5800
company,2023-06-27 16:01:00,Regeneron Stock Slumps After FDA Decision Delays Blockbuster Release,121102790,https://s.yimg.com/ny/api/res/1.2/JHO9.X_M1Wy5clm_KmQp3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/6c27507a0fd84c36c02e291af8f5d2c9,REGN,Yahoo,"The Food and Drug Administration rejected its application for approval of a new, higher-dose version of eye disease treatment Eylea.",https://finnhub.io/api/news?id=8d698fb200de5a3dd447a22bccc3cee3cb6970215cd1c7f170c9ea48a251d5b2
company,2023-06-27 14:46:00,Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema,121102792,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"89% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals through two years Of those assigned to a 16-week dosing regimen at baseline, 83% maintained ≥16-week dosing intervals through two years Many patients met the extension criteria for even longer dosing intervals, including 43% for ≥20-week intervals and 27% for 24-week intervals Visual gains and safety of aflibercept 8 mg remained consistent with the established profile of EYLEA® (aflibercept) 2 mg Injection TARRYTOWN, NY, J",https://finnhub.io/api/news?id=b00ec03bdd6d208e2abb7b41f9cd4773635460486b5b216459a8c55ab7d47cda
company,2023-06-27 14:45:00,FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler,121102794,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"No issues with clinical efficacy or safety, trial design, labeling or drug substance manufacturing were identified in the CRL No additional clinical data or trials have been requested TARRYTOWN, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for aflibercept 8 mg for the treatment of patients with wet age-r",https://finnhub.io/api/news?id=ec88fbf00a822f48702fbff0d9cb1b5d05e00f9b0408ba9a71d5c81d93c8af63
company,2023-06-27 13:48:51,10 Martin Shkreli Stock Picks and Their Performance,121073004,https://media.zenfs.com/en/insidermonkey.com/efdbbcf0a508c37b56e2a6ea0302e3d2,REGN,Yahoo,"In this article, we will take a look at the 10 Martin Shkreli stock picks and their performance. To see more such companies, go directly to 5 Martin Shkreli Stock Picks and Their Performance. Martin Shkreli a.k.a. “Pharma Bro” is known for a variety of reasons, many of which are tinged with notoriety. He cofounded […]",https://finnhub.io/api/news?id=0c143d9b7797f5eabda3d45e2bb5641bf88c208b5275d436890bf87c97ce26ec
company,2023-06-27 12:49:28,Regeneron shares fall after FDA rejects high-dose eye disease treatment,121081742,https://image.cnbcfm.com/api/v1/image/106728578-1601729225514-gettyimages-1228859472-radin_1003203.jpeg?v=1687900230&w=1920&h=1080,REGN,CNBC,"Regeneron said the rejection was ""solely due to an ongoing review of inspection findings at a third-party filler."" ",https://finnhub.io/api/news?id=79718b2fd53ebf9885711a04179b041958edc2d8c7340207c39b43ea4817d561
company,2023-06-27 12:48:00,Regeneron Pharmaceuticals shares fall on US FDA Eylea blow,121096068,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=385fb6289f40266f2d740b2d0abe92c8a95fe2ef28a420302006191d28c0b048
company,2023-06-27 12:42:00,Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors,121079241,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 8.71% to $716.09 Tuesday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=92f61f7b39b6187dec18388df13cc8668be2411929d6e298ea84d34a892f9708
company,2023-06-27 11:22:00,"Regeneron Gets FDA Response Letter on Aflibercept 8 Mg Application, Says Issue Involves Third-Party Filler",121079243,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Stephen Nakrosis Regeneron Pharmaceuticals said it received a complete response letter from the Food and Drug Administration for its aflibercept 8 mg...,https://finnhub.io/api/news?id=1d22153634bb359deb57218805c9a5f0757484d982f81ec1e6d5064a926d0ef1
company,2023-06-27 11:02:00,Regeneron’s high-dose Eylea not approved by FDA,121079244,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,REGN,MarketWatch,Regeneron Pharmaceuticals Inc. said Tuesday that the U.S. Food and Drug Administration issued a complete response letter for the biologics license...,https://finnhub.io/api/news?id=ac248b188ed365df7546685792be4b3bb15d07669fe57f06f55e5382dade1986
company,2023-06-27 07:31:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,121081885,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f4ca8251a485d99d3e25a273a21c701767cae6d00683fb4a65fbb3d71d9a508e
company,2023-06-27 04:20:00,"Regeneron's two-year Eylea data should look 'consistent', says RBC Capital",121096299,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=44010e5737173e17ea86029f732bb2406e00b572c5fd74e45f4d20d61497a155
company,2023-06-27 03:31:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Edwards Lifesciences (EW) and Tonix Pharma (TNXP)",121068866,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e7d0022d69395b3b61a4097c426faf2a70ef04aca5924923f71da29035aea1e9
company,2023-06-26 23:30:00,REGN Makes Notable Cross Below Critical Moving Average,121096304,,REGN,Market News Video,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bb6354b95ec54dfdf583595598197aca73b84d610e7c6be0495272d0f69c4d06
company,2023-06-26 22:48:00,Morgan Stanley says Regeneron likely to come under pressure after surprising CRL,121096306,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e65455b9877246f3115e2291f1f934128d375c2533d70cfe97737de4c2b46ae3
company,2023-06-26 22:24:00,Regeneron falls as FDA rejects high-dose Eylea (update),121074691,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e0ec59dc5681bb8a5291da7cbf0ad5f4d2b73000101ec2ec95aa6338d0e56e36
company,2023-06-26 22:17:00,"Regeneron resumes, down 9% after CRL issued for aflibercept 8 mg BLA",121096310,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0b1adf3d3d5278aa6688bf23690605c488e305758b82a7ade09f69209faf1af7
company,2023-06-26 22:15:00,Regeneron trading resumes,121096312,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=985271b6cafe42d1215eaf8a5e3dc2a1e270e9143418ebd93bcd5f510c645c26
company,2023-06-26 22:12:00,Regeneron high-dose Eylea version rejected by FDA,121074692,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=53bee1164a978f6bf77933ca5f81b47bf83ccc53b14cf890d6021f08330c4487
company,2023-06-26 22:06:00,Roche turns positive after Regeneron issued CRL for aflibercept 8 mg BLA,121091966,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5771fa3680dc141203e873284a1a8166d1d1474aa6e21ffc089dc81638141f49
company,2023-06-26 21:54:00,Regeneron to resume trading at 3:15 pm ET,121096316,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6d283a69c768aa03f621c104e8359ce0ebb131570a39fd7152378c5f4b0e2982
company,2023-06-26 21:51:00,"Regeneron announces top-line, two-year data for aflibercept 8 mg PHOTON trial",121096317,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8bf0d9b0ec5b95a2eebe373f8904ddfbc5ee4e5317f4ce8ecba05a5c610c265f
company,2023-06-26 21:48:00,FDA issues CRL to Regeneron for Aflibercept 8 mg Biologics License Application,121096070,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=32fb525fa186cfd85024ad349d75315c737859bda3f5fd3da73f14fb26544015
company,2023-06-26 21:25:00,"Regeneron trading halted, news pending",121096320,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=aaf2edef4e10d54b56c4f9510d6487af829989eb67368cc962a0d5cbd4c07a8b
company,2023-06-26 21:06:00,Where Regeneron Pharmaceuticals Stands With Analysts,121096321,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e99bbe416406a6883929755caf015bb09d834d24352dfc91294d1bfd6d10fb8d
company,2023-06-26 12:42:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,121079245,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.60% higher to $784.38 Monday, on what proved to be an all-around poor trading session for the stock market,...",https://finnhub.io/api/news?id=92e551ee699e5caf8c79f3536eec7d0f9e38b8707dbd1f2eba4607ef9e4cf128
company,2023-06-26 00:43:00,"Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead",121058560,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6439151289bdbfdeb183e234c678a9b45f7d412c560fadf2339c2d9edc224a85
company,2023-07-01 04:18:20,Wall Street Breakfast: What Moved Markets,121163336,https://static.seekingalpha.com/uploads/2021/8/21/saupload_Stock_Market_-_generic_6.jpg,REGN,SeekingAlpha,"Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.",https://finnhub.io/api/news?id=fad9ac45cee09de091c60afab88b17c54af7c09ca2dfc4f5ab7d9b1a2b1cbe5a
company,2023-06-30 12:43:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,121154873,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 1.43% to $718.54 Friday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=1058cf4d40f7c6d78a6b85b5ab31dba154aa3b56c27cb5df3f8c4db5928e2b2e
company,2023-06-29 16:01:00,"Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023",121130154,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"TARRYTOWN, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 3, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s webs",https://finnhub.io/api/news?id=d33281f4e72b1a9fff99efde0e99f148a20dd245845e09c33a3008d142a29089
company,2023-06-29 14:04:19,Why Regeneron Pharmaceuticals Stock Dipped This Week,121118040,https://s.yimg.com/ny/api/res/1.2/Yn2wIToQCcSe1qBkiSW.OA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xMTEz/https://media.zenfs.com/en/motleyfool.com/5132b8780aa90e3950d8c4c813ae4362,REGN,Yahoo,"Shares of biotech heavyweight Regeneron Pharmaceuticals (NASDAQ: REGN) lost 10% of their value over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence.  The double-digit decline came after the company announced that the Food and Drug Administration (FDA) issued a Complete Response Letter (i.e., a rejection) for its high-dose formulation of Eylea.  Eylea, a biologic therapy for various eye disorders like wet age-related macular degeneration (wet AMD), generated approximately $6.3 billion in net U.S. sales for the drugmaker in 2022.",https://finnhub.io/api/news?id=24d08a8a766d1aaad7f39ec5fe1e17bd01d1768c9b43de2cc1c57738c4c2bef4
company,2023-06-29 11:40:01,Canaccord Genuity Downgrades Regeneron Pharmaceuticals (REGN),121113096,,REGN,Fintel,,https://finnhub.io/api/news?id=0efd2b0d3d12801c2781065f05ef936edb2bad45d95180f8d0132b7ae546181e
company,2023-06-29 11:39:57,RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation,121113097,,REGN,Fintel,,https://finnhub.io/api/news?id=252ff12ce8ab8ccc355571076b34503f193e4eda32608030693b523d30062bde
company,2023-06-29 11:39:53,Baird Maintains Regeneron Pharmaceuticals (REGN) Neutral Recommendation,121113098,,REGN,Fintel,,https://finnhub.io/api/news?id=3583cecf81d72636125ed1139aa59ca7f8fc50f052736e6e0c2b52019c726567
company,2023-06-29 11:39:49,Truist Securities Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation,121113100,,REGN,Fintel,,https://finnhub.io/api/news?id=dee0aa1fd2adeacb523dd7b2bd5efc8d48238aaea929cf170c82b416dce3bb33
company,2023-06-29 11:39:49,Barclays Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation,121113099,,REGN,Fintel,,https://finnhub.io/api/news?id=9611707d82bf3dc28d48ea36cc7912d8f3c23bf64fe1fe0274c2e4baa32e16a3
company,2023-06-29 09:38:00,Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL,121116695,https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307,REGN,Yahoo,"Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.",https://finnhub.io/api/news?id=28bc805e55b8ccc7e51ad9046dfb8f5090280689835098d6843b0b0ab4958d4c
company,2023-06-29 05:08:01,"INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",121109042,,REGN,Finnhub,"The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations o...",https://finnhub.io/api/news?id=e84f49d7afe420ad059cca277507d81a3998f5e298b3896f0067c791f9dfd947
company,2023-06-29 05:00:00,"The Zacks Analyst Blog Highlights Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks",121108135,https://media.zenfs.com/en/zacks.com/f137593ef3b3f5b2675404f14056fe62,REGN,Yahoo,"Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks are included in this Analyst Blog.",https://finnhub.io/api/news?id=aff4223b28f2edb82d5e1d7cec459603d207dc5dddcba054561e26b87bd3b0b9
company,2023-06-29 04:15:00,"Thursday’s Top Analyst Upgrades and Downgrades: Amazon, Bristol-Myers Squibb, Deere, GoDaddy, Pinterest, Salesforce, Uber, Vale, Walgreens and More",121111651,,REGN,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e55aa2a2233779e5a4f5cc6a78e245a379d71339f02c269bd8031aa85cca2843
company,2023-06-28 18:40:00,Why Catalent Stock Flopped Today,121101545,https://s.yimg.com/ny/api/res/1.2/.RM_pDGj8RIRh_xyy_xzqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/motleyfool.com/ed2be25caf0ed206a117282b2435872f,REGN,Yahoo,"It seems Catalent (NYSE: CTLT) was apparently the reason why a key drug was refused approval by the Food and Drug Administration (FDA).  According to a media report from a leading financial news agency, this is what likely happened.  The party applying for it was biotech Regeneron Pharmaceuticals (NASDAQ: REGN), and the drug is a stronger formulation of its previously approved Eylea.",https://finnhub.io/api/news?id=60c25850fbbc940880f21c19ab367c005eadec1a21253ff8779be76650d3f1e5
company,2023-06-28 13:00:01,"INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",121094395,,REGN,Finnhub,"The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations o...",https://finnhub.io/api/news?id=1f6ad3d5b2a12c5d24f3fd039b13a1c72c2a23488bccca2aa2801d4d1ec6ec2c
company,2023-06-28 12:43:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",121154876,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 2.24% to $700.03 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=f2b83c7b1c28b4185115b1ac23e02cc0518998985a789a72bd5d57dc724ff727
company,2023-06-28 12:03:59,Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep,121092035,https://s.yimg.com/ny/api/res/1.2/CkWfhyyV81tHE901UoM.3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/edd6d384f11612101d42c733245bbc5c,REGN,Yahoo,"(Bloomberg) -- Problems at a Catalent Inc. production facility led US regulators to deny a key drug application from Regeneron Pharmaceuticals Inc., the latest headache for one of the main manufacturing partners to the drug industry. Most Read from BloombergPutin Claims He’s Back in Control. Russia’s Elite Isn’t SureUBS Preparing to Cut Over Half of Credit Suisse WorkforceQatar Group Now Confident of Winning Manchester United RaceBiden Can Cancel Student Debt Even If Supreme Court Blocks Order,",https://finnhub.io/api/news?id=7775f643506d0d9a339716fa7437d5e8daf5e5fdcac0f578f1c29eb95dad3bcf
company,2023-06-28 11:53:00,"Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology",121095847,https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6,REGN,Yahoo,"Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU).",https://finnhub.io/api/news?id=681d73de5ffed020d156aadfa02154b1480fb44a0b3adc4efa94380400dba16f
company,2023-06-28 11:12:16,"Three-Stock Lunch: REGN, PINS & GNRC",121096606,https://image.cnbcfm.com/api/v1/image/107264227-16879785711687978567-30082569743-1080pnbcnews.jpg?v=1687979536&w=1920&h=1080,REGN,CNBC,"Lee Munson, Portfolio Wealth Advisors president and CIO, joins 'Power Lunch' to discuss three stocks: Regeneron, Pinterest and Generac Holdings.",https://finnhub.io/api/news?id=51ff666937e8ca70ccd2203470a109d0007353e7f4a5fef527135843fb176a5e
company,2023-06-28 08:09:00,"General Mills, Nvidia fall; AeroVironment, Circor rise, Wednesday, 6/28/2023",121095184,,REGN,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4c6ea47e773c69c4255a443aee2f043bc3df87a5535ff8bea7108ca1ffab06e4
company,2023-06-28 08:02:00,What You Missed On Wall Street This Morning,121090142,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9181ef1a4e891bbe0392aaede23456d577942cb70f1b113bafba52ebfb100860
company,2023-06-28 08:00:37,Regeneron Pharmaceuticals' (NASDAQ:REGN) five-year total shareholder returns outpace the underlying earnings growth,121102786,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"While Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders are probably generally happy, the stock hasn't had...",https://finnhub.io/api/news?id=1f80c4d672201c173cf08b7944e1d7e4e8d4e0a61403420b3ae95508399edb95
company,2023-06-28 07:08:00,"Catalent confirms being Regeneron's Eylea 8 mg third party filler, says Stephens",121093555,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=280465d9b94f8e60dc58dbbcb9e02793095c08061aa3a49b8c2b40955ec11f1f
company,2023-06-28 06:13:00,"Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall",121102787,https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d,REGN,Yahoo,Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.,https://finnhub.io/api/news?id=04747b1e5243da5b5e6c80f2c9e9c11cc10405471a10044be6f917352635fc4b
company,2023-06-28 06:05:00,"Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023",121088687,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=71876dca3649a5e0c3185c544596c1fcc1f5f3dc3ef1d192ea6a378169362890
company,2023-06-28 05:48:00,Catalent confirmed as manufacturer of Regeneron’s high-dose Eylea rejected by FDA,121093558,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6a06b0d939e7c426e7ce48dc39196847ab8b21d992bfbf12e33ad1996410e101
company,2023-06-28 05:18:00,"Catalent says FDA made three observations in Eylea inspection, Bloomberg reports",121093559,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0cffcb855af418773ab37cef639b25234886bf1ce3ca68be5083b32b3899f5ee
company,2023-06-28 04:59:00,"Uber downgraded, Pinterest upgraded: Wall Street's top analyst calls",121089015,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=729a57005c2bb2c745d4514b97d848292e2af714b98a991479a341406e6a619c
company,2023-06-28 04:57:00,Check Out What Whales Are Doing With REGN,121096263,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=eeddb4493871cd64e0077feb495a206fa1ef65f2b8c4dea7bb01a48216fbb231
company,2023-06-28 04:46:00,SVB Securities Sticks to Its Buy Rating for Regeneron (REGN),121096264,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c753a77c27c86a5796fa17cb6676ab3ac7c2068ce2f9ba10b93d49294c90ba4e
company,2023-06-28 03:51:00,"Regeneron price target lowered to $1,045 from $1,050 at Truist",121096266,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3ca59cd399b3e76b6a0ff0531590cc1aadad4540c9688a8509363a2155e10ec8
company,2023-06-28 03:49:00,Regeneron cut to Neutral at Cannacord on FDA snub for high-dose Eylea,121091962,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=61dbefdec931cb5e49d179c46fdf184916517ddcfbc963caa7e94002f488d5b1
company,2023-06-28 03:21:00,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Radnet (RDNT)",121088965,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d8192aa6149c4a413f57f6448ee44bb83c04bfac356f654a1d943401ed5333d4
company,2023-06-28 03:09:00,GLOBAL BROKER RATINGS: Exane raises BHP Group; HSBC likes Prosus,121088869,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ecd5bdc231658b112c8c7688506966dbfa2d8d3c316ee8d76c1113acd11755e3
company,2023-06-28 02:56:00,Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday,121089900,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=859dd00a879f291dfc63ae8892972bd4c0fb8899c9549e32fee5f64f204810d0
company,2023-06-28 02:18:00,Regeneron price target lowered to $789 from $816 at RBC Capital,121091964,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=65cc84c882d38e8ca5e265ae5f1074135c921766a8e0ff2cd6fd9f7e41bdc6fa
company,2023-06-28 02:06:00,BMO Capital Sticks to Its Buy Rating for Regeneron (REGN),121096277,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=04f1afdb8487e9787dbd73a16297daf1821c328cdddfe0240dab5a4500249f93
company,2023-06-28 01:45:00,Regeneron price target lowered to $760 from $800 at Baird,121096278,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3be83af630c6d19897710017cfaa4311946ac7f07e3aaf5b4fb635a26d6a874d
company,2023-06-28 01:26:00,Regeneron price target lowered to $875 from $915 at Wells Fargo,121096280,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=56a839b1fbee2ce36ab1b972abc37bc90ad02ecf897a87900c538e3de021b7dd
company,2023-06-28 01:16:00,Regeneron price target lowered to $888 from $915 at Barclays,121096282,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1c4930487c5ee2c2fa56a36451a21906d7ffeb0a73c6f7608892a78646e3a9a4
company,2023-06-28 00:44:00,Regeneron downgraded to Hold from Buy at Canaccord,121096283,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4a7b2d36ce2e49c4ef5e7d8a075669f21a99ed7df890225ca1a9c7a69596b1e5
company,2023-06-28 00:34:00,"These Stocks Are Moving the Most Today: Nvidia, Micron, Joby Aviation, Carnival, and More",121123204,https://images.barrons.com/im-805893/social,REGN,MarketWatch,"Nvidia slumps after a report says the U.S. is considering new restrictions on exports of AI chips to China, and Joby Aviation surges after getting a special...",https://finnhub.io/api/news?id=83af13d6151104f24ba0d9fb3d07e16700cafe3593bbc0b0c36e176f4df700a8
company,2023-06-28 00:11:00,"Analysts Conflicted on These Healthcare Names: Paycor HCM (PYCR), Regeneron (REGN) and Pharvaris (PHVS)",121089183,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1ac0ad236ad669e41c2f6314a1a95e715f7fe087883234c68e2ca10796402a09
company,2023-06-28 00:02:00,"Analysts’ Top Healthcare Picks: Paycor HCM (PYCR), Regeneron (REGN)",121091305,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=21bccad5d3c08928afb392648da2cad3eb14db8be4518c8cbd026e2d8c6cc1ad
company,2023-06-27 23:24:00,Regeneron Stock (NASDAQ:REGN) Sinks; FDA Snubs Higher-Dose Eye Drug,121091965,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9707aafa02ca5c10dd2c3fd24103162ec60ac002765792d38629299c6cc15730
company,2023-06-27 23:19:00,What You Missed On Wall Street On Wednesday,121093560,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=678aa0937a410dbc2ee0ddd6d7349a96c227fbfbaf605e31fc8cf0b09ba8cc9c
company,2023-06-27 21:54:00,"REGN, CTLT Continue Sliding Following FDA Rejection of Eylea Drug",121092702,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b2d997e52fd10891f0582358fd856c3faab677cb9c413ce7e9baa46635f7c3ef
company,2023-06-27 20:27:55,RBC Capital Reiterates Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation,121084220,,REGN,Fintel,,https://finnhub.io/api/news?id=075ac960a5124152b7c8f1f72aed3fa25c15c48f90d98c8b58c7e371a8ab2066
company,2023-06-27 20:27:51,Truist Securities Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation,121084221,,REGN,Fintel,,https://finnhub.io/api/news?id=ee85b1ca3fef81255afa7006c21839be3d3ff6e4914cbb4ef93f5d4aeffccad7
company,2023-07-05 13:05:57,The 3 Best Biotech Stocks to Buy In July,121317565,https://media.zenfs.com/en/investorplace_417/180ce84be58b62c67d477717f09599bb,REGN,Yahoo,"Although it’s been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at small and midsized biotech companies in the U.S. These are the incubators for medical advancements and where important scientific breakthroughs are happening. New products and treatments are boosting sales and earnings at biotech companies, making them great long-term investments. Although the S&P B",https://finnhub.io/api/news?id=77104d3f0a6a2071dc5cedc055579fa8a7c1bbd6a9d87a1e565ac28cefd3b46e
company,2023-07-05 12:43:00,Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors,121219331,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.04% to $717.83 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=98c99403c55a7108ede1fef60f809b2128f22f2ee2e250662add7b689d860cd7
company,2023-07-05 07:58:00,Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?,121222048,https://media.zenfs.com/en/zacks.com/d4b401a428473a34a4480748dd329007,REGN,Yahoo,Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.,https://finnhub.io/api/news?id=4eddc5c80b62ece436c55dc09aca62f6b7d81af5ca4f91261819bc09e5f71c9b
company,2023-07-05 00:58:00,Regeneron gets FDA orphan drug designation for cemdisiran,121238360,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4f8db67f392f8e5baae9bebcbb888d3f7ccf9cf1fa874dd7460a27e0967323fb
company,2023-07-04 22:31:00,Biotech Blues: Stay Balanced Through July Earnings Season,121214181,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=94f82acac4f79fa0ed779467b25f94fe4ec5dd41578ee61190a8792bc4941c42
company,2023-07-04 08:31:00,"Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Regeneron (REGN) and Blueprint Medicines (BPMC)",121199884,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f58aa79b24b0f3a7f6fcb535cf2385fd79773bd78060b0bf9e148937fc308b0b
company,2023-07-03 04:51:00,Looking Into Regeneron Pharmaceuticals's Recent Short Interest,121188372,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=67839366f225d363e548a2022df5c8dbbaeb160c611b60d742c1e913582254cb
company,2023-07-02 21:34:00,Check Out What Whales Are Doing With REGN,121188373,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0d867158ed8567e2b8582aa559f3fab5287229e9c1937fc143f5d4606644e708
company,2023-07-08 07:00:39,26% Of This Regeneron Pharmaceuticals Insider's Holdings Were Sold,121272549,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Looking at Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) insider transactions over the last year, we can see that...",https://finnhub.io/api/news?id=44dc5e32b30a19120f62de09871932079254ca0563e5dfaba4f21ffb6be8d019
company,2023-07-07 12:43:00,"Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market",121278525,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 1.76% to $692.45 Friday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=92ebd31f4c2555ea75188f315b64a571606a9120c7b6e4d2035566ace89e030f
company,2023-07-07 07:52:00,Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity,121264925,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=85eefe60b38cc6cb14ea750b340c7a8a91a8a31cd4e35024acf5a6b7df65fa7f
company,2023-07-07 07:00:00,Is Regeneron Stock a Buy After a Regulatory Blow?,121261269,,REGN,Yahoo,"Biotech giant Regeneron (NASDAQ: REGN) has been an outstanding performer over the past year.  Regeneron suffered this blow following a regulatory obstacle, as is often the case in the biotech industry (more on that below).  Do these developments represent an excellent opportunity to buy Regeneron's shares on the dip?",https://finnhub.io/api/news?id=85dbf08237931c6869144f9a8282ea8ea06c3eed9615e3e786417b32644544d4
company,2023-07-07 06:15:03,4D Molecular Therapeutics: A Complicated Story,121254342,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326625612/image_1326625612.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"Shares of 4D Molecular Therapeutics, Inc. have more or less hovered near $20 since positive 4D-150 data in November 2022. Read more about FDMT stock here.",https://finnhub.io/api/news?id=113f63a18dcbaf1671765b0742c5cbf760bf9fdbec536524d57545e912f6626d
company,2023-07-07 01:46:19,"REGN FRAUD ALERT : Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws",121251632,,REGN,Finnhub,"NEW YORK, July 7, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Regeneron...",https://finnhub.io/api/news?id=71c02e235b8cd1fc666dcf6a8290c5a0546c7eaa4806af27d675a92a5cd91fc6
company,2023-07-07 01:07:59,"Regeneron: Eylea Hype Past, But '23 H2 Will Be A Gut Check",121251395,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1393953279/image_1393953279.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"Regeneron's stock price has suffered a setback due to concerns over the future of Eylea, its flagship drug, as competition and potential drug pricing regulations loom. Read more here.",https://finnhub.io/api/news?id=c45f69c1f36a4b616658c7a91a649776cc01ad28dd7afa989398370ba53f36f6
company,2023-07-06 13:42:24,Cantor Fitzgerald Maintains Regeneron Pharmaceuticals (REGN) Neutral Recommendation,121238854,,REGN,Fintel,,https://finnhub.io/api/news?id=472df494c4551471b6f7ff2e1ce93cecc9a1789bfa294080b93b787c9117e421
company,2023-07-06 12:43:00,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,121278526,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slid 1.81% to $704.83 Thursday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=014925fe8745552b8f4465e099bdf66087e3134ff507cfbc8a522a663d973c43
company,2023-07-06 07:50:00,Is Regeneron's Stock in Trouble After This FDA Rejection?,121235589,,REGN,Yahoo,"The company's growth rate has been slowing sharply in recent quarters, and Eylea generates the bulk of its product revenue.",https://finnhub.io/api/news?id=554c2680ed1e778fce8dc5ec4802ee583792cc311793ac04c058317f07e1afb1
company,2023-07-06 03:47:00,Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday,121236614,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0a410d0304683f72a9990404eb0096e20c9a6a04823ce6c1700286f55088ec18
company,2023-07-06 01:46:20,"INVESTIGATION ALERT : The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ",121228271,,REGN,Finnhub,"NEW YORK, July 6, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc.:
The investigation focuses on whether the Company issued...",https://finnhub.io/api/news?id=e750fcca4e950e7daf3740f41165f329ca73b83454e87b79ecd220c7ea535dbc
company,2023-07-13 12:44:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market",121435015,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.36% higher to $720.98 Thursday, on what proved to be an all-around great trading session for the stock...",https://finnhub.io/api/news?id=e1e405c57de065e5642d2791f347b89c9c474d1fc07e5a1cc50a2a77082deec9
company,2023-07-13 09:00:05,How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings,121361006,https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9,REGN,Yahoo,Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.,https://finnhub.io/api/news?id=cb781ffc4aab5bfc60fd2473daf4d8c10bbf5c724629fdd03926a77f3bec2070
company,2023-07-13 04:25:00,3 Pharma Stocks That AI is Loving in July,121384827,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=185fc356a85fb1b11af77ffe5df9cf7b2c435995b9746e6ca4cf2aaa5d02bbf2
company,2023-07-13 02:32:00,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Regeneron (REGN),121361870,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7458b51d8932dbface52b89cec0c7d67e1d56eb6f4e031a24f8b0914dafe46bc
company,2023-07-13 01:46:18,"REGN Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc.",121358119,,REGN,Finnhub,"NEW YORK, July 13, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc.   concerning possible violations of federal...",https://finnhub.io/api/news?id=54fd4fe56edb7aa05bdd6d25cadcefdff142d1a30cd2859a9045d9dc31339b7c
company,2023-07-12 12:43:00,"Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market",121354411,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.22% higher to $718.42 Wednesday, on what proved to be an all-around great trading session for the stock...",https://finnhub.io/api/news?id=91236ed6749a07474862aa595aa72c492c6004cf0a556e1e7b72c80e85df8826
company,2023-07-12 09:03:04,"Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN",121336528,,REGN,Finnhub,"NEW YORK, July 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc.  . Such investors are advised to contact Robert S....",https://finnhub.io/api/news?id=b91666613c328514c32d55f18da64331a4b2ce70ff9b60750283abac0dc6a0c2
company,2023-07-12 08:00:25,"Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 33% Discount?",121335352,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Key Insights Using the 2 Stage Free Cash Flow to Equity, Regeneron Pharmaceuticals fair value estimate is US$1,073...",https://finnhub.io/api/news?id=a2ca3b8e91745f074e059fd4a4dc9ec69499f72418c95dc4770d4cb8bded95ec
company,2023-07-12 01:46:17,"INVESTIGATION ALERT : The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ",121330110,,REGN,Finnhub,"NEW YORK, July 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc.:
The investigation focuses on whether the Company issued...",https://finnhub.io/api/news?id=50fb5456a037248dd9f0cb44fec083c91aed0f49e4909d741b1214f2cb35f6a5
company,2023-07-11 20:53:33,Why These 7 Stocks Are the Best Ways to Play Biotech Right Now,121438717,https://media.zenfs.com/en/investorplace_417/155568656c3c7c82033d9d467e5e2a90,REGN,Yahoo,"Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors. You must conduct your own due diligence. However, as a narrative, the biotechnology industry stands at the forefront of humanitarian innovation. The space has never been more important than it is right now. From the strictly financial view of investing in biotech stocks, the underlyi",https://finnhub.io/api/news?id=cdeb09d64f85e311d33509ca8065509349bb10e52be57e0102a3e86e26194a1e
company,2023-07-11 12:43:00,"Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market",121354412,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.92% to $716.83 Tuesday, on what proved to be an all-around great trading session for the stock market,...",https://finnhub.io/api/news?id=f5ef6a358b73fe6ad8de377ce37effefe494494623a8fa502fff9cf17287a2fe
company,2023-07-11 11:40:14,Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation,121312804,,REGN,Fintel,,https://finnhub.io/api/news?id=b27563765d0b82acf4df8802108f8a711f05bca568c83ecac9e8d1b320757dd2
company,2023-07-11 03:16:00,"Regeneron 483 issues might not require reinspection, says Morgan Stanley",121312014,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5d8b835d603997e18cd70191b97bcbf3cb80cd81f4226c6e14a7bddadae1efdd
company,2023-07-11 01:46:23,"REGN NEWS : The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc.",121305987,,REGN,Finnhub,"NEW YORK, July 11, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Regeneron Pharmaceuticals, Inc.   violated federal securities laws.
CURRENT...",https://finnhub.io/api/news?id=804222a46385e0d744dbdfc6a05362a3b05de978a70e2e58871afe42f13e7291
company,2023-07-10 23:02:00,$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today,121347947,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fb9304a7c179c8267cc07317ec4bf53760c8863140f460fd05b86ab2212ac63d
company,2023-07-10 12:44:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,121354413,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 1.58% to $703.36 Monday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=63dcb08699d1f762b63004b70b6ca45c5dd0702f7f94f3f44b3761af04bd4d55
company,2023-07-10 04:51:00,"Analysts Conflicted on These Healthcare Names: Pacira Pharmaceuticals (PCRX), Regeneron (REGN) and Thermo Fisher (TMO)",121316623,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1750d4f8c3fcae0ad66c0bf091e12052d123aa40cf2fa808c58de4c6a800bc37
company,2023-07-10 01:46:20,"REGN ALERT : The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws",121289199,,REGN,Finnhub,"NEW YORK, July 10, 2023 /PRNewswire/ -- Attention Regeneron Pharmaceuticals, Inc.   shareholders:
The Law Offices of Vincent Wong announce that an investigation has commenced into Regeneron and...",https://finnhub.io/api/news?id=3f5075b49c0b3a53c5e2d96325868187a45321f6603506cc8289cb5d7091e5e7
company,2023-07-17 12:45:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,121435013,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.43% higher to $721.61 Monday, on what proved to be an all-around great trading session for the stock...",https://finnhub.io/api/news?id=dd01b5afc2ff2e2071e6ba3c1810031e92aa179095f6d930cda888acbd3d4d12
company,2023-07-17 04:43:00,Regeneron price target lowered to $900 from $935 at Guggenheim,121436062,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=adb04f664c23a791c88e623aaadbfa9367baf4d6c26e5df727ee10c2f69f18c3
company,2023-07-17 01:46:18,"REGN ALERT : The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws",121421360,,REGN,Finnhub,"NEW YORK, July 17, 2023 /PRNewswire/ -- Attention Regeneron Pharmaceuticals, Inc.   shareholders:
The Law Offices of Vincent Wong announce that an investigation has commenced into Regeneron and...",https://finnhub.io/api/news?id=2d92f4b6eb48ed081279fc0bbb0c29f515ab26516bae73d9627462f3f2c44b29
company,2023-07-17 00:13:00,Alnylam announces updated interim results from ALN-APP study,121436064,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a1dcdd3571e9b4d1d44acdde06cd22c6e4046cd5922745228e76e655667400f8
company,2023-07-16 22:49:00,This Is What Whales Are Betting On Regeneron Pharmaceuticals,121436066,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=97fd6a657cf8c18a5d1482299679ad4270b008ca40a5005e26ad057bf717fb2d
company,2023-07-16 07:01:00,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",121414757,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c2c9a2ea7de3c0791fb606978f40b1cc363b868fac7a37d1f4210a3e4e826e6f
company,2023-07-15 08:19:00,Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront,121417188,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9a810e6ffe06d53e565310656ad6fc432f1bef1c6a3fdab88de992a704ab0505
company,2023-07-14 12:43:00,Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors,121435014,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 0.34% to $718.52 Friday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=330383c2772f89ce651902112adbcd15222b6bf70e2a821ac9ad94dc7ea9115e
company,2023-07-14 12:10:11,Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?,121400794,https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c,REGN,Yahoo,Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://finnhub.io/api/news?id=96133de14554dcc8d349e78024df04ac7b087d2f3ae06b7f77d0a65b7ac4a975
company,2023-07-14 01:46:30,"REGN FRAUD ALERT : Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws",121380220,,REGN,Finnhub,"NEW YORK, July 14, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Regeneron...",https://finnhub.io/api/news?id=c2c26e23166d4031f6be445f4bc30b4b99ef5982d326958625bf7e74e233f135
company,2023-07-13 21:24:24,3 Pharma Stocks That AI is Loving in July,121489121,https://media.zenfs.com/en/investorplace_417/5b06085ec403fd81519de4f4d5892664,REGN,Yahoo,"When it comes to investing in pharmaceutical stocks, an intriguing area for future growth is gene editing. This is an exciting field that may provide a solution to some of our most vexing diseases, such as cancer and diabetes. And in 2023, many companies are closer than ever to a solution. So, although I know that’s not how it works, it was interesting that when ChatGPT gave me a list of pharmaceutical stocks, it included several which have partnerships with gene editing companies. It’s importan",https://finnhub.io/api/news?id=d3c9274bb18dc0577045a9514b68ddeb1dcc257cc5d49b010c967c8b4565db98
company,2023-07-20 23:45:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,121549375,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1761f96268a8b1da05d3e433d1a0e56a100fc22f4a6a80176e57482938d8e498
company,2023-07-19 23:45:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market",121514870,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=41fb36438e193c6e64c8bef5a953c075d2cb9b6c57fe4bf00e95726c7f71abe5
company,2023-07-18 23:45:00,Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors,121482484,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ef41b8aa0d98bf83b8093d618c9d059e6749db4a67e9dd309765d9e1c63531a9
company,2023-07-18 08:00:11,Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet?,121451089,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...",https://finnhub.io/api/news?id=06af2b1a5089b58d4ab34f9b43c0b5905d8aa2c1baa1a1e139a844f1921e3cb1
company,2023-07-18 02:08:00,"Regeneron price target lowered to $960 from $1,040 at BMO Capital",121482485,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2a960ac865d69659a388c88444206e4e3340487a6fbad2a5cb89dfdff50d2bf5
company,2023-07-18 01:20:33,Guggenheim Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation,121440624,,REGN,Fintel,,https://finnhub.io/api/news?id=a8c53a3929d8f5742a0cf5a610ac42d8b515365dad1b3fc688b63a3fe848ff97
company,2023-07-17 23:45:00,"Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",121482486,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c7d4c814d268a1cb7e3fe6b5014e75b1ee21f2ad02941078a177c016a7db4018
company,2023-07-25 12:44:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,121744472,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.38% higher to $729.88 Tuesday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=47e301a617e816a2d36cd3f7513aa51006655c75fb9b8f674f2be2397b1b8742
company,2023-07-24 06:05:00,Kodiak Sciences Plumb New Lows After Tarcocimab Failure >KOD,121744473,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Colin Kellaher Kodiak Sciences shares lost more than half of their value and hit a new all-time low Monday after the biopharmaceutical company said it was...,https://finnhub.io/api/news?id=14bd1a85df0b3f821a97cad041d6b795b99a0b898d20d618c1e6fc7010cb8535
company,2023-07-24 02:33:00,Kodiak drops eye disease candidate after Phase 3 setback,121570854,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2021987acea2a527c1dac619629fb68b8b777d82c6d5c129407164328668053e
company,2023-07-24 00:58:00,The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023,121578306,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=052a4792d861fb45e0f5c82a8a9c4b7d7744fc8a618276a95913ede5cf821875
company,2023-07-23 23:45:00,Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors,121570855,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0c6ee98d0891cac7f8d46a9f5d4f20545b01ecfeef0b1154ed851feed67e1ff7
company,2023-07-23 22:54:50,Kodiak Sciences: Navigating Clinical Trials And A Competitive Landscape,121561975,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1457686878/image_1457686878.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"Kodiak Sciences shows improved financial performance in Q1 2023, and it's developing treatments for prevalent retinal diseases. See why KOD stock is a Hold.",https://finnhub.io/api/news?id=bb44f0bb3f62bc923d036da19cce7f33dd1a58792779a59c53a71aab8dce45bc
company,2023-07-22 10:00:19,"Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?",121548364,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...",https://finnhub.io/api/news?id=b2dfcc3c86a85bc64e64d179e84bc36bcddc2af39079561b31cf2bf4bca14c4e
company,2023-07-29 14:25:00,Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS,121695690,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements At two years, 44% of patients met the criteria for ≥20-week dosing intervals, including 27% who were eligible for 24-week dosing intervals TARRYTOWN, N.Y., July 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results fro",https://finnhub.io/api/news?id=530cc556df939c774f37a1fc8d29c58a9e9ee3862d1dbde5d32088757458e2a4
company,2023-07-28 12:44:00,"Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market",121744469,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.19% higher to $746.10 Friday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=05881513211763a8d639891bf011d1747c411f6bf47deaf5071814862468c41a
company,2023-07-28 12:42:00,Regeneron (REGN) to Report Q2 Earnings: What's in Store?,121673455,https://media.zenfs.com/en/zacks.com/f8d575a0c115026ceb0bf92a9861fa02,REGN,Yahoo,Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.,https://finnhub.io/api/news?id=d6de96bf5dc3fe06c5e0e81be11b30b16f83204fa99aa1d1835408dac09f8bd4
company,2023-07-28 08:00:35,Those who invested in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago are up 88%,121665965,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking...,https://finnhub.io/api/news?id=7c2a0e4a812c08ed81f7c032410e9938444afd97870eca47e6497578cee8897b
company,2023-07-28 07:20:00,P/E Ratio Insights for Regeneron Pharmaceuticals,121678734,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=468cd8c866383085f6502819c289da53eb2da45cdc3309139e02355d2bbf9e85
company,2023-07-28 02:46:00,BMO Capital Remains a Buy on Regeneron (REGN),121678735,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ac537a0b4988f3ef6aece3e55578d57373b2f563d3b7352cc72d61cec5431279
company,2023-07-28 00:21:00,"Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), HCA Healthcare (HCA) and Regeneron (REGN)",121678633,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=47c797cebed9df44fe216248efd614f65f39cb99b3e8e5f9b3c69da2517374ca
company,2023-07-27 12:44:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market",121744470,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. advanced 1.87% to $744.66 Thursday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=a0a2ef0a11c0ab761cb6d255aca5acac5937fd89a0d66809c7bdbc8e20f296f5
company,2023-07-27 06:57:33,Kiniksa Pharmaceuticals: Arcalyst's Growth Picks Up,121621815,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1315542570/image_1315542570.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Kiniksa delivered excellent Q2 results that put it in an even better position to deliver long-term growth. Read why I'm bullish on KNSA stock.,https://finnhub.io/api/news?id=39f1a7a2283aa7d8061a20d08a8c44f0382f59ff62297d6c8e9ebf144e98de77
company,2023-07-27 06:00:00,"Roche's 1H Earnings Decline On Lower COVID-19 Sales, CFO Says Late-Stage Pipeline Has Gaps That Needs To Be Filled",121640061,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=75a964dad9d816ac937dc5fe17ec3c9f17060f735f7d549ceac3519f8a10fbd5
company,2023-07-26 19:18:28,Intellia Therapeutics: The Future Is Here,121609253,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345032460/image_1345032460.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. Read why NTLA stock is a Buy.",https://finnhub.io/api/news?id=0a233300f6709ff47b8f0e3829051feb44491f27443462e7cd20861fbed092c5
company,2023-07-26 13:23:00,"If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names",121740490,https://media.zenfs.com/en/investorplace_417/180ce84be58b62c67d477717f09599bb,REGN,Yahoo,"The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is crucial to know the best biotech stocks that can give you great returns. In this article, I’m going to introduce you to three companies that are making waves in this field and are pioneering stocks in biotech. They are making a difference and deserve to be on your radar! Best Biotech Stocks: Regeneron (REGN) Sou",https://finnhub.io/api/news?id=3320563637d26743716986be9315eabb7ae409ffb9c2e77a1623c293892a653d
company,2023-07-26 12:44:00,"Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market",121744471,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.15% higher to $730.96 Wednesday, on what proved to be an all-around mixed trading session for the stock...",https://finnhub.io/api/news?id=8c237864b94ed6a34b043b411a367a14f176c9821a2de8d6e43799f4037b2677
company,2023-07-26 05:29:00,Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List,121625763,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3193c0e63cfc62b06254d23f18aa1339a2f3e4affd2c2d9b4b102e321f538a70
company,2023-07-25 22:11:00,Weight loss drugs excluded from WHO’s 'essential' medicines list,121625764,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=56c44485a21a038f1214c3672ba26eee2bd9659cf0046778370a1a4d9db57dcb
company,2023-08-02 12:16:00,NEW YORK MARKET CLOSE: Fitch downgrade sparks retreat on Wall Street,121777978,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1034a31a077a171ee7839d0e28122aa1d9291970576e92a858268afe8da68106
company,2023-08-02 08:39:00,Notable companies reporting before tomorrow's open,121774120,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=782ba036420724101d3274c64da3caa7035e58e08f0a1c80fe5cde70567e5d3c
company,2023-08-02 08:09:00,Regeneron Pharmaceuticals Earnings Preview,121781676,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9d2b97878bae3d8356b878bd8506be8a7a22d75d2fd29efcb77d826474f37df7
company,2023-08-02 07:05:00,Regeneron Pharmaceuticals Q2 2023 Earnings Preview,121781678,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fe9ded0074944d2c1a1472cfad0739aa45657028aec6b3d3c7cc54fefba8c8d9
company,2023-08-02 04:51:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Zimmer Biomet Holdings (ZBH), Regeneron (REGN) and Addus Homecare (ADUS)",121792147,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8b5e4d4ff5addc38ddcb60c708b87fcc3321517853935d1c66eabf084d90e7bd
company,2023-08-02 04:00:00,Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening,121763946,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1096163842/image_1096163842.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"Regeneron's shares decline as the company faces market delay for Eylea, allowing Roche's Vabysmo to gain ground. Click here to read my analysis of REGN stock.",https://finnhub.io/api/news?id=ecb772b4397fd927b230802d86c23c85dfcc141dde3e6ef05a6215a35f6c2a02
company,2023-08-01 23:47:00,Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day,121781681,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=695c1fe5a0fd1b7fedc6da17e56600b72ce23db0c6e455c68c174e79d457702d
company,2023-08-01 14:59:01,Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points,121878063,https://media.zenfs.com/en/investorplace_417/b65ecbd3cc97c34115d1ca93c78611f0,REGN,Yahoo,"The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%. Despite the massive amount of revenue being generated, most biotech companies remain small and medium-sized enterprises. Many of the companies operating in the space are start-ups. Yet they are performing cutting-edge research and developing life-saving innovations that are in high demand. This presents an opportunity fo",https://finnhub.io/api/news?id=c105937fcc560d724aa85e8cd4194f96e95e1d05251f6a5ec0535fe595fbb268
company,2023-08-01 07:37:00,"If You Invested $1000 In This Stock 20 Years Ago, You Would Have $58,000 Today",121750176,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e61b03c1531fb12a4c9a46cc5bbc96a6bf9d80e46dba9ee7a12d63f01dffc191
company,2023-08-01 07:00:00,Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation,121733465,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"TARRYTOWN, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 11th annual Regeneron Prize for Creative Innovation, a competition designed to honor exceptional talent and originality in biomedical research. Each year, Regeneron invites the nation’s top research universities to nominate up-and-coming postdoctoral fellows and graduate students to pitch their ""dream projects"" within the field of biomedical science. Applicants out",https://finnhub.io/api/news?id=89f741d9ecee2fd08ca5c4b538074af298fadbaebe18aa93bb7b6991a6709973
company,2023-07-31 23:45:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market",121750178,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=07333cb58fba73729b6046a9677b8de596b1e0e3f707052e9108cbf93a968ce6
company,2023-07-31 12:43:00,"Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market",121744468,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 0.56% to $741.91 Monday, on what proved to be an all-around great trading session for the stock market, with...",https://finnhub.io/api/news?id=2fb7a58f53a62eea1b7398b85ee89c9ba2b1f8251dab22c3bf9f5f1afab5282d
company,2023-07-31 06:42:13,"REGENERON PHARMACEUTICALS, INC. - AFLIBERCEPT 8 MG TWO-YEAR RESULTS FROM PIVOTAL PHOTON TRIAL IN DIABETIC MACULAR EDEMA PRESENTED AT ASRS",121713379,,REGN,Finnhub,"TARRYTOWN - Regeneron Pharmaceuticals, Inc.  today announced the first presentation of positive two-year  results from the pivotal PHOTON trial investigating aflibercept 8 mg with 12- and 16-week...",https://finnhub.io/api/news?id=5e0baacdf330f6f6dcf072d9c3ba1dba16cbd42784a4a4bbcd3d14917ec018fc
company,2023-07-31 04:44:00,"Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema",121723548,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e50e77c3f50747e452eb6e734a37562d6af7f696a376803a605db3e906c782c4
company,2023-07-30 02:11:00,Regeneron presents aflibercept 8 mg two-year results from pivotal PHOTON trial,121703748,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8a1b076c7bbd6263415d045212b9df7328d8d812882f61aedc525b5fdcc8d773
company,2023-08-06 09:00:00,2 Top Stocks to Buy in August and Hold Forever,121859809,,REGN,Yahoo,"Technological progress sometimes renders products or entire industries completely obsolete.  With that said, let's look at two healthcare stocks with solid track records of innovation and are worth buying and holding onto for good: Regeneron (NASDAQ: REGN) and Abbott Laboratories (NYSE: ABT).  Biotech giant Regeneron has outperformed the market over the past year, partly thanks to the company's excellent financial results and prospects.",https://finnhub.io/api/news?id=665b355de7045c5dd8eb2e4e8d772efd81021d27c5438bcd78f8e6d95763a721
company,2023-08-05 01:19:40,Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation,121843676,,REGN,Fintel,,https://finnhub.io/api/news?id=0e6308a3c3b7b0e181fdbef264c6b3f8809f67217e1051197ddc2e767e419394
company,2023-08-05 01:19:30,RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation,121843677,,REGN,Fintel,,https://finnhub.io/api/news?id=0ffee4250c53ce9f0c006bd52f7a45a5ccc08a61f3a86be994272b8758ba766b
company,2023-08-04 15:35:59,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2023 Earnings Call Transcript",121832124,https://media.zenfs.com/en/insidermonkey.com/a6725463d5739606c11f523b1bed2c78,REGN,Yahoo,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2023 Earnings Call Transcript August 3, 2023 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $10.24, expectations were $9.92. Operator: Welcome to the Regeneron Pharmaceuticals Second Quarter 2023 Earnings Conference Call. My name is Shannon and I will be your operator for today’s call. At this time, all participants […]",https://finnhub.io/api/news?id=9c7fdaef1c5da240354733871ca5aed705dc7e35396f45d624bc5208e7e5b155
company,2023-08-04 11:59:01,Oppenheimer Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation,121826834,,REGN,Fintel,,https://finnhub.io/api/news?id=ee27c26d407ff86803a6266c315e5d71ab389228cbc09b056c249846ddac8714
company,2023-08-04 07:47:00,(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest,121849992,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=127b46fb4c85575a38bdd6620e9c922c1b057ef22b0a7c0c8bb85dffe08b9ea4
company,2023-08-04 04:29:00,Regeneron halts enrollment in prostate cancer trial following two deaths,121823702,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=63440b95b2dfefd77be690d587ec2fb962ef5a5855339f3256f4265c761b0c81
company,2023-08-04 02:46:00,BMO Capital Gives a Buy Rating to Regeneron (REGN),121823703,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dab97ff3fb1631c20249023df4058f640de3bd099474f3277bad18078f4a4826
company,2023-08-04 01:58:00,Regeneron price target raised to $950 from $900 at Oppenheimer,121823704,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e5ea107c42fa736365660b36e3bd18ee7d6fd90bc6a3ffada7e4756f90b26f8e
company,2023-08-03 23:45:00,Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors,121849993,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2aa61bce7a2c6e976182b58bf06bed698933fd99e0e336743df5e8f327a2ffb3
company,2023-08-03 22:32:00,"Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Zimmer Biomet Holdings (ZBH) and Regeneron (REGN)",121823705,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ef2a3776461dcaf9fee43fbe79163d922b4801e129e87fbe369b37e6fd516e8f
company,2023-08-03 17:58:00,S&P 500 Gains and Losses Today: Stocks Fall After Weaker-Than-Expected Earnings Reports,121805924,https://s.yimg.com/ny/api/res/1.2/1ZFrWuhJvWG7VVGRGH_RFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xMDcy/https://media.zenfs.com/en/investopedia.com/a6563b4713cd2c7749580112b759d123,REGN,Yahoo,"The S&P 500 fell 0.3% on Thursday, Aug. 3, 2023 after weaker-than-expected earnings reports from ecommerce, travel, and chip companies weighed on the index.",https://finnhub.io/api/news?id=e33fd11952e6b5cfec95e1d108b60e487c2e7ef8894e588eddf349d6df5c57e3
company,2023-08-03 16:16:12,Regeneron Shares Jump After Saying It Expects an FDA Decision on Its Eye Treatment Soon,121808274,https://s.yimg.com/ny/api/res/1.2/9fjBWi6hjV1CqdubkQwKig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/investopedia.com/f3992222b1e6e63f5d9917d909aed99e,REGN,Yahoo,Shares of Regeneron jumped after the drug maker indicated it expects the FDA will soon approve a higher-dose version of its blockbuster drug to treat macular degeneration.,https://finnhub.io/api/news?id=b20d3ef1d918903f215c309477c6d68c07d48189022fde2a5aadf82f73df4ccb
company,2023-08-03 16:05:51,The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line,121808275,https://media.zenfs.com/en/ibd.com/b727993c80cd23c03b1f42c9321ae4f1,REGN,Yahoo,"Regeneron guided to a faster-than-expected approval timeline for a high dose of its eye drug Eylea on Thursday, and REGN stock jumped.",https://finnhub.io/api/news?id=2fc834832dc17f86fdff2e686383a8647eaef4acf03809714edb103c05ac9484
company,2023-08-03 12:53:00,"Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline",121803169,https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3,REGN,Yahoo,"Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.",https://finnhub.io/api/news?id=33a5d985df38f07ff0b0a93fc234b4df9af5181552684505f3006b26a898a907
company,2023-08-03 12:33:14,Is Regeneron Pharmaceuticals (REGN) Modestly Overvalued?,121808277,https://media.zenfs.com/en/us.finance.gurufocus/dc73c8f319e6cba31421afcf599addd7,REGN,Yahoo,"Regeneron Pharmaceuticals Inc (NASDAQ:REGN) witnessed a 6.4% gain, with an Earnings Per Share (EPS) of 36.8.  This article provides a comprehensive valuation analysis of Regeneron Pharmaceuticals (NASDAQ:REGN).  Regeneron Pharmaceuticals discovers, develops, and commercializes products that combat eye disease, cardiovascular disease, cancer, and inflammation.",https://finnhub.io/api/news?id=a45bdc040dae122dc5cc99636879f3abe7e3640187f70feb35748f9cf13da7ab
company,2023-08-03 09:30:45,Regeneron (REGN) Reports Q2 Earnings: What Key Metrics Have to Say,121808278,https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f,REGN,Yahoo,"Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",https://finnhub.io/api/news?id=33c1c9bb77d2dd249436aa809feee315cabbae8851790d6ed6d84ca69b720fe8
company,2023-08-03 08:23:03,Regeneron Pharmaceuticals Inc. (REGN) Q2 2023 Earnings Call Transcript,121792607,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,REGN,SeekingAlpha,"Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor RelationsLeonard...",https://finnhub.io/api/news?id=09bd50eb0e633dfd28ac722e7fa7d7242e872c3620127bae2a6aaaf35d88cffe
company,2023-08-03 08:10:00,Replimmune down 8% on skin cancer cancer candidate data delay,121801211,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=59aff51416bd3ba850aeb10e548e657323a31096ebcfcd7d4783ba45b53cf90d
company,2023-08-03 07:59:00,Regeneron Pharmaceuticals Inc: A Biotech Powerhouse with High Outperformance Potential,121800711,,REGN,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=00e34fa766edd10e23d68516b4ba854e3386a8a1ebd38c596b2bd79422064528
company,2023-08-03 07:45:12,Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates,121808279,https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a,REGN,Yahoo,"Regeneron (REGN) delivered earnings and revenue surprises of 3.23% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=c5b9efb5ab5e4622d47178cfa02783f8e7813c0229cb6c9012fe5924da6e6ffa
company,2023-08-03 06:37:22,Regeneron expects FDA decision on higher-dose Eylea this year,121808280,https://media.zenfs.com/en/reuters.com/793eba3d91efbf9dfd37aae3f7043469,REGN,Yahoo,"(Reuters) -Regeneron Pharmaceuticals expects a U.S. decision on a higher-dose version of its blockbuster eye disease drug Eylea in the third quarter, much earlier than market expectations, sending its shares up 5% on Thursday.  The U.S. Food and Drug Administration declined to approve the higher-dose version in June following an inspection at third-party manufacturer Catalent.  Regeneron said it has been submitting manufacturing data required by the FDA on a rolling basis, and expects to finish the submissions by mid-August.",https://finnhub.io/api/news?id=a75d187aca41a343e1ca291b68cff17cd937cf03a20215b585ae735f5423a81a
company,2023-08-03 06:30:00,Regeneron Reports Second Quarter 2023 Financial and Operating Results,121808281,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022Second quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 33% to $2.79 billion versus second quarter 2022Second quarter 2023 EYLEA® U.S. net sales were $1.50 billionSecond quarter 2023 GAAP diluted EPS of $8.50 and non-GAAP diluted EPS(a) of $10.24Two-year results reported for aflibercept 8 mg from pivotal PHOTON trial demonstrated durable vision gains at extended dosing intervals in diabeti,https://finnhub.io/api/news?id=02e0daa81c893efefe82ec0cd4951c246e49ba46851a1b9a086b3aa7cbc75569
company,2023-08-03 04:35:10,Regeneron Pharmaceuticals : August 2023 Corporate Presentation,121790577,,REGN,Finnhub,"Regeneron Corporate Presentation
        
      
      
        
          A u g u s t 2 0 2 3
        
      
      
        
          This non-promotional presentation...",https://finnhub.io/api/news?id=e852e4cc57f62e931de1f33f37193d41e6356e1d32ff4561d38a2ea7c3f59e6e
company,2023-08-03 04:11:00,"Regeneron’s stock rallies after profit, revenue rise above expectations, amid a jump in collaboration revenue",122294567,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. climbed 2.6% toward a 5-week high in premarket trading Thursday, after the biotechnology company reported...",https://finnhub.io/api/news?id=f8b29d8c251924370ae28ddeda3a145f877a17cecb93c2233501abaf9c23915a
company,2023-08-03 04:08:00,Fly Intel: Pre-market Movers,121792135,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8045f333a9f1aa63f9c2701c443ba6253a97050fc403c3f57bb11cc2534b13ec
company,2023-08-03 03:11:00,Regeneron Pharmaceuticals quarterly profit boosted by Dupixent,121792137,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=428010ebeb80485c1a63873ead703efbf1dd5c006b777ca6f5223d523258287d
company,2023-08-03 03:06:00,Regeneron gains after Q2 beat; FDA action on high-dose Eylea expected in Q3,121792138,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d2ea1a794057bb907f9d5dfd57d4b8cac34c6b02f6eef43bd03110e04fc3ba7a
company,2023-08-03 02:59:00,"Regeneron's stock rallies after profit, revenue rise above expectations, amid a jump in collaboration",121792139,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=585c5abe2212b5a7c1d44df01206dd60500a8182b72e942313c85e75729bc71e
company,2023-08-03 02:34:34,Regeneron Pharma beats quarterly profit estimates,121789652,,REGN,Finnhub,"Regeneron Pharmaceuticals Inc
beat Wall Street estimates for quarterly profit on Thursday,
driven by strong demand for eczema treatment Dupixent.
              The company reported adjusted profit of...",https://finnhub.io/api/news?id=71b28856c62b342e8b5c0b911dcdb23f2b26e566a74667542907c8d2e3c147ae
company,2023-08-03 02:03:00,"Earnings Scheduled For August 3, 2023",121792141,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=737b4a98d06671e3778c32d533c3f57ecd04b043c2a58df94dd60ed03fa849b5
company,2023-08-03 01:57:00,"US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month",121791830,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a69a25984d84eddb2a3c618822a5ee84d3886fb297a182644239b6d0d75e76e7
company,2023-08-03 01:51:00,"Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), Humana (HUM) and Regeneron (REGN)",121792063,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4cc91c0f5913924503d8e024836a1e7323065975d167bdad2f9ed8a7b81fb195
company,2023-08-03 01:38:00,"Regeneron Pharmaceuticals Non-GAAP EPS of $10.24 beats by $0.34, revenue of $3.16B beats by $140M",121792144,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=64cd913f7573cbc07fece5438b0eeda70b526c5ace9401ea972cc4c51650fbdd
company,2023-08-03 01:31:00,"Regeneron reports Q2 adjusted EPS $10.24, consensus $9.84",121792145,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f2ba1b1704258efbc9246ccedd785e2cb998ac5c47ca14984364a3e0a5409a51
company,2023-08-02 23:45:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market",121823709,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3378cedac34e22fbd87959a0f7c17a389cdb3c4afc90912db0fa5d8f933e083a
company,2023-08-02 21:00:00,"Stocks Mitigate Losses Ahead Of Apple, Amazon Earnings; Treasury Yields Rocket On Debt Frenzy: Thursday's Market Drivers",121794673,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=642841f6a54caf69dac834fcffd7f0ae103f0a8bc061191288125f462016e44f
company,2023-08-02 20:34:00,GLOBAL BRIEFING: China's services see strong growth in July,121791844,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dc1b26b1a1ed6bf21fdc67a8cf6d8c88dac6ec1224ceef2d099495af2fc8f1cd
company,2023-08-10 12:03:00,"Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies",121976214,,REGN,Yahoo,Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.,https://finnhub.io/api/news?id=c3227e401a405ed23cb0ea01ce5324b746cd80d8866615e3fb61010bcd7ef493
company,2023-08-10 09:58:00,IN BRIEF: Regeneron reports positive trial results for aflibercept,121968485,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=40fcea3cef40ab31d3e06a08f9d154bb2bc3ef2b7a03739f743953b8eddad3e3
company,2023-08-10 08:29:00,Baird downgrades Decibel to neutral to reflect Regeneron takeover,121962112,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a4653ffeb7784ddf85d90c9c49a8502091c1dfd163876fb414c65c2d124a204c
company,2023-08-10 07:34:00,Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years,121968490,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9264d974bb18f3c06ee5a92616db44c4fc49cad1217950e9650d2a265d466a89
company,2023-08-10 07:20:21,Bayer: eye drug shows vision gains in 70% of patients at higher dose,121951270,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Bayer said on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron, has been shown to achieve vision gains in more than 70% of patients when given at a higher dose at a longer interval between injections.  Eylea, which is normally given in doses of 2 milligrams every eight weeks, was given at 8 mg at intervals of up to 24 weeks, resulting in vision gains in more than 70% patients with wet age-related macular degeneration, the company said.",https://finnhub.io/api/news?id=a129ba8c2a2f88e995a0e6be398af3183357e0ab04076f859a4d74a27e28e18a
company,2023-08-10 07:00:00,Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration,121951272,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the end of two years 78% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals throughout the two-year study period 71% met the extension criteria for even longer dosing intervals, including 47% for ≥20-week intervals and 28% for 24-week intervals Visual gains and safety of aflibercept 8 mg remained consistent with the established profile of EYLEA® (aflibercept) 2 mg Injection TARRYTOWN, N.Y., Aug. 10, 202",https://finnhub.io/api/news?id=a91eee1232bd3879a64b6df487aca0946b7af421eb8f68f6b754f2e95cfdc219
company,2023-08-10 06:35:00,This Is What Whales Are Betting On Regeneron Pharmaceuticals,121968492,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d05e09a61c2998d5a869c302f97ffcab647a023d8600e718bc5ec4a2c146843a
company,2023-08-10 05:21:00,3 Top Biotech Stocks Defying the Bear Market,121948605,https://media.zenfs.com/en/motleyfool.com/dce7e2cf49f0fe9c427faecbf7208d98,REGN,Yahoo,"If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming.  The iShares Biotechnology ETF is down more than 3% so far in 2023, and the SPDR S&P Biotech EFT is down more than 5%.  The two ETFs reflect negative market sentiment toward biotech stocks, in general, this year.",https://finnhub.io/api/news?id=bc02d8fd34b650dec45e4add65eb9f9c0db81c610121b7ac4624001d0fcffb87
company,2023-08-10 04:16:00,The 7 Best Value Stocks to Buy in August,121986872,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5957d9cbc385b048874cf6bde4bb23f543fa5f4fcaf10342dd5030ac714ac826
company,2023-08-10 02:26:00,Regeneron announces PULSAR trial met its primary endpoint,121968497,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bbedc988b9ef767e3adb1183bcf91f88a8881b2a1439c76268f18c1f6124faad
company,2023-08-09 23:45:00,"Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market",121968499,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7b93010af0ded75a0e86ccedf8e879a6eda0633449be5a277e0cccc655b6f254
company,2023-08-09 13:56:36,Regeneron to buy Boston-based hearing loss biotech for $213M,121929964,https://media.zenfs.com/en/bizjournals.com/bd2a14c5a56771ac356df44d2fb10efe,REGN,Yahoo,"The Tarrytown, New York-based drugmaker has its sights set on Decibel Therapeutics, which develops gene therapies designed to treat various forms of hearing loss.",https://finnhub.io/api/news?id=afa6db32622e668b82a3246910511a76b9d3f6be46bd242234fdca321848a45e
company,2023-08-09 12:29:43,Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals,121929966,https://s.yimg.com/ny/api/res/1.2/T.8ymhMSqdDwJJE4KTuCMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/investopedia.com/9090ca62c7dcca4e8200788930d0bd05,REGN,Yahoo,Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene therapy pipeline.,https://finnhub.io/api/news?id=d1196f05d90ea7f25f3fa244789ee879d6ee8350909098b158ca549d7b3a360e
company,2023-08-09 07:30:00,"Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs",121920715,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel’s lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biot",https://finnhub.io/api/news?id=6d7cf45c267fb3fd5b5cec7e5b6e05e6508f00a6f0cf413d8cee8989117ba0cb
company,2023-08-09 07:05:00,What You Missed On Wall Street This Morning,121922859,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b31e95fb774e20607450cbcd05213b68380b163f6050e549885832b19587cb7e
company,2023-08-09 06:13:00,Health Care Company Regeneron Pharmaceuticals Announces Acquisition of Decibel Therapeutics,121928235,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b8e0a2fe0beb0118823ff2443904511218da033948d0bd7eb09afcdce6722b72
company,2023-08-09 05:04:00,Decibel Therapeutics Shares Surge on Regeneron Acquisition,122213416,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Dean Seal Shares of Decibel Therapeutics were markedly higher after the company signed a deal to be acquired by Regeneron Pharmaceuticals at a 43% premium...,https://finnhub.io/api/news?id=fd745fc1106300aa7aff358eb215e677da3bcb899590b80c0ae4fb973ae68e59
company,2023-08-09 05:02:00,Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal,121924303,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f8b8c27d3ac1df123a3a4b9ce9ff2cb23c5d3200e16a93858b4c82b156a0a7cf
company,2023-08-09 04:55:00,Decibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By Regeneron,121928245,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c83b95ac581a36de14f167914c89480449bfa5bcf25dcb390b29c2e5cb6a593e
company,2023-08-09 04:46:00,Regeneron to acquire Decibel Therapeutics for USD109 million,121928246,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8fd25cdd55902301a4da9bcbc306ac5436a8203667da663330cc194ae91f3212
company,2023-08-09 04:35:00,Decibel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright,121928248,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=05ea0848a7efdf6711ddbaf460b52feeb0c76cb2f575ec2902957e3ff9e4a509
company,2023-08-09 03:55:00,Decibel Therapeutics stock rallies as Regeneron moves to buy the biotech company,122213417,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,REGN,MarketWatch,Decibel Therapeutics Inc. stock was up 85% in premarket trades on Wednesday after Regeneron Pharmaceuticals Inc. said it would pay $4 a share for the...,https://finnhub.io/api/news?id=09ed0cbcdff9da4751f56e110ad74c3de717634f51c5b7ddc753ae2cb02d14a0
company,2023-08-09 03:44:00,Regeneron To Acquire Decibel Therapeutics,122213419,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,"By Dean Seal Regeneron Pharmaceuticals agreed to acquire Decibel Therapeutics for $4 a share, marking a 43% premium from yesterday's closing price. The...",https://finnhub.io/api/news?id=af5cb38111352f222d6094bc45b817de4ec2d8dc8662050ad707d223882aa514
company,2023-08-09 03:12:00,Regeneron to acquire gene therapy developer Decibel for $4 per share,121928254,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2661a24caf2717d7dcebfd8743c69c0254679abaa81424a7d7198e7a79d91b19
company,2023-08-09 02:57:00,Regeneron buying small cap Decibel Therapeutics for $4 a share,121928255,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5d3ccc2d67319618ff435bb5e83359cb50c02acd85bcb11bf0ec491edc270da7
company,2023-08-09 02:36:00,Regeneron to acquire Decibel Therapeutics for $4.00 per share plus CVR,121928256,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a1f7ea84710dba8c43a24c92e42878c9a3acf0eff647aeef1e0f1f36a300268d
company,2023-08-08 23:45:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,121934592,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2980a6e30ade72b7a488ff06352546bbd447fbcaf4330dfdf3e516a9755200e6
company,2023-08-08 23:31:00,What You Missed On Wall Street On Wednesday,121934108,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5e3c6f5e53c33c772acd953834a82a3adc1898e8d6f0f73c1e3fc37efcf97aea
company,2023-08-08 08:47:00,Cantor biotech/biopharma analysts to hold analyst/industry conference call,121900337,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=79140e544bc403ebfbbc7733f8b0d14d250387a0065144d6548d2cde610e3aff
company,2023-08-08 07:19:00,"Stifel, Guggenheim, Jefferies, Wedbush start Apogee Therapeutics at buy",121900094,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=47c9bf0857ea0c389dea1c311fb050e19e1f968ce3a2888a9eacc2fd4c6a90ef
company,2023-08-08 05:31:00,"Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Stryker (SYK) and Regeneron (REGN)",121923852,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1cdfaf503a0a81be308757ae114c201ab4d54589d48d0d719eb9a6eb512b4066
company,2023-08-07 22:09:00,3 AI Stocks You’ll Regret Not Buying Soon,121902922,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c625a9a67d89c1bdc5e91228de187e639246dce3ce8103db75af00895f7c774e
company,2023-08-07 14:53:56,Barclays Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation,121877113,,REGN,Fintel,,https://finnhub.io/api/news?id=03fbca8408224cd961aa82624e951f4b3b0ab8fbf0bb7c7e2ca57346bee567bb
company,2023-08-07 02:55:00,GLOBAL BROKER RATINGS: Stifel likes ConvaTec; JPMorgan ups Rolls-Royce,121872085,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3c444339b4c530deb6a7436c170f52b98aa2fb2c228b0472dffaa46e3de5273c
company,2023-08-07 00:21:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Becton Dickinson (BDX) and Regeneron (REGN)",121872072,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f1879cdbc9243efc1f3a6adae3bc83272bb366f5a6a6885025b8855961db25c6
company,2023-08-14 08:48:00,This Is What Whales Are Betting On Regeneron Pharmaceuticals,122030855,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7502029502828a0557b93ec676b7b2301ce8d393cc0ceee644736d720c8356e4
company,2023-08-14 03:00:00,Second Half Outlook For Biotech Stocks,122020901,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1135352098/image_1135352098.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%. Click here to read my thoughts.",https://finnhub.io/api/news?id=a07177ca11c3822b3066921c2b90b02d4d96fa59771bca0c5129d11cb3fcb5ea
company,2023-08-13 23:44:00,"Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market",122030858,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=58b3873b00eff0ccdd94f1a3888b40afcfff2e6dcd4b2ba260ce4cefc8d96a4f
company,2023-08-12 21:03:00,Pharma under threat from bill to expand drug price negotiations,122015859,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ae3fd3db8e7f0ad5b0523b61d4f4a2fd43f7bb4e2050fb86e7c97316e9ec71cb
company,2023-08-12 04:43:12,4 big deal reports: Michael Kors parent rockets on huge buyout deal with Tapestry,122011836,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Here is your Pro Recap of 4 head-turning deal dispatches you may have missed this week: Deals at Capri-Tapestry, Decibel-Regeneron, Amazon in talks to potentially anchor Arm's IPO, and  Digital World Acquisition  and Trump Media & Technology Group reaffirm commitment to the merger.  Capri (NYSE:CPRI) shares rocketed more than 55% on Thursday after Tapestry (NYSE:TPR) said it agreed to buy Capri, the parent company of Michael Kors, for $57 per share in cash, as reported in real time on InvestingPro.",https://finnhub.io/api/news?id=d95bafe2f0159b5737064ebf9e0d3f04a7c6122daf52ec42c7e5610ca0816f5b
company,2023-08-11 10:34:00,"Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News",121984560,,REGN,Yahoo,Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.,https://finnhub.io/api/news?id=281d628bca455c573584f606f990eaf15c724f72f5521bd2819564eddb2fa5ac
company,2023-08-11 07:21:00,"Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Alcon (ALC) and Regeneron (REGN)",121985059,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e9c81f1c7ff222e666f422692ef7a0f5271b6a0f7ca357b5947127e7deda9795
company,2023-08-11 05:58:00,Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet,121983847,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=23e1a3933e701536be0e523038dc61b14fb07920fa4124d5dd168435b234238b
company,2023-08-10 23:45:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,122004492,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fcd7bf2334a4e9284fbae3570fec5bbd618e3624c728196b26c3362688f37f41
company,2023-08-10 21:15:18,The 7 Best Value Stocks to Buy in August,122078353,https://media.zenfs.com/en/investorplace_417/b65ecbd3cc97c34115d1ca93c78611f0,REGN,Yahoo,"While several market ideas have blossomed this year, many are overpriced, which naturally draws eyes to the best value stocks to buy. Here, we’re talking about publicly traded securities that trade at a lower price relative to fundamental metrics, most commonly sales or earnings. Obviously, value investing opportunities entice market participants due to their underlying discount. As humans, we’re geared to respond positively toward bargain offers. Essentially, by targeting must-buy value stocks,",https://finnhub.io/api/news?id=e0eae49e91e57f844ddbedcb444444030923b0b9165ca8a6fae32bacee8a2163
company,2023-08-18 19:55:10,UPDATE 2-US FDA approves higher dose of Regeneron's eye disease drug Eylea,122128461,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"The U.S. Food and Drug Administration approved a higher dose version of Regeneron Pharmaceuticals' drug Eylea for treatment of a disease that is a leading cause of blindness among the elderly, the company said in a statement on Friday.  The drug, Eylea HD, is priced at $2,625 per single-use vial in the U.S. and is used to treat patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy (DR), Regeneron said.  Eylea, which is jointly developed with Bayer, is normally given in doses of 2 milligrams every eight weeks.",https://finnhub.io/api/news?id=d3605f61a16e338eb94df0526d66d697c1b81e043f6ee2530b9efb0b546f99a1
company,2023-08-18 19:32:09,Is Regeneron Pharmaceuticals Inc (REGN) Modestly Overvalued?,122132656,https://media.zenfs.com/en/us.finance.gurufocus/dc73c8f319e6cba31421afcf599addd7,REGN,Yahoo,A Comprehensive Analysis of Regeneron Pharmaceuticals' Valuation,https://finnhub.io/api/news?id=deb6961ebccd75b1c67150aae6813f77403e9577fa16d2dcb575c9253152f78b
company,2023-08-18 18:35:00,"EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)",122128463,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment approved in wAMD and DME for immediate dosing at 8-week and up to 16-week intervals following three initial monthly doses TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administ",https://finnhub.io/api/news?id=9b21314717ae77ec2db6995b1c6427f7facb1546b369664cb257f4fbb1f5e36d
company,2023-08-18 15:55:10,US FDA approves higher dose of Regeneron's eye disease drug Eylea,122126023,,REGN,Finnhub,"The U.S. Food and Drug Administrationapproved a higher dose version of Regeneron Pharmaceuticals'drug Eylea for treatment of a disease that is a leadingcause of blindness among the elderly, the...",https://finnhub.io/api/news?id=ceb4f0477137688d89aca1639b9c79c8afef88470e2d8e32e161ce2156aa0868
company,2023-08-18 15:17:01,US FDA approves Regeneron's 8-mg dose of eye disease drug Eylea,122125053,,REGN,Finnhub,"The U.S. Food and Drug Administrationapproved the 8-mg dose of Regeneron Pharmaceuticals'eye disease drug Eylea, the company said in a statement onFriday.(Reporting by Jahnavi Nidumolu in...",https://finnhub.io/api/news?id=3e6a5cfa5f4786dcfbbeef94e1405f7f476fc70370a71bf20db03c9ab9164e82
company,2023-08-18 15:09:00,Regeneron Pharmaceuticals Gets FDA OK for High-Dose Eylea Eye Treatment,122290162,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,REGN,MarketWatch,By Will Feuer Regeneron Pharmaceuticals said the Food and Drug Administration has approved an eight-milligram injection of its Eylea treatment for various...,https://finnhub.io/api/news?id=bbc3e0487dc0814229fbf9e48f93d37a9b2cccd3011ecb4b92afa4aaadc008ea
company,2023-08-18 14:05:18,UPDATE 2-US FDA approves Regeneron's ultra-rare blood disease drug,122128464,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"Regeneron Pharmaceuticals said on Friday the U.S. health regulator approved its drug to treat a rare blood disease.  The drug pozelimab, branded as Veopoz, has been approved to treat adult and pediatric patients 1 year of age and older suffering from the CHAPLE disease.  Veopoz — the first treatment to be approved by the U.S. Food and Drug Administration (FDA) for the life-threatening disease — will be sold in the United States at a list price of $34,615.38 per single-use vial, the company told Reuters in an emailed response.",https://finnhub.io/api/news?id=c3f6e04b75c397ca621385e2497ba0a7c7ad3035990693386a192dec1f0b6257
company,2023-08-18 13:43:00,Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease,122116434,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms Approval represents 10th FDA-approved medicine invented by Regeneron With the approval of Veopoz, the pre-approval inspection issues related to the aflibercept 8 mg biologics license application (BLA) have been addressed FDA action on the aflibercept 8 mg BLA is expected in the next few weeks TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceutica",https://finnhub.io/api/news?id=0ecdf96a2c00b292adc5d44820b51cb561fb7468423c290b4290af184f686e12
company,2023-08-18 12:20:00,Regeneron's (REGN) Application for Blood Cancer Drug Accepted,122116436,https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9,REGN,Yahoo,Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.,https://finnhub.io/api/news?id=ecb0a2267c85c9652109adc293da6410d7ad4c00904788c51218138e825d2aaa
company,2023-08-18 10:27:02,"Regeneron Pharmaceuticals' Veopoz Gets FDA Approval for Adults, Children",122116681,,REGN,Finnhub,By Denny Jacob Regeneron Pharmaceuticals said the Food and Drug Administration approved Veopoz to treat patients aged 1 year old and up who have CHAPLE disease. The biotechnology company...,https://finnhub.io/api/news?id=1c14bcd060ea65e9d2280a1fb74cf6cdd1150560678954d6660b4993a62f988d
company,2023-08-18 10:11:00,Regeneron gets FDA green light on first treatment for life-threatening immune disease,122288865,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,REGN,MarketWatch,"Regeneron Pharmaceuticals Inc. said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease, a rare and...",https://finnhub.io/api/news?id=67a5f73fe27a19c8d89d1bd3c80f2f242b70b1631194754cb7f574942aae0c5c
company,2023-08-18 09:49:45,US FDA approves Regeneron's ultra-rare blood disease drug,122115783,,REGN,Finnhub,"The U.S. health regulator on Fridayapproved Regeneron Pharmaceuticals' drug to treat arare blood disease, the company said. The drug, Veopoz, is the first treatment to be approved...",https://finnhub.io/api/news?id=4fe7d7fbb176346c0b4202bb73a212d91df85d075f24e3f4f21333b73e134d27
company,2023-08-18 08:46:00,Regeneron announces FDA approval of Veopoz for Chaple disease,122137157,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bbd8af29be8a1fd04055fbc94f040bc8fe2897483cc247d416fe97fe589c1453
company,2023-08-18 08:17:00,"AARP, Public Citizen file briefs in Medicare drug price negotiations case",122115048,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=65b1feeea3b038ae68acf97d4a74d586677e9783c85e8c47de6ec53536bedd11
company,2023-08-18 06:02:44,"REGENERON PHARMACEUTICALS, INC. - ODRONEXTAMAB RECEIVES EMA FILING ACCEPTANCE FOR TREATMENT OF RELAPSED, REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA",122110677,,REGN,Finnhub,"TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for odronextamab to treat adult...",https://finnhub.io/api/news?id=bcca26d72689ea4db68d6459e1d45b7853dee382ffdcbe0c183d9c337fab7934
company,2023-08-18 04:13:00,Regeneron high-dose Eylea gains FDA approval,122136721,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2376388adcb2791b6993292bc136ac65d0309a3c748a7c325d6fae545733caee
company,2023-08-17 23:44:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,122137161,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3dc4179084e9afd8f5927dcf250908929916fa328f81d700c89562f52af77ba0
company,2023-08-17 22:05:00,"Catalyst watch: Nvidia earnings, Twilio event, AMC drama and Jackson Hole jitters",122118095,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1b0526df381d3b056d885ada66f81874d0db60d794784fa80e73aa4e702fd6d0
company,2023-08-17 21:31:00,RBC says Regeneron news intimates high-dose Eylea approval likely,122135276,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=567baae224b62963cad9b6d8d7e3a50f1c49be95beee8e530937e075002da7b4
company,2023-08-17 21:26:00,Regeneron wins approval for rare immune disease therapy pozelimab,122122500,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1ed5784f453c6df7b91cde13736f3d36ab843033f8cf0bb825afb49f423935db
company,2023-08-17 09:00:21,"Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 73% Above Its Share Price",122106546,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"Key Insights Regeneron Pharmaceuticals' estimated fair value is US$1,376 based on 2 Stage Free Cash Flow to Equity...",https://finnhub.io/api/news?id=8d32b5f6904e800935568f62262ca926386c8dc6d4c54cd0eea11f2382f12c81
company,2023-08-17 08:30:00,Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,122106547,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. The EMA previously granted odronextamab Orphan Drug Designation for",https://finnhub.io/api/news?id=42605be1eb706da29b0b8c43bcd2fd224ee27eab944c3c63bb6b266e617262ef
company,2023-08-17 08:12:00,Bronte Capital Amalthea Fund June 2023 Letter,122085686,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453639789/image_1453639789.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"The Amalthea fund shed 1.35% in June whereas the globally diverse MSCI ACWI (in $A) was up 2.57%. For the financial year the fund gained 14.75%, outpaced by the ACWIâs 20.78%.",https://finnhub.io/api/news?id=68061b06b210699f30f1e73c21c46c785ca3563f895601d3f5b90f519cc94532
company,2023-08-17 05:26:00,EMA accepts Regeneron's filing for odronextamab for lymphoma form,122090067,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=824ad339027d2a13776675188890bef4d9d68285e1a75b482a05d6842a1d11ea
company,2023-08-17 04:29:00,Regeneron lymphoma therapy accepted for EU review,122090069,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7b166c2efaedfe9adedb5faf36a49b3fad462a00b638dfe3ea2bce1cb70dce52
company,2023-08-17 04:07:00,"Thursday’s Top Wall Street Analyst Upgrades and Downgrades: Chevron, GE Healthcare, Keurig Dr Pepper, News Corp, Visa and More",122085085,,REGN,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=547960915af01e1160a71e8a1bc430eef57c33e35d3195adcbcf025504e93f1d
company,2023-08-17 03:36:00,Regeneron receives EMA filing acceptance for treatment of R/R FL,122090071,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f5d269bb8f60ca6f2d92141ccfd3dbfacaf88e3ff141c13a111ffdbf5e8c7198
company,2023-08-16 23:44:00,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,122113102,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c5d535ec5a0f16644928ae78f163040b8a6612197108d2d0334b9b0d08b9cf6d
company,2023-08-16 19:33:27,Truist Securities Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation,122075738,,REGN,Fintel,,https://finnhub.io/api/news?id=04f216b775f1e9106940f7e2c1dbca902d043268dadfef5070ea214394578a10
company,2023-08-16 07:45:00,Cantor biotech/biopharma analysts to hold analyst/industry conference call,122085287,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e1f5b90647975753ed9e1fcefc4956840cbed7f4fda38091204339148651065d
company,2023-08-15 23:44:00,"Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market",122090074,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=545203d58c299744d80850bb247a9e1f4550f6cc78589d54bcd08ece897883d4
company,2023-08-15 22:07:00,18 Analysts Have This to Say About Regeneron Pharmaceuticals,122090075,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=187a7b976ea462e5968138682b0b8f7b13c398511b3b2cbf4e2271b34c9035d3
company,2023-08-15 08:38:00,"$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today",122052496,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5e8ac892b0be7e35a594a8c4e1409e439d45b3bf4e7883608de071a476668020
company,2023-08-14 23:44:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market",122090076,,REGN,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1a93cf9b6384f2e30e5cf04dfe45bdd5cceeef03400093e89efa36e078464710
company,2023-08-14 22:46:00,Regeneron could see share price bounce with potential approvals,122052498,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4586b0a2096bf206c8f46abfaf0d588c59471eebdb0c1a941df2d652011001b9
company,2023-08-22 15:38:56,"UPDATE 1-US govt awards $1.4 bln for development of new COVID therapies, vaccines",122174216,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,REGN,Yahoo,"The U.S. government said on Tuesday it had awarded $1.4 billion for the development of new therapies and vaccines against COVID-19, including a $326 million contract with Regeneron Pharmaceuticals for a next-generation antibody therapy for prevention of infections.  The funding to Regeneron is a part of a $5 billion initiative dubbed ""Project NextGen"" by the U.S. Department of Health and Human Services (HHS).",https://finnhub.io/api/news?id=4b4ec597a64d2d4c02890c23931817424c924dd1bd3a51b2063ec38982e1a0c0
company,2023-08-22 14:15:00,Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention,122174217,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"Program is part of U.S. Government’s ‘Project NextGen’ and provides partial funding for clinical development of a novel monoclonal antibody therapyTARRYTOWN, N.Y., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has entered into an agreement with Regeneron to support clinical development, clinical manufacturing and the regulatory licensure process of a next-generation COVID-19",https://finnhub.io/api/news?id=862dcef9961cda8a6790dbfbf1b42c67856ef1dc0ed2241818e4a9595dad8c4b
company,2023-08-22 12:43:00,"Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market",122290156,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.44% to $840.63 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=9e531f1e2550dcf4a1cf3fa35bb1dde2b05508accaf03be488854b21a194e881
company,2023-08-22 11:38:56,"US govt awards $1.4 bln for development of new COVID therapies, vaccines",122172147,,REGN,Finnhub,"The U.S. government said on Tuesdayit had awarded $1.4 billion for the development of new therapiesand vaccines against COVID-19, including a $326 million contractwith Regeneron Pharmaceuticals for...",https://finnhub.io/api/news?id=d189448276aefdf0ad4e4c4b4f9b0015bfd859a3e3c69a185f54c3d7ee8c24b0
company,2023-08-22 10:35:00,Regeneron Pharmaceuticals inks new Covid contract with BARDA,122180746,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9dc560c61ce168038b8b912fa5582de990cd5a7ab0101f75f479744666538414
company,2023-08-22 10:34:00,Regeneron gets federal funding for next-generation COVID treatment,122290157,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,REGN,MarketWatch,"Regeneron Pharmaceuticals Inc. said Tuesday that the Biomedical Advanced Research and Development Authority has agreed to support the development,...",https://finnhub.io/api/news?id=eff6f970e3e0129789b67bf1e11ff2aee39bb4d414539264c856e96882e5362d
company,2023-08-22 10:30:26,Regeneron enters $326 mln pact with US to develop new COVID therapy,122169894,,REGN,Finnhub,Regeneron Pharmaceuticals onTuesday said it had entered into a contract worth $326 millionwith a U.S. government agency for the development ofnext-generation antibody therapy for COVID-19...,https://finnhub.io/api/news?id=d4f1366f47b9fcc8f0a83f0cfd6756080b1dc8b64ff72e6b031a05346b33ab4e
company,2023-08-22 07:51:00,Peering Into Regeneron Pharmaceuticals's Recent Short Interest,122180748,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b6c1163f5c42a0ed6f40c5eeb4d8741d195fc0686355ad61d4a162e74e56f06d
company,2023-08-22 04:14:05,Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing,122162368,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1626470215/image_1626470215.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Apogee Therapeutics has the ability to capture large target market indications if it can ultimately achieve a specific outcome. Find out why APGE stock is a Hold.,https://finnhub.io/api/news?id=f05c14ca39b6b94a1a07619f6403c3bc54364600e42ccda7662d328b3e0ef7f0
company,2023-08-22 03:02:00,GLOBAL BROKER RATINGS: Metzler reinitiates SAP at 'buy',122165395,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bf2cde831af47b7452ced306f73b3d3260478828c2711f0ed531b1731c5efc58
company,2023-08-22 01:12:00,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Syndax Pharmaceuticals (SNDX)",122169241,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f749c82d5699a73ae8c5482099e320054ea4b2e4aa23933474877e1dc9201032
company,2023-08-21 22:58:11,Oppenheimer Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation,122159169,,REGN,Fintel,,https://finnhub.io/api/news?id=1dd44ade2aab0490414548a51a4d8c5a2061793dbe07cb3d5be314fcbbfc3736
company,2023-08-21 22:58:08,Truist Securities Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation,122159170,,REGN,Fintel,,https://finnhub.io/api/news?id=8a6e79fbdcf28a44791ed17db70deeb5618492bfc17239f443e3c497eaed745a
company,2023-08-21 22:58:04,Wells Fargo Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation,122159172,,REGN,Fintel,,https://finnhub.io/api/news?id=f28c83db8732e2c072c7df65b78df95e1a82f10b5f67c7ab1cc405e29be7f90b
company,2023-08-21 22:58:04,RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation,122159171,,REGN,Fintel,,https://finnhub.io/api/news?id=40407f5bb5fb99769f2707f0ed9dddc23f07a9defd16749de16faacb56d29aba
company,2023-08-21 22:58:01,BMO Capital Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation,122159173,,REGN,Fintel,,https://finnhub.io/api/news?id=19414a212324974b9a1e39c607f7e463d224a68494721b508558900323175a6c
company,2023-08-21 22:58:00,Canaccord Genuity Upgrades Regeneron Pharmaceuticals (REGN),122159175,,REGN,Fintel,,https://finnhub.io/api/news?id=cdc11cb3e06dcdc8fc84480ca668cd04c6617d0dbd7366a06b758584b646a46c
company,2023-08-21 22:58:00,Barclays Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation,122159174,,REGN,Fintel,,https://finnhub.io/api/news?id=8cf64b77a45b450faf99b714b4d2d54da03deeee488fecda23371459691f2134
company,2023-08-21 22:24:00,"Canaccord ups Regeneron to buy, sees high-dose Eylea re-igniting sales",122180753,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=676b8d8f988b4cc974f7faf0f275f61c09cdde62658d86a70b78960a1be7ad00
company,2023-08-21 21:54:00,"Regeneron, J&J receive millions to develop new COVID therapies",122180754,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a5595ccf84402a573ff2a008967e721349e56510bfaeb0f52c1f63b03cbb016f
company,2023-08-21 21:23:00,Regeneron confirms $326M BARDA funding for Covid antibody therapy,122180756,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=de79624b7f7ab78df899e2c87836691ddb3e24df0c4f5d85fb24ee8b31d460a1
company,2023-08-21 21:04:00,Regeneron awarded $326M from U.S. for next-generation COVID antibody,122180757,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a209b696ce1cc6f88b2237013dd21a0bb3d1fde437f5fcf02700bc82800a7c9e
company,2023-08-21 16:06:00,Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough',122156161,https://media.zenfs.com/en/ibd.com/6fe9488e6037c71a19f4fb4a4ed23b2d,REGN,Yahoo,Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.,https://finnhub.io/api/news?id=5a96e1d148448c09bd78f375ffb7689f717f0858dede4fb81e123d2acf9a47fd
company,2023-08-21 12:43:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,122290158,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. rallied 3.94% to $844.37 Monday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=07b1edf08c267fe1e0280b145096da1e8089c72382c432387bb01b824b5854d0
company,2023-08-21 12:18:09,FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder,122152578,https://media.zenfs.com/en/Benzinga/950813490c3d0b110616bc3e5e0508c9,REGN,Yahoo,"The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient protein-losing enteropathy. Veopoz is the first and only treatment indicated specifically for CHAPLE. CHAPLE is an ultra-rare and life-threatening hereditary immune disease driven by an overactivation of the complement system. In healthy individuals, the complement system is a mechanism for destroying micro",https://finnhub.io/api/news?id=dcf260481619f29c9e298e6c53aafd51309743662518952f52a14f059c7bce2c
company,2023-08-21 12:16:00,Regeneron Hits The High End Of Its Buy Zone On The Approval That 'Could Not Come Soon Enough',122152579,https://media.zenfs.com/en/ibd.com/6fe9488e6037c71a19f4fb4a4ed23b2d,REGN,Yahoo,Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.,https://finnhub.io/api/news?id=70f80b8eb26a21eefd0f7f1b10cdb6e42df196018b2f60b3a95ff7803dbeeb77
company,2023-08-21 12:03:46,Regeneron Pharmaceuticals Inc: A Deep Dive into Its Financial Metrics and Competitive Strengths,122152581,https://s.yimg.com/ny/api/res/1.2/D9TU2tHeSHKJm7j3mcUE_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05NTU-/https://media.zenfs.com/en/us.finance.gurufocus/a3e2cde91798900cdc22c692a07ec62f,REGN,Yahoo,Unpacking the Growth and Competitive Edges of Regeneron Pharmaceuticals Inc,https://finnhub.io/api/news?id=d4fc34325c3281ee453bf0bc26a1691bddb6e9681c7bbfe5f2cfac637bb56b3e
company,2023-08-21 11:23:00,Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea,122158997,https://media.zenfs.com/en/zacks.com/71b99858039e975a135a06fcb21a51cd,REGN,Yahoo,Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.,https://finnhub.io/api/news?id=eca385c1808f593523d2d382ea63ef691a8c9075f9e061f043c1a474a56f6362
company,2023-08-21 09:57:06,Is Merck's Long-Term Investment Brilliance Unshaken By COVID-19 Drug Sales Slump?,122154261,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1388090347/image_1388090347.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"On August 1, Merck released its financial report for the second quarter of 2023, which showed excellent results. Read more about MRK stock here.",https://finnhub.io/api/news?id=3d0f701f55b0bda63f95bd7dc3dc90f3836f1d811b956e0de0df5700d36b0f6b
company,2023-08-21 09:23:00,Regeneron Stock-Price Targets Rise as FDA Approves Higher Dose of Eye Drug,122152583,https://s.yimg.com/ny/api/res/1.2/IzXKDgsr7_W6ja6TloRP8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/95c87e51855c2bfb41e2faa413381357,REGN,Yahoo,"The Food and Drug Administration approved 8-milligram doses of Eylea, a treatment for wet age-related macular degeneration.",https://finnhub.io/api/news?id=f1a11342e4e346565e69cad68cc667cb4b7595f11745a19c3850506777f0a94d
company,2023-08-21 08:59:00,Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed,122165359,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a59d650151cb20db6308e060c3c986b61dd26094244d5c89bb6fec330f1673a2
company,2023-08-21 08:17:00,"Palo Alto, Earthstone Energy rise; Napco Security, Nikola fall, Monday, 8/21/2023",122165159,,REGN,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6622a8e9a741d24980bbe2000d4e9b0979bf17fa2bb9cce1367b91a715ce9e05
company,2023-08-21 07:32:00,Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner,122167987,,REGN,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=69cc7b9ae897565daa11296f7604a1c94e5f9d1ead14b73d33cb55044f706e31
company,2023-08-21 06:48:27,This biotech name is one of Jim Cramer's favorite stocks and he thinks it can go even higher,122157046,https://image.cnbcfm.com/api/v1/image/106728578-1601729225514-gettyimages-1228859472-radin_1003203.jpeg?v=1692629307&w=1920&h=1080,REGN,CNBC,"""I think it's going to be worth more,"" Jim Cramer said Monday after Regeneron got good news from the FDA on its macular degeneration treatment.",https://finnhub.io/api/news?id=80a790a923cf824ab2b5fe99a4b621a524b8a5471602597a3aa4c4b1cdce77f4
company,2023-08-21 06:35:40,Cramer’s Stop Trading: Regeneron,122157047,https://image.cnbcfm.com/api/v1/image/107289445-16926283361692628334-30851330083-1080pnbcnews.jpg?v=1692628540&w=1920&h=1080,REGN,CNBC,CNBC’s Jim Cramer explains why he is keeping an eye on shares of Regeneron,https://finnhub.io/api/news?id=1e0149a7750b530945acbddbd45bb786ce8c44530083133ce191bab453b63aef
company,2023-08-21 06:33:00,Is Regeneron Pharmaceuticals Modestly Overvalued?,122180762,,REGN,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=54bda85a56b8bed2549a1d1884aca006a1addfb09979eed1fc3a930f285fc7ba
company,2023-08-21 06:30:00,Is Regeneron Pharmaceuticals Still a Top Growth Stock?,122152584,https://s.yimg.com/ny/api/res/1.2/EC2hXst_1r32DfIEr761nQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00OTA-/https://media.zenfs.com/en/motleyfool.com/e372813e40b27cc2f2f6533f12c77b1a,REGN,Yahoo,"Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence.  The biotech has partnered with Bayer to create a dominant eye-disease franchise, led by Eylea (aflibercept), the best-selling anti-VEGF drug in the market.  The biotech has also collaborated with Sanofi to develop cutting-edge therapies for cancer, inflammatory diseases, and lung disorders.",https://finnhub.io/api/news?id=71475c8df41420cd6cd74009397b2e9b7fdf48ae78f1aed7677fb1a2b42c3f3b
company,2023-08-21 06:02:09,"REGENERON PHARMACEUTICALS, INC. - VEOPOZ RECEIVES FDA APPROVAL AS THE FIRST TREATMENT FOR CHILDREN AND ADULTS WITH CHAPLE DISEASE",122150692,,REGN,Finnhub,"TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration has approved Veopoz for the treatment of adult and pediatric patients 1 year of age and older with...",https://finnhub.io/api/news?id=4b7d80ca608a92a4c00a459dd390c453ad2fffe1017911d43033c1c50dcd0faa
company,2023-08-21 06:00:25,"REGENERON PHARMACEUTICALS, INC. - EYLEA HD INJECTION 8 MG APPROVED BY FDA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION, DIABETIC MACULAR EDEMA AND DIABETIC RETINOPATHY",122150651,,REGN,Finnhub,"TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA HD Injection 8 mg for the treatment of patients with wet age-related...",https://finnhub.io/api/news?id=6585c8469199442320414bae970a98e9170ba9d9cf87e209646b77dbc5f22481
company,2023-08-21 04:28:00,Regeneron upgraded to Buy at Canaccord after high dose EYLEA approved,122170349,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4b53d6e42503e62b6821469e97d9cc0830161f01b5acf5db8588d4602b40d4f6
company,2023-08-21 04:25:00,Regeneron upgraded to Buy from Hold at Canaccord,122180766,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=491f210af673e544544fbae9aecc161c75a5877856f429de01269f8037999ae4
company,2023-08-21 03:52:00,Regeneron shares climb after FDA approval of macular degeneration treatment,122288864,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,REGN,MarketWatch,Shares of Regeneron Pharmaceuticals Inc. gained 1.4% premarket on Monday after the company said late Friday that the U.S. Food and Drug Administration had...,https://finnhub.io/api/news?id=9f886a66ef9d62e3bba3372ed1da5037f036611e5be316cb1d5adc0b5c60edf9
company,2023-08-21 03:45:00,Regeneron price target raised to $830 from $820 at RBC Capital,122180767,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4e4a8b33c44ea8b3b86e70a0fc33e332fcb412b5b89d07b8759b2fdfa0e5276b
company,2023-08-21 03:42:00,FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness,122176840,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f6dc92ee24d5eec49651f2ea79098044ff9eddcbd51002702a8ff39c9f0c1037
company,2023-08-21 03:20:00,"Analysts Are Bullish on These Healthcare Stocks: Supernus Pharmaceuticals (SUPN), Viatris (VTRS)",122175475,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c042d654ab1d9267db7e9d1061ba9c4adc41d2926f8b1dc9451a21164b0cd860
company,2023-08-21 02:45:00,Regeneron price target raised to $985 from $960 at BMO Capital,122170350,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ed9e9b6e644647e75eec6e08653031b05ecc4746e4584e38a363de0e3b92746d
company,2023-08-21 02:23:00,Regeneron price target raised to $980 from $875 at Wells Fargo,122180773,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b91df04701476f81c710e54571eb1b9b1c522bd5750f34e0f7ce836cedce00d4
company,2023-08-21 02:21:00,Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT) and Regeneron (REGN),122179500,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=99e3ec5680979b427c162cc04b635b6753ac8763bbe8c4de3fda7ebea4b5d932
company,2023-08-21 01:50:00,"Analysts Offer Insights on Healthcare Companies: Nemaura Medical (NMRD), Kineta (KA) and Regeneron (REGN)",122179499,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b674c4668af63e280ea4c2a39e591b8eb00f2d1043a597568d41c212f03f41a8
company,2023-08-21 01:38:00,"Regeneron price target raised to $1,050 from $950 at Oppenheimer",122180776,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ab5635c470bd22053cfc7fc82dbb0fdd42719f2d5203ea2a34df0c3373e53e3d
company,2023-08-21 01:32:00,"Palo Alto Networks shares surge after earnings, Tesla climbs and more stocks on the move",122204165,https://images.mktw.net/im-787374/social,REGN,MarketWatch,"Palo Alto Networks, Napco Security, Tesla and Jet.AI were among the biggest moving stocks on Monday.",https://finnhub.io/api/news?id=f92655e41dae6529d42d34a346e3d510450b9ee91026033f8303842be74e242a
company,2023-08-21 01:31:00,"Analysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)",122170846,,REGN,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1fff5b05d1f311e4902211e1ea0ca33f59788870063bfd47281d1f2c6308609c
company,2023-08-21 00:27:00,Regeneron price target raised to $925 from $900 at Barclays,122180778,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=17da23dc3fff392a73fec1f886983d510d2d8bd4c0dda813ea10fd76be09f008
company,2023-08-21 00:26:00,Regeneron announces FDA approval of Eylea HD for three indications,122180779,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=88daef6cd3116fff297fc8907d277f06ae8682ba5d048c499d8773a601316fb4
company,2023-08-20 23:24:00,Regeneron celebrates as Eylea HD and Veopoz gain FDA approval,122176842,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7436deb923086e6cb450432bdc5935cb373f9e11bfcb8a0e0242d5e439c683fc
company,2023-08-20 23:02:00,"Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk",122168625,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=95a1501146562e48225074d47e1a4cdd910b67e6f13898cf0553e1465901b9b9
company,2023-08-19 02:18:09,Regeneron Gets Boost With FDA Approval Of High-Dose Eylea (Rating Upgrade),122131508,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407879117/image_1407879117.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"Regeneron reported strong Q2 2023 financial results, with an 11% YoY revenue surge to $3.2B, outperforming expectations. Read more about REGN stock here.",https://finnhub.io/api/news?id=1dbd2c3bcecedaa41af26bbedf727e6490af6761cb4ab99a562f73b96c743e1b
company,2023-08-18 21:04:00,"With two approvals in one day, Regeneron could be headed higher",122137154,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=65b5a7eec661282e1dabe50bc8b79981ce4bdc68077989c079336f3c786b584b
company,2023-08-18 20:51:42,Canaccord Genuity Maintains Regeneron Pharmaceuticals (REGN) Hold Recommendation,122127661,,REGN,Fintel,,https://finnhub.io/api/news?id=4606f1f2a01ca84dbd70b409de4452db8107d8e0b1f3d59f520a2d8f3c92168d
company,2023-08-25 22:22:00,These Are the ONLY 7 Penny Stocks to Consider in August 2023,122260041,,REGN,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7bfea46773bfbab56086fe0330273ae96ea2d28cc419aa233a52be383169698e
company,2023-08-25 12:43:00,"Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market",122290153,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 0.10% to $830.35 Friday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=75b87435fd504292ba8a03492e1a45945c4daf427abe11ec8cd00794bdc6bc01
company,2023-08-25 10:15:00,Is Regeneron Stock a Buy Now?,122244510,,REGN,Yahoo,"There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors.  The company could soon face biosimilar competition from one of its key growth drivers, Eylea, while it recently received an important regulatory approval from the U.S. Food and Drug Administration (FDA).  With that said, let's dig deeper into what's happening with Regeneron and figure out whether it is worth investing in the drugmaker.",https://finnhub.io/api/news?id=dd1662b91b4b23678991c7fd33cdc70581a4dfc2d9ff5da509abbf350948c411
company,2023-08-25 09:16:00,"The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics",122239180,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,REGN,Yahoo,"Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.",https://finnhub.io/api/news?id=3d889f90ada5d45046212517ad13a0bb941d0724c0bf449622f0de6c15d5c3e4
company,2023-08-25 05:47:00,Merck starts phase 3 program for oral PCSK9 inhibitor to lower cholesterol,122240319,,REGN,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=79f630dd2569b2af3e1f2e508e5dad64908cb494ea4c606e81eff4bb1868afd6
company,2023-08-25 05:44:00,Biotech Alert: Searches spiking for these stocks today,122237506,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b3c2de58fee36c4f0fcec1c2e578df800f04d6781e8479273fe3b4bcc7cd091b
company,2023-08-24 21:04:00,Check Out What Whales Are Doing With REGN,122244383,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=325bfac65690c131697a0b4fc3b4280281d7493725a60bb1d1b5c74af48cfac6
company,2023-08-24 12:42:00,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,122290154,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slipped 1.14% to $831.21 Thursday, on what proved to be an all-around dismal trading session for the stock market,...",https://finnhub.io/api/news?id=d3aaaf8708f2eccd75780f241d76462cf17ad4a970ed31b9fc8c4422f336fc25
company,2023-08-24 10:15:00,"Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More",122203300,https://media.zenfs.com/en/zacks.com/7f0fb6bf42f42cec0a78ad3110808365,REGN,Yahoo,Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.,https://finnhub.io/api/news?id=6968387c299377ab479a013cfe5c4d0d924faa0587d48e02544a92e894cdc1ba
company,2023-08-24 03:11:00,Agilent receives European IVDR certification for companion diagnostic assay,122207442,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7b441c368b5ad6f14c85daa252bbd18840392ba0f9d9521bfd34c8536d4caed4
company,2023-08-23 16:05:00,Regeneron Announces Investor Conference Presentations,122191327,https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142,REGN,Yahoo,"TARRYTOWN, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • 2023 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 6, 2023 • Morgan Stanley 21st Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, September 11, 2023 The sessions may be accessed from the ""Investors & Media"" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays of th",https://finnhub.io/api/news?id=5058f4082c5a15c9fad494ff4a42c44c80328dc7b6c3b9f4f5be00206a5d53cc
company,2023-08-23 12:42:00,"Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market",122290155,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.02% higher to $840.81 Wednesday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=547d37152526b3e17ce98c6b9e800a0e9ad3f8aad51692a0d2c7a914ad6eaabe
company,2023-08-23 12:31:00,Health Care Roundup: Market Talk,122191328,https://s.yimg.com/ny/api/res/1.2/C_fe_IUBKwFmbkZU86pVxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/415bd7691b51b7ebfe7e0ae603ef79b1,REGN,Yahoo,"Find insight on Roche, Regeneron and Emergent BioSolutions in the latest Market Talks covering the Health Care sector.",https://finnhub.io/api/news?id=71f97a70deb18b3e4ba587246e2f40c3d26fba838d3af32f86a6254c26f9f571
company,2023-08-23 10:46:51,Adverum: H2 2023 Data Readouts For Wet-AMD Gene Therapy,122189614,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413606459/image_1413606459.jpg?io=getty-c-w1536,REGN,SeekingAlpha,Adverum is expecting two data readouts of Ixo-vec for the treatment of patients with Wet age-related macular degeneration in 2023. Read why ADVM is a strong buy.,https://finnhub.io/api/news?id=7fb087ab22a6705c3649c7955eeba214d1ecf5a33ea0ca966e8ea6a3ef0bbcb0
company,2023-08-23 08:12:12,Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patent,122188728,,REGN,Finnhub,"On August 18, Samsung Bioepis Co., Ltd. , filed a petition for Inter Partes Review, IPR2023-01312, challenging the validity of claims 1-18 of U.S. Patent No. 10,464,992, assigned to Regeneron...",https://finnhub.io/api/news?id=ce773a6152f4e807086aa7ad781f259b206836184180aaa01b0ddbcdbe952904
company,2023-08-23 07:00:26,"Are Robust Financials Driving The Recent Rally In Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock?",122191330,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,Most readers would already be aware that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased significantly by 14...,https://finnhub.io/api/news?id=55875c27e0e8eb6a4efaa53017d819fd2b010b94400bab3651eb063be7acd5f1
company,2023-08-23 03:22:00,GLOBAL BROKER RATINGS: Redburn cuts Adyen; Morgan Stanley lifts SocGen,122207884,,REGN,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e9bed686d5fad96f63d1d9fab4ed587209705f80a5e19481bc930e292c6d98b5
company,2023-08-23 03:00:00,Top 5 Health Care Stocks That May Fall Off A Cliff,122209640,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bcaf00dba16f3050ce44f1e610f67a99c52503be4a24f17c6da342abd4053eaa
company,2023-08-22 23:10:00,Regeneron VP Stahl sells $9.8M in company shares,122215598,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d52c6ac852d4ead3ef388fbc9d837df8dbf3ebe53f62bcb213c395600c306642
company,2023-08-30 12:43:00,Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day,122331270,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.57% higher to $834.95 Wednesday, on what proved to be an all-around favorable trading session for the stock...",https://finnhub.io/api/news?id=486c34acee728af1b259a9beaeac06cfcb0bd888e06b6eaedeecac6795ff6dcf
company,2023-08-29 23:47:00,Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity,122347857,,REGN,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a9b0cc571e83e9ccca288532acf13374c1e844dde0b595207dd1c5d743abdb28
company,2023-08-29 12:43:00,Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors,122331272,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. slumped 0.08% to $830.19 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=a27434d2866dadd1ff3613ccfc337c17e08973c9824ac7b9a2714c555683b370
company,2023-08-29 04:11:00,Celularity enters Research Collaboration Services Agreement with Regeneron,122320797,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2395226b9b88b4fbca39532ba48f43a36ff4cc99e5b7e6b73619abd850a7cc75
company,2023-08-29 04:06:00,"Tuesday’s Top Wall Street Analyst Upgrades and Downgrades: Boston Scientific, Ciena, CrowdStrike, Emerson Electric, Kimco Realty, Nike and More",122302582,,REGN,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fdf1f3013f9f6c21ec367a1da86cd90bf145853e99037627514774c3338806d1
company,2023-08-28 12:42:00,"Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market",122290152,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.07% higher to $830.89 Monday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=75366bb9d1fe69abab2ffadff662afca0cf76dac3c7d5dbb7602946bf356530b
company,2023-08-27 21:57:00,Regeneron treatment of myasthenia gravis granted FDA orphan status,122347863,,REGN,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6ce1e00b75e3da2d9c4e8547ce49fea5ebf00e0fc5eec508e62b801d1bf7204c
company,2023-08-27 08:00:25,Regeneron Pharmaceuticals (NASDAQ:REGN) Seems To Use Debt Quite Sensibly,122266264,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,REGN,Yahoo,"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...",https://finnhub.io/api/news?id=848890806840fdc9f2ec2bc4bd378d5be8be188eb51c8b22dae11e4b6c1b7ae5
company,2023-09-01 12:43:00,Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day,122396267,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. inched 0.62% higher to $831.63 Friday, on what proved to be an all-around positive trading session for the stock...",https://finnhub.io/api/news?id=497ba0c72e6965cbed3617f240e2be690fac12e5301e1d842c747a2f4e7e8ce5
company,2023-08-31 13:43:00,Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD,122357305,https://media.zenfs.com/en/zacks.com/253e1f4ba631403e19576a0346277e39,REGN,Yahoo,Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.,https://finnhub.io/api/news?id=80ed179aca55299867a217699cdbc6b1f2597c02234f2bcee43723a4afba95ce
company,2023-08-31 13:26:00,It’s Still Tech’s Year. These Stocks Led the Market in August.,122395809,https://images.barrons.com/im-28827626/social,REGN,MarketWatch,"For much of Thursday, it looked drug stocks would be August's biggest gainers in the Dow, S&P 500 and Nasdaq 100, but tech firms took the top spots.",https://finnhub.io/api/news?id=25bf11dc0c47857146f82ff1e167119922578057cea54143b0d507c140aba8f2
company,2023-08-31 12:43:00,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,122396269,https://images.mktw.net/im-220105/social,REGN,MarketWatch,"Shares of Regeneron Pharmaceuticals Inc. shed 1.01% to $826.49 Thursday, on what proved to be an all-around rough trading session for the stock market, with...",https://finnhub.io/api/news?id=d0333415b73c2528ee808ee21d6dac5ba3bbb06baf11d318853b32cb010ff33a
